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Cover: NABC 17 focused on agricultural biotechnology products and processes 
beyond food and energy. The bottom illustrations represent examples that are 
under research and development. The top illustrations represent areas of expected 
benefit, including improved economics and decreased environmental impact, 
as well as expanded opportunities for agriculture and rural communities. As 
identified at NABC 17, governmental regulations are needed for commercial-
ization and societal benefits to be realized, as represented by the disconnection 
between the segments.
Trees are being genetically engineered (represented bottom left) for faster 
growth to diminish demands on natural forest stands, to clean up toxic wastes, 
and with lignin content modified to improve efficiency of pulp production. 
Chinese brake fern (bottom middle) is being appraised as a means of remov-
ing arsenic from contaminated soils, and genetically engineered (GE) species 
of Nicotiana (bottom right), related to tobacco, are under study as vehicles for 
the production of pharmaceuticals—vaccines, antibodies, etc. Trees, genetically 
engineered for reduced lignin content, will require less chlorine for bleaching of 
pulp from dark brown to white (top left) for paper manufacture. Benefits to the 
environment (represented top middle) will accrue also as a result of using GE 
plants for phytoremediation of soils contaminated with metals such as mercury, 
lead and cadmium, and/or toxic organic compounds and explosive materials. 
Using plants as vehicles for production of long-shelf-life pharmaceuticals (and 
industrial compounds) holds promise for developed and developing countries 
alike, as well as possibilities for improving farm incomes and rural economies 
(top right).
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PREFACE
The seventeenth annual meeting of the National Agricultural Biotechnolongy Council 
(NABC 17)—Agricultural Biotechnology: Beyond Food and Energy to Health and the 
 Environment—focused on the following areas:
 • Plants as new sources of medicinals,
 • Bioremediation, phytosensing, and ecorestoration,
 • Gene-to-product development, and 
 • Regulation, consumer acceptance, and risk management. 
Prior to addressing these issues, the stage was set with plenary presentations from Roger 
Beachy (Donald Danforth Plant Science Center) and Michael Rodemeyer (Pew Initiative 
on Food and Biotechnology).
 NABC 17 was our second meeting to focus on emerging product and/or process op-
portunities for agriculture outside of the traditional food, feed and fiber markets. The 
first, NABC 12—The Biobased Economy of the Twenty-First Century: Agriculture Expand-
ing into Health, Energy, Chemicals, and Materials—led to the initiation of the World 
Congress on Industrial Biotechnology and Bioprocessing: Linking Biotechnology, Chemistry 
and Agriculture to Create New Value Chains. Summary Proceedings of the 2004 and 2005 
World Congresses, edited by NABC’s Executive Director Allan Eaglesham, are available 
from NABC.
 The products and processes of NABC 17 are almost all at the research stage, whereas 
there is up to 15 years experience with commercial products in the enzyme and crop areas. 
Economic and environmental benefits of the products discussed at NABC 17 could be 
large, e.g. plants engineered to produce low-cost medicinals with ease of scale-up stated 
as a unique advantage compared to traditional methods of manufacturing pharmaceu-
ticals, plants that remediate soils in situ instead of wholesale excavation and landfill 
placement, and trees modified for lower lignin content so as to decrease processing costs 
while increasing pulp yields with less environmental impact. However, all have major 
not-yet-well-defined regulatory hurdles to navigate. This report provides cutting-edge 
information on a cross-section of these novel products and processes and includes open 
dialog on regulatory and related issues. It emerged that some academic scientists believe 
that biotechnology products are over-regulated, because regulation is based on process 
not trait. All, including those from industry and the Biotechnology Industry Organi-
zation, support the necessity for regulation. The bottom line is cautious optimism for 
commercial use of these products; at this time there are few green lights, many yellow 
and some red. 
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 NABC 17, hosted jointly by the Universities of Kentucky and Tennessee June 27–29, 
2005, had 151 attendees, including representation from twenty-one countries.
 At the conclusion of the formal presentations, expert panelists made brief statements 
followed by audience Q&A. Attendees then convened in breakout sessions for further 
discussion of issues raised by the speakers and the panelists, and to make recommenda-
tions to policymakers.
 This volume contains an overview of the meeting, a summary of the breakout workshops 
and the recommendations, the plenary and module presentations, and presentations made 
during the banquet and luncheons. Transcripts of panelists’ statements and the Q&A 
sessions are also provided.
 NABC 18, Agricultural Biotechnology:  Economic Development through New Products, 
Partnerships, and Workforce Development, will be hosted by Cornell University June 12–14, 
2006, with sessions on the Ithaca and Geneva campuses. Further information may be 
accessed via http://nabc.cals.cornell.edu.
Allan Eaglesham Ricardo Bessin Robert Trigiano Ralph W.F. Hardy
Executive Director Professor of Entomology Professor of President
NABC University of Kentucky Plant Pathology NABC
  University of 
  Tennessee
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PArt I
Meeting Summary

 Agricultural Biotechnology: Beyond Food and Energy to Health and the Environment
NABC’s seventeenth annual meeting, co-hosted by the Universities of Kentucky and 
 tennessee, convened at the renaissance Hotel, Nashville, tN, June 7–9, 005, a few 
blocks from the ryman Auditorium (the original venue of the Grand Ole Opry), Broadway 
(Music City’s famous “heartbeat”) and the Country Music Hall of Fame. The modular 
structure of NABC 7 juxtaposed sessions on plant-made pharmaceuticals, bioremedia-
tion and associated issues, product development, and regulatory and risk-management 
considerations. The 5 attendees included university and industry researchers and 
administrators, educators, members of federal agencies and non-governmental organiza-
tions, and journalists.
In the plenary session, keynote addresses were delivered by roger Beachy (Donald 
Danforth Plant Science Center) and Michael rodemeyer (Pew Initiative on Food and 
Biotechnology). These were followed by modules composed of formal presentations and 
brief contributions from panelists:
• Module I–Plants	as	New	Sources	of	Medicinals:	Production	of	Protein	Pharmaceuti-
cals	in	Food	and	Non-Food	Plants
 – Speakers: Maelor Davies (University of Kentucky) and Schuyler Korban 
(University of Illinois)
 – Panelists: Henry Miller (Hoover Institution) and Mark Nelson (Grocery 
Manufacturers of America)
• Module II–Bioremediation,	Phytosensing,	and	Ecorestoration
 – Speakers: Bruce Ferguson (Edenspace Systems Corporation), Jacqueline 
Shanks (Iowa State University) and Scott Merkle (University of Georgia)
 – Panelists: Lena Ma (University of Florida), Steve rock (EPA Cincinnati) and 
Neal Stewart (University of tennessee)
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• Module III–Gene-to-Product	Development
 – Speakers: Maud Hinchee (ArborGen), Vincent Chiang (North Carolina State 
University) and Elizabeth Hood (Arkansas State University)
 – Panelists: roger Conway (USDA Office of Energy Policy and New Uses), 
Alex Day (Kentucky Life Sciences Organization) and William Goldner 
(USDA Small Business Business Innovation research)
• Module IV–Regulation,	Consumer	Acceptance,	and	Risk	Management
 – Speakers: Cindy Smith (USDA-APHIS Biotechnology regulatory Services), 
Thomas redick (Gallop, Johnson & Neuman LC) and Kim Waddell (Ameri-
can Vineyard Association)
 – Panelists: Thomas Hoban (North Carolina State University), Canice Nolan 
(European Commission to the United States) and Allan Bennett (University 
of California at Davis)
Banquet and luncheon presentations were delivered by Wayne Parrott (University of 
Georgia), Gregory Jaffe (Center for Science in the Public Interest) and Michael Phillips 
(Biotechnology Industry Organization).
Discussion among the participants occurred within three breakout sessions composed 
of four smaller groups. A summary of those discussions and emerging recommendations 
is provided elsewhere..
Plenary Session
roger Beachy (“Controlling traits in transgenic Plants: tools that Enhance Value and 
reduce Environmental release”) discussed the benefits of controlling expression of 
transgenes in plants, for example to maximize the effect of a gene product in a specific 
tissue at a specific growth stage as a means of eliminating adventitious presence of the 
product or nonessential release into the environment. He described the development of 
systems to control gene expression at will, upon induction by environmental conditions 
or by chemical (small molecule) application to cause a gene to be turned on—at a high, 
medium or low level like a rheostat—or shut off. The basic components of a good gene-
switching system are a suitable inducer and a receptor-like protein that binds to a ligand 
that regulates the inducer. A promoter that responds to the inducer increases or decreases 
expression of the gene of interest. An Ecr (ecdysone receptor) approach has been devel-
oped, employing receptors found in lepidopterous insects that are activated by specific 
juvenile hormones. When the Ecr protein in the cytoplasm complexes with the ligand, 
it is transported to the nucleus and binds with the gene of interest inducing expression. 
In this case, the ligand is the insecticide methoxyfenozide (Mimic®). Arabidopsis plants 
have been engineered with a gene-switching unit that causes production of transcription 
factors that bind to chimeric promoters that are expected to activate eight or ten different 
promoters and, therefore, eight or ten different reporter genes. It may soon be possible 
to modify metabolism in several biochemical pathways simultaneously. How science 
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becomes relevant to the public and to commercialization depends upon many factors. 
Gene switching may assist consumer acceptance.
Michael rodemeyer (“Can You Get There From Here? Speed Bumps in the road to 
Health And Environmental Biotech Applications”) questioned whether plant biotechnol-
ogy can be harnessed to provide benefits outside of the area of food and feed. Can the 
kind of global deadlock that has emerged from the introduction of genetically modified 
(GM) crops and food be avoided? Is the opposition to the use of plant biotechnology 
limited to its use in food? Can the potential health and environmental benefits of the 
next generation of plant biotechnology change the contours of the global debate? What 
obstacles await the commercialization of health and environmental applications of plant 
biotechnology? Experience and common sense suggest that every application is likely to 
have its own opportunities and challenges; rodemeyer suggested that across-the-board 
predictions are likely to be misleading. Although the hurdles to commercialization of 
health and environmental plant-biotechnology applications are significant, he sees reason 
for cautious optimism. The regulatory system is slowly responding to the need to evolve 
for new and different types of biotechnology products. Management and stewardship 
requirements are becoming clearer. And experience suggests that the market welcomes 
safe, innovative products that provide perceived benefits to buyers and to the public. The 
challenge to developers is to ensure that the potential benefits of this technology are clearly 
explained to the public while the government continues to ensure safety. If developers 
can do that, then there is indeed a way to get there from here.
Plants as New Sources of Medicinals: Production of Protein 
Pharmaceuticals in Food and Non-Food Plants
The concept of “molecular farming” was born in the early 980s when it became possible 
to envisage crops as sources of proteins that originally derived from microbial or animal 
sources. Maelor Davies (“Plant-Made Pharmaceuticals: An Overview and Update”) de-
scribed the advantages of plant-made pharmaceuticals: overall economy of production, lack 
of need for major capital investment (e.g. in fermentation bioreactors), ease and economy 
of scale-up, lack of risk of contamination with human pathogens, etc. However, significant 
markets for plant-made proteins failed to develop; by the mid-990s plant molecular 
farming was essentially stalled. Concerns about contamination of existing crops—and 
food or feed products—with compounds from the corresponding transgenic crop would 
be moot if pharmaceuticals, for example, were synthesized with “vehicle” plants that had 
hitherto not been developed for food or feed. tobacco and related Nicotiana species of-
fer excellent potential for development of a new, dedicated system for crop synthesis of 
pharmaceuticals and other useful products.
Schuyler Korban (“Opportunities and Challenges for Plant-Based Vaccines”) described 
the move, in recent years, towards developing subunit vaccines whereby linear immuno-
genic epitopes of a pathogen elicit production of antibodies. These alleviate concerns over 
risk of reversion of attenuated strains to aggressive forms of the pathogen. And a novel 
approach for developing subunit vaccines has emerged as a result of genetic engineering 
technology: use of plants as vehicles for developing new products. As the technology to 
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produce vaccines in plants goes through the regulatory pathway and demonstrates its 
economic feasibility, it may also overcome public-perception concerns that have dogged 
agricultural biotechnology in the past decade. The likelihood that plant-based vaccines can 
be administered via oral or intranasal routes—rather than via the hypodermic needle—will 
add to their desirability as well as their economic benefits. All this will have a major impact 
on public health, particularly in developing countries. However, much work remains to 
be done, including the establishment of standardized safety-assessment models. risk as-
sessment must be science-based for the results to be believable and trustworthy. Increased 
funding of research in this field will accelerate the advances made thus far, and bring this 
technology closer to commercialization and worldwide use.
Henry Miller, who spent several years with FDA, made the case against regulation of 
transgenic organisms based on the process used to produce them rather than on the host 
and the added trait. He criticized both highly activist and more moderate public-inter-
est organizations, and emphasized that the regulatory system and associated costs have 
debilitated public-sector agricultural biotechnology.
Mark Nelson expressed concern over the possibility of adulteration of food if PMPs are 
produced in crops such as corn, soy and canola. The Grocery Manufacturers of America 
has asked for a safety evaluation of the implications if PMP-producing food crops are 
commingled in the food supply; reasonable standards are needed.
Bioremediation, Phytosensing, and Ecorestoration
Bruce Ferguson (“Systems Agriculture: towards a Sustainable Agricultural and Envi-
ronmental Policy”) described Edenspace’s projects in phytotechnology: using ferns to 
remove arsenic from soils; engineering plant biosensors—“phytosensors”—to detect and 
monitor environmental parameters such as heavy metals; engineering plants to produce 
higher yields of ethanol per acre; and forming a new agricultural cooperative to provide 
additional income to producers who work on environmental projects. These and similar 
projects have afforded a broad range of experiences, including site characterization and 
environmental remediation, plant genetic engineering and APHIS field permitting, market 
research, and marketing and sales. From this experience Ferguson offered the following 
observations and recommendations:
• Change agricultural policy from insulation to innovation.
 – When subsidies cease, farmers may be left without a means of competing 
with lower-cost food imports. to address this problem, rapid innovation and 
product development should be encouraged allowing farmers to compete by 
offering higher-margin value-added products.
• Promote “systems agriculture.”
 – Systems agriculture is the engineering of plant traits and agricultural pro-
tocols on an integrated basis with other production technologies so as to 
minimize total costs of end-user products and services. The approach requires 
that new agricultural products and techniques be developed by considering 
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multiple areas of upstream and downstream production expertise together—
on an integrated basis—that are now considered separately.
• Create more-receptive public opinion.
 – traditional breeding methods are too imprecise and too slow to achieve the 
rapid product development needed to support a competitive US agricultural 
sector. A key element is to develop public demand for new transgenic plant 
products that directly promote human health, provide low-cost energy, etc., 
rather than simply (though importantly) reduce producer costs with no sig-
nificant benefit perceived by consumers.
• Increase government r&D funding.
 – transgenic plant development is under-funded by the private sector, largely 
because of the divisiveness of the transgenic crop wars of the last 0 years. to 
address this market imbalance, the plant biotechnology budget should be at 
least quadrupled in size. Half of the increase should be apportioned to the 
USDA and half to other government agencies—EPA, NIH, HUD, DOt, 
etc.—to fund crop-plant research related to their missions.
Explosive chemicals that contaminate groundwater and soil—at ammunition-produc-
tion and military-training sites—are toxic to many microorganisms, mammals and plants. 
However, some plant species have the ability to remove and transform them into less 
harmful compounds. Jacqueline Shanks [“Plant transformation Pathways of Energetic 
Materials (rDX, tNt, DNts)”] described genetic and biochemical studies of pathways 
that transform explosives and development of transgenic plants for phytoremediation 
purposes. An important consideration is that explosive compounds assimilated by plants 
can be released from the tissues by action of water, e.g. rain and runoff, and thus may be 
returned to the environment as hazardous contaminants; research is required on post-har-
vest fate. Less information is available on phytoremediation of dinitrotoluenes, compared 
to trinitrotoluene (tNt) and hexahydro-,3,5-trinitro-,3,5-triazine (rDX).
Forest trees, with their extensive root systems and ability to rapidly accumulate 
biomass, would be attractive tools for remediation of soil and water contaminated with 
heavy metals—mercury, arsenic, etc.—if they could be modified to handle high levels. 
Scott Merkle (“Engineering Forest trees with Heavy Metal resistance Genes for Phytore-
mediation”) discussed the engineering of fast‑growing trees with modified bacterial 
genes that allow them to detoxify or sequester some heavy metals, with the objective 
of using them for phytoremediation. Insertion of these genes required optimization 
of in vitro culture systems followed by adaptation of Agrobacterium‑ and micropro‑
jectile‑mediated gene‑transfer methods for each species. Yellow poplar (Liriodendron 
tulipifera) expressing a modified bacterial mercuric‑ion reductase (merA) showed 
enhanced resistance to mercuric ion in vitro. Eastern cottonwood (Populus deltoides) 
engineered with the same gene demonstrated the ability to tolerate ionic mercury up 
to 400 ppm in soil; these trees are being field‑tested at a mercury‑contaminated site. 
While eastern cottonwood engineered with the organomercurial lyase (merB) gene 
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showed only slightly enhanced tolerance of organomercury, trees engineered with both 
merA and merB were able to convert phenylmercury acetate to elemental mercury. 
Preliminary work with eastern cottonwood expressing a γ‑glutamyl synthetase (γECS) 
gene indicated that it had slightly enhanced tolerance to arsenate in vitro. Continuing 
work involving the combination of γECS with other genes for mercury or arsenic 
resistance may enhance the phytoremediation ability of transgenic trees.
Lena Ma noted that phytoremediation of organic contaminants, energetic materials 
and metals is mostly in the demonstration stage; there are no full-scale applications to 
date. Problems and needs are the slowness of the process—5 to 0 years—and what to 
do with the resultant biomass.
Neal Stewart pointed out applications of phytosensors: as indicators of phytoremedia-
tion progress, coupled with GPS to guide management of crops, to monitor agro-security, 
and to detect explosives (e.g. buried landmines). He also suggested that we need to rebuild 
regulations based on our current knowledge-base.
Steve rock called attention to the Interstate technology regulations Council, a group 
of about forty state regulatory bodies that banded together to share regulation informa-
tion and eliminate repetition and duplication. He observed also that many researchers in 
transgenics in Europe have redirected their efforts to phytoremediation.
Gene-to-Product Development
Maud Hinchee (“The Application of Biotechnology to Sustainable Forestry”) stated that 
forest genetics, because of long generation times, is only now reaching the stage at which 
genetically superior trees are being planted. Improved tree genetics is occurring through 
mass controlled pollination: controlled crosses to create varieties that capture superior 
parental qualities. Biotechnology is being applied to this new germplasm base. ArborGen’s 
mission is to develop and commercialize technologies, products and services that will en-
sure sustainability of the world’s forests. The first-tier products are focused on Eucalyptus, 
Populus and Pinus. The largest market for Eucalyptus is Brazil’s pulp and paper industry, 
and ArborGen is examining the potential to modify lignin for improved efficiency of 
pulp production and to accelerate growth rate. Accelerated growth in plantations, without 
compromising wood quality, is an objective also for Populus	and Pinus; asexual propaga-
tion technologies are being employed. ArborGen is developing transformation methods 
applicable to elite varieties of Eucalyptus spp. and hybrids, loblolly pine (Pinus	taeda), 
Monterey pine (Pinus	radiata), grown in Australasia, and eastern cottonwood. Pine is 
transformed using a somatic embryogenesis-based protocol, with Agrobacterium-mediated 
transformation. Eucalyptus transformation is based on micro-propagated elite material; 
a shoot organogenic process is used after inoculation with Agrobacterium. ArborGen has 
the capacity to generate thousands of transgenic events per year for field screening and 
selection for each of the species of interest.
Vincent Chiang (“Understanding Gene Functions and their Control for Lignin Forma-
tion in Wood”) summarized his research on genetic engineering of lignin biosynthesis 
for the purposes of improving wood-pulping and bleaching efficiencies. His objectives 
include the production of transgenic trees of low lignin content. Using aspen (Populus	
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tremuloides) as a model species, he and colleagues have characterized the biochemical 
functions of various genes and kinetic properties of products involved in the monolignol 
biosynthetic pathway. There is strong evidence that a principle phenolic flux leads to the 
formation of monolignols. Biochemical evidence has further demonstrated that, in this 
principle flux, -coumarate:CoA ligase (CL) could be the enzyme limiting total lignin 
accumulation, whereas coniferaldehyde 5-hydroxylase (CAld5H) might control the lig-
nin syringyl:guaiacyl (S/G) ratio. These propositions are fully supported by the in	vivo 
functions of these enzymes. transgenic trees with inhibited CL enzyme activity exhibit 
5% to 5% reduction in lignin content. The chemical structure of the resulting lignin 
is essentially unchanged. More importantly, lignin reduction is compensated for by a 
concomitant increase in cellulose content. When antisense 4CL and sense CAld5H genes 
were simultaneously transferred into aspen via Agrobacterium, transgenic trees expressing 
each one and both of the transgenes were produced. Lignin reductions up to 55% were 
achieved in antisense 4CL plants and up to three-fold increases in S/G were observed in 
sense CAld5H plants. These effects were independent but additive, and plants expressing 
both transgenes had less lignin and higher S/G ratio. These transgenics are potentially 
valuable for pulp production. But, more importantly, these benchmark transgenics are 
rich sources of information for functional genomics and metabolic engineering, allowing 
the generation of the ultimate raw materials for wood-pulp production.
Elizabeth Hood (“Commercialization of a Protein Product from transgenic Maize”) 
described the steps involved in commercializing bovine trypsin as a product synthesized 
in transgenic maize, including proof of concept, product development (market develop-
ment, patent protection, final formulation, safety assessment, etc.) and public acceptance 
and sales. Lack of public acceptance is the major barrier to producing pharmaceutical or 
industrial products in plants. response to this public distrust has driven current regula-
tions to be quite restrictive. The scientific community and the regulatory agencies are 
striving to gather substantive safety data to support regulations that are based on scientific 
principles and will protect the public as well as allow this new industry to develop. The 
critical asset for general acceptance is whether the consumer sees benefits and whether 
these perceived benefits outweigh costs and risks. When products with obvious benefits 
are available to the consumer, public acceptance, science-based regulations and sales will 
fall into place.
William Goldner described a new initiative to assist in the navigation of regulatory re-
quirements for specialty or minor crops: the Specialty Crops regulatory Initiative. It should 
assist public-sector and small private companies in meeting regulatory requirements.
Alex Day described obstacles in bringing products to market. He mentioned the chal-
lenge of bridging scientists and business people for effective communications, and noted 
the lack of money for seed-stage investments.
roger Conway listed programs that assist commercialization of industrial biotechnology 
products. These include the Federal Biobased Products Preferred Procurement Program, 
which provides government markets especially for early-stage products, and the USDA 
CCC Bioenergy Program, which has catalyzed investment in the biodiesel industry. Other 
opportunities/needs exist in capital investment and education.
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regulation, Consumer Acceptance, and risk Management
The United States Department of Agriculture’s Animal and Plant Health Inspection 
Service (APHIS) has regulated transgenic organisms since 987, and in 00 established 
Biotechnology regulatory Services (BrS) to place a renewed emphasis and priority on 
biotechnology. APHIS has authorized more than 0,000 permits and notifications for the 
introduction of GM organisms and deregulated over sixty products for use, establishing 
itself as an international leader in the safe regulation of transgenic products. Cindy Smith 
(“regulating Pharmaceutical Plants: Meeting the Challenge”) described the significant 
reorganization that has occurred at BrS since its inception, making it better prepared to 
anticipate and respond to challenges resulting from the evolving nature of biotechnology. 
The newly reorganized BrS goes beyond a staff of scientists to evaluate permit applications 
and petitions for deregulation. It includes a Compliance and Inspection Branch, a Com-
munications and Capacity Building Branch, a regulatory Analysis Branch, an Office of 
Science, and a forecasting function that help BrS address these challenges and keep pace 
with the advancing science. In addition, BrS has developed five priority areas of emphasis 
that set program direction and provide the foundation for decision-making. The following 
priority areas are key to BrS’s ability to meet the challenges of regulating biotechnology 
in general, and, specifically, plants engineered to produce pharmaceuticals:
• maintaining rigorous regulation that thoroughly and appropriately evaluates and 
ensures safety and is supported by strong compliance and enforcement;
• ensuring that BrS’s regulatory process and decision-making are transparent to 
stakeholders and the public; 
• maintaining a science-based system that ensures that the best science is used to 
support regulatory decision-making and to assure safety;
• maintaining communication, coordination, and collaboration with the full range 
of stakeholders; and
• establishing international leadership to ensure that international biotechnology 
standards are science-based, international regulatory capacity building is sup-
ported, and international implications of domestic policy and regulatory decisions 
are considered.
As the science progresses, BrS will continue to evaluate the implications of new tech-
nologies, enhance its processes and procedures, and develop appropriate regulations to 
meet the challenges posed by this new science while continuing to safeguard American 
agriculture, the nation’s food supply, and the environment.
Thomas redick (“Liability Prevention and Biotechnology: A Brief History of Successful 
Industrial Stewardship”) summed up the regulatory and liability hurdles that stand in the 
way of launching a new transgenic product. He briefly reviewed successes and failures 
and existing risk-management methods to help overcome legal barriers to entry. Despite 
past successes, and the knowledge gained from failures and near misses, the road to future 
commercial success in agricultural biotechnology remains fraught with difficulties. The 
European Union and its like-minded trading partners will continue to hold their zero-
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adventitious-presence standards over the heads of grain exporters and will increasingly 
drive innovation in agricultural biotechnology into contained, closed-loop production 
systems. Like a game of three-dimensional chess, transgenic crops will face three levels 
of regulatory oversight, starting with federal approvals, but with more requirements 
emerging at the state level (even in counties or cities) and overseas. For many transgenic 
crops, international approvals may be required prior to market launch within the United 
States (for soybean, rice, wheat and other primarily export-bound crops). As a result, US 
agricultural biotechnology operations will need to maintain perfect divisions between its 
“green,” “white” and “red” sectors—food and feed, plant-pharmaceutical, and industrial 
applications.
In 000, the federal government completed an interagency review of its regulatory 
oversight of biotechnology products that revealed that ensuring confinement could 
become a regulatory requirement for approval of some transgenic organisms. In 00, 
the USDA asked the National Academies to review and evaluate biological methods and 
report on their application in confining transgenic crop plants, shellfish, trees, grasses, 
fish, microbes, insects and other organisms. Kim Waddell (“Biological Confinement of 
Genetically Engineered Organisms: Opportunities for reducing Environmental risks?”) 
summarized that report (Biological	Confinement	 of	Genetically	 Engineered	Organisms) 
with particular emphasis on: definition of bioconfinement, when and why to consider 
bioconfinement, bioconfinement of plants, bioconfinement of animals, bioconfinement 
of microorganisms, and biological and operational considerations for bioconfinement. 
recommendations in the report include:
• Evaluation of the need for bioconfinement should be considered for each trans-
genic organism separately.
• Early evaluation of the need for bioconfinement in the development of a trans-
genic organism or its products is recommended.
• Bioconfinement techniques should be assessed with reference to the temporal and 
spatial scales of field release.
• An adequate level of bioconfinement should be defined early in the development 
of a transgenic organism, after considering worst-case scenarios and the probabil-
ity of their occurrence.
• An “integrated confinement system” approach (defined in the report) should be 
used in deployment of the transgenic organism.
Current lack of quality data and science is the single most significant factor limiting abil-
ity to assess effective bioconfinement methods. Methods need to be tested in a variety 
of appropriate environments and in representative genotypes of the transgenic organism 
under consideration. In order to implement effective bioconfinement of GM organisms, 
the report recommended support for additional scientific research that:
• characterizes the potential ecological risks and consequences of a failure of bio-
confinement,
• develops reliable, safe, and environmentally sound bioconfinement methods, 
especially for transgenic organisms used in pharmaceutical production,
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• designs methods for accurate assessment of the efficacy of bioconfinement,
• integrates the economic, legal, ethical, and social factors that might influence the 
application and regulation of specific methods, and
• models the dispersal biology of organisms targeted for genetic engineering and 
release, where sufficient information does not exist.
Thomas Hoban was highly critical of industry, government and universities regarding 
agricultural biotechnology and its products, especially those from cloned animals and 
PMPs from food crops.
Canice Nolan identified the major problem in European acceptance of GM foods 
as the consumer not the regulators; food processors aren’t going to source when risk is 
commonly associated with GM. There is consensus in Europe that the regulatory system 
works well and should remain in place.
Allan Bennett described the Public Intellectual Property resource for Agriculture 
(PIPrA), a public-sector consortium that hopes to provide bundles of proprietary 
technologies—enabling and trait—to allow the benefits of biotechnology to accrue to a 
broader base of crops and consumers, e.g. specialty crops and developing-country farmers. 
He noted that 5% of crop-biotech patents belong to the public sector.
Banquet and Luncheon Presentations
Wayne Parrot (“The Nature of Change: towards Sensible regulation of transgenic Crops 
Based on Lessons from Plant Breeding, Biotechnology and Genomics”) reminded the 
audience that the literature contains many suggestions that plant genomes are highly 
variable. One early indication was the discovery that maize inbreds differ in the number 
of rDNA copies, ranging from a low of 5,000 in “W3” to 3,000 copies in “Illinois 
reverse High Protein.” total DNA content varies also within crop varieties—up to % 
for soybean, 5% for red pepper and % for maize. Until the advent of genetic engi-
neering technology, it is true that scientists had not crossed the species barrier in terms 
of gene transfer between kingdoms. On the other hand, it must be acknowledged that 
DNA from unrelated species is transferred and incorporated into plant genomes. Plantain 
bananas contain the entire genome of the banana streak virus, rice contains DNA from 
the rice tungro bacilliform virus, and tomato has DNA from the tobacco vein-clearing 
virus. The integration of viral sequences may be widespread in the plant kingdom, having 
occurred for a long period of time. Genes from the bacterium, Agrobacterium	rhizogenes, 
have been found incorporated into the genome of some tobacco species while DNA from 
unrelated higher plants has been found to be transferred between their mitochondria, 
and, from there, to their nuclei. Although not a common phenomenon, horizontal gene 
transfer does take place, at least on an evolutionary time scale, and does not appear to 
pose any hazards to recipient plants. This and other information lead Parrot to conclude 
that plant genomes are variable and dynamic, constantly changing in response to breed-
ing efforts and even to environmental conditions. Therefore, it is a mistake to treat 
transgenes and their associated DNA changes as inherently dangerous. Ultimately, it is 
the trait imparted by the transgene that matters, and, as such, it is the trait that should 
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be the focus of regulatory efforts, should these be warranted. In Parrot’s opinion, risk to 
health and the environment posed by most traits is sufficiently low as to preclude the 
need for regulatory oversight.
Gregory Jaffe (“Creating the Proper Environment for Acceptance of Agricultural 
Biotechnology”) stated that the past 0 years have been extremely successful for the bio-
technology industry. Several blockbuster products were marketed in the 990s, including 
soybeans, corn, cotton, and canola that are herbicide-tolerant and corn and cotton that 
produce their own insecticide to control specific pests. These varieties have been widely 
adopted by farmers in the United States and, to varying extents, in seventeen other 
countries: over eight million farmers grew 00 million acres of GM crops in 00. These 
herbicide-tolerant and insect-resistant crops—biotechnology’s “first generation”—have 
provided benefits to farmers and the environment by increasing yields and reducing 
the use of insecticides. Despite this success, the introduction of new GM products has 
slowed considerably. In February, 005, CSPI released a study—Withering	on	the	Vine:	
Will	Agricultural	Biotech’s	Promises	Bear	Fruit?—showing that from 995 through 999, 
forty-seven crops (an average of nine per year) completed the FDA regulatory process, 
whereas from 000 through 00 only fifteen crops (an average of three per year) com-
pleted the process. Although the pipeline has slowed, international controversy over GM 
crops has continued. Whereas most governments and many distinguished scientists have 
found that these crops are safe, some people continue to be concerned over perceived 
risks to human and/or environmental health. The controversy over genetic engineering 
will only increase with the next generation of products. Biotechnology-industry and 
university researchers are inserting a wide range of engineered traits into many different 
organisms. While research on drought or salt tolerance may reduce the controversy over 
genetic engineering if it benefits small-scale farmers in developing countries, engineering 
plants to make pharmaceuticals or industrial products is particularly worrisome when 
food crops are employed; no one would want to eat corn flakes containing a vaccine, 
for example. With the current state of affairs and controversial new applications on the 
horizon, international debate over the pros and cons of agricultural biotechnology is 
likely to increase.
Michael Phillips (“The Importance of Stewardship in Agricultural Biotechnology”) 
described a training program being developed by the Biotechnology Industry Organiza-
tion (BIO), laying out principles for confining plants making pharmaceuticals and those 
making industrial products. Workshops dealing with compliance aspects affecting GM 
corn, cotton and soybean will be offered in conjunction with professional society meetings 
and conferences such as those organized by NABC. Not only is industry participation 
expected, the courses will be offered also to universities and federal research agencies to 
help ensure that all abide by the federal requirements and understand the legal implica-
tions involved in conducting field trials with GM crops. Furthermore, BIO is planning 
to provide accreditation as part of the incentive to participate. It is hoped that continu-
ing education credits (CECs) will be offered. For biotechnology to continue to evolve, 
commitment to good stewardship on the part of the industrial sector will be essential, 
together with embracement of federal regulatory policies.
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The NABC-7 workshop discussions focused on Bioremediation,	Phytosensing,	and	Ecores-
toration; Gene-to-Product	Development; and Regulation,	Consumer	Acceptance	 and	Risk	
Management. For the first two topics, the following aspects were discussed: opportunities 
for innovative applications, obstacles to innovative applications, how public policies could 
overcome the obstacles, and how research and development could be advanced. For the 
third topic, discussants focused on the public’s beliefs and attitudes about agricultural 
biotechnology, actions that industry could undertake to address consumers’ fears and 
concerns. Participants were encouraged by the facilitators to focus on non-food applica-
tions for genetically modified (GM) plant technologies in defining appropriate evaluation 
criteria. The workshop discussants focused largely on impediments to commercializa-
tion and public acceptance of non-food products of biotechnology. The predominant 
observations were that the companies involved in commercialization of new, non-food 
technologies tend to be small, such that the regulatory process is particularly burdensome. 
Broad-ranging recommendations listed below focused on industry, the regulatory agen-
cies, public acceptance and associated policy needs, and the role of public-sector entities 
such as universities and the government:
role of Industry 
• Improve communications between and among scientists in the private and public 
sectors, and with consumers and policymakers. Pro-actively seek partnerships 
with groups who share mutually desired outcomes who would help with funding, 
regulatory approval, commercial development, and market acceptance of geneti-
cally modified products. 
This summary draws upon a verbal report on the workshop discussions delivered at the end of the conference 
by Lori Garkovich (University of Kentucky) who received input from fellow-facilitators Kim Jensen (University 
of tennessee), Bill Park (University of tennessee) and randy Weckman (University of Kentucky).
Breakout Sessions:
Summary of Discussions and Recommendations
Nancy Cox
University	of	Kentucky
Lexington,	KY
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• Create more effective messages that fairly and adequately address the costs and 
benefits of biotechnology, emphasizing how GM products can help address criti-
cal public concerns (e.g., improvement of environmental quality).
• Acknowledge public concerns and fears by explaining how the current research, 
development and regulatory processes already guard against potential problems.
regulatory Agencies
• A strong theme of the conference was that regulatory policies should be focused 
on the product rather than the process used to produce it. Therefore, partici-
pants recommended redesigning the regulatory process by basing decisions on 
a broader, different, and more clearly defined set of criteria and developing new 
roles for participants in the process. 
• regulatory decision processes should be transparent and should utilize cost, ben-
efit, and liability analyses that include a cost accounting throughout the life cycle 
of the product to determine the speed and priority of regulatory reviews.
• regulators should clearly define what steps must be completed and what in-
formation is necessary for approval of a genetically engineered product. Small 
companies in particular lack the intellectual infrastructure and financial capital to 
effectively negotiate a regulatory approval process that is still dynamic and often 
lacks clarity with respect to criteria for decision-making.
• As part of redefining the regulatory process, agencies should evaluate current 
definitions and standards for key concepts used in the evaluation and approval 
process and consider their applicability to GM plants with respect to site remedia-
tion, risk assessment, liability and adventitious presence. 
• Dialogues with regulatory agencies and multiple stakeholders should be opened 
in an effort to identify common ground, and encourage regulators to become pro-
active spokespersons in explaining the decisions they render. 
Consumer Acceptance and Public Policies
• For the smoothest path to commercialization to occur, a shift to a “market-
driven” rather than a “science-driven” focus needs to guide the research and 
development process. In particular, because of issues related to GM foods, other 
GM technologies must be developed with a clear understanding of consumer 
acceptance and risk-benefit analyses. These needs are compounded when one 
considers international cultural, social and political environments. 
• A knowledge/information gap exists between scientists who develop technolo-
gies and those who will use them. With respect to the technologies addressed 
at NABC 7, there is a clear opportunity to educate the public about potential 
risks and benefits. With bioremediation in particular, the purchaser is likely to 
be a government agency but perhaps still subject to the same perceptions as the 
general consumer. 
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• It is also recommended that an informed public-policy discussion begin to assure 
that planning and funding for bioremediation activities be placed up-front into 
site-planning for industrial and commercial construction sites. These activities 
should include preference for phytoremediation practices, where possible, at 
federally funded cleanup sites, tax incentives to promote the use of phytoremedia-
tion, and allocation of pollution fines or Superfund monies for this activity.
• Strategies should be employed to build on existing public support for technol-
ogy applications such as the following: animal vaccines and veterinary uses, 
agricultural crop phytosensing to improve the efficiency of crop production, and 
research on plant-made pharmaceuticals (PMPs) directed at “orphan” diseases and 
health needs in developing countries.
• A clear recommendation to encourage continued public acceptance of PMPs is to 
focus such research on crops that cannot cross with other food/feed species, such 
as Nicotiana plants developed by the Kentucky tobacco research and Develop-
ment Center. 
role of Universities, Government and 
Public-Sector Organizations
• Workshop participants recognized the role of public research institutions as a 
driving force in creating knowledge for development of new technologies. It is 
recommended that the reward system of universities be reoriented to encourage 
intellectual efforts directed towards the commercialization pipeline.
• Continued coordination and communication with regard to university-owned 
technologies, as conceptualized by the Public Intellectual Property resource for 
Agriculture (PIPrA), is strongly recommended. The PIPrA initiative recognizes 
the collective strength of public research institutions with respect to the number 
of patents controlled. Most importantly, PIPrA not only serves in clarifying is-
sues related to freedom to operate, but also promises to inform and streamline the 
regulatory approval process. 
• Creation of a repository of novel GM organisms was recommended to ensure 
their preservation for possible future use. Development of many products is in 
abeyance due to the current climate of regulatory requirements and consumer 
acceptance, which collectively result in less venture capital investment. 
• The workshop participants advocated study by a newly commissioned National 
research Council committee to examine scientific, regulatory and liability issues 
related to non-food, non-energy uses of GM plants. The charge should include 
evaluating the roles of phytoremediation and PMPs in enhancing environmental 
quality and human health and to make recommendations on regulatory aspects.
• Increase funding to regulatory agencies sufficient to address the greater challenge 
posed by biotechnology research and its commercial products.
Cox
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• Universities also need to expand the scope of work of their Offices of technology 
transfer to include seeking potential partners for GMO research at the beginning 
so that commercialization issues (such as market applications) can be incorpo-
rated into the research and development process. 
• Universities should promote science literacy by developing K– science educa-
tion modules to introduce students to biotechnology and working with state 
curriculum committees to include biotech issues in science curricula.
• A recurring theme of the conference was that public-sector entities like NABC, 
universities, and government agencies should strive to improve communications 
between/among scientists, industry, public and policymakers, with particular 
emphasis on risks and benefits of new technologies. It is considered that the 
extension services of land-grant universities could be important forces in reinvigo-
rated communications efforts. These efforts should acknowledge public concerns 
and fears by explaining how the current research, development and regulatory 
processes already guard against potential problems.
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Controlling Traits in Transgenic Plants:
Tools that Enhance Value and Reduce 
Environmental Release
roger N. Beachy
Donald	Danforth	Plant	Science	Center
St.	Louis,	MO
Having just come from Montreal where I participated in the Meeting of the Parties of 
the Cartagena Biosafety Protocol and then later at BIO005, it is clear that a number of 
issues face plant science and biotechnology. There is much to be said about the impor-
tance of public-sector scientists speaking their minds and stating the facts with regard to 
the issues of applications of agriculture biotechnology. Now is an absolutely appropriate 
time. Last year’s conference—gleaned from leafing through the NABC- proceedings 
volume—reminded us how difficult it is for scientists in the public sector to develop a 
product via agricultural biotechnology. The costs required to take a product from the 
experimental stage to commercialization are overwhelming for scientists in the public 
sector. The regulatory oversight policies that have accompanied this industry have, in my 
opinion, gotten so far out of hand that we in the public sector can no longer effectively 
bring products to market.
How	does	one	capture	trait	value	and	how	does	one	prevent	the	
escape	of	a	trait?
today I will discuss the rationale for controlling the expression of transgenes—including 
the use of gene-switching technologies—that will reduce the transfer of transgenic traits 
and may reduce regulatory concerns of agricultural biotechnology. A description of the 
technology of chemical control of gene expression will be followed by a brief discussion 
of some of the potential issues of concern about the use of gene-expression technology. 
Lastly, I’ll put the technology in the context of the topic of this conference: How does one 
capture trait value and how does one prevent the escape of a trait where it is not wanted, 
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Controlling	gene	expression	for	commercially	valuable	traits	may	
be	necessary	as	a	means	of	capturing	value.
either through theft or through out-crossing, while reducing adventitious presence of a 
GM product in a non-GM crop.
It is important to find ways to continue to innovate while making the products of 
 agricultural biotechnology profitable, if the technology is to reach its potential. My concern 
is that if we don’t find ways to capitalize on the significant investments that have been 
made in the basic plant sciences by federal and non-federal funding sources by developing 
relevant knowledge and potential products, there will eventually be reductions in research 
funding in the public sector. 
There are several benefits of controlling expression of transgenes in plants.
• For basic studies of gene function. Many gene functions are lethal if mis-ex-
pressed and it may be desirable to exert tight control over gene expression.
• to reduce the spread of a genetic trait to a weedy relative or to non-GM varieties 
of the crop plant. Control of trait expression can significantly reduce likelihood of 
adventitious presence of a controlled product and, of course, nonessential release 
to the environment. For example, when considering the use of plants to produce 
a novel food product, an industrial or pharmaceutical material, gene switching 
will limit expression of the materials to plants or plant tissues in which the gene is 
activated. 
• to capture value of the new trait. Controlling gene expression for commercially 
valuable traits may be necessary as a means of capturing value, in particular in 
crops that are inbred, or where seeds can be saved. 
Methods to Control Gene Expression and 
Applications in Biotechnology
The regulation of gene expression is a complex process that requires the coordinated 
activity of proteins and nucleic acids that ultimately determine whether a gene is or is 
not transcribed, and if transcribed, results in production of a protein that produces a 
phenotype. Most of the emphases of studies of gene expression have been on regulation 
of gene transcription, and a number of technical methods are used to affect the control of 
gene expression. First, one can use a promoter that has known regulatory characteristics; 
for example, a promoter that is expressed only in vascular tissues, in the leaf epidermis, 
seed endosperm or embryo, and so on. Or one can mix and match fragments of DNA 
and transcription factors to develop chimeric promoters that have the desired patterns 
and levels of gene expression. 
5Beachy
In my laboratory we study a promoter that is expressed in plant vascular tissues [a 
promoter from rice tungro bacilliform badnavirus (rtBV)] and two transcription fac-
tors (rfa and rFb). The factors, in conjunction with other co-factors and components 
of rNA polymerase II, are responsible for tissue-specific gene expression of the rtBV 
promoter. The rtBV promoter is expressed only in vascular tissues in transgenic rice, 
Arabidopsis and tobacco plants. However, when genes encoding rFa or rFb are consti-
tutively expressed (using the constitutive 35S promoter) the rtBV promoter was likewise 
expressed constitutively (Petrucelli et	al., 00; Dai  et	al., 00). As a consequence of this 
and other research, we identified the DNA-sequence element to which rFa and other 
transcription regulators bind to govern expression of the promoter (Dai et	al., 00). We 
have used these and other elements to create a regulatable gene-transcription cascade that 
can be “put to work” to control the expression of transgenes in plants, including using 
a chemical gene switch.
The remainder of the discussion will be devoted to describing systems that can be 
used to control expression of genes at will. The challenge with all systems is that none is 
perfect for all applications, and it is important to define the intended application prior 
to making a choice. Some switches are more appropriate than others for experimental use 
and for field use. to date, most research on gene switching has been applied to laboratory 
studies. Nevertheless, the potential applications of gene switching are numerous and it is 
anticipated that a number of commercial applications will be developed. 
Basic Components
The basic components of a good chemical gene-switching system include: () a suitable 
inducer; () a receptor-like protein that binds the ligand; (3) a promoter that is activated 
or repressed as a consequence of binding of ligand to the receptor. Over the last 5 years, 
a number of gene-switching technologies have been developed, including those induced 
by cations, phytohormones, steroid-related molecules, antibiotics, ethanol, herbicide 
safeners, and other organic molecules. Several recent reviews have described the state of 
the science in this topic area (e.g., Padidam	et	al., 003).
A suitable chemically regulated or inducible gene-expression system will have a number 
of characteristics, including: () high specificity of the ligand for the receptor to ensure 
that genes are tightly regulated to be “on” or “off” in the absence of the ligand; () the 
ligand should be readily taken up by the plant and move to all organs and tissues; (3) 
the ligand should elicit a rapid response; () the ligand should be non-toxic to the target 
and non-target organisms; (5) the ligand should be active at low concentrations and have 
a favorable environmental profile; () the ligand should be suitable for convenient ap-
plication, either as a foliar spray, seed treatment, or root drench; (7) application should 
be low cost.
We	have	experimented	with	and	adapted	a	system	based	on	the	
ecdysone	receptor	(EcR)	found	in	lepidopteran	insects
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the Ecr-Methoxyfenozide System
In my laboratory, we have experimented with and adapted a system based on the ecdysone 
receptor (Ecr). These receptors are found in lepidopteran insects that are activated by 
ecdysone, a compound that regulates insect growth. In this system an inactive Ecr recep-
tor remains in the cytoplasm until ecdysone, or a suitable agonist, binds, after which the 
ligand-receptor complex is transported to the nucleus where it binds to the responsive 
DNA-sequence element. Under appropriate conditions, binding of the complex causes 
a change in gene expression. In insects and other animal cells, the system is bi-partite, 
and requires an additional endogenous protein. Padidam et	al. (003) developed a mono-
partite inducible expression system that is appropriate for use in plants and plant cells. 
The chimeric receptor comprises the VP-activator domain from SV0, the gal- DNA 
binding domain, and Ecr (the chimeric receptor is referred to as “VGE”). When the gene 
encoding the chimeric receptor is produced from a promoter that is either constitutive or 
tissue-specific, it remains inactive until ecdysone or a suitable agonist binds and causes the 
complex to activate gene expression by binding to the gal- cis element that is a component 
of the target promoter. Methoxyfenozide is a suitable agonist of ecdysone and a suitable 
ligand in this system. It is proposed that methoxyfenozide causes the formation of a dimer 
with the receptor, which binds to the DNA-binding site on a chimeric gene. The system 
is easy to use and is highly active in Arabidopsis	and other plants. Methoxyfenozide is the 
active ingredient in the insecticide Mimic® (Dow AgroSciences LLC). 
Methoxyfenozide has a suitable safety profile for use as a gene switch in laboratory and 
greenhouse conditions. Furthermore, it does not cause non-specific expression of a high 
number of genes in Arabidopsis (S. Dai, I. Ordiz and r.N. Beachy, unpublished data), an 
indication that the ligand has very little direct effect on the host plant. Furthermore, the 
level of expression of a target gene can be controlled by the concentration of the ligand. 
In other studies, we developed several hundred transgenic Arabidopsis plant lines that 
produce luciferase upon addition of methoxyfenozide. These studies confirmed that, like 
other transgenes, expression of the gene-switch system is controlled by position effects 
and different lines respond to different concentrations of the ligand and exhibit different 
rates of responsiveness (S. Dai, I. Ordiz and r.N. Beachy, unpublished data).
We used the methoxyfenozide gene-switch system to demonstrate that the ligand is 
taken up and systemically distributed in Arabidopsis plants and can induce the expression 
of the transgene in a variety of tissue types. These studies demonstrated that the ligand is 
taken up rapidly when applied to roots, is transmitted throughout the plant and causes 
expression in all cells. We then went on to show that the system can be used to induce 
expression of a gene encoding the coat protein of tMV-Cg tobamovirus, and induce 
coat-protein-mediated resistance against the virus following addition of methoxyfenozide 
(Koo	et	al., 00). In one plant line, the level of accumulation of coat protein exceeded 
the highest level produced by the enhanced 35S promoter. to date we have developed 
more than 750 plant lines using this system and have observed a variety of levels of gene 
induction, from 0-fold to more than ,000-fold following addition of the ligand. 
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Applications of the Gene-Switch System
In an ongoing study, we are evaluating the methoxyfenozide gene-switch system to de-
termine whether or not gene-switching technologies can be used to induce tissue-specific 
expression of genes. For these studies we selected promoters that are known to be expressed 
only in selected plant tissues, and constructed genes with the VGE-coding sequence. 
The gene was co-introduced with a uidA	(encoding GUS) reporter gene that is under 
control of a minimal 35S promoter ligated with the DNA-binding site for recognition 
by the receptor. In these studies the reporter gene was silent in the absence of VGE and 
methoxyfenozide. Although the study is not yet completed, we are encouraged with the 
results and are confident that they will show that the gene-switch system can be used to 
restrict gene expression to specific tissues after addition of the ligand.
How might one use a gene-switching system? One of the experiments in progress is to 
develop a system to control multiple genes with application of the ligand. If successful, 
we will use the system to activate expression of genes that cause the repression/suppression 
of a gene in one or more metabolic pathways while activating other genes in the same 
or other pathways. If successful, this will make it possible to substantially alter primary 
and/or secondary metabolism in plants. We do not yet know the limits of the system, but 
are confident that it is sufficiently robust to make significant changes in the metabolism 
as well as growth and development of the target plant.
the Next Generation 
The next generation of chemical gene switches will likely be substantially different and 
better than current systems. There will be improved receptors that eliminate proteins of 
animal origin, and receptors that provide active repression as well as activation of gene 
expression. We also anticipate that a variety of ligand:receptor pairs will be developed, and 
that future developments will create plants that will respond to multiple gene switches.
rheoGene Co. (Philadelphia, PA) has developed several different receptor:ligand pairs 
that function in animal cells. It is anticipated that some of these will function in plants 
either in a two-protein or one-protein gene-switch system. This may make it possible to 
use one ligand to turn on a target gene and a second ligand to turn the gene off. Such 
flexibility in the system would have other uses: for example, company A might want to 
use a unique receptor:ligand pair while company B will want another receptor ligand 
pair, and so forth.
It is likely that there will be additional opportunities for ligand-receptor develop-
ment with a variety of different biological characteristics. The challenge is, of course, to 
identify gene-switching systems that are safe for the environment, the plant, and for the 
final product. And, if a chemical ligand is to be released to the environment, it must pass 
The	next	generation	of	chemical	gene	switches	will	likely	be	
substantially	different	and	better	than	current	systems.
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standard EPA toxicology tests. For this reason, scientists anticipate that early adoption 
of chemical gene-switching systems will involve ligands that have been approved as safe 
or that can be thus approved with modest investment.
regulatory Considerations
The development of safe and reliable gene switches that are used commercially will rely 
on new applications of existing chemistry or on new chemistry; regulatory approvals 
will be required either for new use or for new chemicals that will be used. Furthermore, 
one must ensure that there is strict on/off control of gene expression; leakiness of gene 
expression will not be acceptable. This is essential if one expects the public to agree to 
selected types of agricultural biotechnology. 
In order for chemical gene switching to be widely used, it will be necessary for regulatory 
agencies to adapt and undergo certain types of change. At the present time, the agencies 
regulate transgenic organisms on the basis of the presence or absence of transgene DNA 
and/or the presence of the gene product. Many scientists agree that the most important 
criterion for phenotype is not the presence or absence of a transgene per	se, but whether or 
not the product of gene expression (i.e., the rNA or a protein product) and the resulting 
phenotype are produced. Thus, the manner in which products are subjected to regulatory 
control will need to be established. 
Public Discussion
As with any new technology, it is important to engage the public, both academic and 
non-academic, in discussions related to issues that may have impact on regulatory 
structures, on environmental safety, and with regard to possible ethical issues that may 
arise. It’s perhaps more important now than it was in following the first breakthroughs 
in agricultural biotechnology in the 980s. In January, 005, we held a workshop at 
the Danforth to discuss chemical gene switching with ethicists and environmentalists 
to help us better understand the challenges that might be faced in bringing forward a 
viable gene-control system. I think that engaging the public and non-scientists in such 
discussions is important for all of us.
There is concern amongst some parties that limitations on trait expression will 
limit access of some technologies to those farmer/producers that can afford to pay high 
technology fees. It is considered likely that gene-switching systems will be first used on 
crops that will produce high-value materials; uses on field crops or other food crops are 
much less likely, except to restrict trait flow to non-GM crops. It is highly unlikely that 
gene switching will be used in the foreseeable future in commodity crops or crops that 
There	is	concern	amongst	some	parties	that	limitations	on	trait	
expression	will	limit	access	of	some	technologies	to	those	farmer/
producers	that	can	afford	to	pay	high	technology	fees.
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are produced by small-scale, economically disadvantaged farmers. Unlike the so-called 
sterile seed technologies, gene switching as outlined here will not be applied to restrict 
seed germination per	se.
I am convinced that we have an opportunity to make outstanding strides forward in 
biotechnology, but am increasingly concerned that much of the potential will not be 
realized unless we learn to deal with some of the issues that can be addressed by gene 
switching. Whether or not gene-switching technologies emerge as a tool to bring new 
agricultural biotechnologies to the public marketplace depends on many factors. Chal-
lenges notwithstanding, the potential of the technology is high and I am confident that 
it will be an important component of agricultural biotechnology.
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The global division over genetically modified (GM) foods has, by now, assumed a familiar 
dimension. In the United States and Canada, farmers routinely grow GM varieties of 
crops and consumers readily (if unknowingly) eat foods containing ingredients derived 
from GM crops. The US media have paid relatively little attention to GM foods, and 
while one cannot say that the public has accepted GM foods, it is clear that the majority 
of US consumers do not view GM foods with active concern. Indeed, the most salient 
finding of numerous polls is that US consumers remain largely uninformed about GM 
foods and their presence in the food supply (Hallman, 005; PIFB, 005).
The situation is far different in other parts of the world—parts of the world that also 
happen to be major markets for US farm exports. European consumers in particular are 
hostile to GM crops and food. Even when approved as safe by European Commission 
regulators, few GM foods are available for sale in the EU because retailers and manufac-
turers fear hostile consumer reaction to foods labeled as containing genetically modified 
organisms (GMOs) (USDA, 005). As a consequence, the global market for commodi-
ties like corn has been divided into GM and non-GM zones, complicating trade. In part 
because of these trade disputes and market uncertainties, the future for new GM-food 
crops is clouded.
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provide	benefits	outside	of	the	area	of	food	and	feed.
3 Agricultural Biotechnology: Beyond Food and Energy to Health and the Environment
The question is whether plant biotechnology1 can be harnessed to provide benefits out-
side of the area of food and feed. Can the kind of global deadlock that has emerged from 
the introduction of GM crops and food be avoided? Is the opposition to the use of plant 
biotechnology limited to its use in food, or can the potential health and environmental 
benefits of the next-generation of plant biotechnology change the contours of the global 
debate? What are some of the obstacles that await the commercialization of health and 
environmental applications of plant biotechnology? 
The temptation to generalize too much should be resisted. Experience and common 
sense suggest that every application is likely to have its own opportunities and challenges, 
and across-the-board predictions are likely to be misleading. Some of the issues specific to 
different types of applications are explored later in this paper. Nevertheless, any new GM 
plant is likely to have to face four critical hurdles that will require both time and money to 
overcome on the road to commercialization. Some of these hurdles are no different from 
those faced by any novel product, while others are unique to products developed through 
biotechnology. First, of course, is the development of the product itself—proving technical 
and economic feasibility. Second, products of plant biotechnology need stewardship and 
management beyond that required for plants developed through conventional breeding, 
both as a requirement of regulators as well as the necessity of sound business practice. 
Third, plant biotechnology products need to pass through a regulatory review and ap-
proval process that involve both direct and indirect costs. Finally, as with any product, a 
plant biotechnology product must meet the ultimate marketplace test: are there buyers 
willing to buy it at a price that delivers a profit to the developer?
the Market Potential of Health and Environmental 
Biotech Applications
A number of products are being developed through plant biotechnology that could 
have significant health or environmental benefits beyond food or feed. Understanding 
what the potential market may be for these applications is an important starting point 
in understanding the hurdles that they face on the road to commercialization. Other 
contributors to this volume will develop these points in much greater detail, so only a 
summary is offered here.
Plant-Made	Pharmaceuticals
The potential economic and safety benefits of producing therapeutic proteins from plants 
have been explored in a number of venues (PIFB, 00; BIO, 005a). The market for 
antibodies is projected to be $ billion by the year 00 (Novis, 005), but current 
production practices for antibodies cannot keep pace with demand and there appears 
to be a significant supply shortfall. In particular, the costs associated with scaling up 
traditional bioreactors using animal or microbial cells create a significant bottleneck in 
1For the purpose of this paper, the term “biotechnology” is used in the popular (rather than scientific) sense to 
refer to recombinant DNA techniques. Similarly, the terms “genetically modified” and “transgenic” are used 
interchangeably and refer to plants modified through recombinant DNA technology to introduce novel or 
enhanced traits.
33
the development of therapeutic proteins. One of the potential advantages of plant-made 
pharmaceuticals (PMPs) would be the ability to scale up relatively quickly and at relatively 
low cost. In addition, there may be fewer safety concerns about proteins derived from 
plants rather than from animal cells. 
Unlike food-biotech applications, PMPs potentially distribute benefits along the value 
chain. For farmers, growing a high-value crop from low-cost commodity species could 
offer a way to enhance farm income. For consumers, the potential lower cost of thera-
peutic proteins would be of considerable benefit. For that reason, it is not surprising that 
the use of biotechnology to create lower-cost pharmaceuticals remains one of the reasons 
most strongly supported by the US public (PIFB, 005). The potential application of the 
technology to develop vaccines that may be of particular benefit to developing countries 
is also the subject of considerable research and development effort in the non-profit arena 
(Mason et	al., 00).
Forestry	Applications
The application of biotechnology to forestry would also appear to have significant mar-
ket advantages. Increasing demand for wood and wood products from a growing world 
population poses a challenge for forestry management and forest-product companies, 
which are increasingly under pressure to reduce logging in natural forests and to adopt 
environmentally sustainable practices (Hardaker, 997; Brooks, 00; PIFB, 00). 
While these pressures have led to the development of forest plantations carefully managed 
to enhance growth, commercial forestry has not yet captured the benefits of improved 
genetics that have accounted for significant productivity gains in crop agriculture. The 
use of biotechnology may provide an opportunity for forestry to make genetic improve-
ments more quickly that could help increase yields by reducing disease, improving pest 
resistance, and promoting faster growth. In addition, the use of biotechnology to control 
certain traits more directly could lead to the introduction of trees better suited for pro-
cessing in specific applications, such as pulp and paper (PIFB, 00; ArborGen, 00; 
El-Lakany, 00).
The spread of disease among major species of trees in the United States, including 
elms, chestnuts, oaks and the eastern dogwood, has also created an urgent need to de-
velop disease-resistant varieties. While research using conventional breeding techniques 
continues, biotechnology may offer a way to introduce desirable disease-resistance traits 
more quickly (Osusky, 000; PIFB, 00; ArborGen, 00;).
Phytoremediation
The clean up of environmentally contaminated sites remains a huge challenge in this 
The	market	for	antibodies	is	projected	to	be	$26	billion	by	the	
year	2010,	but	current	production	practices	for	antibodies	cannot	
keep	pace	with	demand.
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country. The Environmental Protection Agency (EPA) estimates that tens of thousands 
of contaminated sites still need clean up in the United States (EPA, 00). In most cases, 
the technology of choice is simply to dig up contaminated soil and cart it to some other 
place. technologies for treatment in	 situ remain costly and controversial. Phytoreme-
diation offers a number of potential benefits, including lower costs, better performance 
and greater public acceptability (EPA, 005). According to EPA (005), field trials of 
phytoremediation techniques have reached a promising stage, and estimated costs of 
various phytoremediation techniques vary from 0% to 50% of physical, chemical, or 
thermal clean-up techniques. At the same time, phytoremediation is likely to be useful 
for only a small subset of affected sites where the contaminants lie within the root zone 
(EPA, 005). Estimates made in the late 990s suggested that the domestic market for 
phytoremediation ranged from $3 million to $30 million, with projections ranging as 
high as $370 million by 005 (Kidney, 997; Glass, 998). Given this extraordinarily 
wide range of estimates, it is clear that there is still significant uncertainty about the 
potential market for the application of phytoremediation, and that much will depend 
on how well phytoremediation actually performs in-site clean ups. The goal of research 
is to use biotechnology to develop plants that are more efficient, further reducing costs 
and potentially decreasing the time it takes to decontaminate a site.
There	is	still	significant	uncertainty	about	the	potential	market	
for	the	application	of	phytoremediation.
threshold Question: Who Bears the Cost of 
Product Development?
Clearly, there appear to be significant market opportunities for applications in these three 
areas. However, the threshold question faced by any developer is easy enough to state: who 
is going to pay the cost of taking the product through all of the critical stages of proof of 
concept, development, testing, regulatory approvals and marketing? For the private sector, 
products can be self-financed if the developer is a large, well capitalized company with 
r&D budgets, but small businesses and start-ups will need to look to venture capital and 
partnerships to sustain them through the development and approval processes. 
The willingness of the private sector to invest in product development will depend 
largely on the anticipated return on investment, which includes not only consideration of 
potential revenues downstream, but also the costs associated with the process of bringing 
a product to market. Products that are likely to be commercialized through traditional 
private-sector incentives are those for which there is a well defined and profitable mar-
ket. In addition, the private sector will tend to invest in products only where there is 
strong intellectual-property protection to prevent potential “free rider” and competition 
problems. On the cost side of the equation, some of the uncertainties unique to plant-
biotechnology products make predicting development costs more difficult and raise the 
risk for investors. 
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As the history of the development of plant biotechnology demonstrates, many poten-
tial applications are unlikely to meet the conditions for private-sector development and 
investment. In some instances, products may lack a viable market capable of returning 
sufficient revenues—such as in the case of niche food crops or the development of plants 
modified to provide vaccines for endemic diseases in the developing world. In other 
instances, steep development or regulatory costs or uncertainty about market acceptance 
could deter private-sector development. If products with potential “public” value are 
going to be developed, they will have to come from the non-profit sectors: government, 
university, and other non-profit research institutions. 
But the non-profit developer faces the same question: where does the money come 
from to pay the cost of taking a plant-biotechnology product through all the required 
steps? Since non-profit developers tend to focus on the “public goods” that are unlikely 
to return a profit to a private investor, they must rely on sources of funding from govern-
ments, foundations and other donors. The funding plight of non-profit plant-breeding 
research in the United States and throughout the world has been well documented (Frey, 
99; Heisey et	al., 00). While most plant breeding used to be in the public sector, 
private-sector research now dominates as a result of declining public funding and new 
forms of intellectual-property rights and modern biotechnology that spurred increased 
private investment (Alston, 00).
The	funding	support	for	plant-biotechnology	products	that	are	
truly	“public	goods”	remains	a	serious	problem.	
Non-profit institutions face additional challenges when it comes to the use of agricul-
tural biotechnology and plant-breeding programs. Such institutions traditionally have 
little experience with the stewardship and regulatory issues associated with the manage-
ment and development of bioengineered crops. In an environment characterized by scarce 
resources, the increased costs and uncertainties faced by products of plant biotechnology 
also operate as a significant constraint. In some instances, particularly where a product has 
some potential for commercialization, non-profit organizations may enter into partner-
ships or licensing agreements with private-sector entities that have more experience in 
commercialization as well as the management capabilities to deal with stewardship and 
regulatory issues. However, the interest of the private sector in such partnerships will still 
be limited by the potential profitability of the product. As a result, the funding support for 
plant-biotechnology products that are truly “public goods” remains a serious problem. 
Speed Bumps in the road to Market
The threshold question, stated above, is simple: who pays? The next question, of course, is: 
how much? Surmounting the hurdles of development, management, regulatory approval 
and commercialization all require investments of time, resources, and money. Having a 
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clear understanding of those costs is critical to all developers, but is of particular interest to 
private-sector developers and investors who are making business decisions about whether 
or not to invest in the technology. Below, the potential costs—and uncertainties—associ-
ated with each stage, with reference to health and environmental plant biotechnology 
applications, are considered in more detail. 
Technical	and	Economic	Feasibility
The initial hurdle, of course, is technical feasibility—that is, simply getting the technology 
to work. It is one thing to get a protein expressed in a plant in a laboratory; it’s another 
thing altogether to get the trait expressed in a plant in the real world. Proponents of bio-
technology have been talking about the remarkable promise of this technology for more 
than 0 years, but the only two commercially significant traits on the market today are 
herbicide tolerance and insect resistance. Part of the reason for the relatively few traits 
is that getting plants to do some of the things that developers long ago envisioned has 
proven to be more difficult than originally expected. 
For example, Ingo Potrykus’s development saga of “golden rice” continues today, years 
after the original concepts and early products were tested. researchers are now following 
up on the recent development of SGr, a golden rice variety developed by Syngenta that 
may produce ten times as much beta-carotene as the original SGr variety (Derham, 
005). Drought tolerance, a trait long pursued by plant-biotech developers in the private 
and non-profit sectors, appears at last to be close to moving toward the regulatory ap-
proval phase (Melcer, 00). Even when gene sequences are successfully identified, it takes 
time to integrate that trait successfully into a variety with desirable agronomic or output 
traits. The science of plant genomics is moving ahead quite rapidly, but the complexity 
of gene modification to achieve commercially acceptable output or input traits is still a 
time-consuming and somewhat uncertain process.
One issue related to technical feasibility is access to intellectual property (IP). The 
impact of the introduction of strong IP-protection schemes in the plant-breeding and 
plant-biotech world remains a hotly debated issue. However, it seems fairly clear that, 
at a minimum, the development of strong IP-protection schemes raises the transaction 
costs (in time and money) for non-profit developers by requiring due-diligence searches 
to avoid infringement and to negotiate licensing arrangements when needed. On the 
other hand, strong IP protection is a precondition to investment by the private sector 
(Alston, 00; BIO, 005b).
Proving technical feasibility clearly remains a challenge for a number of specific non-
food health and environmental plant-biotech applications. For pharmaceutical crops, for 
example, it remains to be seen whether plants can be modified and grown in a manner 
that allows consistent expression of the protein, and whether the protein will prove to be 
clinically equivalent and equally safe and effective as those grown in animal-cell cultures. 
Merispase®, a PMP designed to treat a condition that affects patients with cystic fibrosis, 
has been through some phase-II clinical trials intended to answer these types of questions 
(Meristem, 005). Whether the predicted cost efficiencies will be realized is another key 
issue associated with proof of concept for PMPs.
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Biotechnology applications to forestry are complicated by limited scientific knowledge 
of tree genomics as well as the inherent complexity of engineering an organism intended 
to grow for years before harvesting (PIFB, 00). For example, it is possible that genetic 
changes could result in undesirable effects that would not be observed until after several 
years growth. Ensuring consistent expression of traits over the lifetime of a tree is also 
important for traits like insect and disease resistance (PIFB, 00).
In the area of phytoremediation, there are promising laboratory and field-trial develop-
ments using genetic modifications to enhance plants’ abilities to take up environmental 
contaminants such as metals (Bañuelos et	al., 005). The question, of course, is how well 
such plants will work in the real world of contaminated sites; to date, field-trial data have 
been limited to simulated contaminated sites. For reasons discussed later in this paper, 
more compelling data of the efficacy and efficiency of this technology are likely to be 
needed before it will be applied in real-world environmental clean ups.
Product	Management	and	Stewardship
The second hurdle is the cost of management and stewardship associated particularly with 
the development of bioengineered plants. Because of the environmental, food-safety, and 
marketing issues associated with bioengineered plants, they require special handling and 
management to ensure containment and, in some cases, tracking and identity preserva-
tion. Management and stewardship requirements start early in the development process, 
long before a plant may be ready to be commercialized; indeed, key product-development 
phases, including field trials, will be required to be under US Department of Agriculture 
(USDA) permit. 
Arguably, these stewardship and management costs could be considered a part of regula-
tory compliance costs, because in many cases these requirements are actually mandated by 
regulatory agencies—as with USDA transportation and field-trial permits or notifications. 
On the other hand, it could also be argued that bioengineered crops would be subject to 
special handling and management even in the absence of regulatory requirements given 
potential concerns about liability under the common law of torts (Kershen, 00) or to 
fulfill private contractual requirements. Particularly in the wake of the StarLink™ episode, 
seed companies, farmers, grain distributors and processors, and others in the food-produc-
tion chain have become more conscious of the need to adopt best management practices 
to ensure that customers are getting what has been represented, and to avoid potential 
liability for GM-plant products mixing with plants where GM components are undesir-
able for any number of reasons.
However, as a representative of ProdiGene (00) noted in a recent comment to 
USDA:
…no	matter	what	system	of	production	is	employed,	accidents,	natural	disasters,	
or	other	unforeseen	events	may	allow	the	loss	of	containment	despite	best	efforts....	
[D]espite	adherence	 to	 rigorous	 containment	protocols,	 low	 level	products	not	
intended	for	food	or	feed	have	the	potential	to	be	present	in	commercial	crops	
at	some	time.
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Given this potential, developers and investors seeking to reduce potential exposure to risk 
are likely to consider the availability of liability insurance in this area.
Part of the difficulty faced by developers and investors in this area is the lack of clarity 
and certainty about the standards to which they are being held accountable. At the present 
time, there are no legally binding standards or even guidelines to provide developers a 
“clear harbor” for adventitious presence. In the absence of legislation or regulation, liability 
will be determined through the rather ineffective process of litigation. to date, few cases 
have been litigated that shed any light on appropriate duties and responsibilities, leaving 
the field ripe for speculation by lawyers in law-review articles (Kershen, 00). 
Not even the regulatory agencies have taken on the task of defining tolerances or 
thresholds for materials from GM plants that have not completed the regulatory review 
process. Instead, USDA and EPA have imposed conditions on field trials that are, as a 
practical matter, intended to prevent any gene flow and thereby achieve a zero-tolerance 
level (PIFB, 00b). Not only are these conditions expensive to follow, their existence 
implies there may be a legal liability for even a de-minimus level of contamination. It is 
also unclear if these conditions will be successful 00% of the time.
This issue has already been a particular challenge for developers of PMPs. Farmers, food 
manufacturers and others have expressed concern about any mixing of PMPs with food or 
feed crops, even if such mixing is unlikely to raise any environmental or health concern 
(Nutraceuticals International, 003). Clearly, food manufacturers are concerned about 
the potential economic damage to their brands in the event of a publicized event where 
PMPs are found in their products. Growers are concerned that even the remote possibil-
ity of adventitious presence of PMPs in their food or feed crops could dry up lucrative 
markets, particularly in nations with markets hostile toward GM crops. This concern 
recently became a reality when Ventria’s proposal to grow rice that has been genetically 
modified to produce a pharmaceutical compound in Missouri prompted Anheuser-Busch 
and riceland Foods to threaten to boycott all rice produced in Missouri (Kasler, 005).
Stewardship and management issues may also pose a challenge to the developers of 
GM-forestry applications, particularly given the long lifetimes of plantation trees. While 
somewhat different, given the food application, there have already been two incidents over 
gene flow from GM papaya trees to conventional papaya trees in Hawaii and Thailand 
(Creamer, 00; Elias, 00; Mathes, 005). As the technology moves forward, there 
almost certainly will be issues associated with managing gene flow from GM trees in 
plantations to trees in unmanaged forests. 
Managing plants to prevent unintended gene flow is less likely to be a concern with 
GM plants intended for phytoremediation since such plants are intended to be used on 
contaminated sites, far from any food or feed crops. How these plants are disposed of, 
however, will need to be the subject of careful consideration so that further soil contami-
nation does not take place and to ensure these plants do not inadvertently move into the 
food or feed chain.
Management and stewardship issues are particularly troubling for university and 
other non-profit researchers who generally lack the experience of navigating regulatory 
requirements and managing long-term field trials under conditions of strict confinement. 
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Moreover, university researchers frequently lack the infrastructure and funding for such 
activities, an issue discussed in more detail below. 
Management and stewardship requirements have clearly emerged as a significant 
hurdle—in money, resources, and time—on the road to product commercialization or 
deployment. What has made it even more difficult, of course, for developers and inves-
tors trying to make judgments about development costs, is that there remain significant 
uncertainties about the standards to which developers are expected to adhere. Clearly, the 
development of gene-expression restriction technologies, like those described by roger 
Beachy elsewhere in this volume, would go a long way to reducing the costs of managing 
unwanted gene flow.
Regulatory	Requirements—Direct	Costs
The third major “speed bump” in the road to product commercialization is the regulatory 
review and approval process. regulations impose additional costs on the development 
of bioengineered plants compared to improved varieties created through conventional 
breeding, but it is difficult to estimate the cost with any great precision (Alston and 
Kalaitzandonakes, 005). Certainly much of the product-testing and development work 
required by regulators would be conducted by developers in any case, simply as a part 
of ensuring the quality, safety and performance of a new GM plant. As noted above, 
management and stewardship costs would, in many cases, be required by prudent busi-
ness practices even in the absence of regulation. But, plainly, the costs associated with 
additional testing, data production, data-package submission, and the time associated 
with regulatory review, are significant. Costs for some of the initial GM-crop approvals 
have been estimated at $5 million to $5 million (Alston, 00). Some analysts have 
estimated that half of all total development costs are associated with regulatory require-
ments (PIFB, 00a). However, these costs have not been well characterized and studies 
are ongoing to obtain some independent analysis of those estimates.
One of the factors affecting the costs of regulatory approval is the novelty of the trait or 
the novelty of the product in which the trait is being inserted. Not surprisingly, regulators 
tend to approach novel issues with greater caution, often demanding more studies and 
additional information to help answer their questions. As a result, first products through 
the regulatory system unquestionably bear a disproportionate amount of the regulatory 
burden. today, it is unlikely that approval of a commodity food crop with a genetic con-
struct already approved by the regulatory agencies would cost as much or take as long as 
the initial approval. On the other hand, a recent report by the Center for Science in the 
Public Interest noted that the time for regulatory approval of a new GM plant appears 
to be growing longer, not shorter, even though the plants being reviewed did not seem 
to present novel regulatory issues (Jaffe, 005, this volume). 
Costs	for	some	of	the	initial	GM-crop	approvals	have	been	
estimated	at	$5	million	to	$15	million.
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Once again, the regulatory approval hurdle places a disproportionate burden on 
university and other non-profit researchers who lack the experience with navigating the 
regulatory agencies and, perhaps more importantly, often lack the funding to carry out 
the required testing and to prepare the regulatory approval documents. Most non-profit 
researchers rely on government or foundation grants that typically support basic research, 
but not the kind of “regulatory science” needed to develop the data package to obtain 
product approvals (PIFB, 00a).  
Regulatory	Requirements—Indirect	Costs
The most visible cost of regulation is the direct cost of testing, data submission, and delay. 
Delaying the time in which the product can come to market imposes real costs, particularly 
for products that have time-limited intellectual property protection.
Beyond these direct costs is another, perhaps less obvious set of costs associated with 
regulatory uncertainty. In this case, the issue is not so much about what the regulations 
currently require, but uncertainty about what the regulations might require in the future. 
Without clarity from an agency about what a product approval requires, it is impossible 
for developers and potential investors to estimate the total costs of bringing a product to 
market. today, for example, a developer may have a fairly good sense of what it would 
cost to bring another Bt or herbicide-tolerance gene through the regulatory system. But 
the question of what it will cost to approve a different type of trait—such as a drought-
resistance gene—is much less certain. That kind of uncertainty discourages private-sector 
investment.
While some parts of the regulatory framework are relatively clear, others are not. As 
noted previously, agencies have not addressed the issue of adventitious presence except 
through permit requirements intended to prevent it from occurring. Even here, the rules 
continue to shift, as occurred in 003 when USDA increased setback requirements and 
other conditions on PMP permits, sharply limiting where PMP field trials could be 
conducted. The White House Office of Science and technology Policy has called on 
EPA, FDA and USDA to adopt rules to address adventitious presence resulting from 
field trials of GM crops intended for use as food or feed (OStP, 00), but there has 
been no similar call for guidance on plants not intended for use as food or feed—such as 
PMPs. While USDA has indicated that PMPs will always remain under APHIS permit, 
the Food and Drug Administration (FDA) could also exercise its authority over the drug-
manufacturing process to oversee the planting, growing, harvesting, and transporting of 
PMPs (FDA, 00).
New products inevitably raise novel issues for regulators. For example, it is not clear how 
plants modified through biotechnology for phytoremediation purposes will be regulated. 
While USDA’s rules with respect to transport and field testing would certainly appear 
to apply, EPA has asserted that it has the authority—not exercised to date—to regulate 
plants intended for commercial bioremediation under the toxic Substances Control Act 
as “new chemical substances” (EPA, 005).
Likewise, while USDA’s authority over GM trees is fairly clear, whether USDA will 
“deregulate” long-lived trees intended for plantations—or what information it would 
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require to make that decision—is much less clear. (EPA would presumably be in charge 
of approving pest-resistant trees under the pesticide laws.) Even more opaque is how 
USDA would make a decision to approve the release of a GM disease-resistant chestnut 
intended to grow and spread in unmanaged forests.
It’s worth noting here that the regulatory system for GM plants is a paragon of clarity 
compared to the regulatory system for transgenic animals, where we still lack any formal 
statement from the administration as to what agency is responsible for what decisions 
about transgenic animals. 
Finally, the ever-changing international regulatory environment poses an additional 
set of challenges for plant products that move out of the United States. In addition to 
specific laws adopted by countries with respect to GM foods and GM crops, the Cartagena 
Protocol on Biosafety continues to evolve and will certainly affect the inter-boundary 
transportation of any type of genetically modified organism, including plants and trees. 
How the Cartagena Protocol will continue to evolve and whether it will impose new legal 
or regulatory requirements remain a major source of uncertainty.
Marketplace	Acceptance
The final hurdle is, of course, the test of the marketplace. As with any new product, the 
question will be whether buyers are willing to pay a price for it that returns a profit to 
its developers.
Are there any unique marketplace challenges that face health and environmental ap-
plications of plant biotechnology? The history of the introduction of GM foods offers a 
cautionary tale. regardless of regulatory approvals, consumers in a number of countries 
remain suspicious about, and hostile to, GM crops and foods. In a market where consum-
ers have alternative choices, their rejection of GM foods has had an enormous impact on 
trade and has dramatically slowed the introduction of new varieties of GM foods. Farm-
ers, food manufacturers, grain processors and distributors and others have balked at the 
introduction of new GM varieties out of concern over negative consumer and marketplace 
reaction. GM potatoes, GM wheat, and GM sugar beets are all examples of products that 
made it through the regulatory process, but were rejected in the marketplace. 
There are a number of reasons to believe that consumer and market attitudes toward 
non-food products of plant biotechnology may be different.
First, there is some reason to believe that the opposition to biotechnology is tied to 
its use as food. While there are environmental and other concerns about GM plants in 
Europe, the strongest opposition is associated with GM food products, and the oppo-
sition is based in large part on fears about safety (Allum et	al., 003). In comparison, 
there has been little opposition to the non-food products of GM plants, such as cotton. 
For example, there has been little consumer opposition to blue jeans and few demands 
that they be labeled. So there is some reason to believe that the stigma attached to food 
biotechnology in some parts of the world may not automatically translate to other non-
food applications of plant biotechnology.
Second, since the public is the ultimate buyer and consumer of GM foods, its choices 
have enormous influence on the food-marketing chain. Farmers may be enthusiastic 
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buyers of GM seeds, but unless they can find markets for their crops, they will buy 
something else. Interestingly, consumers appear to be most concerned about foods that 
contain GM ingredients but there is far less concern about meat or milk from animals 
fed with GM grains.
In most of the non-food health and environmental applications of biotechnology, 
however, the public is not the buyer, and the products and services they ultimately receive 
are not “genetically modified.” For example, the buyers of lumber and pulp are simply 
businesses that, like farmers, are concerned primarily with cost and performance. The 
forestry products ultimately bought by consumers—paper, cardboard, houses—do not 
contain “GMOs.”
Similarly, the “product” bought and used by consumers from GM plants that produce 
PMPs is the drug or therapeutic protein itself—typically prescribed by a doctor and ap-
proved by the FDA. Again, the product will be long divorced from the process by which 
it was made. 
Third, at least some of the consumer opposition to GM food has been the result of a 
risk-benefit consideration where consumers see no benefit in the current generation of 
GM foods and elevated risk. Health and environmental plant-biotechnology applications, 
almost by definition, offer the prospects either for public benefits or direct consumer 
benefits. Using plants to produce lower-cost, potentially safer drugs has the strong sup-
port of a number of disease-research advocacy groups.
The fact is, consumers do make distinctions among applications of plant biotechnology 
(PIFB, 005). It should not be surprising, for instance, that in light of the above discus-
sion, the applications of plant biotechnology most strongly supported by Americans are 
those that would provide lower-cost pharmaceuticals or that would reduce world hunger 
(Figure ).
Figure . ratings of “very good” or “somewhat good” reasons, respectively,
to produce GM plants (PIFB, 005).
3
Nevertheless, given the history of predictions about biotechnology, one must be humble 
when predicting the future. It frankly is too early to know whether the stigma against 
GM technology in some parts of the world will cling to these health and environmental 
applications. Mixed in with concerns about food safety are environmental concerns 
and embedded cultural, social, and economic issues that are often not clearly expressed. 
Even in the absence of a food-safety issue and direct consumer concerns, some of these 
other issues could still surface as opposition that could impact the market acceptability 
of these products.
In particular, the use of biotechnology in forestry will almost certainly be controversial, 
if for no other reason than, as with aquaculture and agriculture, there already are strong 
disagreements about the role of intensive forestry practices. to the extent that biotechnol-
ogy makes plantation forests more economically viable, it is likely that it will be opposed 
by those who are already critical of existing forestry practices. In addition, forests have a 
cultural significance that row crops do not. In a PIFB-sponsored conference in 00, a 
number of speakers referred to the emotional and moral value that people place on forests 
as natural places worthy of protection and respect. As a consequence, people are more likely 
to view the use of genetic modification technologies in forestry as unnatural, which could 
conceivably translate into opposition to forest products derived from GM trees along the 
lines of similar campaigns relating to “sustainable” forestry (PIFB, 00). 
On the other hand, potential environmental benefits from this technology may be ap-
pealing to some of the same segment of the public. For example, the ability to grow trees 
that require less energy to produce paper and pulp could be seen as an environmental 
benefit, not to mention the development of disease-resistant varieties of elm, chestnut, 
and dogwood. And the ability to create disease-resistant strains of key tree species could 
introduce the unique ability to preserve species that otherwise might become extinct. As 
noted, concerns about PMPs have little to do with the products, but rather with the poten-
tial that gene flow could move unwanted biological materials into food or feed crops. 
GM plants intended for use in environmental clean ups present a different set of 
marketing issues, since the primary buyer is the government or a clean up contractor 
working under government standards. As with any treatment technology, regulators 
choosing a particular remediation technology must find the product to be “protective of 
human health and environment, maintain protection over time, and minimize untreated 
waste” (0 CFr 300. 30). For example, if a treatment technology is being selected for 
use in the clean up of a Superfund site, the EPA remedial project manager is required to 
consider nine factors to evaluate alternatives and determine the remedy preference, with 
cost being merely one of the considerations (EPA, 990). 
The environmental-technology market is highly risk-adverse (OtA, 985). Government 
and their contractors do not want to take a chance in adopting a technology that does not 
work and risks making a problem worse. EPA has noted that clean up-project managers 
will need strong assurances—and a viable backup plan in the event of failure—before they 
are likely to select phytoremediation as an option (EPA, 005). Community support is 
an additional factor in remediation-technology choices. If there is concern about the use 
of GM plants, public opposition could constrain the use of this particular technology.  
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On the other hand, communities could embrace GM phytoremediation as a cost-effec-
tive, quick, and more “natural” process than employing chemical or thermal destruction 
treatment processes, or more desirable than typical dig-and-dump techniques. It simply 
is too early, particularly without experience using GM phytoremediation in real-world 
clean up tests, to know what the public will accept.
Conclusion
The hurdles to commercialization of health and environmental plant-biotechnology 
applications are significant. Much about them is uncertain. Few developers have the 
kind of financial security or “bet the company” attitude to risk being the first product to 
“test” the system. Unquestionably, some potentially valuable applications remain sitting 
on bench shelves in universities and companies around the country waiting for someone 
else to go first. 
Nevertheless, there are reasons for cautious optimism. The regulatory system is slowly 
responding to the need to evolve for new and different types of biotechnology products. 
Management and stewardship requirements are becoming more clear. And experience 
suggests that the market welcomes safe, innovative products that provide perceived benefits 
to buyers and to the public. The marketplace makes distinctions between products—even 
between products made with biotechnology. 
Not surprisingly, Pew Initiative polls tend to show that when consumers see a strong 
benefit for themselves, their families, or their community, they respond positively. As 
this technology moves forward, the bulk of the concern and opposition may prove to 
be rooted in food and the unwillingness of affluent consumers to take a small perceived 
risk in the absence of a clear benefit. The challenge then to the developers is to ensure 
that the potential benefits of this technology are clearly explained to the public while the 
government continues to ensure safety. If developers can do that, then there is indeed a 
way to “get there from here.”
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Dann	Okoth	(Nairobi,	Kenya):	I’m a journalist from the same country as the current Nobel 
Peace Prize holder, environmentalist Wangari Maathai. This question is directed to Dr. 
rodemeyer. Perhaps I should get some information to take back to Wangari Maathai on 
environmental conservation. How can GM help us conserve our environment? Thank 
you very much.
Michael	Rodemeyer: You’ll hear more about that in the next few days from people who 
are working on some of those applications. But certainly, one of the arguments, for ex-
ample is in forestry. If we can develop ways to meet the needs of populations for timber 
and wood products from more intensively managed plantations, harnessing genetics to 
make those trees more appropriate for those uses, then we can begin to take some pres-
sure from the destruction of natural forests, which is clearly an issue in many countries 
in the developing world. So that’s certainly one part of the issue. Bt crops potentially 
reduce the use of insecticides and drought resistance has the potential to conserve scarce 
water resources. There is a number of possible environmental applications that could be 
of benefit in the developing world.
Roger	Beachy: I think you can’t avoid the obvious. By increasing food yields per acre you 
also reduce the pressure to require more land. I listened recently to the governor of one 
of the states in Madagascar where very fine centers of biodiversity are in operation, and 
he was lauding the efforts of agencies, including the US government and the United 
Nations, for working with his state for conservation, although it was a very small piece, 
about 380 hectares. He said, “You know the problem is that our farmers grow cassava that 
are severely diseased, causing continuous need for more and more land. Can you help us 
get disease-resistant cassava so we don’t have to do that?” It’s a continuing challenge in 
these economies—struggling to maintain this vast wealth of important biodiversity along 
with food production. While we are considering value-added traits, such as plant-made 
pharmaceuticals, there is the expectation that our food needs will be met. Not instead 
of, but on top of.
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Okoth: In Kenya, we don’t have regulations in place to govern the agricultural biotechnol-
ogy sector. It’s in parliament, but the legislators keep turning it around every other year. 
Hopefully soon they will be able to debate and decide what to do. In terms of biotech-
nology research we are very well established, but the regulation part of it is dragging us 
down. I hope very soon they will formulate laws to regulate this and this economy will 
be on the way.
Oyeley	Olukayode	(Lagos,	Nigeria):	I don’t know whether to classify this as a question 
or an observation. In Nigeria we have the problem of bush burning and I think we are 
losing species of potential economic importance. Are there ways through biotechnology 
application and and regulation to conserve species that are at risk of extinction through 
bush-burning?
Rodemeyer: Part of the response to that is similar to what we’ve said before. Most of the 
diversity exists in unmanaged and natural areas, and to the extent that you save that habitat 
by doing agriculture and forestry in other places, you help take the pressure off development 
of those areas. That’s one answer. But there is a broader question—and this is certainly 
not something that I’m an expert on—of trying to identify and save, for example, seeds 
and other resources, creating a biological diversity type of inventory. Certainly others have 
tried to ensure that there is a “savings bank,” so that those genetic resources are at least 
available. But there is larger debate. Are we trying to preserve these things in place or are 
we trying to simply preserve them as germplasm for future development?
Beachy: In African countries where we’ve had discussions vis-à-vis biosafety, there was 
confusion between the importance of having biodiversity solved before implementing 
biosafety regulations. The issues are very separable. You are talking about agriculture in 
one case and biodiversity in the other, and the issue is not biotechnology’s impact on 
biodiversity. The question is, “Is agriculture affecting biodiversity?” And sometimes in 
countries where a scientist is not placed at the head of the regulatory agency, then other 
influences, other externalities and philosophies, enter the regulatory process from the 
standpoint of the environment that are not based in science. Our concern is, as science 
is respected at high levels in all countries, so science should make an informed impact on 
policies. That’s the challenge that we see in Africa. There’s concern that biodiversity is so 
important—and it really is—but the issue is biodiversity and agriculture, not biodiversity 
and biotechnology. Although those are very separable they are too often confused, and 
that stops countries from making decisions with regard to biotechnology. We heard that 
over and over and over at the Montreal Cartagena Biosafety Protocol meetings. These are 
important issues, but separable, and need to be dealt with differently.
Milt	Zaitlin	(Cornell	University,	Ithaca,	NY): Dr. rodemeyer, I’m not quite as comfortable 
as you are with your assertion that food system fears won’t carry over to these PMPs. I mean, 
let’s face it, the objection to bioengineered food is not based on science and is not always 
based on risk. There are activist organizations that are very effective in combating…[audio 
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lost]…rice and Anheuser Busch is a good example of that.
Shelton: Michael, it would be good if you state what the example is. I’m not sure everyone 
in the audience knows about rice and Anheuser Busch.
Rodemeyer: A company called Ventria is developing a transgenic rice to produce a number 
of proteins, including lactoferrin. There was opposition in California from conventional 
rice growers and they made an agreement with the University of Missouri, to carry out 
some field trials there. There was opposition from environmental consumer groups and, 
interestingly, from food companies and other producers. It’s not that people are concerned 
about the safety of the protein that is developed from the pharmaceutical plant. The con-
cern is over how to protect the food supply. Until there is some additional guidance on 
what those standards are going to be, there will be a clash. Some in the food industry and 
others have called for a ban on the use of pharmaceuticals produced in any food crop, to 
preclude adventitious presence in the food chain. On the other hand, some say that these 
proteins are ubiquitous and it makes no difference whether they get into our cornflakes 
or not. But that decision hasn’t been made yet, and that is part of the problem.
Beachy: This is an issue of marketing not an issue of safety. riceland is a major buyer of 
rice in the delta—in the Mississippi region and throughout Arkansas and Missouri and 
other growing areas—and the question is who buys their rice? Well, if it’s Kellogg and 
Kellogg said that there might be accidental mixing, whether it’s safe or not is not the 
issue. It’s a marketing issue because somebody in another company can say, “We grow 
our rice elsewhere, therefore, ours is not mixed.” Whether the contamination is 0.00% 
or 0.%, it becomes marketing, not safety. We certainly don’t want to be glib and think 
that the future for value-added traits will be smooth. It won’t. We’ve heard for the last 0 
years, “Just bring us a consumer product and the consumers will approve GM crops.” I 
think that’s a red herring and meant to put us off, meant to make us all feel like we are 
on the right track. I’m cynical at this point, after 0 years of agbiotech and still not get-
ting new products out very often. You have to be ready for every eventuality. There are 
so many products in development that are in great states of readiness that aren’t coming 
to market. There is such great fear of bringing things into foods. I must say I was very 
pleased to hear Michael’s positive leaning because that is not what I expected. I’m hopeful, 
but I wouldn’t say I’m optimistic.
Neal	Stewart	(University	of	Tennessee,	Knoxville,	TN): I’ve often wanted to ask this question 
but I’ve always hesitated and especially now that we’ve had such heavy stuff —bush burn-
ing and people starving. Well anyway, this is it. We are always thinking about benefits of, 
potential benefits of biotechnology in products. What about just fun stuff? For example, 
flowers with novel fluorescent traits or bioluminescence or just new colors? There was a 
company that spun out of Carnegie Mellon a few years ago that had bioluminescent squirt 
guns. So I guess my question is, “Would consumers actually need benefits if something 
was fun?” A genetically modified golf ball that would fly a thousand yards?
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Rodemeyer:	Now you’re talking benefits!
Stewart: But that would not necessarily be very safe, especially if I was hitting it. Are 
there any scale effects of risks and benefits that we apply to food vs. nonfood and then 
just frivolous stuff that is fun?
Beachy: remember that regulatory agencies no longer capture on just outcome, they now 
capture based upon method of production. That’s the major challenge. We’re not regulating 
product, we’re regulating process. As long as that’s the overriding consideration, then a golf 
ball that is locatable with a radio beam because of genes or luminescence will be regulated 
by those agencies and the cost goes up as a consequence. So, I think it gets back to this 
issue of rationalization of regulation. There is a way to rationalize and so far we’ve been 
in a reactive mode listening so much to every potential doomsday scenario in response to 
every product that comes out that we keep imposing more regulations. And so a few years 
ago the cost for a new product was a million dollars, then it went to five, now its twenty 
so what will it be in 5 years unless you bring regulation under rationalization?
Stewart: Of course, unless it’s a zebra fish—then there’s no regulation, right?
Rodemeyer: right. But the glowfish is, in fact, partly the answer to your question. I am 
unaware of any protests or consumer or environmental or ethical issues with response to 
having a genetically modified aquarium fish.
Beachy: Yet they were banned from certain counties in California. 
Rodemeyer: Well, except for California; maybe that’s an outlier. But it’s an interesting 
story. From consumers, from the public, I’ve heard absolutely nothing and I have talked 
to the folks who make this thing and they say they’ve heard very little.
Beachy: In the case of green roses—that’s also been a nonoffender. The blue rose, I suspect, 
would be the same.
Rodemeyer: One of the reasons I distinguish between food products and nonfood 
products—I’m not aware of any efforts to boycott blue jeans that have been made 
from—
Beachy: Patagonia did it.
Rodemeyer: Well you’re right, Patagonia maybe. There’s no reason that you couldn’t launch 
exactly the same campaigns against fabric that you launch against food and this is one 
of the reasons that I argue that this may be different because it’s not food. So that makes 
me a little bit more cautiously optimistic about these applications.
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Henry	Miller	(Hoover	Institution,	Stanford,	CA): There’s an interesting historical example 
that melds agriculture and the last question—fun aspects of biotech—and that’s the 
old example of Pseudomonas	syringae, the old ice-minus organism, that was field tested 
to prevent frost damage. Now, for those of you who don’t recall, frost is promoted on 
plants by an ice-nucleation protein that is in Pseudomonas	syringae. And so scientists at 
the University of California devised a mutant that lacked the gene for the ice nucleation 
protein and found that, indeed, it did have some protective effect. Now, the regulatory 
aspect of this is interesting. EPA in its wisdom decided that frost is a pest and so this 
deletion mutant of Pseudomonas	syringae is a pesticide, and they regulated it as a pesticide. 
As a result, although it was shown to be effective in field trials, ultimately it was never 
commercialized because it would have to be registered as a pesticide. Now, what gets us 
to the last questioner is that the wild-type Pseudomonas	syringae, which is ice-plus, is used 
in snowmaking equipment at ski resorts. It’s sprayed into the air and there are skiers all 
around. And what’s interesting about it is that if somebody using recombinant DNA 
techniques made an overproducing mutant, that would be regulated by USDA and/or 
the EPA at the cost of tens of millions of dollars for registration. This is the kind of thing 
that roger is talking about—the need for rationalizing regulation. Currently, it makes no 
sense. It’s extremely destructive. It limits the number of experiments that can be done, 
it limits what gets into the pipeline, it limits what gets through the pipeline and it raises 
the cost ultimately for anything that does manage to get through.
Ralph	Hardy	(NABC,	Ithaca,	NY): You were talking about the regulatory process. We 
have a number of people from foreign countries here that do not yet have regulatory 
processes. What sort of guidance might you give them, and just as a lead off to that, I 
might suggest the Canadian system vs. the US system. The Canadian system regulates 
on the basis of novel traits. The US system regulates on the basis of process. In the US 
system we can use ionizing radiation—all sorts of things that can be produce massive 
changes in genomes—that require no regulation, but if its by a molecular process it does. 
In the Canadian system if it’s a novel trait, it doesn’t matter how you got there, it requires 
regulation. So, I’d be interested in your comments on that and as an add-on question, 
you’ve described one way of getting containment of genes, could you assess where the 
other processes, like the Daphne Preuss synthetic chromosome and chloroplast modifica-
tion, fit into accomplishing the same end point?
Rodemeyer: Well ralph, I think you’ve just thrown the entire agenda off if you want to open 
up what the regulatory system should look like. The initial point is that the administra-
tion, back in 98, made a decision that we were going to regulate biotechnology using 
existing laws, and I would argue that part of the problem is that by having to shoehorn 
the review under our existing laws, we don’t have an optimal system in place. Everyone 
was concerned that if Congress enacted a new system it would be worse than what the 
regulators could invent on their own. So, I’m not sure I have any great wisdom to share 
with you about our own system. There is no question that the regulatory system has done 
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pretty well with respect to the crops that are out there today. I don’t think there are any 
major environmental issues. There are certainly no health issues. The issue that we have 
tried to raise is: is the system ready for the new kinds of products that are coming along? 
And as I said, given the nature of novelty, every time you get a new issue, regulators are 
going to want to ask new questions. I’m not sure there’s a magic bullet. There have been 
arguments that we should have a system with minimal or no regulations. But—and 
I’m probably going to get a lot of disagreement on this—the reason that we have ac-
ceptance of biotechnology in this country is largely because people have confidence in 
the institutions that regulate it. That’s one of the differences between us and Europe. I 
think no regulation would be a mistake because the people wouldn’t have confidence in 
the technology. You have to have a rational system that’s based on science and on actual 
risk. There’s no magic bullet.
Beachy: I agree that we needed regulations early on. That was an important thing to 
implement. We have built a bigger system than we need and more onerous than neces-
sary because we haven’t learned from the last 0 years. I mean a Bt gene, the same one 
put in crop “X” and approved, going into a second crop, or even into another variety 
by a different transformation event, gets re-regulated as if it’s not known before. What’s 
the rationale for that after 0 years of safe use of the Bt gene? What’s the rationale for 
limiting some of the use of the virus-resistance technology or some of the anti-fungal 
technology? The Canadian system regulates the protein product that gives a trait. China 
seems to have done it in a way that is rational and one that meets their needs. They are 
looking for ways to reduce the use of agriculture chemicals. So I think China has moved 
ahead in the regulatory process in a different way. I think Kenya and Nigeria have an 
opportunity to do it in a different way, learning from what we’ve done in the last 0 
years and what China is moving to. And rather than reinventing the wheel, you start 
with a knowledge-base after 0 years. And that’s what we don’t find in countries where 
the regulation is not in place. Most want to start over from scratch, as if we have never 
had regulation. That doesn’t make any sense. We don’t do that when we regulate drugs. 
Having approved aspirin or tylenol® in this country, they’re acceptable in Kenya because 
there is a long history of safety.
With regard to how else to control trait flow, this issue of gene-switching versus the 
artificial chromosomes are apples and oranges and the reason why Daphne Preuss pro-
motes the use of the artificial chromosome is to reduce the likelihood of insertion of the 
gene at a place on the chromosome where there might be a negative impact. That might 
be useful in some cases or to move full genes in. So there may be some advantages, but 
I think they are apples and oranges. They are not the same. There are other ways to get 
to trait-control. There might be suicide genes where with x numbers of generations you 
trigger the gene to come back out again. Or you may make expression dependent upon 
hybridization and if that hybrid outcrosses to something else it won’t function. There 
are lots of ways to do it. I think the one that’s the most effective will be one that you can 
control ultimately with a small molecule.
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Robert	Wager	(Malaspina	University,	Naimano,	BC): It seems to me that marketing of fear 
has been driving policies, to a greater or lesser extent in North America, but certainly to 
a great extent in international policies. The MOP  talks seemed almost totally driven by 
fear as opposed to science and I’m curious what your feeling is about the MOP  talks 
on the Cartagena Protocol.
Beachy: I was there for only  hours, which was a long enough time for me to be there. 
I was there with the Public research and regulation Foundation. This is a move that 
started in Holland and England to try to engage public-sector scientists from all around 
the world including in Africa, Latin America, Asia, South Asia, Southeast Asia, in the 
discussion of the impact that the Cartagena Biosafety Protocol has on public researchers 
like us. What are the impacts and how do they stop innovation? How are they preventing 
us from doing our jobs? As ralph indicated earlier, more than 70% of the biotechnology 
that is known about in the United States is done by his member organizations. If you 
look in developing countries, far more biotech is done in the public sector at KArI for 
example, or at universities in Nairobi and Abuja and other places around West, East and 
South Africa. That’s where it’s done. Yet lack of understanding of what biosafety is has 
prevented public-sector scientists from doing their jobs and delivering improved vegetables 
and grains for their populations. So, for the first time, public-sector scientists were not 
afraid to speak out, at MOP . We had a preliminary meeting at the Danforth Center in 
March and that group and more were in Montreal to understand the process and make 
inputs when given the opportunity to do so, to correct some of the misunderstandings. 
The feeling that I had there—the accusation is—this is a big multi-national way to take 
charge of food production worldwide, and by George we’re not going to have that hap-
pen and we’re going to put in place regulations to prevent that, while doing so under the 
guise of preventing transfer of DNA between my country and your country. In the past 
there was an intention to use the process to listen to the antitechnologist and to block 
applications of relevant biotechnology around the world. I do agree that that was the 
goal at MOP . I think we’ve seen a slowdown towards that, and maybe a realization that 
the public sector has a lot to contribute here. Some of the delegates at the conference 
expressed surprise that university people are actually doing biotechnology! They didn’t 
know—so that was a learning. We should have been there the last time. The public sector 
should have been a lot more vocal over the last 0 years than it has. We bear some of the 
responsibility for how far the Cartagena Protocol has already gone because we’ve not been 
there often enough. We haven’t spoken out. We haven’t made our voices heard. We need 
to find better ways to get our message across or we’ll look a lot like Austria or Switzerland 
in the next few years. There is a possibility we’ll see ourselves slip back.
Shelton: Michael, in the title of your talk you used the words “speed bumps.” You didn’t 
use “wrong streets” or “crashes,” so I’m taking that as an indication of an optimistic future 
for some of these products. I’d like to thank both speakers. It was a great session.
Shelton
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Plant-Made Pharmaceuticals: 
An Overview and Update
H. Maelor Davies
University	of	Kentucky
Lexington,	KY
The development of plant genetic transformation in the early 980s introduced the pos-
sibility of having plants express non-native (“foreign”) genes, and thereby accumulate 
non-native proteins in their cells and tissues. Thus the concept of “plant molecular farm-
ing” was born, envisaging crop plants as production “vehicles” for useful and/or valuable 
proteins that originally derived from microbial or animal sources. Several advantages 
were claimed for such plant-based production, relative to bulk production of the natural 
source for the corresponding protein, including overall economy of production, lack of 
need for major capital investment (e.g. in fermentation bioreactors), ease and economy 
of scale-up, lack of risk of contamination with human pathogens, etc. (For a background 
overview of plant molecular farming, see Collins and Shepherd, 99). Because the case for 
using plants as the production system became more compelling as the yield of protein per 
plant increased, proprietary gene-expression technologies were developed specifically for 
achieving very high concentrations of “foreign” proteins in plant tissues. These technolo-
gies, in turn, resulted in the emergence of several agricultural biotechnology companies 
specializing in plant molecular farming. A wide variety of proteins were expressed in a 
number of plant species, illustrating the potential of the approach to supply products for 
pharmaceutical, industrial-enzyme, structural-polymer, etc., markets. Clinical trials in 
humans were conducted, successfully, with protein pharmaceuticals generated in plants 
(e.g. Ma et	al., 998). A particularly attractive feature of the plant molecular farming 
concept, which was apparent from its outset, is its potential to provide opportunities for 
both the agricultural sector and the biotechnology business sector simultaneously.
A variant on the molecular farming theme, which developed contemporarily with it, 
is the concept of “edible vaccines.” In this strategy, the entire plant tissue or organ (such 
as a fruit) in which the protein pharmaceutical accumulates is also the final delivery 
device for the protein product, and no extraction of the protein from the plant material 
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is necessary. Edible vaccines are considered elsewhere in this conference, and will not be 
discussed further here.
In contrast with the spectacular scientific progress in “proving” the principle, however, 
the development of significant markets for plant-manufactured proteins failed to hap-
pen, so that by the mid-990s the plant molecular farming field was essentially stalled. 
The companies that were based on appropriate gene-expression technologies were in a 
survival-oriented mode rather than in a state of vibrant growth, and little was happen-
ing in terms of further technology enhancements. Most troubling was the sense that the 
end-users of the technology, i.e. those companies who owned protein pharmaceuticals, 
enzymes and other possible product “targets” for plant-based production, appeared to 
be unconvinced regarding the plant manufacturing platform. Field-level production had 
been demonstrated on a pilot scale, and some post-harvest bioprocessing capability was 
constructed. But, in spite of these advances towards scaled-up commercial applications, 
the plant molecular farming biotechnology sector continue to lack much-needed en-
dorsement by significant clients whose protein medicinals and protein reagents addressed 
substantial and sustainable markets. The plant-based production “platform” was, in effect, 
a technology searching for an application.
Fortunately, much has changed in the last 5 years or so, largely as a result of biotechnol-
ogy’s increasing impact on drug development. The fledgling molecular farming industry 
is ideally placed to address the resulting demand for protein pharmaceuticals, and con-
sequently has re-characterized its technology platform as “plant-made pharmaceuticals” 
(PMPs). Applications to other proteins such as industrial enzymes, now referred to as 
“plant-made industrial products,” are seen as a future priority.
This brief overview will consider the current status of the PMP industry and the chal-
lenges facing large-scale implementation of the PMP opportunity today. Using some of 
our own research at Kentucky tobacco research and Development Center (KtrDC) as 
an example, I will also discuss the interface between the PMP industry and conventional 
crop agriculture. This is an aspect that has often been neglected in the past, but one that 
comes sharply into focus when one recalls that conventional crops are not optimized for 
these new applications and that today’s regulatory, containment considerations render 
them even less suitable. rather than providing new plant varieties and corresponding 
new markets for production through existing crop agriculture—as was at one time en-
visaged—it now seems much more likely that a new, specialized crop agriculture will be 
constructed specifically to service the PMP opportunity.
It	now	seems	much	more	likely	that	a	new,	specialized	crop	
	agriculture	will	be	constructed	specifically	to	service	the	
PMP	opportunity.
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the PMP Opportunity today
to appreciate the current status of the PMP industry, we need to review both the capa-
bilities of the industry itself and the condition of the protein-pharmaceutical markets 
that it is designed to address. 
The basic philosophy of the PMP opportunity today can be stated in the following 
way:
• there is a substantial, and increasing, worldwide demand for protein pharmaceuti-
cals and therapeutics;
• existing and traditional methods of manufacturing proteins in bulk to the re-
quired level of purity and quality are stretched to capacity and will soon become 
limiting in protein-drug manufacturing;
• specialized plant-based gene-expression technologies are ready to provide an 
alternative manufacturing platform that can help meet the demand and thus over-
come the perceived “bottleneck” in protein production; and
• taken together, these situations make a strong case for commercial development 
of PMPs.
The following summary reviews each of the above aspects in relation to the current status 
of PMP commercialization.
Protein	Demand
The development of novel protein pharmaceuticals, vaccines, therapeutics and other 
medically useful molecules is an expected consequence of biotechnology-driven drug 
discovery. Accordingly, it is not surprising that proteins feature prominently in new drug 
development today, and that they are predicted to comprise a larger and larger propor-
tion of new medicines over the next decade or so. For example, an estimate of % of 
the pharmaceutical market as proteins in the year 000 is projected to expand to 0% 
by 00 (Price, 003). A 00 survey by the Pharmaceuticals research and Manufactur-
ers’ Association (http://www.phrma.org) indicated that 3 “biotech medicines” were 
in clinical trials or in advanced development (such as preparation for clinical trials) in 
the United States alone, in that year. Most of these prospective new drugs were proteins 
such as antibodies, enzymes, peptides, etc. Worldwide, many hundreds of monoclonal 
antibodies and other medicinally active proteins are in all stages of development from 
discovery through human trials. Moreover, some of these proteins will be administered 
in large amounts (e.g. mg/dose) that will necessitate large production volumes (Garber, 
00), and the prospect of personalized or individualized medicines for some products 
will pose particularly tough challenges for economical, custom, batch-wise production 
(e.g. Alison et	al., 003). Thus, the demand for pharmaceutical proteins is considerable, 
and growing, creating a market opportunity that was almost nonexistent when plant 
molecular farming was conceived in the 980s.
Protein-Manufacturing	Capacity
Next, let’s consider the extent to which this demand has created a supply-level crisis that 
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might stimulate the expansion of PMPs. An increasing demand for proteins creates oppor-
tunity for all possible production platforms, including the established way to manufacture 
proteins to the stringent standards laid down for veterinary and human applications, 
i.e. via fermentation of specialized microbial (bacteria and yeast) and mammalian (e.g. 
Chinese hamster ovary) cell lines, engineered to express the appropriate genes. We can, 
therefore, expect some expansion in this fermentation industry. While this will represent 
competition, the increasing need for proteins may also provide a chance for PMP tech-
nology not only to prove its fundamental capability but also to illustrate its efficiency in 
responding quickly, flexibly and perhaps economically to a rapidly evolving demand for 
product quantity and diversity.
Fermentation facilities require considerable capital investment and have finite capacity 
so that expansion also requires substantial capital. Such facilities are typically said to cost 
$300–$500 million to build, with a time frame of  to 5 years to cover construction, 
validation, and licensing (Thiel, 00). Not surprisingly, therefore, the initial surge of 
progress in protein drug development stressed existing fermentation capacity, raising seri-
ous concerns about a coming “capacity bottleneck.” As recently as 00, a representative 
from a contract manufacturing organization (CMO) in this field was quoted as saying 
(cited in Garber, 00):
…the	only	 long-term	solution	 is	 to	 shift	 some	production	(from	fermentation	
systems)	to	transgenic	animals	and	plants,	which	can	in	theory	be	scaled	up	much	
more	efficiently	to	virtually	any	level.
In our opinion at KtrDC, this period of “protein crisis” (Garber, 00) in the late 
990s and over the last few years generated considerable new interest in the PMP con-
cept. two more gene-expression technologies emerged as PMP companies during that 
time, and pharmaceutical companies began to examine the PMP-manufacturing option 
more seriously. The PMP industry and associated organizations (e.g. KtrDC and other 
PMP-relevant research programs) also became more recognizable as a biotechnology sec-
tor in its own right, featuring prominently in the Biotechnology Industry Organization 
(BIO; http://www.bio.org) and holding a biannual conference (Conference	on	Plant-Made	
Pharmaceuticals; http://archives.cpmp005.org).
The protein crisis might have become a forceful creator of new end-users and signifi-
cant markets for the PMP industry. However, sufficient expansion has taken place in 
the fermentation industry that the crisis appears to be over, at least for now. Indeed, the 
biomanufacturing news spotlight is now focused on the end of the capacity-expansion 
boom, and industry analysts opine that “…there is little immediate pressure for compa-
nies to move to alternative platforms (e.g. PMP) that are as yet commercially unproven” 
(Thiel, 00). Whereas just a few years earlier the transgenic animal- and plant-production 
systems were viewed with new interest as potential ways around the bottleneck, they are 
again left to make their own case for advantages, economy, etc., relative to the traditional 
methods of making proteins.
While it seems unlikely that there will be another sudden surge in demand for pro-
teins, the steady growth in demand will continue to apply pressure to the manufacturing 
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 industry. It will be interesting to see if the CMOs will repeatedly be able to raise financing 
for expansions, and whether the larger pharmaceutical companies that have their own 
protein products will invest further in fermentation capacity. Another possibility is that 
protein production will grow sufficiently as a business sector that it will become much 
more internally competitive, triggering new interest in more economical methods of 
production and hence, potentially, in PMPs.
PMP	Technologies
The need, once again, for the PMP industry to convince the pharmaceutical community 
that PMPs can become an established route of large-scale production, brings us conve-
niently to a short overview of PMP technologies, their capabilities, characteristics, strengths 
and weaknesses. table  lists the more prominently visible PMP companies, together with 
the kinds of gene-expression technologies on which they are based and the plant species 
with which they are compatible. The majority, if not all, of these proprietary technologies 
were derived originally from research conducted in the academic sector. The majority 
of them share an important attribute, namely the ability to drive protein accumulation 
in the appropriate plant tissue to very high enrichment levels relative to the native plant 
proteins in that tissue. Indeed, for a commercial PMP, an accumulation of product to 
a level of at least % of total soluble protein (tSP) by weight is considered necessary, 
with enrichments of 5–0% of tSP being preferable. With certain gene products that 
are particularly stable in the plant cell, and/or with certain technologies, enrichments 
approaching 80% of tSP may be attainable (e.g. Marillonnet et	al.,	00).
For	a	commercial	PMP,	an	accumulation	of	product	to	a	level	
of	at	least	1%	of	total	soluble	protein	by	weight	is	considered	
	necessary,	with	enrichments	of	5–10%	of	TSP	being	preferable.
Table 1. Some* exampleS of pmp companieS and TechnologieS
 Company name “Vehicle” plant Proprietary technology
 Large Scale Biology tobacco Viral transfection vector
 Icon Genetics tobacco Viral vector (and others)
 Chlorogen tobacco Chloroplast-based expression
 Planet Biotechnology tobacco Antibody production
 SemBioSys Safflower Oilseed-based expression
 Ventria Bioscience rice Seed-based expression
 Medicago Alfalfa Expression in forage crop
 Biolex Duckweed Expression in aquatic plant
*This is necessarily an incomplete list, on account of limited space and scope of this review article; omission of 
any company or technology does not imply any negative assessment or view.	
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While sharing a common feature of highly productive gene expression, the PMP tech-
nologies otherwise exhibit considerable diversity in regard to other characteristics and 
perceived advantages. Expression in stably transformed plants contrasts with expression 
through transfection with modified virus particles. Many of the expression technologies 
are restricted to certain plant species, but the overall list includes food/feed plants such 
as corn and canola, feed crops such as alfalfa, and non-food species such as tobacco and 
duckweed. Depending on the particular technology, expression may occur in the leaf and 
hence in the bulk of the plant’s above-ground biomass, or it may occur exclusively in seed 
or fruit tissues. Also, expression in the transgenic systems may be from vectors inserted 
in the nuclear genome or in the chloroplast genome. 
An in-depth comparative analysis of all these different PMP technologies is beyond 
the scope of this paper, but suffice it to say that each has particular advantages or unique 
features. Expression in the chloroplast, for example, may offer advantages in regard to 
containment and regulatory compliance when deployed in plants that exhibit little or 
no transfer of chloroplasts through pollen [for a review of chloroplast transformation, 
see Bogorad (000)]. Viral transfection systems (Lacomme et	al., 00; Marillonnet et	
al., 00) will pose different regulatory approval considerations from those required for 
transgenic plants, and this may be advantageous in some circumstances. Ease of post-
harvest isolation of the protein product, and subsequent bioprocessing is a unique claim 
made by an oilseed-based system (Moloney, 000). And at least one system is proven 
in the production of complex antibody molecules requiring simultaneous and balanced 
expression of several genes in the same plant cell (Wycoff, 005). Overall, this diversity of 
characteristics and features should work to the advantage of the PMP strategy, enabling 
it to address a wider range of product “targets” and production constraints (e.g. growing 
location, farming know-how, and special regulatory/containment considerations) than 
might be possible with only one or two gene-expression technologies.
The	PMP	industry	is	still	working	towards	its	first	truly	large-
scale	(100	acres	or	more),	preferably	ongoing,	provision	of	a	
protein	drug	to	a	client	company	or	to	consumers.
PMP	Engagement	of	Protein	Markets
The status of the PMP opportunity today is largely consistent with the ideal philosophy 
presented at the beginning of this section. Proteins represent an increasing proportion of 
pharmaceutical products, worldwide. While there is currently less concern about produc-
tion capacity for those proteins relative to the situation a few years ago, it seems possible 
that growth in markets for protein drugs, along with dosage and personalization issues, 
will continue to pose challenges for the capital-intensive, cell-culture-based manufactur-
ing platforms. The PMP platform comprises a range of impressive technologies with a 
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broad range of capabilities, ready to address these opportunities. But while there have 
been a few instances of commercial products’ being made via the PMP route, most have 
been small-scale (–00 acres), one-time, or experimental endeavors. to date, the PMP 
industry is still working towards its first truly large-scale (00 acres or more), preferably 
ongoing, provision of a protein drug to a client company or to consumers.
We will next examine the challenges that must be met for the industry to break through 
into such mainstream protein-drug manufacturing.
Challenges to PMP Development
The basic scientific and technical challenges of making “foreign” proteins in plants were 
met many years ago. And while it is true that plant-based production may not be feasible 
for some proteins [e.g. on account of different post-translational modifications such as 
glycosylation (Gomord et	al., 00)], and that technical advances continue to be made 
in expression levels and other aspects that may improve the range of products that can 
be made in plants, there is no shortage of viable PMP targets today. 
rather, the factors that most influence the growth rate of the industry at the present 
time are financial and business related. PMP companies must compete for the atten-
tion of investors who also review business models formed around other manufacturing 
platforms, and who may be more inclined to invest in companies that own the innova-
tive new protein drugs. (PMP companies sometimes own the product target as well as 
the production technology, but all seek to partner with companies who own additional 
prospective targets.)
This competition may become easier to beat once the PMP approach is embraced by 
the pharmaceutical industry as an established production platform. Factors that influence 
the pharmaceutical community’s acceptance of PMPs include the “cultural” differences 
between the pharmaceutical sector and the agricultural biotechnology sector, an overall 
lack of understanding of the economics of plant-based production (discussed further 
below), the lack of familiarity with large-scale purification of proteins from plants to 
the stringent specifications required for clinical application, and quite possibly a desire 
not to be the first drug company to adopt the PMP concept. to appreciate the cultural 
differences, one has only to contrast the highly controlled, highly contained, nature of 
bulk cell-culture systems in which every cell is almost identical to every other, with the 
PMP image of a greenhouse or a field of plants; it must be tempting for those engaged 
in protein-pharmaceutical manufacturing to persist with their established, long-proven, 
methods for reasons of familiarity and “comfort-level” alone.
If a protein-supply crisis does not drive a wider adoption of plant-based manufactur-
ing, attractive and superior economics would certainly be expected to do so. Indeed, the 
PMP industry has recently been challenged to demonstrate the economic advantages of 
its platform, particularly in regard to production scale-up where the relationship between 
capital investment and capacity increase may be distinctly advantageous (Thiel, 00). 
Unfortunately, many published papers and review articles over the years have mislead-
ingly characterized the PMP technology as a “cheap” way to make a protein. There is, of 
course, always a finite cost associated with producing a crop, and with PMPs there can 
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be specific additional costs associated with containment (at least until the plant becomes 
deregulated), particular harvesting practices, etc. Moreover, a complete estimate of cost-of-
production for a plant-derived pharmaceutical cannot be made without data on extraction 
and bioprocessing expenses. For any particular PMP product under consideration, these 
post-harvest details are usually either unknown or based only on experience at small scale. 
Thus, the majority of statements in the literature that proclaim an inherent cheapness 
for PMPs, without justifying that claim, cannot be taken seriously. On the other hand, 
incremental costs associated with PMP scale-up should be appealing, for the simple reason 
that planting more acres in the field, or constructing additional contained facilities such 
as greenhouses, has to be significantly cheaper than building bioreactors for fermenta-
tion. (Bioprocessing expansion costs would likely be very similar for all platforms.) It 
is in this aspect of flexibilty and expansion that the economics of PMPs deserve careful 
consideration.
Most recently the PMP industry has found that its potential pharmaceutical-indus-
try clients are not the only stakeholders needing to be convinced. The potential use of 
food/feed plants as the crop species of choice for some PMP systems has drawn criticism 
from the respective food industry organizations, as well as from environmentalists and 
biotechnology-opposing groups (e.g. see the editorial on page  of Nature Biotechnology 
33, 00, for an overview, and http://www.gmabrands.com/news/docs/Newsrelease.
cfm?docid=09 for an example of food-industry perspective). Concern has been expressed 
over the degree of protection and assurance that could be provided to obviate an envisaged 
possibility of contamination of the food/feed supply with pharmaceutical proteins from 
the PMP variant of the crop, either via genetic means (cross-pollination) or by direct 
mixing of plants or harvested material. Anxiety on this point has generated local/regional 
opposition to one PMP platform that uses a food plant, resulting in that company’s reloca-
tion of its pilot production trials and the resulting loss of a new opportunity for farmers 
at the original site. The fear of food contamination is also reflected in the presently very 
high level of governmental regulation and risk assessment applied to field releases (field 
trials, pilot production) of PMP plants (Peterson and Arntzen, 00). 
Despite these concerns, it has been speculated that PMP crops might fare better than 
most genetically-modified (GM) crops in terms of public perception and acceptance in 
those countries that are uneasy about GM plants in general [for further discussion and 
relevant citations see Einsiedel and Medlock (005)]. The often-heard criticism that 
input traits such as herbicide tolerance do not provide sufficiently obvious benefit for 
the consumer no longer applies, and the product is readily understood as a beneficial 
medicine.
Developing a Dedicated Crop System for PMPs
Concerns about contamination of existing crops with pharmaceutical products coming 
from the corresponding PMP crops would be moot if PMPs were produced using “vehicle” 
species that had hitherto not been developed into crops, i.e. plants that had not previ-
ously been domesticated. However, suitable gene-expression technologies would have to 
be adapted for use with these previously uncultivated species, or developed from scratch, 
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and the domestication aspect alone might take many years. Even with the non-food 
plant, tobacco, there is concern to prevent any possible contamination of the traditional 
crop; the tobacco-production industry in the United States currently has zero tolerance 
for GM contamination.
There is an additional reason to consider the development of a dedicated vehicle plant 
exclusively for PMP applications, namely the lack of desirable characteristics in existing 
crop varieties. Modern crop cultivars are highly customized to the particular applications 
for which they are used. Adaptive enhancements continue to be made through advanced 
breeding and genomics research, improving yield, resistance to pests, and other useful 
traits. Some of these qualities, particularly the more agronomically oriented ones such 
as disease resistance, will still be relevant when the plant is used as a protein-production 
vehicle. However, other traits specific to the PMP application may also be lacking in the 
commonly grown varieties. Examples include productive response and systemic spread 
when infected with virus-based PMP gene vectors, sterility or limited (or late) flowering 
to minimize gene flow via pollen, special morphology and growth habit suited to a specific 
harvesting method that will be used with the PMP application, absence of certain metabo-
lites that may compromise product integrity or quality during bioprocessing, etc. Indeed, 
the design and development of new plant varieties customized for PMP applications is to 
be expected, given the general practice of variety development in crop agriculture.
tobacco is convenient for illustrating vehicle-plant customization. The Nicotiana 
genus contains a large number of species that are found in diverse regions of the world 
and which exhibit a wide range of morphological and other relevant characteristics. Most 
importantly, many of these undomesticated species are already large, bushy and productive 
plants, in contrast to the “wild” relatives of many crop plants, which so often exhibit small, 
low-yielding forms. Moreover, many Nicotiana species have disease-resistance traits not 
found in the traditional, commercial N. tabacum cultivars. Thus, there is an extensive and 
useful germplasm resource, and the domestication breeding path is conveniently short. 
Most of this germplasm has been ignored in breeding traditional tobacco types, presum-
ably because the exotic species and associated variants are unsuited to the manufacture 
of traditional products such as cigarettes. Naturally, these issues have no relevance in the 
new PMP applications of the plant.
table  provides a listing of the most desirable characteristics to be incorporated into 
the new vehicle plant that we are constructing at KtrDC for use with all tobacco-spe-
cific PMP gene-expression technologies. In order to achieve optimal compliance with 
federal regulations concerning limitation of gene flow (genetic “containment”), we have 
adopted a hybridization strategy. Thus the plants set out in the field for production will 
be interspecific hybrids that exhibit a high degree of sterility. One parent of the hybrid 
is an appropriate cultivar of N.	tabacum, whereas the other is a different species of Nico-
tiana. Each parent also contributes different characteristics that are important features 
of the final custom hybrid. For example, for transgenic PMP strategies one parent will 
be expressing the PMP transgene via the appropriate high-level expression system. For 
chloroplast-based expression, this would be the maternal parent. The other parent may 
also be transgenic for other characteristics such as herbicide tolerance, etc.
Davies
8 Agricultural Biotechnology: Beyond Food and Energy to Health and the Environment
It will be noted that the table of characteristics includes economy of production. One 
disadvantage of conventional tobacco for PMP applications is the very high cost of pro-
duction of the traditional crop, resulting from the use of transplants, wide plant spacing, 
and considerable manual labor even pre-harvest. In developing the customized Nicotiana 
hybrids for PMPs, we can also take the opportunity to address the cost-of-production 
issue. For example, mechanized harvesting enables the crop to be produced by sequential 
harvesting and regrowth, unlike traditional tobacco, which is (manually) harvested once. 
This contributes significantly to improved production economics, so productive regrowth 
becomes an important performance trait for the new PMP hybrid lines. 
Along with the development of new hybrid Nicotiana plants, much can be done to 
usefully customize the production practices, further reducing the cost of production for 
PMPs. The mechanized harvesting mentioned above, using plants grown much closer 
together and employing three or four rounds of growth from the same plants over an 
extended growing season, are good examples. Eliminating transplants, and producing the 
crop by direct seeding into the field, would also lower production costs. However, at the 
present time transplanting is actually viewed advantageously relative to direct seeding for 
PMPs, as it further reduces the possibility of volunteer plants’ emerging in the following 
year. Accordingly, we are examining the possibility of achieving more economical raising 
of transplants in the greenhouse, and good progress is being made with higher densities 
of transplant production.
Table 2. deSirable TraiTS and characTeriSTicS of 
a new crop planT cuSTomized for uSe wiTh Tobacco-baSed 
pmp gene-expreSSion TechnologieS.
 Performance traits Production-related traits
 transformable Eonomical production*
 regenerable from cell culture Vigorous regrowth*
 PMP-vector-system compatible Disease resistance
 Sterile Herbicide tolerance
 Identity-preserved Insect resistance
 Desirable metabolite profile High biomass-yield*
 Bioprocessing-optimal Good protein production
  Suited to mechanized harvesting
*Vigorous regrowth (for multiple harvests) and high biomass-yield contribute directly and importantly to eco-
nomical production, but the latter is listed separately as well so as to include improved economy of seedling 
production, transplanting, and many aspects of crop maintenance, as well as economical disposal of waste 
material post-bioprocessing, etc.
We	are	hopeful	that	the	increasing	market	opportunity	(demand)	
and	the	demonstrated	production	capability	(PMP	technology)	
will	soon	converge.
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In Conclusion
The continuing development of protein-based medicines worldwide bodes well for the 
future of the PMP concept. Gene-expression technologies for plant-based production are 
proven and productive. We are hopeful that the increasing market opportunity (demand) 
and the demonstrated production capability (PMP technology) will soon converge to 
achieve large-scale, and ongoing, manufacturing of valuable proteins from one or more 
plant-based platforms. Meanwhile, much can be done to enhance the agricultural inter-
face with PMPs, as I have illustrated above with reference to our work with Nicotiana. 
Existing crops and associated production methods are frequently sub-optimal for ap-
plication to PMPs, but the use of related germplasm that remains compatible with PMP 
gene-expression technologies can not only enhance production economics and facilitate 
regulatory compliance, but also mitigate potential conflict with traditional food and other 
applications of that plant.
Acknowledgments
The Kentucky tobacco research and Development Center is funded by the Common-
wealth of Kentucky, and is administered by the Kentucky tobacco research Board and 
the University of Kentucky (College of Agriculture). research on the development of 
new Nicotiana hybrid plants and associated production methods, described above, is 
conducted by Orlando Chambers, David Zaitlin, Baochun Li, richard Mundell and 
colleagues at KtrDC.
references
Alison A et	al. (003) Individualized human scFv vaccines produced in plants: humoral 
anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. Journal 
of Immunological Methods 78 95–0.
Bogorad L (000) Engineering chloroplasts: an alternative site for foreign genes, proteins, 
reactions and products. trends in Biotechnology 8 57–3.
Collins GB Shepherd J (eds.) (99) Engineering Plants for Commercial Products and 
Applications. Annals of the New York Academy of Science 79.
Einsiedel EF Medlock J (005) A public consultation on plant molecular farming. AgBio-
Forum 8 –3
Garber K (00) Biotech industry faces new bottleneck. Nature Biotechnol. 9 8–85.
Gomord V et	al. (00) Production and glycosylation of plant-made pharmaceuticals: 
the antibodies as a challenge. Plant Biotechnology Journal  83–00.
Lacomme C et	al. (00) Plant viruses as gene expression vectors. In: Genetically En-
gineered Viruses (ring CJA and Blair ED eds.). Oxford: BIOS Scientific Publishers 
Ltd., pp 59–99.
Ma J K-C et	al.	(998) Characterization of a recombinant plant monoclonal secretory an-
tibody and preventative immunotherapy in humans. Nature Medicine  0–0.
Marillonnet S et	al. (00) In	planta engineering of viral rNA replicons: Efficient as-
sembly by recombination of DNA modules delivered by Agrobacterium Proceedings 
of the National Academy of Sciences of the USA 0 85–857.
Davies
70 Agricultural Biotechnology: Beyond Food and Energy to Health and the Environment
Moloney MM (000) Molecular farming using seeds as hosts. In: Seeds technology 
(Bewley D Black M eds.). Sheffield: Academic Press, pp –53.
Peterson rKD Arntzen CJ (00) On risk and plant-based biopharmaceuticals. trends 
in Bioechnology  –. 
Price B (003) Personal Communication.
Thiel KA (00) Biomanufacturing, from bust to boom….to bubble? Nature Biotech-
nology  35–37.
Wycoff, K (005) Secretory IgA antibodies from plants. Current Pharmaceutical Design 
 –9.
Maelor Davies is director of the Kentucky tobacco research and Development 
Center (KtrDC) at the University of Kentucky. He received his graduate and 
postgraduate education at the Universities of Oxford and London (United King-
dom), respectively, then undertook postdoctoral research at the Plant research 
Laboratory at Michigan State University. Prior to joining KtrDC, he was a senior 
scientist with Calgene Inc., a pioneering agricultural biotechnology company 
in California. During his  years with Calgene, Dr. Davies played key roles in 
r&D programs that produced some of the world’s first genetically engineered 
crops. His Calgene work focused on, inter	alia, crop use of fertilizers, herbicide 
tolerance, improved fruit quality, and novel natural products.
Since 99, Davies has been responsible for designing and overseeing the 
transition of KtrDC from health-related research to its present mission of fa-
cilitating the development of new crops for Kentucky agriculture. The research 
in plant-made pharmaceuticals (PMPs) emphasizes the development of a new, 
PMP-dedicated crop plant and an associated agricultural production system that 
will be useful to all companies using tobacco-based gene-expression technologies 
for protein production. The Center also supports unique research into natural 
products, anticipating that the development of new applications for intrinsic, 
small-molecule plant metabolites will, in turn, create new crop opportunities 
for growers.
Vaccination has become an important and effective public-health measure for safeguard-
ing against devastating outcomes of infectious diseases. Current vaccines rely on the use 
of either attenuated (weakened) or killed strains of pathogens, e.g. against diphtheria, 
tetanus, measles and mumps. For some vaccines, such as the one against human smallpox, 
a strain from a different species (cowpox) is used instead. Some of these vaccines (espe-
cially parenteral vaccines) contain toxic preservatives such as formaldehyde, thiomersal 
(a mercury-based compound), and aluminum phosphate (Buetow and Korban, 000; 
Streatfield and Howard, 003). In recent years there has been a move towards developing 
subunit vaccines, linear immunogenic epitopes of the pathogen that elicit production of 
antibodies. This alleviates concerns over risk of reversion of attenuated strains to aggressive 
forms in pathogen-based vaccines (Buetow and Korban, 000). Scale-up production of 
current vaccines takes place either in specific pathogen-free (SPF) eggs or in mammalian 
cells grown in large fermentors or bioreactors. Therefore, these vaccines require purification 
before they are available for use. Moreover, most are delivered via intramuscular injection, 
and, therefore, require the use of sterile hypodermic needles.
In the last several years, a novel approach for developing subunit vaccines has emerged 
as a result of the genetic engineering technology: the use of plants as hosts—biological 
bioreactors. At this time, the most economical and technically feasible class of products 
using this approach involves the engineering of genes to express novel proteins. This has 
resulted in a $0-billion industry of new therapeutics and industrial enzymes (Howard, 
005).
A	novel	approach	for	developing	subunit	vaccines	has	emerged	
as	a	result	of	the	genetic	engineering	technology:	the	use	of	
plants	as	hosts—biological	bioreactors.
Opportunities and Challenges for  
Plant-Based Vaccines
Schuyler S. Korban
University	of	Illinois
Urbana,	IL
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Opportunities
The important features of any effective vaccine include safety, protective immunity that 
is sustained for long periods of time (preferably a lifetime), stability, ease of administra-
tion, low cost and few side-effects. In recent years, plants have emerged as alternative 
production systems for subunit vaccines as they are likely to contribute to all of these 
critical features of effective vaccines. Plants that have been engineered with genes encoding 
antigenic proteins of various pathogenic viral and bacterial organisms have been shown 
to correctly express the proteins that elicit production of antibodies in mammalian hosts. 
Plants can readily and properly handle the downstream processing of foreign proteins, 
including expression, folding, assembly, and glycosylation, all contributing to the fidelity 
of antigenic proteins (Wycoff, 005). As a result, these proteins maintain their activity 
and efficacy, thus contributing to their viability as subunit-vaccine candidates (Figure ). 
Plants can produce not only single, simple foreign proteins, but also complex multimeres, 
such as secretory proteins and antibodies (Wycoff, 005). All these capabilities render 
Figure . Subunit-vaccine candidates against human and animal diseases for possible 
production in various crops.
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plants as targets of opportunity for marketing of high-value protein products. However, 
that’s not all that plants have to offer. 
Plant systems do not harbor human or animal pathogens (such as virions or prions) 
and, therefore, they do not transmit such pathogens along with the target subunit vac-
cine. Moreover, they cost less to produce than via fermentation or bioreactors; plants can 
be grown in the field or in a greenhouse relatively inexpensively (Howard, 005). When 
produced in edible parts of the plant, such as grain, fruit or even leaves, subunit vaccines 
may not require purification. Maintaining the antigenic protein within plant cells that 
are edible may also contribute to stability and reduce degradation. Another advantage 
of producing subunit vaccines in edible parts of a plant is the potential to deliver them 
orally rather than intramuscularly (Streatfield and Howard, 003), providing a simple and 
easy means of administration to humans and animals. Moreover, oral delivery stimulates 
mucosal immunity (the first line of defense) in the tissues lining the mouth, nose and 
esophagus (among others) that provide the first target of opportunity for pathogens to 
enter and infect the human body. In addition, production in plants reduces the overall 
cost of vaccinations, which is often prohibitive in developing countries; for example, 
sterile hypodermic syringes are not required.
The advantages and opportunities from producing subunit vaccines in plants may be 
summarized as follows:
• Elimination of risk of contamination with infectious agents
• With oral delivery, they activate the mucosal immune system—the first line of 
defense
• Avoidance of injections
 – Improved patient compliance
 – reduced risk of transmission of other infectious agents through contaminated 
needles
• Longer shelf-life
• Cost-effective in large quantities
However, myriad challenges are yet to be overcome before the promise of this technol-
ogy will be fully realized.
Challenges
The challenges facing plant-based-vaccine development include technical, regulatory and 
economic aspects and public perception. Among the technical challenges it is critical to 
select a plant system that can be grown under conditions that minimize environmental 
risks, such as transfer of pollen from transgenic to conventional varieties or to related 
The	challenges	facing	plant-based-vaccine	development	include	
technical,	regulatory	and	economic	aspects	and	public	perception.
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species. Expression of antigens in plants is a major regulatory concern. Whether or not 
the protein is confined to specific tissues will enable or nullify exposure to the environ-
ment. targeting expression via a tissue-specific promoter driving the transgene may 
reduce regulatory concerns (Korban, 00). For example, elimination of expression of 
the transgene in pollen will reduce dissemination of the antigenic protein to other plants 
and alleviate environmental contamination, although not completely.
Among other technical challenges to be considered, the crop should provide ample 
biomass for accumulation of a sufficient quantity of the antigenic protein. Whether it is a 
grain, vegetable or fruit crop, protocols will be needed to ensure transcription, translation, 
intracellular localization, tissue specificity, adequate gene-copy number, and metabolism 
and accumulation of the protein of interest (Buetow and Korban, 000; Streatfield and 
Howard, 003). Determining the level of expression of the transgene and stability of 
expression over generations of the transgenic line will be essential for determining the 
economic feasibility of a proposed plant-based vaccine. Depending on the target protein 
product, levels of 0 mg/kg of plant dry weight of a crop may be sufficient, although levels 
of 00 mg/kg or higher are more likely to be necessary (Howard, 005). Approximately 
50 kg per year of a particular antigenic protein would certainly meet economic feasibil-
ity. Other issues related to technical challenges include formulation: will the vaccine be 
marketed as an encapsulated powder, a concentrated liquid or a nasal aerosol? By what 
route will it be delivered? What will be the proper dosage? Would a single dosage suffice, 
or will (a) booster(s) be necessary? All of these technical questions are yet to be answered 
for plant-based vaccines.
Among regulatory challenges, issues relevant to any genetically modified (GM) crop 
that have to gain regulatory approval from the USDA, FDA and/or EPA apply to plant-
based vaccines. In addition, issues related to separation of a pharmaceutical product from 
the original crop targeted for the food chain have become increasingly important as con-
cerns over adventitious presence of medicinal products in the food supply have surfaced 
in recent years. Physical separation of dual-purpose crops is needed—whether achieved 
by geographical isolation or by greenhouse containment—as is dedicated equipment for 
harvesting and handling, as well as standardized monitoring procedures. Concerns over 
the use of food crops for production of plant-based vaccines have been accompanied with 
calls for targeting non-food crops for pharmaceutical purposes, whether for the production 
of therapeutic proteins or plant-based vaccines. However, as indicated above, food crops 
remain highly desirable as targets for production of plant-based vaccines because of their 
amenability for oral delivery, avoiding the necessity for isolation and purification of the 
subunit vaccine prior to delivery. In addition, regulatory issues related to clinical trials, 
going through phase I–IV trials—similar to any other pharmaceutical product—must 
be pursued to assess efficacy, safety and reliability, followed by FDA approvals. For more 
than 30 years, live attenuated vaccines have been produced in SPF eggs, and success-
fully used to immunize infants and adults against common diseases such as measles and 
mumps. So, how can we take advantage of the regulatory history already established by 
the vaccine industry to push for plant-based vaccines?
7 Agricultural Biotechnology: Beyond Food and Energy to Health and the Environment
Expanding Markets
Until recently, the vaccine market was considered low-margin, but that is changing as 
technology advances and new diseases are being addressed with vaccines. Worldwide, 
the market is $ billion according to Peter Young, CEO of AlphaVax (research triangle 
Park, NC), which is developing viral-vector vaccines for HIV, malaria, Marburg virus 
and cancer, among others. At least one plant-based vaccine must prove to be an economic 
success story in order to pave the way for others to make it through to commercialization. 
This new technology may also serve as a platform for delivery of multiple antigens against 
several economically important diseases. This would certainly alleviate economic concerns 
over the plant-based vaccine approach, and boost its impact on the market.
Three years ago, the Partnering	 for	Global	Health	Forum [co-sponsored by the Bio-
technology Industry Organization (Washington, DC) and the Bill and Melinda Gates 
Foundation (Seattle)] brought together individuals from biotechnology companies, 
government agencies, foundations, and NGOs interested in pursuing biotechnology-
based solutions for overcoming malaria, tuberculosis, typhoid, cholera, dengue fever, 
river blindness, AIDS and other diseases that plague developing nations. This was the 
beginning of an ongoing process to match funding sources and biotech companies, and 
to influence legislation and the regulatory process to encourage drug development for 
impoverished markets. Many biotechnology laboratories currently have proven technol-
ogy and compounds ready for late-stage development, but lack funding to bring them 
to fruition to assist the individuals who need them. The message of the meeting was that 
funding from foundations, the government, and not-for-profit groups is available to further 
these efforts. Unfortunately, plant-based vaccines were not specifically spelled out in the 
announcement for request for proposals, although it was clear that this technology has 
great potential to help meet the goals of this major worldwide initiative. 
As for the issue of the public’s acceptance of plant-based vaccine technology, it is im-
portant to point out that the pharmaceutical industry has become a target for critics, and 
negative opinion is reflected in public polls. In a Kasier Family Foundation poll (spring 
005), pharmaceutical companies were ranked seventh in a list of nine industries, deemed 
less trustworthy than HMOs, but more trustworthy than oil and tobacco companies.
The pharmaceutical industry estimates that the cost of bringing a new chemical entity 
to market is around $800 million (including time-value of money; i.e., factoring in the 
interest a company has to pay to borrow capital). Therefore, it is deemed justifiable that 
the public pays more in order for these drug companies to see returns on their invest-
ments. This, in turn, has contributed to the public’s anger over drug prices. The shortage 
of influenza vaccine supply in the winter of 00–005 revived an issue that predates 
the biotech industry: what is the best way to make vaccines? For the influenza vaccine, a 
confluence of cost, pricing legal liability, and inertia provides an odd, but now familiar 
answer. Influenza vaccine is produced in chicken eggs, a manufacturing process blessed by 
regulatory bodies worldwide despite the fact that it has not been substantially upgraded in 
0 years. The plant-based technology may circumvent long-standing production problems 
inherent in the egg-based system.
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Summary
Producing vaccines in plants offers numerous advantages over current vaccine methodolo-
gies. Among them, safety, ease of production and low cost of production provide strong 
justification for developing the technology. However, many challenges remain within the 
pharmaceutical industry; requirements for generating non-food products in transgenic 
plants are different from those for food products. These challenges include technical, 
regulatory, economic, and public-perception issues. Physical isolation, delayed planting, 
agronomic support, dedicated equipment and frequent monitoring all contribute to the 
technical challenges involved. 
As the technology to produce vaccines in plants goes through the regulatory pathway 
and demonstrates its economic feasibility, it may also overcome public-perception con-
cerns that seem to have been dodged by the pharmaceutical industry. The likelihood that 
plant-based vaccines can be administered via oral or intranasal delivery systems will also 
add to their desirability as well as their economic benefits. There is potential for major 
impacts on global health, particularly in developing countries. However, standardized 
safety-assessment models must meet with approval from the general public along with the 
regulatory agencies and other interested parties. risk assessment must be science-based in 
order for the results to be believable and trustworthy. Funding of research will accelerate 
the advances made thus far, and bring this technology closer to commercialization and 
worldwide use. 
Producing	vaccines	in	plants	offers	numerous	advantages	over	
current	vaccine	methodologies.	However,	many	challenges	remain.
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Module I
Plants as New Sources of Medicinals:
Production of Protein Pharmaceuticals in Food and Non-Food Plants
Panel Discussion and Q&A
Moderator:
Anthony M. Shelton
Cornell	University
Ithaca,	NY
Panelists:
Henry Miller Mark Nelson
Hoover	Institution	 Grocery	Manufacturers	of	America
Stanford,	CA	 Washington,	DC
Henry	Miller: I’m sure you are all familiar with the adage that the three most important 
factors in the value of real estate are location, location and location. Well the equivalent 
in public policy is context, context and context. Unfortunately, public-policy discussion 
groups, like Pew, the misnamed Center for Science in the Public Interest, Greenpeace, 
the Union of Concerned Scientists and other anti-technology groups consistently omit 
the context that is essential for judging and crafting public policy toward recombinant 
DNA technology and products from it. Contrary to these organizations’ claims that they 
are nonpartisan and agnostic and honest brokers about biotech, in fact their workshops, 
conferences and publications invariably show a pervasive risk-averse and pro-regulatory 
bias and they attempt to create a presumption of genuine controversy where none ex-
ists. Mr. rodemeyer’s comments earlier seemed very moderate, so you have to scratch 
beneath the surface a little bit to find the disingenuousness. He spoke about unique re-
quirements for recombinant-DNA modified organisms. And he mentioned animals and 
forestry. In fact, as roger Beachy pointed out several times, it’s not the technology that 
should serve as the trigger for regulation, rather it’s the intrinsic risks imposed by the host 
organism and any new traits that have been introduced, whatever the technology that’s 
used. Genetically improved trees and forestry are not, in effect, new. Who here would 
say that the forests that were planted and maintained by companies like Weyerhaeuser 
and Georgia Pacific are not in fact genetically engineered. Animals are a good example. 
There are animals that are natural mutants about which we might be concerned. There 
is a natural mutant of the rat, that’s about five times larger than normal. regulators 
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aren’t interested in that, but they are interested in innocuous organisms that have, say, a 
marker gene introduced with recombinant DNA techniques. Often on bulletin boards 
I see advertisements for animals that have resulted from a cross between a timber wolf 
and a German shepherd. Some of these are F generation and three-quarters timber wolf 
and one-quarter shepherd, and these aren’t regulated. Perhaps they should be—they have 
potentially worrisome characteristics. What’s the motive for these misrepresentations, this 
lack of context about biotech and about process versus product as a trigger for regulation? 
Activists understand that over-regulation is an effective tool to inhibit innovation and to 
slow the diffusion of even a superior technology or product of which they disapprove, 
and they’ve had modest success. You’ve heard how expensive and debilitating our current 
regulatory schemes are.
What is the essential context that I’m referring to? It has to do with food safety so I 
won’t belabor this, but, as you are aware, with the exception of wild berries, wild mush-
rooms, wild game and fish and shellfish, virtually all of the organisms—plants, animals, 
microorganisms—in our food supply have been modified by one genetic technique or 
another, and in crude and sometimes unpredictable ways. Second, because recombinant 
DNA techniques are more precise than their predecessors, biotech-derived plants and 
foods, including those making PMPs and other industrial materials, are likely to be even 
more safe, more predictable than other products. Yet, they alone are much more highly 
regulated. And so we’ve ended up with a regulatory process in which there is an inverse 
relationship between risk and the degree of regulation, which makes absolutely no sense. 
Third, the FDA does not normally perform safety determinations on new food varieties, 
but primarily conducts surveillance of marketed foods and takes action if any are found 
to be adulterated or misbranded. And lastly, unwarranted excessive regulation discourages 
innovation, imposes costs that are passed along to the consumer and are a disproportion-
ate burden on smaller companies and academics. Again, roger Beachy talked about how 
debilitating regulation and its expense and its distraction have been to research in the 
public sector. Nina Federoff made that point repeatedly in her excellent book, Mendel	
in	the	Kitchen. In both flagrant and subtle ways, anti-biotech lobbyists and propagan-
dists—that’s really what they are—continue to perpetuate various manifestations of the 
big lie. That is, that agbiotech is untested, unproven and unregulated. Their agenda is 
not to advance environmental protection or public health, but really to arrogate control 
over what r&D can be done and which products and technologies can have access to the 
market place. You heard a very moderate sounding presentation from Mike rodemeyer. 
Don’t take my word for it. Go to Google and put in my name and Pew or my name and 
Pew and biotech and CSPI and read the articles. You will get hundreds of links. Some of 
these articles are peer-reviewed and you can examine them for yourself. Also look at the 
specious surveys that these organizations have done and the extremely poor, unscholarly 
quality of the reports they produce and make up your own minds.
Much of the anxiety about the kinds of products that we are concerned with here does 
not take into account the realities of contemporary agriculture. As you’ve heard and as you 
know, gene flow is ubiquitous. Gene transfer is an age-old consideration for farmers and 
plant biologists. Farmers in North America who grow hundreds of crops, virtually all of 
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which have been genetically improved in some way, have meticulously developed strategies 
for preventing cross-contamination in the field, when and if it is necessary. The demands 
by some, including parts of the food industry, for food plants to be largely off limits for 
biopharming are really quite absurd. At the same time that such a prohibition would 
 offer minimal incremental safety, it would severely stigmatize the technology and push the 
development of costs of biopharm products into the stratosphere, limiting development 
to very high value-added substances and inflating the ultimate costs to the consumer of 
those few products that do reach the marketplace. USDA’s approach to regulation of 
biopharm crops, which, by the way, largely follows the demands of the food industry 
and the radical environmental lobby, is unscientific and debilitating: purely technique-
based, process-based triggers to regulation. typical of federal agencies whose approach 
to the regulation of recombinant-DNA-modified plant varieties in general, USDA’s rules 
impose highly prescriptive design standards that don’t take into account the actual risks 
of a given situation, but mindlessly dictate one-size-fits-all requirements. Moreover, the 
regulators exclude the establishment of tolerance levels although, ironically, regulators 
have established tolerances for unwanted contaminants in food, including fungal toxins, 
insect parts and rodent droppings. Although we do have long experience in segregating 
crops when necessary, human error is inevitable so it’s reasonable to ask what the likeli-
hood is of consumers sustaining injury in a worse-case scenario in which biopharm crops 
enter the food supply. Well, consider that, first, the active substance would have to be 
present in the final food product, say tofu or a salad dressing made with soybean oil, or 
in corn chips, at sufficient levels to exert an adverse effect, the result either of direct toxic-
ity or allergy. But as with the ProdiGene incident several years ago in which biopharm 
corn stalks that contaminated a subsequent crop of soy, in most instances there would 
likely be a huge dilution effect. For example in the ProdiGene case, miniscule amounts 
of biopharm corn stalks and leaves were pulled into a massive soybean harvest. Second, 
the active agent would need to survive milling and other processing and cooking. Third, 
it would need to be orally active, as, by the way, the ProdiGene product was unlikely to 
be. And in any case it was simply a vaccine protein that was intended for veterinary use. 
So the probability that all of these events would occur is extremely low.
The regulatory obstacles to many of these products are going to be prodigious. Hav-
ing spent 5 years as a federal regulator, I can tell you that regulators are suspicious of 
innovation, they are uncomfortable with new technology and the easiest way to cope 
with it is simply to stall, not to approve much, to ask for more and more studies and to 
be extremely, conservative.
Tony	Shelton: Okay. That will certainly open up some questions. I was just looking over 
the NABC theme, which is providing an open forum for exploring issues in agricultural 
biotechnology, so we will certainly have an open forum on that. Mark?
Mark	Nelson: There are some people in the food industry who, if PMP plants were planted, 
grown, harvested and processed on the moon, that would be fine with them, but the 
position of the Grocery Manufacturers of America (GMA) is a little more nuanced than 
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that, and I will return to that. GMA is the largest food-, beverage- and consumer-products 
association in the world. Our 0 members have a combined sales of about $500 billion 
a year, with two and a half million employees in all fifty states. Somewhat above 95% of 
supermarket products are from GMA’s members. The earlier talks in the plenary session 
and then what we heard from the two previous speakers, I found fascinating—intellectually 
very stimulating. You folks doing this every day, you reach these goals, you make these 
accomplishments, it has to be incredibly satisfying and no doubt I will be a beneficiary 
from some of these products in the future. But the concern the food industry has with 
this is the simple fact of adulteration. It may not be a safety issue, but while we do like 
to talk with our consumers, we don’t like to have conversations like: “About that cancer 
drug in your corn flakes? Don’t worry, the FDA says its de	minimis.” Our concern is not 
based on marketplace issues as was mentioned earlier, e.g. that company A would say 
company B’s product is contaminated. There are people like that in the food industry—as 
there are in any industry—but most don’t engage in schadenfreude because they know it 
could happen to them. They have a common approach to make sure that the food sup-
ply continues to be safe. It comes down to our pocketbooks. If you have an adulteration, 
it will cost a lot of money to deal with it, particularly where a safety evaluation in the 
food has not actually been done yet. That’s why, as an organization, we have asked FDA 
on more than one occasion for more regulation. Now I know that’s different from what 
Henry was just talking about and what we heard earlier, but again it depends on context. 
As I understood it, your concern and your frustration was with regulation of transgenic 
events and it makes a lot of sense to me that if it’s the same event or the same gene, why 
do we have to reinvent the wheel every single time. We are Homo	sapiens, we should be 
able to learn from experience. But, in our situation—in the food industry—we want to 
make sure that the food supply is safe, and, currently, as these PMPs are being reviewed 
for field tests there is no full safety evaluation of the implications if these are commingled 
in the food supply. The FDA in its own documents and proposals for various guidelines 
and regulations has indicated that as these field tests increase in number, the probability 
of commingling also is likely to increase. Dr. Davies mentioned some very compelling 
points about why there is increasing pressure to make pharmaceutical proteins in plants. 
It makes a lot of sense. And while the economics would suggest that we are not going to 
rush to tobacco any time soon, the fact of the matter is we do know a lot more about some 
of the food crops and have experience in handling and managing them, and so they make 
perfect vehicles. Dr. Korban mentioned oral vaccines with fresh tomatoes and carrots, 
providing a new take on the concept of health-food stores. But regulations already exist 
for those, which would be considered drug-delivery vehicles and they would have to be 
separated; they wouldn’t be in our food supply. So what have we asked FDA to do to help 
maintain the safety of the food supply, to allow PMPs to deliver benefits but at the same 
time make sure that the food supply is maintained in a safe way? We have asked for a 
mandatory food-safety review for these. Currently, a PMP would be evaluated by USDA 
by the APHIS Biotechnology regulatory Services and it would deal with the center in the 
Food and Drug Administration responsible for drugs. [audio lost] Specifically, we have 
asked FDA to evaluate the compound, look at the quantity in the food, the impact of the 
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food in the diet, look at the possibility that it would be changed or degraded or denatured 
by processing and then assess it against existing regulations. Some of these proteins may 
in fact already be approved food additives or GrAS substances, in which case if they got 
into the food supply they wouldn’t be a problem, unless they were in foods that they are 
not supposed to be in or if they were at levels that were beyond the regulatory limits. But 
those probably are few and far between. If it is not a GrAS substance or a food additive 
then by definition it’s an adulterant and what we have asked then is for FDA to set up 
reasonable approximate standards. If a crop contains this compound at X level, at 0 or 
5% and there is no health problem, then perhaps you just need a simple Class- recall. 
On the other hand, if the amount in the food supply is at a dangerous level then there 
should be a Class-3 recall if it’s in the food supply through commingling. Then that food-
safety assessment should be used to inform the permit requirements. So perhaps there are 
different levels of physical separation or biological separation. The gene-control cascade 
concepts we heard of earlier would probably be something that would be very helpful to 
limit that. Dedicated equipment, trained employees with standard protocols are already 
being asked for by USDA and those would make perfect sense in our estimation as well. 
So, as I said earlier, some people in the food industry would like to see these things grown 
on the moon, but we recognize that that’s not feasible but we do think that we can use 
our experience and our knowledge and existing regulations to take a much more reasoned 
and nuanced approach to help the biotechnology industry—and particularly the PMP 
part—develop and also maintain a safe food supply.
Shelton:	Are there questions from the audience or questions that panelists would like to 
ask each other?
Steve	Rock	(Environmental	Protection	Agency,	Cincinatti,	OH): As a research scientist, the 
definition of “side-effect” was something I didn’t think about or didn’t want to think 
about. And I want to ask the panelists to think about what happens if you change your 
mind. And in terms of what Mark was saying about recalls—we have had recalls. We 
have had products that we put into the food supply that we decided we didn’t want in 
the food supply and were able to recall at some point—cyclamates, red dye #. Those 
things were fairly easy to extract from the process. And I wondered if you all have thought 
about how easy it would be to extract these from the process? As a scientist in research and 
development, I don’t know anybody who is against innovation. Most of my colleagues 
in the research world are all for innovation as long as there is a significant probability of 
getting it right, and when you miss there is some way to correct the error. I spend a lot 
of my time cleaning up historical contamination on hazardous waste sites, specifically 
oil and DDt. The oil I’m working with has been in the ground since rockefeller set up 
his first refinery, 00+ years ago. And although DDt hasn’t been used since the 90s 
in the United States, we still find it in food supplies around the world. It’s hard to get it 
back into the bottle once you let it out. And there are other examples from the world of 
1Generally regarded as safe.
Panel Discussion/Shelton, Miller, Nelson
8 Agricultural Biotechnology: Beyond Food and Energy to Health and the Environment
ecology—rabbits in Australia, innocently released into the environment and it’s now one 
of their biggest problems. I am wondering how to make it possible to recall our mistakes, 
which is why it makes a lot of sense, not to stop progress but to go very, very slowly. 
twenty years in terms of technology innovation, seems like a huge amount of time. We 
run on a time scale where a long-term investment is 3 months. And that’s crazy. We have 
to be thinking on at least a generational, if not a geological, time scale because that’s what 
we have to live with. How do you put the genie back in the bottle and what do you do 
when you change your mind?
Miller: We just had a good example. I hope I don’t understate it when I say that that’s why 
EPA may be the worst regulatory agency in the history of the world. I gave the example 
of the ice-minus fiasco. Nobody, I think, is arguing that there shouldn’t be any regula-
tion. What we are arguing is that it should make sense, it should be based on science 
and that the triggers for regulation should be risk-based. I’ll give you an example. About 
0 to 30 years ago, a new variety of wheat was developed in a number of countries, the 
United States, the Soviet Union, Germany and so on. This construction contained all the 
chromosomes, all of the genes of bread wheat plus all of the genes of wild quackgrass or 
couch grass. So it contained the entire genome of red wheat and tens of thousands of new 
genes that were introduced who knew how, who knew with what effect. Nobody, least of 
all, EPA or other regulators or the anti-biotech activists asked whether the introduction 
of these genes from a wild grass could make the plant more weed-like, more aggressive 
in the field, nobody asked whether the gene products of any of these tens of thousands 
of new genes could be toxic or allergenic in any way. And so these went into the field, 
they went to large-scale, they went to commercial scale, they went into the food supply 
with no oversight and not a whimper. But now if someone were to move a single gene 
of couch grass into Triticum using recombinant DNA techniques—even a housekeeping 
enzyme of some sort—it would bring down this massive, debilitating, very expensive, very 
lengthy regulatory process from EPA and/or USDA and/or FDA, adding tens of millions 
of dollars to the regulatory process. This is irreconcilable scientifically. It’s preposterous. 
roger and I are arguing, not for the absence of regulation—that it be rolled back—but 
that it be rationalized, that it make some scientific sense.
Shelton: I wonder if the previous speakers, Davies and Korban, who commented on that 
technology, have any questions for the panel members.
Maelor	Davies:	Thank you. With the Nicotiana system—we don’t call it tobacco because 
we are using other species, we are moving away from conventional crops—we hope to 
facilitate further development of PMPs with a plant that cannot cross-pollinate with the 
existing related crop, conventional tobacco. It will be different enough to represent a 
unique plant variety for PMPs. My hope is that, as we do that, if those companies—and 
we do work with all the companies that have significant activity now in tobacco-based 
2See page 53
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PMP technology—can also advance our situation we may be able to prototype, as it 
were, a larger-scale commercial PMP in the field setting. In time then, that may enable 
companies with food-plant-based PMP technologies to advance as well. So, we hope to 
facilitate the whole thing almost by circumventing this issue for the time being. We’ll 
just have to see how that goes and how that develops.
I hope that I didn’t, in any way, cast any negative perspective on USDA. I think USDA-
APHIS-BrS is doing what it has to do. It has to go carefully and check out every detail 
of this whole PMP situation. But what I did point out is that those regulations—such as 
they are today—are probably not commercially workable. temporary stringency is neces-
sary to build up a comfort level, and as experience is gained in the field we will look at 
gene flow. At our center, we are designing specific experiments to look at these issues over 
the next few years to examine how effective is the mandated containment, what is the 
gene-flow situation and other such issues. My hope is that eventually things can lighten 
up significantly because the regulatory system needs to be one that companies can work 
with economically, commercially successfully, and that growers can afford to implement 
and safely and routinely comply with, without excessive cost.
Miller: One set of precedents, although they are not perfect for PMPs, are such pharma-
ceuticals as morphine, codeine and even Metamucil®, which come from plants and with 
which regulators and industry and consumers have a great deal of experience.
Schuyler	Korban: I would echo the comments just made. We do not object to the regula-
tory processes as long as they are based on sound science and are realistic. Vaccines are 
produced in eggs or in yeast cells, both of which are part of our food supply. We have to 
similarly isolate those food crops that are used as vehicles for producing subunit vaccines 
or other therapeutic proteins. And we heard of some of the ways of reducing or minimiz-
ing or essentially eliminating their presence. However, there is no such thing as 00% 
safety in anything that we deal with. With any of the food or environmental issues that 
we are trying to resolve, there is no such thing as a 00% guarantee for anything. We can 
think in terms of minimizing the risk and that’s being realistic. Our expectations must 
be sound, science-based and realistic.
Nelson: I agree that the regulations need to be based on sound science and they need to 
be proportional. That’s why we are suggesting that permit requirements be based on the 
potential risk if the product were to get into the food supply. And I agree with that no 
system is 00% perfect. That’s why we are asking that safety evaluations be done ahead 
of time so that we understand what the agencies’ actions will be ahead of time, so that 
we can work with them. We want to avoid another StarLink™ situation, which ended 
up not being a safety issue but an adulteration issue that caused hundreds of millions 
of dollars in recall costs and the food safety system took a dent. And we have had huge 
decline in corn exports because of that exercise and that experience. So, we would like to 
make sure that it’s proportional and know ahead of time what it is we are going to do. 
We’re smart enough to do that. We’re smart enough to make that kind of assessment so 
we aren’t scrambling around like a bunch of chickens.
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Shelton: Speaking of chickens and eggs and their getting into the food system—if the 
plants are not going to be grown on the moon, like you said, but if they were grown in 
the field like tobacco would that be something that GMA would support—the idea of 
producing PMP’s in tobacco?
Nelson: Well it’s a non-food crop, but clearly the smoking and chewing tobacco industry 
has certain concerns about GMOs, I guess. Yeah, our preference would be for non-food 
crops. But, we know that that is not always going to be economically or biologically 
feasible. We are asking that if it is grown in a food crop, that the assessment is done and 
then appropriate controls be put in place to manage it so that we do minimize entry into 
the food supply.
Shelton: GMA has a tremendous amount of clout. The decisions that you make are re-
ally going to affect PMPs in the future. Have you given guidelines in terms of crops that 
would be acceptable and not acceptable?
Nelson: No we haven’t gotten into that detail because we are not experts on particular 
crops. For the primary food crops—wheat, corn, soy, rice—field tests are limited at this 
point. We are concerned that management controls be in place. We are seeing that in 
some of the permit requirements now coming out for such field trials; they do seem to 
be stronger. They emphasize greater separation, better training, and so on, to make sure 
that they are contained.
Gregory	Jaffe	(Center	for	Science	in	the	Public	Interest,	Washington,	DC): Going back 0 to 5 
years, a combination of small and large multinational companies did a lot of the research 
on the GM plants that eventually were commercialized. In the bio-pharming/vaccine area 
some very small companies are involved and the multinational pharmaceutical companies 
are not. Why is that? Why are the big, multinational companies that are producing these 
kinds of drugs and biologics, not doing research and field trials in this area? Also, will the 
success of these products need those companies to get involved as partners or to assist 
in bringing the products to market?  I’m sort of curious as to why they haven’t become 
involved. The speakers listed all the benefits of this type of production model, so why 
aren’t they dabbling in this?
Korban:	It is surprising, considering the advantages of using plants for developing vaccines, 
not only from a production standpoint but also from a delivery standpoint. But, the way 
I understand it is that the vaccine industry is not very big and the margin of profit is not 
very high. As a result, interest is not strong at this point. However, with the recognition 
that they need to move away from animal-source contamination of biopharmaceutical 
products I think you will see expressions of interest, including from Monsanto. The big 
pharmaceutical companies are not partnering—especially with university researchers—to 
push this further. If major investment in this technology does not come along, it will 
fail eventually.
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Davies: I would certainly concur with that. We’ve thought about this for a number of years 
and we’ve talked to the industry both on the ag side and the pharma side. Let me hit on a 
couple of points. First of all, the technologies for expression in plants were initiated mostly 
by university faculty who then started companies. In other words, the big guys didn’t have 
the technologies. But that isn’t the ultimate answer because then you could ask why doesn’t 
big pharma or big ag invest in or acquire them. We were very encouraged early in 005 to 
get a visit at our facility by a major pharma company. I’m not at liberty to say who it was, 
but that company is becoming concerned about the pressure on protein production and 
is beginning to scout out and explore the plant-based technologies. But why has it taken 
so long to get to this point? It’s a business issue. It has to deal with big ag companies and 
big pharma having their particular strategies. In the case of big ag, not owning the drugs 
means that they don’t see how they would make sufficient money out of it ultimately. 
On the big pharma side, they tend to be very conservative and very cautious about even 
new drug technologies. They are waiting for university spin-off drug companies to prove 
that their particular vaccine or whatever is a real winner and then they will come in and 
acquire it. So it has to do with business play and market fit and corporate-strategy fit and 
similar issues. I think that increasing demands for proteins will eventually change this 
paradigm and make big pharma pay attention to these alternative platforms.
Tom	Reddick	(Global	Environmental	Ethics	Council,	Clayton	MO): Glycosylation was men-
tioned. I heard that hamster ovaries are used for mammalian cell lines to create proteins 
that will glycosylate properly. Is that a technical hurdle that lies in the future? Will the FDA 
balk at approving a plant system for efficacy if it doesn’t glycosylate like a hamster?
Davies: Probably yes to all of the above. There are certain modifications to proteins that 
animal cells do, including glycosylation—attachment of carbohydrates—that plants either 
don’t do or do differently. This is a challenge that the microbial fermentation world has 
also been somewhat limited by and that’s why mammalian systems are used to produce 
mammalian protein drugs. Some protein drugs will not be suitable for plant-based 
production. They would be more suitable for mammalian cells in culture or whatever. 
If it turns out that the non-protein component, the carbohydrate substituent, is not es-
sential for function, the plant-made protein with the necessary biological function but 
without the substituents might be regarded as a new drug and need to be registered as a 
new synthetic. We’ll see how those things play out in time. We don’t know the complete 
portfolio of products that the PMP companies are looking at, but we certainly get the 
sense that they are focusing on the ones for which this will not be an issue. Dr. Beachy 
has alluded to some work that is going on to actually modify the plant so that its produc-
tion of the substituent groups, like these carbohydrates, would be so-called “humanized.” 
Probably quite a lot remains to be done for that to be successful because differences in 
the carbohydrates are quite complex.
William	Goldner	(USDA	Small	Business	Innovation	Research	Program,	Washington,	DC):	If 
you produce industrial enzymes or industrial proteins in crop plants are the same issues 
faced as for pharmaceutical proteins?
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Nelson: Yes. We have raised the same concerns with the FDA, not just with reference 
to PMPs but also plant-made industrial chemicals. The same issues apply, but it would 
be an adulterant. The safety issues may not be as great, but we have asked that it be 
looked at.
Miller: Once again, it’s useful to look for applicable precedents and a very good one is rape 
seed. The original rape seed oil was highly toxic. It was used as an industrial lubricant; it 
couldn’t be used as a cooking oil because it was extremely toxic. Plant breeders came up 
with what is called a “double-low” variety, low in erucic acid and glucosinolates. Both 
varieties are still grown—one to produce industrial lubricants, one to produce canola 
oil—and we’ve established means for keeping them segregated. We’ve established tolerances 
for the toxins in food. Again, it’s extremely useful and important to look for applicable 
precedents to figure out where we need to go and what makes sense.
Milt	Zaitlin	(Cornell	University,	Ithaca,	NY). I’ve seen in the literature that some plant-
based vaccines do elicit antibodies, but why don’t other proteins that we eat also elicit 
antibody formation? I guess people get allergenic responses to wheat proteins and so 
forth, but what characteristics would lead you to believe that a transgene product would 
be more immunogenic than normal proteins that we eat?
Korban: You could ask the same question of any vaccine that you take, especially when 
you are dealing with subunit vaccines. These are antigens that produce specific antibodies. 
All we are doing when we use plants to produce such an antigen is to provide a vehicle for 
production. Now you can purify that antigen if you so desire and introduce it intramus-
cularly. That’s what the tobacco system would be used for. Or, you can strictly consume 
it orally without purification in that plant system.
Zaitlin: I don’t think you’ve answered my question. We’re talking about an oral route. 
We’re not talking about injections.
Korban: The way to think about it is that with the antigen administered orally, it’s inducing 
specific antibodies that provide protection. Now, there are other proteins within the plant 
system that we ingest that are used to provide nutrition and do not induce antibodies 
except if a protein is allergenic and that’s when you have a concern over ingestion of this 
particular protein. I don’t know if I’ve answered your question correctly.
Elizabeth	Hood	 (Arkansas	State	University,	 Jonesboro,	AR): At ProdiGene we did some 
animal experiments to address this issue. There’s a distinction between whether or not 
you make antibodies against a protein that you ingest vs. having an allergic reaction. The 
rabbits had already raised their own antibodies to orally consumed corn-seed proteins 
that were naturally there. So, we made our own antibodies for testing on pre-screened 
rabbits that did not already have these antibodies in their blood serum. There’s been a 
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lot of misuse of the term “immunogenic response” with respect to food based proteins. 
We make a lot of antibodies to things that we ingest; they are not all allergic reactions. 
The mechanism of making antibodies against an orally consumed antigen is a normal 
response to proteins that we ingest. We make antibodies to lots of things that we ingest, 
we just don’t always have allergic reactions to them.
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Edenspace Systems Corporation seeks to transform industries with innovative plant-based 
services and products that protect health, increase property values and improve environ-
mental quality. Within the general area of environmental phytotechnologies, the company 
has specialized in the use of plants to extract minerals from soil and water, with more than 
three dozen successful contracts completed or ongoing. Current company research seeks 
to develop multi-trait plants for biosensing, phytoremediation and renewable energy. 
The company’s -year experience as a commercial pioneer in environmental phyto-
technology has provided it with an unusual perspective on the intersection of agriculture, 
biotechnology and the environment. Four of Edenspace’s current projects illustrate some 
of the opportunities and challenges presented by this confluence: 
• using ferns to remove arsenic from soils in a Washington, DC, suburb; 
• engineering plant biosensors—“phytosensors”—to detect and monitor environ-
mental parameters such as heavy metals; 
• engineering plants to produce higher yields of ethanol per acre; and
• forming a new agricultural cooperative to provide additional income to producers 
who work on environmental projects.
After summarizing these projects, I will list some conclusions and recommendations 
as to where agriculture, biotech and environment may intersect in the future.
Environmental Phytotechnology Projects
Arsenic	Phytoremediation
In 005, Edenspace expanded a project with the US Army Corps of Engineers to remove 
arsenic from soils of residential properties in Washington, DC. The project uses Edenspace’s 
edenfern™ phytoremediation plants to extract and concentrate soil arsenic in fern fronds, 
which may then be harvested for safe disposal. 
Systems Agriculture:
Towards a Sustainable Agricultural and 
Environmental Policy
Bruce W. Ferguson
Edenspace	Systems	Corporation
Dulles,	VA
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In 00, approximately ,800 edenfern™ plants were installed in fourteen test plots 
at three different sites in the Northwest Washington suburb of Spring Valley. The ferns 
showed excellent growth and arsenic uptake, removing an average of approximately 9 
mg/kg of soil arsenic across all sites from starting concentrations that ranged from  to 
7 mg/kg. remediation activities were completed with no apparent harm to specimen 
trees or shrubs, and with little interference to homeowner activities on the properties. 
Importantly, many of the edenfern™ plants overwintered and showed new growth in 
spring 005, a key to reducing costs of arsenic phytoremediation in northern latitudes. 
Based on these results, in 005 the project scope was increased significantly, with 0,000 
ferns planted on thirty-four plots at twelve residential sites.
The techniques under evaluation in this ongoing project include the planting, cultiva-
tion, treatment and harvesting of special ferns that accumulate large quantities of arsenic 
in their fronds. The edenfern™ has demonstrated that bioconcentration coefficients (ratios 
of arsenic in the plants to arsenic in the soil or water) greater than 00 promise much 
lower costs for removing and disposing of this dangerous element. For example, at some 
sites phytoremediation of arsenic may cost as little as 0% of the cost of excavating and 
removing contaminated soil. The technique also may be useful at sites where excavation 
is difficult, such as near valuable landscaping plants or above buried pipes or cables. 
The arsenic-extracting capabilities of the edenfern™ were discovered by Dr. Lena Ma of 
the University of Florida. Edenspace has signed an exclusive license agreement with the 
university, which has received two patents based on the discovery, to enable cost-effective 
commercial cleanup of arsenic from soil and water. 
Arsenic causes cancer, mutations and birth defects and also has been associated with 
the development of diabetes. The element was once widely used in insecticides in farm-
ing, gardening and ranching, and is used as a component of preservatives in lumber and 
furniture. In some parts of the world, arsenic occurs naturally in groundwater. In some 
states, decades after arsenic was introduced into the environment, soil concentrations can 
be hundreds of times higher than the residential standard. Because of its toxicity to humans, 
farm animals and household pets, the stability of its compounds in soil and groundwater, 
its once widespread use, and the lack of cost-effective remediation techniques, arsenic 
today constitutes a significant environmental health hazard. 
The ability of plants such as the edenfern™ to serve as solar-powered pumps and filters 
for removing environmental contaminants offers numerous potential advantages over 
other remediation techniques. These advantages include preservation of topsoil, potential 
recycling of contaminants, joint products or use, and, importantly, lower cost. A cost 
comparison of different evaluation techniques is provided in table .
The	project	uses	Edenspace’s	edenfern™	phytoremediation	plants	
to	extract	and	concentrate	soil	arsenic	in	fern	fronds,	which	may	
then	be	harvested	for	safe	disposal.	
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Phytosensors
State-of-the-art collection of soil, water, plants and air is typically based on a sampling 
grid. For example, to measure concentrations of contaminants in soil or water, a trained 
professional, such as an environmental technician or home inspector, collects samples on 
a 30-foot grid for laboratory analysis using atomic absorption spectrometry, ICP mass 
spectrometry, etc. Including collection, this method is expensive, providing data at a cost 
of $0 to more than $00 per sample. One problem with a grid-based technique is the 
low spatial resolution of the data—the large “pixel” size. No information is provided for 
areas between the grid-sampling points, so that the reported concentrations may not fairly 
represent the level or extent of contamination at the site as a whole (Demougeot-renard 
et	al., 00). Thus, a high lead concentration in a house’s drip zone does not necessarily 
indicate high concentrations in a play area or pathway, nor does a low lead concentration 
in a composite sample indicate that a property has low soil levels of lead in all zones of 
concern. In addition, different sampling events may result in markedly different assess-
ments due to soil and sampling variability. This problem presents additional expense to 
customers, who usually are required by regulators to remediate the soil some distance 
outside the perimeter defined by the “high” sample points, in order to account for uncer-
tainty about contaminant distribution. In addition, areas of contamination may escape 
detection and treatment, presenting a future liability and health risk. 
Table 1. coSTS of alTernaTive environmenTal remediaTion TechniqueS 
(glaSS, 1999).
 
Technique
 Cost per cubic yard
  ($)
 Soil Washing  50–50
 Soil Flushing  75–0
 Acid Leaching/Extraction 50–00
 Solidification/Stabilization  75–05
 Vitrification  0–00
 Thermal Desorption/treatment 50–500
 Excavation/Landfilling 00–500
 Phytoremediation  5–00
Development of wide-area sampling techniques that provide higher spatial resolution 
at lower cost and over time is desirable. Of particular interest would be the development 
of indicator plants to provide rapid, low-cost, in-situ monitoring of environmental and 
Of	particular	interest	would	be	the	development	of	indicator	
plants	to	provide	rapid,	low-cost,	in-situ	monitoring	of	
environmental	and	plant	conditions.
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plant conditions. Phytosensors could be easily replicated, solar-powered, and unobtrusive. 
Phytosensors may be thought of as signal transducers and amplifiers that detect and report 
on an environmental condition such as the presence of a contaminant or a plant condi-
tion such as “hidden hunger.” Phytosensors address the “grid problem” by inexpensively 
providing information with high spatial resolution. Because each plant represents a sample 
point, information provided can be near-continuous. Such phytosensors could also be 
used in joint applications such as environmental cleanup, agriculture, and landscaping.
Three elements are essential to successful development of phytosensors: 
• an element in the plant, such as a promoter gene, that is sensitive to the target  
parameter; 
• a plant reporter pathway that can provide measurable evidence—such as a color 
change in leaves or stems—of changes in the target parameter; and
• a plant species that is suitable for the intended use.
Current Edenspace phytosensor projects include using a metal-responsive promoter 
gene, BjMTP, identified by Professor David Salt at Purdue University, linked to different 
reporters such as green fluorescent protein (GFP) and the anthocyanin gene B in Indian 
mustard, maize and turf grass. The transformed plants may be used to detect the presence 
of heavy metals such as lead, cadmium and mercury in soil, groundwater and/or landfill 
leachate. Edenspace is also working with Professor C. Neal Stewart, Jr., at the University 
of tennessee to insert an arsenic-responsive promoter from Shewanella	into the edenfern™. 
Successful insertion of this construct will create an indicator that is visible under UV light 
in response to arsenic uptake, potentially showing when arsenic is present in the plants 
and soil as well as when cleanup has been completed. 
Energy	Crops
In 00, ethanol production in the United States attained a record 3.35 billion gallons, 
up 9% from 003 (Hillgren, 005). While it is still a small part of the total US fuel 
market, representing approximately % of the gasoline sold in 00, the recent rapid 
increase in oil prices has increased the cost-competitiveness of ethanol and indicates that 
it can continue to capture market share, particularly if production costs can be decreased. 
Production of energy, and of ethanol in particular, from plant biomass is especially attrac-
tive because of plants’ renewable conversion of solar energy and recycling of atmospheric 
carbon dioxide. In October 00, the Biomass technical Advisory Committee established 
by the Biomass r&D Act of 000 issued national goals for biobased transportation fuels, 
calling for a substantial increase in the use of such fuels from 0.7 quads in 00, or 
only 0.5% of US transportation fuel consumption, to 0% in 030 (BrDtAC, 00a). 
to achieve these ambitious goals, the Advisory Committee subsequently recommended 
a comprehensive research plan, the elements of which include increased biomass yields, 
lower biomass costs, new enzymes and catalysts, multi-trait crops, and environmentally 
sound biomass production (BrDtAC, 00b). The overall objective of this plan is 
to reduce the price of biofuels. In 00, the Advisory Committee updated its recom-
mended research plan, recommending specifically that the US Departments of Energy 
and Agriculture (DOE and USDA) significantly increase funding for r&D programs 
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on cellulosic ethanol (BrDtAC, 00). In 005, the US Congress appeared likely to 
implement this recommendation.
A promising biofuel co-production opportunity exists based on a convergence of goals 
between biomass production for energy and biomass production for phytoremediation. 
High biomass yields sought for bioenergy, for example, are also desirable in phytoremedia-
tion of metals, metalloids and radionuclides, because the rate of contaminant removal is 
a function of biomass as well as of bioconcentration. In addition, new ways of disposing 
of contaminated biomass are sought that minimize landfill burdens. Current treatment 
methods can remove 0% to 90% of recovered metals from plant biomass (Edenspace, 
unpublished data), which for some contaminants is insufficient to allow disposal of the 
treated biomass as non-hazardous waste. Metals are typically sequestered inside cell walls, 
which are difficult to break down cost-effectively using current techniques. The ability 
to degrade cell walls with low-cost cellulases could significantly improve the current 
state of the art in contaminant recovery from phytoremediation crops, allowing treat-
ment of contaminated biomass to reduce the costs and liabilities associated with landfill 
disposal, facilitate recycling of recovered metals, and produce clean, renewable bioenergy 
feedstocks. 
With DOE funding, Edenspace and its research partners, Drs. Mariam Sticklen and 
Bruce Dale at Michigan State University, have engineered tobacco (Nicotiana	tabacum) 
and maize for (i) constitutive production of an hydrolytic enzyme, endoglucanase, to 
aid post-harvest hydrolysis of plant biomass to simple sugars that are useful as biofuel 
feedstocks, (ii) greater biomass, and (iii) delayed flowering, which reduces the likelihood 
of transfer of the transgenes to non-engineered plants. Cellulase levels of about % of 
the plant dry weight (less than 0 mg of enzyme protein per g) are sufficient to convert 
essentially all of the cellulose and hemicellulose in ammonia-treated plant matter to 
fermentable sugars in less than  h (Dale et	al., 999). Preliminary results indicate that 
transgenic corn can produce endoglucanase at levels higher than 9% of total soluble 
protein, close to this benchmark.
Using such “endoplant” cellulases and biomass augmentation, a primary technical 
objective of this project is to demonstrate ethanol yields greater than those achievable 
based on hydrolysis of starch alone, currently at .5 to .8 gallons of ethanol per bushel 
of corn grain, or roughly 50 to 00 gallons of ethanol per crop acre. Efficient hydrolysis 
of the  to 8 tons dry weight of corn stover grown per acre, and of the distillers grain 
that remains after corn grain is processed with amylase, could more than double current 
ethanol yields. A second major objective is to reduce biomass pretreatment steps that are 
now necessary to remove lignin and hemicellulose. Performance against these objectives 
will be measured in a pilot demonstration scheduled for 00, when transgenic plants 
Using	such	“endoplant”	cellulases	and	biomass	augmentation,	
a	primary	technical	objective	is	to	demonstrate	ethanol	yields	
greater	than	those	achievable	based	on	hydrolysis	of	starch	alone.
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will be processed, and the yields and costs of ethanol production assessed, at the National 
renewable Energy Laboratory’s Bioethanol Pilot Plant facility in Golden, Colorado. A 
parallel project between Edenspace and the US Department of Agriculture for switchgrass 
began in mid-005.
By sharing biomass production and post-harvest treatment costs with phytoremedia-
tion, another plant-based technology that has similar goals, costs of producing hydrolyzed 
feedstocks for biofuels could be dramatically reduced—an essential, if not in itself suf-
ficient, step toward increasing the cost-competitiveness of renewable fuels. In addition, 
production of biofuel feedstocks, cellulase and cellulase-rich plants, and phytoremediation 
crops can provide farmers with new sources of income at a time when traditional crops are 
increasingly subject to severe market price and trade pressures. A joint 003 USDA/DOE 
analysis of the economic impacts of bioenergy crop production showed the potential to 
increase farm income by up to $ billion.
Plantavit	Cooperative
In the United States, an estimated 9,000 hazardous waste sites await cleanup, with 
total costs aggregating $09 billion (USEPA, 00). These numbers exclude potential 
cleanup costs on agricultural and many residential properties, as well as the costs of pol-
lution prevention over wide areas. Given the costs of current environmental technologies 
and current funding levels, the environmental challenges posed by such sites will persist 
for decades.
Capitalizing on the low costs and other advantages of environmental phytotechnologies, 
many companies, individuals and government agencies are now using plants to restore and 
protect the environment. Plantavit, a new national agricultural cooperative established 
in 00 by Edenspace and farmers in California’s San Joaquin Valley, seeks to identify, 
train and hire its producer members to apply such environmental phytotechnologies in 
the United States and other countries. Large-scale application of such technologies, both 
on and off the farm, is expected to achieve significant environmental benefits while at the 
same time providing a new source of income to farmers. The cooperative’s goals are to:
• provide additional sources of nonfarm income to agricultural producers, based 
on application of producer skills, equipment and other agricultural resources to 
environmental projects;
• provide professional training to members in agriculturally based environmental 
techniques and related fields, such as plant sciences and soil sciences;
• increase public recognition of member achievements in environmental activities;
• reduce environmental health risks on farm property; and
• increase farm property values.
Many	companies,	individuals	and	government	agencies	are	now	
using	plants	to	restore	and	protect	the	environment.
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Environmental phytotechnologies offer a promising way to address wide-area prob-
lems. Grasses, trees and other plants can be used to construct riparian barrier strips to 
retain runoff. trees can be planted to sequester atmospheric carbon and remove other 
contaminants from the air, soil and water. With the use of appropriate techniques, crop 
plants such as mustard, corn and tobacco can remove arsenic, lead, cadmium, selenium 
and other contaminants from soil and groundwater. Some of these techniques are already 
used on farms and ranches by agricultural producers with support from the Conserva-
tion reserve Program, Environmental Quality Incentives Program, the Wetland reserve 
Program and the Wildlife Habitat Incentives Program, and other government programs. 
These techniques are not currently used on the farm, nor is current funding provided for 
producers to use any of these techniques outside the farm or ranch.  
The reliance of environmental phytotechnologies on agricultural techniques provides 
scale efficiencies similar to those in agriculture: the larger the area, the lower the cost per 
acre. Because most current phytoremediation sites are less than three acres in size—small 
for a modern farm—the full cost savings enabled by large-scale phytoremediation have 
not yet been achieved. For appropriate sites, substantial cost savings may be attained by 
farmers experienced in modern agricultural techniques, who are also trained in phytore-
mediation techniques. In particular, the environmental problems that often must be 
addressed in land development in urban and metro areas may be particularly amenable to 
environmental phytotechnology techniques employed by adaptive farmers. Edenspace is 
currently funded by USDA to study the potential environmental markets for agricultural 
producers under this approach.
Observations	and	Recommendations
These and similar projects have afforded Edenspace a broad range of experiences, includ-
ing site characterization and environmental remediation, plant genetic engineering and 
APHIS field permitting, market research, marketing and sales. Environmental science 
and regulation, agricultural policy and practice, and plant biochemistry and genetics 
have all played prominent roles in Edenspace’s work. From this experience, we offer the 
following observations and recommendations.
Change	Agricultural	Policy	from	Insulation	to	Innovation
Current agricultural policy poses high risks for farmers. The 00 Farm Bill provides 
nearly $0 billion in farm support annually, primarily intended to slow or stop the ero-
sion of the farm base experienced over the last several decades. However, rapid growth in 
the federal budget deficit, recent decisions by the World trade Organization against high 
tariffs and other farm support, and the ethical issues involved in restricting food imports 
from developing countries, indicate that, over the long term, agricultural subsidies are 
not sustainable. The financial supports that allow farmers to ride out temporary rough 
spots are themselves temporary. When, and not if, these supports disappear, farmers 
may be left without a means to compete with lower cost food imports, leading to ac-
celerated industry consolidation and the accelerated demise of small farms. One good 
way to address this problem, successfully achieved in many high-tech US industries, is 
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to encourage rapid innovation and product development, allowing farmers to compete 
by offering higher-margin, value-added products rather than commodity products, with 
life cycles of an increasing number of agricultural products measured in months rather 
than years or decades. 
Promote	Systems	Agriculture
In most of its projects, Edenspace regards its plants as just one element in the overall 
solution it provides to a client. In remediating a small arms firing range, for example, 
Edenspace must sift out and recycle the bullet fragments, as well as phytoextract ionic 
lead, if site goals are to be met. This integrated perspective on designing plants into 
customer solutions is an essential element of future agriculture, and provides an im-
portant pathway for engineering new high-margin plants to be grown by agricultural 
producers. I call this approach “systems agriculture”—the engineering of plant traits and 
agricultural protocols on an integrated basis with other production technologies so as to 
minimize total costs of end-user products and services. Examples are the integration of 
new plant traits with new farm techniques and new ethanol production steps in order 
to minimize the cost of ethanol at the fuel pump, and developing new plant traits that 
facilitate storage of hypoallergenic vaccines in the syringe. The approach requires that 
new agricultural products and techniques be developed by considering multiple areas of 
upstream and downstream production expertise together, on an integrated basis, that 
are now considered separately. New collaborations will be needed between agriculture 
and other industries, such as the energy and healthcare industries, that today are found 
infrequently, if at all. Systems agriculture is likely to lead to the creation of surprisingly 
good products—such as fuels that are better than ethanol, better than gasoline—that are 
undiscovered today because of a lack of creativity deriving from the failure to take an 
integrated design engineering approach.
Create	More	Receptive	Public	Opinion
Systems agriculture is dependent on use of biotechnology to create transgenic plants. 
traditional breeding methods are simply too imprecise and too slow to achieve the rapid 
development of products needed to support a competitive US agricultural sector. While 
the regulation of transgenic plants today imposes increasingly high hurdles for the intro-
duction of new crops, the antecedent cause of the problem isn’t regulation but the public 
perception that too often sees the risks of transgenic plants as outweighing the benefits. 
Public opinion, in turn, has been shaped by a complicated combination of factors, includ-
Transgenic	plant	development	is	underfunded	by	the	private	
	sector,	largely	because	of	the	divisiveness	of	the	transgenic	crop	
wars	of	the	last	10	years.
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ing economic competition among countries, substitution competition among industries, 
product competition among companies, and a host of scientific and nonscientific beliefs. 
While this will be a complex area to address, a key element is to develop public demand 
for new transgenic plant products that directly promote human health, provide low-cost 
energy, or improve property values, rather than simply—though importantly—reduce 
producer costs with no significant benefit perceived by consumers. 
Increase	Government	R&D	Funding
transgenic plant development is underfunded by the private sector, largely because of 
the divisiveness of the transgenic crop wars of the last 0 years. to address this market 
imbalance, the USDA plant biotechnology budget should be at least quadrupled in size. 
Half of the increase should be apportioned to other government agencies—EPA, NIH, 
HUD, DOt, etc.—that should be instructed to fund crop-plant research related to their 
missions. USDA should encourage customers to tell farmers what types of plant they’d 
like farmers to grow. The only “NIH” in government should be the National Institutes 
of Health. 
The United States has one of the strongest agricultural industries in the world, with 
tremendous natural advantages including fertile soils, a temperate climate, good precipita-
tion, and skilled producers. These advantages are offset in part by another US blessing: a 
high quality of life that translates to high labor and materials costs relative to many other 
parts of the world. If we are to continue to realize the benefits of our strong position, we 
need to pursue systems agriculture and the plethora of new high-margin markets and 
products that it promises.
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,,-trinitrotoluene (tNt) and hexahydro-,3,5-trinitro-,3,5-triazine (rDX) are 
commonly found in surface soil and groundwater at ammunition-production and 
military-training sites. Approximately ,000 US Department of Defense facilities are 
contaminated with explosives both in soil and in groundwater (Medina et	al., 003). 
Dinitrotoluenes (DNts), such as ,-dinitrotoluene (,-DNt) and ,-dinitrotoluene 
(,-DNt), contaminate the sites as by-products of tNt. tNt and DNts are classified 
as nitroaromatic explosives having aromatic ring structures, whereas rDX is a nitramine 
explosive possessing N-nitro groups (Hannink et	al., 00). The explosives are trans-
ported to soil and groundwater after open detonation, seepage and/or improper disposal 
at military and munition-production sites. tNt and DNts have higher octanol-water 
partition coefficient (Kow) values than does rDX, suggesting that they are strongly bound 
to soil organic matter, whereas rDX is mobile as a result of poor sorption. The explosives 
are not volatile due to their low vapor pressures. Physical and chemical properties of the 
explosives are shown in table .
Plant Transformation Pathways of Energetic 
Materials (RDX, TNT, DNTs)
Jong Moon Yoon, David J. Oliver and Jacqueline V. Shanks
Iowa	State	University
Ames,	IA
Several studies have reported abiotic methods of treatment of explosives, such as in-
cineration, carbon adsorption, alkaline hydrolysis, and catalytic and advanced oxidation 
(Garg et	al., 99; rodgers and Bunce, 00). Harmful by-products, requiring further 
treatment, and transport of contaminated soils or groundwater have drawn attention 
to bioremediation. Phytoremediation is a promising technology using plants to clean 
up contaminated soil and groundwater in	situ because of low cost of maintenance and 
operation, and public acceptance (Schnoor et	al., 995). The fact that plants are able 
Phytoremediation	is	a	promising	technology	using	plants	to	clean	
up	contaminated	soil	and	groundwater	in situ	because	of	low	cost	
of	maintenance	and	operation,	and	public	acceptance.
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to accumulate metals to high concentrations in their tissues is well known (Salt et	al., 
998). Phytoremediation research has been conducted on organic pollutants ranging 
from pesticides, e.g. atrazine (Burken and Schnoor, 997), to industrial pollutants such 
as trichloroethylene and polycyclic aromatic hydrocarbons (PAH) (Newman et	al., 997; 
Paquin et	al., 00; Vervaeke et	al., 003). The transformation products of xenobiotics 
by plants are less toxic than parent compounds. In addition, root exudates are reported 
to enhance microbial activity for degradation of xenobiotics (Miya and Firestone, 00; 
Anderson et	al., 993). The cost for soil remediation is $0 to $00 per cubic meter 
whereas vegetative cleanup of contaminated soils costs only $0.0 to $ per cubic meter 
(Cunningham et	al. 995).
This short review summarizes the toxicity of energetic materials (tNt, rDX, and 
DNts) and pathways of transformation by plants. 
toxicity of the Explosives
tNt and its degradation products have been reported to be mutagenic and toxic to 
several organisms. Survival of the midge (Chironomus	 tentans) decreased significantly 
after exposure to 00 mg/kg of tNt, ,3,5,-trinitrobenzene (tNB), and ,-diamino-
-nitrotoluene (,-DANt); and the amphipod (Hyalella	azteca) was more susceptible to 
tNt, tNB, and ,-DANt than the midge (Steevens et	al., 00). Gogal et	al. (00) 
reported that northern bobwhite quail showed decreases in total red blood-cell counts and 
plasma protein as dietary tNt intake increased, and they determined a low observed-
adverse-effect level of 78 mg of tNt per kg of weight per day. Survival and growth 
Table 1. chemical and phySical properTieS of TnT, rdx, and dnTS.
 TNT RDX 2,4-DNT 2,6-DNT
Molecular weight 7.5 . 8. 8.
Molecular formula C7H5N3O C3HNO C7HNO C7HNO
Log K ow .–.8 0.8–0.87 .98 .9–.0
Solubility in water (mg/L) 00  70–73 90
Vapor pressure (mm Hg) .99×0- .0–.0×0-9 .7×0- 5.7×0-
Henry’s constant 
.57×0-7 .×0-5 .3×0-7 9.×0-8(atm-m3/mole)
Molecular structure
Data from Yinon and Zitrin (993), talmage et	al. (999) and HSDB (000).
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of two freshwater invertebrates were not affected after a 0-day exposure to ,000 mg 
of rDX per kg of sediment (Steevens et	al., 00). The growth and survival of benthic 
invertebrates, Neanthes	arenaceodentata and Leptocheirus	plumulosus, were not affected 
by exposure up to ,000 µg rDX per kg dry weight of sediment (Lotufo et	al., 00). 
Inhibition to growth and reproduction of adult earthworms can occur at less than 95 mg 
of rDX per kg of artificial soil (robidoux et	al., 000, 00), but acute toxicity was not 
observed up to 75 mg per kg dry soil for rDX.
Gong et	al. (00) investigated the influence of rDX on indigenous microbial activities. 
They measured soil dehydrogenase activity, potential nitrification activity, heterotrophic 
nitrogen fixation activity, substrate-induced respiration, and basal respiration for  
weeks. Significant reductions (up to 30% of control) in these parameters were observed 
in rDX-spiked soil. In the case of a luminescent marine bacterium (Vibrio	fischeri), the 
EC50 value of rDX ( mg/L) was above the solubility in water ( mg/L for rDX) 
after incubation periods of 90 min (Drzyzga et	al., 995). 
Neither ,-DNt nor ,-DNt were mutagenic with the Ames assay, whereas their 
hydroxylamine isomers proved to be mutagenic (Padda et	al., 003). Using the uptake 
response of HIIE rat hepatoma cell cultures to neutral red, the Nr50 values were 5 mg/L 
for ,-DNt, 50 mg/L for ,-DNt, and 7 mg/L for tNt, suggesting dinitrotoluenes 
are less cytotoxic than tNt (Mitchell and Burrows, 995). 
tNt was toxic to hybrid poplars at a concentration of 5 mg/L in hydroponic solution 
(Thompson et	al., 998) and at 50 mg/kg soil there were adverse effects on germination 
and seedling growth of cress and turnip (Gong et	al., 999). Alfalfa did not grow at 0.55 
mM (00 mg/kg) ,-DNt in soil (Dutta et	al., 003), and lettuce was more sensitive 
than wheat, mustard, and lentil, indicating that phytotoxic effects of nitroaromatic 
explosives depend on plant species (Picka and Friedl, 00). The highest non-observed 
adverse effect concentrations (NOAEC) for the growth of lettuce were 0 mg/kg for 
tNt,  mg/kg for ,-DNt and 0 mg/kg for ,-DNt. Hydroponic toxicity of rDX 
to maize and wheat was estimated to be  mg/L rDX, while soybean and sorghum did 
not show a toxic effect up to  mg/L for 30-day exposures (Chen, 993). rDX was not 
toxic to hybrid poplars up to  mg/L (Thompson, 997).
Mechanisms of Degradation of Xenobiotics by Plants
Prior to the introduction of xenobiotics to plant cells, they must be taken up through 
the roots. Several studies reviewed predictive relationships between the uptake rate of a 
compound and its physical-chemical properties (Briggs et	al., 98; Burken and Schnoor, 
998). root uptake and translocation of the compounds are related to the logarithm of 
the octanol-water partition coefficient, log Kow. root concentration factor (rCF), defined 
as the the concentration sorbed to the roots divided by the concentration in the aque-
ous phase, is generally proportional to the log Kow value. The relationship is proposed 
as follows:
log (rCF–3.0) = 0.5 log Kow – .57 by Briggs et	al. (98)
log (rCF–0.8) = 0.77 log Kow – .5 by Burken and Schnoor (998)
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The transpiration stream concentration factor (tSCF) is calculated as the concentration 
in the transpiration stream divided by the aqueous concentration. The values of tSCF 
for various chemicals show Gaussian distribution curves over the range of log Kow values, 
indicating that hydrophilic compounds (log Kow < .8) are not able to pass through lipid 
membranes of roots, whereas hydrophobic compounds (log Kow > 3.8) tend to bind 
strongly to root tissues and are not then translocated to shoots (Dietz and Schnoor, 00). 
The relationship between tSCFs and log Kow is proposed as follows:
tSCF = 0.78 exp{–(log Kow – .78)/.} by Briggs et	al. (98)
tSCF = 0.75 exp{–(log Kow – .50)/.58} by Burken and Schnoor (998)
Enzymatic transformation of xenobiotics by plants follows the green-liver model and 
involves three steps. First, the foreign compounds taken up by plants are transformed by 
enzymes such as cytochrome P50, carboxylesterases, and peroxidase (Sandermann, 99). 
Secondly, the transformed xenobiotics are conjugated with D-glucose, glutathione, or 
amino acids (Komoba et	al., 995) by enzymes such as glutathione S-transferases, gluco-
syltransferases and malonyltransferases, resulting in either soluble or insoluble products. 
The third step is storage and compartmentation; the soluble compounds are stored in 
vacuoles or as cell-wall materials by further processing, and the insoluble compounds are 
generally assumed to be stored in the cell wall (Schroder and Collins, 00).
Uptake of the Energetic Materials by Plants
Nitroaromatic explosives showed different uptake and fate in plant systems than nitramine 
explosives. According to Thompson et	al. (998), 95% of the tNt was removed from 
solution in less than  h by hybrid poplar, whereas 7% of the rDX was removed from 
hydroponic solution in 7 days (Thompson et	al., 999). The uptake of both rDX and 
tNt from soil was slower than in the hydroponic systems because of decreased bioavail-
ability in soil. Bush beans took up less than % of rDX in soil after 0 days; in contrast 
0% was removed from solution after 7 days (Harvey et	al., 99). 
Over 0% of radioactivity of C-rDX taken up by hybrid poplars was found in the 
leaves after  days. In contrast, 78% of radioactivity of C-tNt taken up by the poplars 
remained in the roots after the same exposure time (Thompson et	al., 998), suggesting 
that rDX is translocated more readily. In addition, an overall low recovery of rDX with 
no significant mineralization by plants suggested that the final transformation products 
are volatile compounds (Just and Schnoor, 000). recently, poplar nodule cultures were 
reported to mineralize rDX under sterile conditions (Van Aken et	al., 00). 
regarding DNts, knowledge of uptake by plants and transformation products is limited 
compared to information on tNt and rDX. Best et	al. (00) applied wetland systems to 
remove explosives from groundwater at ammunition plants, resulting in average removals 
of 58% and % for ,-DNt and ,-DNt, respectively, in a 5-day operation at the 
Volunteer Army Ammunition Plant, Chattanooga, tN. todd and Lange (99) observed 
that 7% of ,-DNt from soil was removed in a phytoremediation system using parrot 
feather (Myriophyllum	brasiliense). They found -amino--nitrotoluene (ANt) in the 
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plant tissues after 90 h of treatment prior to -amino--nitrotoluene (ANt) which was 
detected after 90 h of exposure. However, other transformation products of the DNts, 
as well as their fate in plants, are unknown.
transformation Pathways
2,4,6-trinitrotoluene	(TNT)
Subramanian and Shanks (003) proposed the tNt transformation pathway by plants 
based on experiments with periwinkle (Catharanthus	roseus) and parrot feather, as shown 
in Figure . 
two monoamino compounds [-amino-,-dinitrotoluene (ADNt) and -amino-
,-dinitrotoluene(ADNt)] have been found as the primary reduction products by plants 
(Palazzo and Leggett 98; Thompson et	al. 998; Bhadra et	al., 999a). Diaminotoluenes 
(,-diamino--nitrotoluene and ,-diamino--nitrotoluene) and azoxy compounds were 
observed under strong reducing conditions and by the condensation of hydroxylamines, 
respectively (Pavlostathis et	al., 998; Sens et	al., 998; Thompson et	al., 998). 
As for oxidative transformation of tNt in plant systems, Bhadra et	 al. (999b) 
isolated six oxidized metabolites such as -amino-,-dinitorbenzoic acid, ,-
dinitro--hydroxy-benzyl alcohol, -N-acetoxyamino-,-dinitrobenzaldehyde, 
,-dinitro--hydroxytoluene, and two binuclear metabolites from azoxytetranitro tolu-
enes. In addition, they showed that oxidation of tNt by the plant could occur before 
the reductive transformation. This was based on results where monoamino compounds 
were added to plants and the oxidized metabolites of tNt were not produced. to date, 
oxidized metabolites have only been found in parrot feather; they were not detected in 
Catharanthus or Arabidopsis (Subramanian, 00).
-hydroxylamino-,-dinitrotoluene (HADNt) and - hydroxylamino-,-di-
nitrotoluene (HADNt) were observed following reduction of nitro groups of tNt 
in non-axenic and aquatic plant systems (Pavlostathis et	al., 998; Wang et	al., 003). 
Measurement of hydroxylamines was difficult due to their instability. Wang and Hughes 
(998) developed an efficient assay for hydroxylamines by derivatization with acetic an-
hydride. recently, these hydroxylamines were shown to be present in axenic hairy roots 
of Catharanthus and axenic Arabidopsis seedlings (Subramanian, 00; Subramanian et	
al., 005). The hydroxylamines are considered the first transformation products resulting 
in other metabolites of tNt by reduction, oxidation, conjugation, and polymerization 
(Subramanian and Shanks, 003; Wang et	al., 003).
The transformed products of tNt are further conjugated and sequestered in plant 
cells. Over 80% of the tNt label was associated with plant biomass, suggesting that 
the labeled carbon from tNt was sequestered in the plant tissues (Harvey et	al., 99). 
Thompson et	al. (998) showed that 75% of the radioactivity of C-tNt was present in 
unextractable and bound residues in the poplar roots. Bhadra et	al. (999a) characterized 
the four conjugates of tNt metabolites with a -carbon moiety by Catharanthus	roseus and 
Myriophyllum	aquaticum. They found that two of them have molecular structures similar 
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Figure . tNt transformation pathway by Subramanian and Shanks (003). Abbre-
viations—tNt: ,,-trinitrotoluene; ADNt: -amino-,-dinitrotoluene; ADNt: 
-amino-,-dinitrotoluene; HADNt:-hydroxylamino-,-dinitrotoluene; HADNt: 
-hydroxylamino-,-dinitrotoluene; ,’Azo: ,’,,’-tetranitro-,’-azoxytoluene; 
,’Azo: ,’,,’-tetranitro-,’-azoxytoluene; HDNt: -hydroxy-,-dinitrotoluene; 
HDNt: -hydroxy-,-dinitrotoluene; ADNB: -N-actamido-,-dinitrobenzaldehyde; 
ADNB: -N-actamido-,-dinitrobenzaldehyde; HDNBA: -hydroxy-,-dini-
trobenzyl alcohol; and ADNBA: -amino-,-dinitrobenzoic acid. tNt-, tNt-, 
A- and A- represent conjugates with six carbon sugars (r, r, r3, and r).
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to that of ADNt (labeled tNt- and A-) and the others were similar to ADNt 
(tNt- and A-), indicating that the monoamines were precursors to the conjugates. 
recent studies have elucidated these tNt conjugates. The conjugates of tNt metabolites 
by tobacco cell cultures are formed by conjugation of glucose on the hydroxylamine group 
of either HADNt or HADNt, and various diglycoside conjugates with gentiobioside 
or sophoroside forms were identified, including monoglycosides (Vila et	al., 005). In 
precursor-feeding studies, Subramanian (00) and Subramanian et	al. (005) found 
evidence for conjugation of monoamines and hydroxylamines with plant sugars.
Hexahydro-1,3,5-trinitro-1,3,5-triazine	(RDX)
Studies on the transformation of rDX by plants are rare, whereas several microbial 
transformation pathways have been proposed and some established. After being taken 
up and translocated to leaf tissues, direct photolysis of rDX in the leaves is a feasible 
fate under natural sunlight. Just and Schnoor (00) proposed the photodegradation 
pathway of rDX by reed canary grass, as shown in Figure . They identified ring-cleav-
age products, such as nitrous oxide (NO) and -nitro-,-diazabutanal in leaves under 
simulated sunlight, including nitrite (NO-) and formaldehyde (CHO) in solution. Van 
Aken et	al. (00) proposed three processes for the pathway of degradation of rDX by 
using poplar tissue cultures and crude extracts from leaves, as shown in Figure . First, 
reduction products such as hexahydro--nitroso-,3-dinitro-,3,5-triazine (MNX) and 
hexahydro-,3-dinitroso-5-nitro-,3,5-triazine (DNX) were produced by intact plant cells 
regardless of light. In the second step, the reduced metabolites were further transformed 
to formaldehyde and methanol, both in crude extracts and in intact cultures under light. 
In the final step, light-independent mineralization of one-carbon metabolites by intact 
plant cultures, but not crude extracts, occurred. Some transformed products may be 
re-incorporated into plant cells. Formaldehyde may be conjugated by plant enzymes to 
form compounds like S-formyl-glutathione (Just and Schnoor, 00). Small quantities of 
CO produced by degradation of rDX by plants may be re-assimilated by photosynthesis 
(Van Aken et	al., 00).
Dinitrotoluenes	(DNTs)
In contrast with bacterial systems, little information is available on the transformation 
of DNts by plants. We are aware of only one study: monoamino isomers, ANt and 
ANt, were reductive transformation products in plants (todd and Lange, 99). 
The bacterial reduction of dinitrotoluenes can take place under aerobic and anaerobic 
conditions, resulting in the production of monoamines isomers (Hughes et	al., 999). 
Hydroxylaminotoluenes and dihydroxylaminotoluenes were produced anaerobically in 
cell cultures of Clostridium	acetobutylicum (Hughes et	al., 999). Further transformed 
products, aminohydroxylaminotoluenes and diaminotoluenes, were observed in the cell 
extracts. Hydrogenophaga	palleronii	and Burkholderia	cepacia produced oxidative interme-
diates and mineralized DNts to CO by mono- or dioxygenases (Nishino et	al., 999). 
The bacteria converted ,-DNt into 3-methyl--nitrocatechol with release of nitrite, 
and then -hydroxy-5-nitro--oxohepta-,,-dienoic acid and -hydroxy-5-nitropenta-
,,-dienoic acid (Nishino et	al., 000). 
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transgenic Plants and Gene Expression
In the past  years there has been significant activity in using genetic approaches to enhance 
transformation and to reduce phytotoxicity of energetic materials. Genetically modified 
plants expressing bacterial genes have been developed for phytoremediation. transgenic 
tobacco plants expressing nitroreductases of Enterobacter	cloacae showed enhanced ability 
to tolerate and remove tNt at high concentration (0.5 mM), which is toxic to wild-type 
tobacco (Hannink et	al., 00). Another transgenic tobacco line expressing pentadryth-
ritol tetranitrate reductase from the bacterium showed better germination and growth in 
the presence of tNt (0.05 mM) than did wild-type plants (rosser et	al., 00; French 
Figure . rDX degradation pathways proposed by Van Aken et	al. (00) and Just and 
Schnoor (00). The bracketed compound was not observed. Abbreviations—rDX: 
hexahydro-,3,5-trinitro-,3,5-triazine; MNX: hexahydro--nitroso-,3-dinitro-,3,5-
triazine; and DNX: hexahydro-,3-dinitroso-5-nitro-,3,5-triazine.
Transgenic	tobacco	plants	expressing	nitroreductases	of	
	Enterobacter cloacae	showed	enhanced	ability	to	tolerate	and	
remove	TNT	at	high	concentration.

et	al., 999). In addition, these researchers showed enhanced rDX removal in tobacco 
engineered with an XplA cytochrome P50 from Rhodococcus	rhodochrous (unpublished 
results). Clearly, genetic modification with microbial redox enzymes has the potential to 
enable faster transformation of tNt and rDX and reduced phytotoxicity. 
transcriptomic studies are providing clues to endogenous plant genes involved in 
transformation. Specific genes such as those for glutathione-S-transferases and cytochrome 
P50 in Arabidopsis were proposed by Ekman et	al. (003) to be involved in transfor-
mation of explosives. They used serial analysis of gene expression (SAGE) to compare 
-day-old Arabidopsis, exposed to 5 mg/L of tNt after  h, to untreated plants. A 
glutathione-S-transferase was found to be induced up to 7-fold. Among the highly 
induced genes were those encoding cytochrome P50 (CYP8D-A-tYPE), an ABC 
transporter that is known to expend AtP energy to transport hydrophobic molecules into 
or out of the cytoplasm, and a -oxophytodienoate reductase having high homology to 
nitroreductases of Enterobacter sp. (Ekman et	al., 003). However, as noted previously, 
oxidative compounds were not found in Arabidopsis (Subramanian, 00), thus the role 
of P50s in transformation pathways in Arabidopsis is unclear. In microarray experiments, 
Arabidopsis gene expression was monitored after long-term exposure (0 days) to various 
concentrations of tNt (Mentewab et	al., 005). In response to tNt amendment, fifty-
two genes were upregulated and forty-seven were downregulated, many of which have 
cell-defense and detoxification functions. Glutathione-S-transferases and cytochrome 
P50s were not found to be significantly upregulated in this study. Most of the genes 
differentially expressed were observed at the higher concentration of tNt amendment 
(0 µM) and genes expressed at  and 0 µM rarely overlapped. They confirmed the gene 
expressions of pathogenesis-related protein- precursor, DNA-binding protein, and ABC 
transporter-like protein by real-time PCr analysis. 
The transcriptome studies provide clues to genes that may be involved in tNt trans-
formation. Upregulation of some of the genes may be the result of a generalized stress 
response without synthesis of enzymes involved in the tNt phytotransformation path-
way or in a reduced phytotoxicity response. reverse-genetics approaches using the genes 
identified should enable further clarification of the transcriptome results. In a forward-
genetics approach, ten activation-tagged Arabidopsis mutant lines showing significantly 
better germination rates than the wild type on the tNt-amended medium were isolated 
from 300,000 mutant seeds (Moon et	al., 00). 
Selection of high-performing native plants, engineering plants with enhanced trans-
formation capabilities, identifying the fate of transformation products in plants, and 
designing the external variables to operate a more effective phytoremediation process 
are all dependent on a knowledge base of the genetic structure, enzymatic structure, and 
biochemical reaction pathways. The genetic approaches discussed here will enable the 
design of effective strategies for remediation of energetic materials in the future.
Conclusions and Future Directions
Plants can remove contaminants from soil and groundwater, and transform them into 
less harmful compounds. Based on information on transformation pathways and gene 
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expression, further studies on metabolic engineering and genetic modifications may 
make plants tolerant to higher concentrations of xenobiotics by inducing faster rates of 
uptake and using less toxic metabolic pathways. In addition, the explosives taken up by 
plants can be released by action of water—e.g. rain and river—and thus may be returned 
to the environment as hazardous contaminants. research on further treatments and the 
post-harvest fate of explosives is required. Information about phytoremediation of dini-
trotoluenes is lacking compared to that for tNt and rDX; thus, it also merits further 
investigation.
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Over the past century, mining, agriculture, manufacturing and urban activities have all 
contributed to extensive contamination of soil and water with heavy metals. In the United 
States, mercury is a common pollutant at government production sites, where it is used 
in energy- and defense-related activities. Thousands of square miles of land, rivers, lakes 
and estuaries are contaminated with millions of kilograms of mercury. Methylmercury, 
produced by bacteria in contaminated aquatic areas, is particularly toxic. Because it is 
quickly biomagnified in the food chain, it can have devastating effects on humans and 
other animals. Another common pollutant in the United States and worldwide is arsenic, 
a naturally occurring element widely distributed in the earth’s crust. In the environment, 
arsenic combines with oxygen, chlorine, and sulfur to form inorganic compounds. These 
extremely toxic metalloids, classified as “group A” human carcinogens, cause skin lesions, 
lung, kidney and liver cancer, and damage to the nervous system. Conventional procedures 
for cleaning up heavy-metal-contaminated sites (i.e. excavation, dredging, electrolytic 
extraction, chemical leaching) are all prohibitively expensive and destructive of the natural 
environment. An alternative to these physical remediation approaches is the use of plants 
to remove pollutants from soil and water through their root systems, an approach known 
as phytoremediation. Once extracted, plants may sequester the pollutants in their tissues 
and/or convert them to less toxic forms. They can accomplish this at a fraction of the cost 
most physical/chemical methods and without disrupting the environment. Although some 
plants, known as hyperaccumulators, can take up and sequester normally toxic amounts 
of heavy-metal pollutants, most of these species accumulate little biomass, and thus are 
probably not suitable for rapid remediation of extensive areas. An alternative approach is 
to genetically engineer plants possessing faster growth and greater biomass-accumulation 
potential with genes allowing them to handle these pollutants. Forest trees, in particular, 
with their large biomass and penetrating root systems, make excellent candidates for en-
gineering with phytoremediation genes. Such an approach is under development at the 
University of Georgia, where a number of plant species, including some forest trees, have 
been engineered with genes from bacteria that have been modified to function efficiently 
in plants. Our work indicates that forest trees can be engineered to thrive on and detoxify 
a variety of heavy metals on polluted sites.
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Forest	trees	can	be	engineered	to	thrive	on	and	detoxify	a	variety	
of	heavy	metals	on	polluted	sites.
Engineering trees for Mercury Phytoremediation
Mercury-resistant bacteria express MerA to convert highly toxic mercuric ion, Hg(II), to 
much less toxic elemental mercury, Hg(0). Following a demonstration that a modified 
merA gene conferred mercuric ion resistance to Arabidopsis plants (rugh et	al., 99), we 
used embryogenic culture (Merkle et	al., 990) and gene-transfer systems (Wilde et	al., 
99) that we had previously developed for the fast-growing forest species yellow-poplar 
(Liriodendron	tulipifera) to generate trees expressing a modified merA gene (rugh et	al., 
998). Yellow-poplar proembryogenic masses (PEMs) were transformed with three modi-
fied merA constructs via microprojectile bombardment. Each construct was synthesized 
to have altered flanking regions with stepwise increases (0%, 9%, and 8% blocks) of 
modified coding sequence. All of the merA constructs that we tested conferred resistance 
to toxic ionic mercury that had been incorporated into the tissue-culture medium. Yellow-
poplar somatic seedlings containing the most modified merA gene (merA18) germinated 
and grew vigorously in media containing a normally toxic level (50 µM) of ionic mercury. 
A mercury volatilization assay indicated that the merA18 plantlets released elemental 
mercury at approximately ten times the rate of untransformed control plantlets, indicat-
ing that they efficiently reduced mercuric ion to the elemental form. 
While our work with yellow-poplar demonstrated the potential to engineer a forest tree 
with mercury-handling genes, we did not test these trees outside of in	vitro conditions. 
Yellow-poplar is not adapted to the wet soils or riparian sites where mercury contamina-
tion is a major problem. For this reason, we proceeded to look for another tree species 
to engineer with mercury-handling genes. Populus, a forest-tree genus of the Salicaceae 
that includes aspens and cottonwoods, is easy to establish and grows quickly. Its high 
transpiration rate and wide-spreading root system make it ideal to intercept, absorb, 
degrade and/or detoxify contaminants, while reducing soil erosion (Dix et	al., 997). 
Many Populus species, in particular the cottonwoods, are especially adapted for growth on 
riparian sites, making them a good choice for establishment on sites requiring remediation. 
In addition, Populus is amenable to in-vitro propagation and genetic engineering (e.g. 
Han et	al., 000), making it a suitable target for enhanced phytoremediation ability via 
transgenic technology. Non-transgenic poplars had already been tested by some groups for 
phytoremediation applications (Licht, 990; Newman et	al., 997; Burken and Schnoor, 
997). We used Agrobacterium-mediated transformation of leaf explants to generate 
transgenic eastern cottonwood (P.	deltoides) trees expressing merA9 and merA18 genes. 
Leaf sections from transgenic plantlets produced adventitious shoots in the presence of 
50 µM Hg(II), supplied as HgCl, which completely inhibited shoot induction from leaf 
explants of wild-type plantlets. transgenic shoots cultured in medium containing 5 µM 
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Hg(II) rooted and showed normal growth, whereas wild-type shoots were killed. When the 
transgenic cottonwood plantlets were exposed to mercuric ion, they evolved two to four 
times the amount of Hg(0) relative to wild-type plantlets. transgenic merA9 trees tested 
in a Georgia Piedmont soil contaminated with approximately 00 ppm Hg(II) showed 
growth indistinguishable from those in uncontaminated soil, while control plantlets were 
completely defoliated and dead within a week following potting (Che et	al., 003).
trees of one merA eastern cottonwood clone, along with wild-type control trees 
(approximately 00 trees total) were planted on a mercury-contaminated site that was 
formerly the location of a hat-making factory in Danbury, Ct, in June 003; merA and 
control trees all grew well. Leaves were sampled from merA and control trees in fall 00, 
and analysis indicated that those from the merA trees contained one-third to one-half 
the amount of Hg as leaves from the control trees. This result was expected since the 
merA trees produce and volatilize Hg(0), which is then able to leave the plants as a vapor, 
whereas the control trees are unable to do so.
Methylmercury (MeHg), produced by native bacteria at mercury-contaminated wetland 
sites, is more toxic than elemental or ionic mercury. Because it is efficiently biomagnified 
up the food chain, it poses the most immediate threat to animal and human populations. 
Building on work performed in Arabidopsis (Bizily et	al., 999), we produced eastern cot-
tonwood shoots engineered with a bacterial merB gene, which converts MeHg to Hg(II). 
These shoots expressed the MerB protein and demonstrated their resistance to the methyl-
mercury analog phenylmercuric acetate (PMA) by producing longer adventitious roots and 
higher fresh weights than control shoots cultured on rooting medium supplemented with 
 or 5 µM PMA (Che et	al., submitted). However, in order to remove organic mercury 
from a contaminated site, it is desirable to have trees expressing both the merA and merB 
genes, so that organic mercury compounds can ultimately be converted to the least toxic 
form, elemental mercury. results with Arabidopsis indicated that combining the merA 
gene with the merB gene in the same plant can increase the ability to grow on levels of 
organic mercury up to fifty-fold higher than wild-type plants and up to ten-fold higher 
than plants engineered with merB alone (Bizily et	al., 000). This enhanced resistance 
to organic mercury is probably due to the fact that plants expressing the merA and merB 
genes together are able to transform both organic and ionic mercury to volatile Hg(0). 
Thus, the goal of our recent research has been to engineer both genes into eastern cot-
tonwood. to accomplish this, we developed a system to re-transform merA cottonwood 
trees with the merB gene. Preliminary results comparing the merA/B trees to wild-type 
controls and trees engineered with either merA or merB alone indicate that these merA/B 
trees can efficiently convert PMA to Hg(0) (Lyyra et	al., in preparation).
Transgenic	cottonwood	plantlets	exposed	to	mercuric	ion	
evolved	two	to	four	times	the	amount	of	Hg(0)	relative	to	
wild-type	plantlets.
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Engineering trees for Arsenic Phytoremediation
Using similar in-vitro culture and gene-transfer methods to those we employed with 
merA	and merB, we engineered a bacterial γ-glutamyl synthetase (γECS) gene into eastern 
cottonwood. A month after being cultured on the medium supplemented with 800 mM 
arsenate, leaf sections from γECS transgenic lines remained green and began to develop 
callus, while the leaf sections from wild-type plantlets showed no evidence of callus and 
became chlorotic. After 30 days on medium containing 800 mM arsenate, wild-type ad-
ventitious shoots did not form roots and their leaves became chlorotic. The γECS shoots 
appeared similar to those maintained on medium with no arsenate, and adventitious roots 
began to appear at  days after initial culture. The difference between the γECS lines 
and the wild-type plants in their abilities to produce adventitious roots in medium with 
800 mM arsenate was statistically significant (Lima et	al., in preparation). Despite the 
apparent slight enhancement of arsenate resistance conferred to our eastern cottonwood 
trees by the γECS gene, work with transgenic γECS Arabidopsis	plants indicated that they 
removed no more arsenate from the medium than did wild-type control plantlets (r.B. 
Meagher, unpublished data). Thus, not only does the mechanism of arsenate resistance 
for γECS plants remain unknown, but it is unlikely that engineering plants with this 
gene alone will be useful for removing arsenic from contaminated soil or water. recent 
research in which the γECS gene was combined with other arsenic-handling genes, such 
as arsenate reductase, in transgenic Arabidopsis plants indicates that some of these multi-
gene approaches have promise (Dhanker et	al., 00). Thus, we plan to engineer these 
same gene combinations into eastern cottonwood and other trees and test their potential 
for arsenic remediation.
references
Bizily SP et	al. (999) Phytoremediation of methylmercury pollution: merB expression in 
Arabidopsis	thaliana confers resistance to organomercurials. Proceedings of the National 
Academy of  Sciences of the USA 9 808–83.
Bizily SP et	al. (000) Phytodetoxifiaction of hazardous organomercurials by genetically 
engineered plants. Nature Biotechnology 8 3–7.
Burken JG Schnoor JL (997) Phytoremediation: uptake of atrazine and the role of root 
exudates. Journal of Environmental Engineering  958–93.
Che D et	al. (003) Expression of mercuric ion reductase in eastern cottonwood confers 
mercuric ion reduction and resistance. Plant Biotechnology Journal  3–39.
Che D et	al. Expression of organomercurial lyase in eastern cottonwood enhances or-
ganomercury resistance (submitted).
We	plan	to	engineer	these	same	gene	combinations	into	
eastern	cottonwood	and	other	trees	and	test	their	potential	
for	arsenic	remediation.

Dhanker OP et	 al. (00) Engineering tolerance and hyperaccumulation of arsenic 
in plants by combining arsenate reductase and gamma-glutamylcysteine synthetase 
 expression. Nature Biotechnology 0 0–5.
Dix ME et	al. (997) Potential use of Populus for phytoremediation of environmental 
pollution in riparian zones. In: Micropropagation, Genetic Engineering and Molecular 
Biology of Populus (Klopfenstein NB et	al. eds.). USDA Forest Service General tech-
nical report rM-Gtr-97, pp 0–.
Han KH et	al. (000) An Agrobacterium	tumefaciens transformation protocol effective on 
a variety of cottonwood hybrids (genus Populus). Plant Cell reports 9 35–30.
Licht LA (990) Poplar tree buffer strips grown in riparian zones for biomass production 
and non-point source pollution control. Ph.D. Dissertation, University of Iowa.
Lima A et	al. Enhanced arsenic tolerance of transgenic eastern cottonwood plants over-
expressing γ-glutamyl cysteine synthetase (in preparation).
Lyyra S. et	al. Co-expression of mercuric ion reductase and organomercury lyase in eastern 
cottonwood or detoxification of organomercurials (in preparation).
Merkle SA et	al. (990) Maturation and conversion of Liriodendron	tulipifera somatic 
embryos. In Vitro Cellular and Developmental Biology  08–093.
Newman LA et	al. (997) Uptake and biotransformation of trichloroethylene by hybrid 
poplars. Environmental Science and technology 3 0–07.
rugh CL et	al. (99) Mercuric ion reduction and resistance in transgenic Arabidopsis	
thaliana plants expressing a modified bacterial merA gene. Proceedings of the National 
Academy of Science of the USA 93 38–387.
rugh CL et	al. (998) Development of transgenic yellow poplar for mercury phytore-
mediation. Nature Biotechnology 0 95–98.
Wilde HD et	al. (99) Expression of foreign genes in transgenic yellow-poplar plants. 
Plant Physiology 98 –0.
Merkle
 Agricultural Biotechnology: Beyond Food and Energy to Health and the Environment
Scott Merkle received his BS in biology from the 
College of William and Mary in 97 and his MS 
and PhD in forestry from Virginia tech in 978 and 
98, respectively. His graduate training was in forest 
genetics and tree improvement and in predicting cone 
and seed yields in southern pine seed orchards using 
computer models. Dr. Merkle was a postdoctoral as-
sociate with tom Adams at Oregon State University 
during 983–98; his research was on population 
genetics of Douglas fir using isozyme markers. In 
98, he began postdoctoral work with Claud Brown and Harry Sommer at 
the Daniel B. Warnell School of Forest resources at the University of Georgia, 
focusing on tissue culture and protoplast culture of hardwood forest trees. He 
joined the University of Georgia faculty in 987 and is currently a professor in 
the Warnell School.
His lab has developed embryogenic regeneration systems for over a dozen forest 
tree species and hybrids, including American chestnut, yellow-poplar, black locust, 
sweetgum, magnolia and longleaf pine. Merkle has employed these cultures in 
research involving mass clonal propagation, biomass energy, genetic engineering, 
artificial seeds and cryopreservation. He has collaborated with richard Meagher 
of the UGA Genetics Department to engineer forest trees with heavy-metal-re-
sistance genes for use in phytoremediation.
3
Lena	Ma: Environmental phytotechnologies are being applied to various types of con-
taminants: organic contaminants, energetic material (mentioned by Jacqueline Shanks), 
and metals including nickel, cadmium, lead, selenium, arsenic and mercury. Although 
the last three are not really metals, we still refer to them as such. Phytoremediation of all 
three types of contaminants is mostly in the demonstration stage; we don’t have full-scale 
applications yet. There are many aspects to environmental phytotechnologies, of which we 
covered some this morning. One is phytoextraction, which Bruce Ferguson mentioned, 
and I guess everybody knows about the arsenic hyperaccumulator, the Chinese brake fern 
(Pteris	vittata). Over 00 hyperaccumulators have been reported. In addition to phyto-
extraction, Bruce mentioned phytofiltration, for extraction of contaminants from water. 
Then there is phytostabilization, which Scott Merkle touched on—the use of poplar trees 
to control contaminants. Phytovolatilization, also mentioned by Scott, may be applied to 
remediation of mercury and selenium. One of the issues that we are faced with when we 
use phytoremediation is how to deal with biomass. You can’t really recycle arsenic, but you 
can recycle valuable metals such as nickel. Furthermore, a phytomining demonstration 
project is in progress in Canada, using plants to actually mine nickel.
I want to borrow Mr. rodemeyer’s term “speed bumps.” Phytoremediation is a relatively 
new technology and it is not yet well accepted. One “speed bump” is that phytoremediation 
is a slow process. Using plants, you cannot remediate a site overnight or in a few months; 
usually you are talking about 5 to 0 years. We need research to speed up the process. 
Similarly, to demonstrate the efficacy of the technology will take time. And the longer it 
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takes, the more money it costs. You have to show efficacy through many years and that’s 
not an easy job. And the last thing is biomass. In theory you can use the biomass gener-
ated from phytoremediation projects as fuel or to recycle metal. Of course, if it contains 
arsenic or lead it is less valuable. This area of research needs more attention. 
Neal	Stewart: I’d like to mention three things. One deals with phytosensing and the 
second is ecorestoration—a couple of things that we’ve touched on in this session, but 
not really delved into—and I’d like to just fill in a few blanks. And then I’ll talk a little 
bit about regulation.
Phytosensing is actually a word that I made up. The idea is that phytosensors are 
genetically engineered to operate like a check-engine light. We might not know exactly 
what’s there or how much, but we know that something is wrong. That’s the reason to 
pursue phytosensing as a technology. One of the applications is to couple phytosensors 
with phytoremediation. to have the plant tell you where arsenic is or where tNt is and 
then—if you have a sensor that is appropriately designed—as it removes the contaminant 
from the soil, the signal would diminish. A lights-off to lights-on phytosensor would have 
an inducible promoter fused to GFP or a chromo-protein or another fluorescent protein 
or bioluminescence; when you don’t have the contaminant the lights are off and when 
you do have a contaminant, the lights are on. rNA interference, going from a lights-on 
to lights-off situation, will probably work better in the field and we are looking at that 
now.
Another application for phytosensors is in precision agriculture, which Bruce Ferguson 
touched on. You can use the sensor to give you information about what’s going on in a 
farmer’s field, coupled with GPS. In 0 to 0 years, I think this will be a reality.
A third application is agro-security: plants in the field that can report in real time where 
there is a disease outbreak, either due to natural infection or an intentional release.
And then the fourth one, which is what Jacqueline Shanks talked about, applies to 
explosives. She talked mainly about phytoremediation. We are interested in doing in mak-
ing phytosensors that detect explosives, mainly as a means of landmine sensing—using 
genetically engineered plants that indicate where landmines are situated, where the lights 
will go on or will go off, or with a color change in the plant. There are a hundred million 
landmines in the world and there is no good detection technology, so I think that this 
humanitarian application is certainly worth pursuing. 
I’m glad that Scott Merkle mentioned ecorestoration. Let’s say that we could introduce 
a genetically modified chestnut into the field for chestnut-blight resistance. The current 
regulatory paradigm is that gene flow from a GM crop to a wild relative, or from a GM 
crop to its non-transgenic counterpart, is bad. However, this approach would turn that 
whole notion upside down; we would want and expect gene flow. On the other hand 
this may be viewed as ecological disruption. Scott mentioned that one in four trees in 
Appalachia was a chestnut, which grew to large size. With the return of the chestnut, 
some species will be displaced, because their niche will be retaken by the rightful “king.” 
This will be something to think about.
A lot of people have talked about rationalization of regulations. I think that a more 
5
descriptive term is “reformation.” We need to totally rebuild regulations in light of what 
we know. We have learned a lot in the past 0 to 0 years. For the near term, we have to 
protect the markets for farmers. That’s certainly key. We have to think about using non-food 
plants as the only way forward in the near term. We have to make sure that these plants 
have obvious and compelling environmental benefits, and also realize that there are costs 
for not adopting a beneficial technology. If we don’t adopt phytoremediation, for example, 
and continue to dig up soil and send it to Utah or Idaho—or wherever it goes—that has 
an environmental cost and is ecologically damaging. For the economists here, we have to 
think about opportunity costs when we talk about adopting or not adopting.
Steve	Rock: I’m not sure everybody noticed, but if you took away the phytoremediation 
part of the three speakers’ presentations you would have seen three different case studies 
of how to get genetically modified plants into the field. Three different field demonstra-
tions and the process of negotiating the regulatory hurdles and testing them out in the 
wild where they are loose and able to walk around and shoot spines at people, if that’s 
what they are going to do. I was privileged to work on a couple of those projects, espe-
cially the Danbury one. Jack Kozuchowski, the city environmental officer wanted to do 
something with this piece of land, but no remediation technologies were available. Jack 
and I talked a lot about toolboxes. Coincidentally, I have an uncle who is Jack and my 
Uncle Jack’s toolbox was an amazing thing for me growing up. He worked at Edwards 
Air Force Base at the time when they were building experimental airplanes. People would 
hand him a set of blueprints and tell him to build it. Before he could build the engine, 
he had to build the tools for it and he had wrenches and screwdrivers that were made for 
a particular bolt. One of the things he taught me was that when the only tool in your 
toolbox is a hammer, everything looks like a nail. It’s critical that you understand what 
you need to accomplish and then build the tools and take the project into the world like 
Bruce Ferguson, Jacqueline Shanks and Scott Merkle and their groups have done.
I sat in on the meetings with the people in Connecticut and the region  regulators 
were very concerned about taking genetically modified cottonwood trees and planting 
them in a public area. One by one their objections were raised and were answered, and 
in a fairly short amount of time we got the plants into the ground. I don’t think we lost 
any growing season to that particular hurdle. There were plenty of other hurdles on that 
project. But enough interest was raised that we got 3 years of funding to keep looking 
at it, to check what is transpiring from the plants and to dig up the soil afterwards and 
analyze effectiveness. So, that is an interesting response to what was said yesterday about 
how hard it is to get field trials done. You all have done it quite nicely. I would also suggest 
that people in this group look at the ItrC model. The Interstate technology regulatory 
Council is a group of state regulatory bodies, approximately forty at this point, that have 
banded together so they don’t have to each approve the use of a technology. When they 
looked at the Edenspace lead-uptake project, for example, and other projects, they were 
able to say that if this works in New Jersey we don’t have to do it again in California and 
Idaho and everywhere else across the country. It saves a tremendous amount of time from 
the company standpoint and also from the regulatory side.
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For those who are wondering what happened to your European colleagues when the 
market moved against them for genetically modified food, they have moved into phy-
toremediation. I just came back from a European Union meeting where a very interesting 
set of people, Cooperation in the Field of Scientific and technical (COSt) research. A 
tremendous number of papers have been written in this group—greenhouse and lab-scale 
stuff at this point. They haven’t figured out how to get outside with it, but a lot of people 
are working on how to get better accumulators, producing genetic maps of accumulators 
so we can transfer elite characteristics to poplars and cottonwoods. No pun intended, 
it’s a great growth market that is much, much less scary to the public, and hence to the 
regulatory bodies, than genetically modified foods.
Scott	Merkle: I’m glad Neal brought up the complexity of what is going to happen with 
chestnut, because discussions are going on now with the American Chestnut Founda-
tion and other groups. Do we really want these trees to be put out to pollinate their 
wild relatives? It seems like a no-brainer; we want the resistance to spread in the natural 
population. At the same time, this is not just a forest tree. It’s a nut-crop tree and will 
again be a nut crop tree and eaten by consumers all over the country. Therefore, it’s a 
complex issue and it won’t be dull when we get to the point of deciding what we’re going 
to do with transgenic chestnuts.
Bruce	Ferguson: In response to Steve’s point about funding in Europe for phytoremedia-
tion, there has been support at a low level in the United States for very ambitious research 
on transgenics including phytoremediation. This reflects a fairly low emphasis on the 
environment in general over the last several years. It’s something we need to keep an eye 
on if we are going to maintain our research lead in this area.
Henry	Miller	(Hoover	Institution,	Stanford,	CA): We heard some really stunning science 
today in various stages of development, but it’s important to keep in mind the public 
policy, particularly regulatory obstacles, that many of these products will confront. For 
example, the chestnut-blight-resistant plants are more stringently regulated by EPA than 
organophosphate pesticides would be because chemical pesticides are subject to a 0-acre 
research exemption whereas recombinant plants of any sort are subject to a zero-acre 
research exemption. So, these products are potentially going to have to be registered as 
pesticides—not trivial and not particularly helpful, I think.
Stewart: I would like to bring up one point—the back-crossing project that Scott Merkle 
alluded to. They’ve crossed American chestnut with Japanese chestnut (Castanea	crenata), 
which is a small tree grown a lot as an ornamental. It’s not like American chestnut. Al-
though in the back-crossing you remove Japanese-chestnut genes, many will remain in 
the America chestnut background. I don’t see the Japanese chestnut as a pest, but the 
greatest ecological damage in my opinion, in the United States and worldwide, has re-
sulted from introducing exotics. Another interesting example is insect-resistant trees. In 
the Appalachians we have a tremendous problem with hemlock woolly adelgid, so we are 
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introducing a biological control agent. That might seem to be innocuous, but it would 
make a lot more sense to put a single gene in for resistance. Yesterday, Henry Miller said 
context, context, context.
Miller: I know, but we’re not talking about sense. We’re talking about government 
regulation. Again we go back to the ice-minus Pseudomonas where a deletion unit of an 
innocuous microorganism was considered to be a pesticide.
Stewart: We agree that we need reformation.
Miller: right, and I agree—but you have to remember there’s no incentive for government 
regulators to alter what they do, particularly if it involves a decrease in their responsibilities 
and their budgets and their empires. The USDA and EPA—look at their Web-sites—have 
created enormous empires for regulating products superior to those that they used to 
regulate with much, much smaller bureaucracies.
Stewart: So, you are saying that it’s not exactly a bump in the road.
Miller: Exactly.
Merkle: Henry, thanks for your comments. We had a meeting  weeks ago, including two 
representatives from APHIS and I was really very taken with their positive attitude about 
wanting to be helpful with the chestnut project. I’m sure we’ll find, people at the EPA who 
will want to work with us on this. I think it will be an interesting situation and I hope we 
will find a way to work together on it. The APHIS people really impressed me.
Robert	Wager	(Malaspina	University,	Naimano,	BC): In British Columbia, we have a huge 
problem with the mountain pine beetle—millions and millions of hectares—and we see 
nothing natural that’s going to knock it down. Is anybody aware of transgenic research 
to deal with that issue specifically?
William	Park: How about Maud?  Maud do you know anything about this?
Maud	Hinchee	(ArborGen,	Summerville,	SC):	I think people in BC are afraid of transgenics 
and are holding back research in that area.
Daniel	McDonald	(Phenotype	Screening	Corporation,	Knoxville,	TN): I am interested in the 
biosensor approach. We are developing artificial soil as growth media and we find with 
Arabidopsis that almost any stress turns it purple. So we use that as an indication that our 
watering is off, or nutrients or lighting or temperature, and it’s been very effective. The 
goal is to keep them green. How specific can you get that? When it turns purple in your 
case, is it due to a particular stressor versus just broadly stressing the plant?
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Ferguson: Our initial results have not been very specific. We usually grow wild-type plants 
with the transformed plants in the same conditions so that we can see if in fact there is a 
differential response, which is the way we calibrate right now. Eventually, tissue specificity 
will be very important—to show a change say in the stems rather than the leaves or produce 
a variegated type of pattern to indicate a difference from the normal stress response.
Stewart: We work a lot with engineers and protonics people who have drummed into our 
heads that when we take something into the field, it must have a unique spectral signa-
ture. That’s going to be the key and it’s one reason why we’ve looked at adding spectral 
properties to plants that are not there naturally.
Kaye	Knowles	(Fort	Valley	State	University,	Fort	Valley,	GA): I am a student and I have a 
question concerning phytoremediation. How do you dispose of the plants that absorb 
these metals? take, for example, the fern. What happens after it absorbs arsenic?
Ferguson: We have looked at various approaches. In the United States, the most common 
is to put the plants in the same landfill as for the untreated soil. The advantage is that a 
lot less mass is transferred because the plants typically concentrate the contaminants. The 
disadvantage is you are still moving contamination from point A to point B and eventu-
ally the people living near point B will object. The more elegant solution is to process the 
biomass to extract the contaminant for reuse. That’s feasible with lead, but less so with 
arsenic, which is in less demand in industry but is still used in gallium arsenide chips and 
to some extent in pesticides. That’s the elegant solution. The Japanese are working with 
us in that area, but it’s more expensive so most of our US customers are less interested. 
It’s almost a variation of phytomining—recovering a valuable resource. It’s still not easy 
to do because the metals are often sequestered in the cell walls. The reason we got into 
the energy side with cellulases was to seek ways of breaking down biomass to extract the 
metals more easily. We hoped to sell some feedstocks for energy on the side and help pay 
for the cleanup process, and then realized that there is a $00+ billion market for energy 
and there is a $0 billion dollar market for cleanup, which is fragmented. So we flipped 
it around to look at the energy side first. So this is an active area of research. Customers 
prefer cheap solutions—no surprise—but there are some good long-term paths.  
Ma: One of the disadvantages or “speed bumps” for phytoremediation is how to deal with 
the biomass. Unless we come up with some more cost-effective solution, phytoremedia-
tion may require a few more years of research.
Stewart: A question for Scott. With respect to remediation with merA and merB, the 
mercury will be blown off into the air. Is that a good thing? Do the regulators like that? 
It’s not something you’d want to have in your office, no doubt; what’s the latest skinny 
on that?
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Merkle: Almost every time I give a talk on merA, that question comes up. The mercury 
cycle is similar to the water cycle. There is a global atmospheric pool of mercury vapor, 
comprising many tons. All bacteria in soil and water containing mercury continuously 
generate mercury vapor. You might not want to place your grove of merA cottonwood 
trees next to a kindergarten, but at most sites what these trees would produce would be 
a drop in the bucket compared to what is already being volatilized globally.
Rock:	We are measuring the volatilization at the Danbury plant and we can’t find it. It’s 
not above background—not measurable.
Tingting	Chen	(Tennessee	State	University,	Nashville,	TN): We have heard a lot of about the 
technologies and that they are almost ready or already implemented in food or environ-
mental aspects. About the regulations, can we implement a cost-benefit analysis approach? 
Let’s say the chestnut has been wiped out for the last 00 years and the only way to restore 
it is with genetically engineered plants. Furthermore, insect-resistant plants can now be 
planted. In China, for example, they are significantly reducing insecticide application. 
When I was 3 or  years old in China, I applied pesticide with no protection at all. In 
that regard, the benefits from transgenic plants will be very, very significant in terms of 
reducing pesticide use. With respect to environmental remediation, the current technology 
is to haul contaminated soils from Connecticut, let’s say, to Utah or North Dakota for 
burial and storage. If you use transgenic plants there might be minor negative aspects, but 
we can tremendously increase the good aspects. Why are a couple of grains of transgenic 
corn in tons of non-transgenic corn considered hazardous to human beings? Implementing 
a cost-benefit approach would help in designing regulations for transgenics.
Park: Thank you very much.
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Author Henry David Thoreau, well known for his romance with the woods near Walden 
Pond, had great appreciation for the beauty and majesty of forests. But he also was realistic 
about the practical value of trees: “They warmed me twice—once while I was splitting 
them, and again when they were on the fire.”
The Application of Biotechnology to 
Sustainable Forestry
Maud Hinchee, Les Pearson and Dawn Parks
ArborGen,	LLC
Summerville,	SC	
Forestry	products	are	the	third	most	valuable	commodity	after	
oil	and	gas.
The challenge of foresters today is to maintain the natural characteristics of forests 
while meeting society’s need for products produced from trees. Forestry products are the 
third most valuable commodity after oil and gas. trees supply the bulk of fiber for pulp, 
paper, packaging and building needs. Some 5,000 products are made from trees. Three 
billion people depend on wood for fuel. So we must harvest wood. But forests also are 
an essential component of our ecology. They provide wildlife habitats. They help control 
erosion. They purify water. They sustain the world’s environment by emitting oxygen and 
sequestering carbon dioxide. And their beauty is unquestioned.
It is, therefore, essential that our forests are managed sustainably for ourselves and 
future generations. During the twentieth century, wood consumption tripled around 
the world and continues to grow. The most practical way of preventing this increased 
demand from further impacting our natural forests is to increase productivity of man-
aged tree plantations. 
Silviculture is the agriculture of trees—how to grow them, how to maximize growth 
and return, and how to manipulate species composition to meet specific objectives. Sil-
vicultural research increased loblolly pine plantation productivity from an average of 0 
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to 0 tons/acre 0 years ago to 90 tons/acre today on the most productive sites. Advance-
ments in site preparation and selective tree breeding have been the primary contributors to 
this significant increase. Biotechnology will be another important tool in the sustainable 
silviculture “tool kit” for stepwise improvements in productivity per acre.
As biotechnology helps to conserve natural forests, it also will give new roles to trees, 
such as pollution cleanup and restoration of threatened species. It has long been said that 
people who fail to see the big picture “can’t see the forest for the trees.” In this case, it is 
important that we not lose sight of trees’ potential by focusing solely on the forest. By 
improving plantation trees, we can help sustain forests.  
How Biotechnology Can reduce the Impact on Natural Forests 
today, managed tree plantations provide only about a third of the world’s need for wood 
and wood products. The remainder comes from other sources, including natural forests. 
Clearly, if tree plantations produce more, less will be needed from natural forests. 
For example, loblolly pine—the major pulp species in the southeast United States—has 
a rotation of about 5 years. A 5-year reduction in time to harvest would have a tremen-
dous impact over time on total cellulose production per acre. Genetic research, including 
biotechnology, holds promise to produce faster-growing trees and to increase the cellulose 
content of individual trees. Eucalyptus, another major source of pulp for paper manufac-
ture, has been manipulated to grow faster through advancements in tree biotechnology. 
In the Pacific Northwest, by crossing the eastern cottonwood with the region’s indig-
enous black cottonwood, University of Washington scientists have attained yields five 
to ten times greater than from trees in the wild. Oregon State University has produced 
poplar trees capable of reaching 0 feet in height in  years. 
Biotechnology can also reduce threats to tree health. research is showing promise in 
the introduction of traits that confer resistance to pests and pathogens that weaken or 
kill trees. Improvements through tree biotechnology may also improve weed control, 
enabling young trees to get a head start over nutrient-robbing competitors. trees with 
these traits will improve the competitiveness of the United States forestry industry in 
international markets for forest products and will improve productivity of lands intended 
for pulp production.
Other Potential Benefits of Biotechnology
tree biotechnology promises benefits beyond increased productivity, including:
Genetic	research,	including	biotechnology,	holds	promise	to	
	produce	faster-growing	trees	and	to	increase	the	cellulose	content	
of	individual	trees.
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• restoration and preservation of heritage trees. research is underway at several in-
stitutions, including the State University of New York, the University of Georgia 
and the University of tennessee to develop disease-resistant varieties of important 
and desirable tree species that are threatened with extinction due to blight. Bio-
technology provides the best hope to save and restore species such as American 
chestnut, American elm, flowering dogwood and various oak species, which have 
been so important to our culture and the beauty of our cities and woodlands. 
• Cleanup of toxic waste and Superfund sites. It may be possible through biotech-
nology to develop trees capable of absorbing specific toxins from the soil. This 
has the potential to reduce by millions of dollars the amount of money spent on 
cleaning up toxic sites. The University of Georgia is among several institutions 
conducting research with trees for phytoremediation. 
• Improvement of water quality. Just as trees can be engineered to absorb toxic 
metals, they also can be modified to absorb excess nitrogen, which contributes to 
water pollution and algal blooms in waterways. rutgers University is pioneering 
research in this area.
• Biofuels. The US Department of Energy is researching the potential for trees to 
provide clean, sustainable fuels. One possibility is to convert the cellulose in wood 
to ethanol as transportation fuel. Biotechnology can play a vital role in producing 
wood better suited for the production of ethanol, which can reduce our reliance 
on foreign oil.  
• Decreased lignin content for pulping. Biotechnology can reduce the amount of 
lignin in trees intended for paper manufacture. Lignin—which gives wood its 
strength—must be removed in the pulping process. trees that have less lignin 
or more-extractable lignin are more readily pulped, allowing mills to reduce the 
chemicals and energy required to purify cellulose (the basis for paper, packaging 
and many absorbent products) from wood. Thus, pulp mills are expected to better 
achieve their ambitious environmental objectives while reducing inputs and costs.
• Better lumber. Biotechnology may also produce straighter trees with fewer limbs, 
resulting in increased production of better-quality lumber.
Continued research in biotechnology may address and solve other issues, such as why 
some woods resist rot and others do not and why some species are susceptible to insects 
and others are not. Through this continually expanding knowledge will come advance-
ments that will maximize the value and efficiency of trees.
techniques Used
While people may think of biotechnology as involving the transfer of genetic material from 
one species into another, in fact transgenic research is only one of the multiple methods 
involved. Current applications of tree biotechnology include techniques that identify 
genes or alleles within a species that contribute important traits. By identifying these 
genes, researchers can select and breed better genotypes. This work currently is directed 
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towards improving the growth, health and quality of trees grown in plantations. Meth-
ods employed include molecular marker-assisted breeding and the selection and asexual 
propagation of elite trees. These research areas have been applied relatively recently to the 
genetic improvement of plantation forestry species, with the most advanced applications 
practiced in eucalyptus plantations in Latin America and Australasia, and in plantations 
of Monterey pine in New Zealand, Australia, and Latin America. Further research seeks 
to apply the technology to additional plantation species such as loblolly pine, spruce and 
poplar species and hybrids.
technologies to improve loblolly pine will rely on the development and commercial 
application of cost-effective mass propagation techniques (such as ArborGen’s Arbor-
Genabled® process) for specially selected elite genotypes. Once these genotypes have been 
identified, they will be the foundation for the introduction of value-added traits through 
gene-insertion technology. These genotypes, in addition to being the best of their species, 
will impart the various benefits discussed above, such as wood-quality improvements, 
disease and stress tolerance, and bioenergy and bioproduct applications. ArborGen cur-
rently is focused on faster growth and altered lignin content.
Field testing and Deregulation
Several institutions, including ArborGen, have made significant progress in introducing 
and testing genes that improve wood-volume gains as well as in reducing lignin content. 
These trees are currently in multiple field tests to determine trait expression and to ensure 
overall tree performance in plantation conditions. ArborGen has multiple field sites for 
testing trees in geographies and environments in which industrial forestry is practiced 
for these species. Some of the trees currently under evaluation will be selected for further 
product development and future commercial sale.
Commercialization will require that genetically engineered trees go through the regula-
tory process that has a proven track record for agronomic crops, such as soybean, corn 
and cotton. The regulatory framework has been successful in its current risk-assessment 
approach in regulating field tests and commercial deployment. The system under which 
APHIS has regulated biotechnology since 987 is effective and protective, as evidenced 
by the fact that more than 0,000 field trials have been done and more than sixty biotech 
products have been commercialized without adverse effects on human or environmental 
health.
This science-based approach allows assessment of risk on a case-by-case basis for a 
particular trait in a particular crop of interest. This approach is equally applicable for 
many of the new products under development, including plantation trees. The significant 
knowledge base that already exists for plantation species must be considered in the regu-
latory process. The academic community will play a critical role in the trial and testing 
phases of product development.
ArborGen	is	focused	on	faster	growth	and	altered	lignin	content.
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Summary
In summary, tree biotechnology will have many environmental and societal benefits. 
Faster-growing trees, developed through biotechnology, will contribute significantly to 
sustainable silviculture by diminishing the demand for wood harvested from old growth 
and natural forest stands. Many other benefits are possible, including restoration of heri-
tage tree species, such as American chestnut and American elm; cleanup of toxic wastes; 
nitrogen absorption; biofuels; and lignin modification to improve the production of 
paper. A robust, science-based regulatory system is essential to bring these improvements 
to market. The regulatory process should be similar to the coordinated framework cur-
rently used for agronomic products, which operates on a case-by-case, trait-by-species 
basis. Biotechnology will help the forestry industry advance its goals of providing wood 
products for society while protecting the natural forests that provide beauty and essential 
ecological benefits.
The	regulatory	process	should	be	similar	to	the	coordinated	
	framework	currently	used	for	agronomic	products,	which	operates	
on	a	case-by-case,	trait-by-species	basis.
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Maud Hinchee has been Chief technical Officer for ArborGen LLC since 
its inception in 000. ArborGen, a forestry biotechnology company, conducts 
research and develops products to improve the value, productivity, and sustain-
ability of plantation forests. 
Prior to joining ArborGen, Dr. Hinchee was instrumental in the development 
of transformation technologies for soybean, sugarbeet, potato, and strawberry 
at Monsanto, and led the introduction of herbicide tolerance, insect tolerance 
and disease resistance traits into these crops. At Monsanto she also successfully 
led a business unit aimed at applying biotech traits to specialty crops—alfalfa, 
sugarcane, forestry species—through collaborative partnerships. 
Hinchee is an inventor on five patent applications, and author of over twenty 
scientific publications. She has organized annual meetings and symposia for the 
International Union of Forest research Organizations and the Society of In	Vitro 
Biology, has served for four years on the board of the Institute for Forest Bio-
technology, and has also been a board member for the Council for Agricultural 
Science and technology.
She received her PhD in Plant Morphogenesis from the University of California, 
Davis, and holds an MS in Botany from the University of Washington, Seattle, 
and a BS in Botany from Davis.
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tremendous effort has been devoted to developing genetically engineered trees, with 
the emphasis on reducing lignin quantity to improve woodpulp-production efficiency. 
However, lignin chemical reactivity also is a critical barrier to woodpulp production, as 
lignin removal from wood is either initiated by chemical degradations or—as in most 
cases—accomplished entirely through chemical reactions. Thus, the current tree-bio-
technology emphasis on low lignin quantity must be expanded to include greater lignin 
reactivity and, ultimately, a combination of low and reactive lignin traits.
Lignin reactivity depends on the frequency of its structural units, guaiacyl (G) and syrin-
gyl (S) monolignols. More syringyl monolignol units, or high S/G lignin monomer ratios, 
are known to induce high lignin reactivity. For more than 50 years, it has been thought 
that syringyl monolignol biosynthesis in angiosperms occurs via conversion of caffeate 
to sinapate via ferulate and 5-hydroxyferulate (Figure ) (Grisebach, 98; Grand, 98; 
Higuchi, 985). Based on high-performance liquid chromatography/mass spectrometry 
(HPLC/MS) characterization of products from reactions of microsomal proteins from 
lignifying stem xylem of sweetgum (Liquidambar	styraciflua) with a mixture of four po-
tential 5-hydroxylation substrates—ferulate, feruloyl-CoA, coniferaldehyde and coniferyl 
alcohol—Osakabe et	al. (999) discovered that 5-hydroxyferulate was not synthesized. 
Instead, the exclusive product from this mixed substrate reaction was 5-hydroxyconiferal-
dehyde, demonstrating for the first time that a coniferaldehyde 5-hydroxylase (CAld5H) 
is involved in monolignol biosynthesis, and that ferulate 5-hydroxylase (F5H) may not 
be (Osakabe et	al., 999).
Understanding Gene Function and Control in 
Lignin Formation In Wood
Vincent L. Chiang
North	Carolina	State	University
Raleigh,	NC	
Tremendous	effort	has	been	devoted	to	developing	genetically	
engineered	trees,	with	the	emphasis	on	reducing	lignin	quantity	to	
improve	woodpulp-production	efficiency.	
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Subsequently, CAld5H cDNAs were cloned from aspen and sweetgum. When co-
niferaldehyde was incubated with a mixture of CAld5H-containing yeast P50 and E.	
coli-expressed caffeate O-methyltransferase (COMt), it was converted to sinapaldehyde 
via 5-hydroxyconiferaldehyde (Osakabe et	al., 999). Thus, CAld5H catalyzes 5-hydrox-
ylation of coniferaldehyde into 5-hydroxyconiferaldehyde, which in turn is methylated by 
COMt to sinapaldehyde, supporting the idea of a hydroxylation/methylation flux in	vivo 
from guaiacyl to syringyl monolignol biosynthesis via coniferaldehyde (Figure ). Based 
on HPLC/MS characterization of the kinetic properties of purified recombinant aspen 
COMt, Li et	al. (000) demonstrated that, indeed, COMt is a 5-hydroxyconiferaldehyde 
O-methyltransferase (AldOMt) that catalyzes methylation of 5-hydroxyconiferaldehyde 
(Km = . µM) with some affinity for caffeate (Km = 75. µM) and 5-hydroxyferulate 
(Km = 5.0 µM). However, when a mixture of 5-methylation substrates—caffeate, 5-hy-
droxyferulate and 5-hydroxyconiferaldehyde—was incubated with recombinant COMt 
(now designated as AldOMt) or soluble proteins from stem xylem, a complete inhibition 
of caffeate and 5-hydroxyferulate methylation was observed, while the conversion of 5-
hydroxyconiferaldehyde into sinapaldehyde (Figure ) was conserved (Li et	al., 000). 
Enzyme inhibition kinetics further showed that 5-hydroxyconiferaldehyde is a competitive 
inhibitor of AldOMt-catalyzed methylation of both 5-hydroxyferulate and caffeate with 
Ki values of 0. and . µM, respectively, but 5-hydroxyferulate and caffeate are not 
effective inhibitors of 5-hydroxyconiferaldehyde methylation (Li et	al., 000). Thus, the 
presence of CAld5H/AldOMt-mediated coniferaldehyde 5-hydroxylation/methylation 
eliminates the pathway from caffeate to sinapate via ferulate and 5-hydroxyferulate, and 
CAld5H/AldOMt diverts the guaiacyl pathway from coniferaldehyde to sinapaldehyde 
via 5-hydroxyconiferaldehyde to initiate syringyl monolignol biosynthesis (Figure ).
CAD and SAD
The CAld5H/AldOMt pathway together with the long-thought coniferyl alcohol dehy-
drogenase (CAD) function with sinapaldehyde was once believed to lead to the biosynthesis 
of syringyl monolignol. However, HPLC/MS-based enzyme functional analyses of aspen 
xylem protein and E.	coli-expressed recombinant aspen CAD protein demonstrated that 
CAD is in fact coniferaldehyde- or guaiacyl-specific (Li et	al., 00). This strongly sug-
gests that a discrete sinapyl alcohol dehydrogenase (SAD) is needed for metabolizing the 
CAld5H/AldOMt product, sinapaldehyde, into sinapyl alcohol, the syringyl monolignol. 
This discovery led to the isolation of an SAD cDNA from aspen developing xylem (Li 
et	al., 00). Like the CAld5H/AldOMt-mediated initiation of the syringyl pathway, 
SAD protein is widely distributed in angiosperms (Li et	al., 000), but SAD as well as 
CAld5H and AldOMt proteins and their functions are absent from gymnosperms (Li et	
al., 00). These results challenge the traditional model of monolignol biosynthesis and 
suggest that CAD mediates the reduction of coniferaldehyde into guaiacyl monolignol 
and that SAD along with CAld5H/AldOMt controls the biosynthesis and utilization of 
sinapaldehyde for syringyl monolignol.
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Lignin reduction
Biochemical evidence further demonstrated that, in this principle flux, -coumarate:CoA 
ligase (CL) may limit total lignin accumulation (Hu et	al., 999). CL, an enzyme up-
stream of coniferaldehdye (Figure ), has been demonstrated to limit lignin accumulation 
in various plant species. transgenic aspen trees with downregulated lignin-specific CL, 
PtCL (Hu et	al., 999), exhibited up to a 5% reduction in lignin, but this did not alter 
lignin structure with respect to the S/G ratio, as revealed by lignin thioacidolysis (Hu et	
al., 999). two-dimensional heteronuclear single quantum correlation nuclear magnetic 
resonance (HSQC NMr) further confirmed that the common lignin structural units 
are all similarly represented in wild-type and lignin-reduced transgenic trees (Hu et	al., 
999). Thus, these data provide strong evidence for the absence of any significant branch 
pathways at caffeate, the preferred CL substrate (Hu et	al., 998), that would otherwise 
divert caffeate metabolism away from the principal phenolic flux (Figure ) to result in 
an abnormal type of lignin. We proposed that, with respect to this principal flux, the 
result of CL downregulation is simply the attenuation of metabolite pools downstream 
of caffeate, limiting the availability of the normal precursors, the monolignols, for lignin 
polymerization. 
Combinatorial	gene	manipulation	had	led	to	38%	to	52%	
reductions	in	stem	lignin	and	to	22%	to	64%	increases	in	the	
lignin	S/G	ratio.
When antisense 4CL and sense CAld5H genes were simultaneously transferred into 
aspen via Agrobacterium, phenotypically normal transgenic trees expressing each one 
and both of the transgenes were produced (Li et	al., 003). Forty transgenic aspen lines 
were obtained, of which 37, 0, and 3% harbored antisense Pt4CL, sense LsCAld5H 
and antisense Pt4CL + sense LsCAld5H gene constructs, respectively, as confirmed by 
genomic PCr. From each of these three transgenic groups grown in a greenhouse, several 
trees were randomly selected and harvested at the age of 0 months during the growing 
season for various characterizations. CL-protein levels were drastically reduced in lines 
harboring only antisense Pt4CL transgene, leading to a 70% to 90% reduction in xylem 
CL enzyme activity, and a 30% to 0% reduction in stem lignin (table ). No significant 
effect on the lignin S/G ratio was found (table ). Over-expressing the LsCAld5H gene 
alone drastically elevated the xylem CAld5H-protein levels, giving rise to a .-.8-fold 
increase in xylem CAld5H enzyme activity. As a result, these transgenics exhibited up to 
a remarkable .5-fold increase in the S/G ratio as compared to the control (table ). The 
single CAld5H gene effect had no influence on total lignin accumulation in transgenic 
trees (table ). However, the single-gene effects became additive in transgenics harboring 
both antisense Pt4CL and sense LsCAld5H genes. Alterations of CL- and CAld5H-
protein levels in these trees were consistent with changes of the corresponding enzyme 
activities: 80% to 90% reduction in CL and 0% to 0% increase in CAld5H. This 
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combinatorial gene manipulation had led to 
38% to 5% reductions in stem lignin and to 
% to % increases in the lignin S/G ratio 
(table ).
Transgenic	trees	with	
reduced	lignin	exhibited	
increases	in	cellulose	content.
These	transgenics	are	
potentially	valuable	
lignocellulosic	substrates	for	
woodpulp	production.
transgenic trees with reduced lignin ex-
hibited increases in cellulose content—up to 
a remarkable 30% increase—was observed in 
antisense-Pt4CL/sense-LsCAld5H transgenic 
line , due to a 5% lignin reduction (table 
). Consistent with the observation reported 
by Hu et	 al. (999), the increased cellulose 
content together with reduced lignin quantity 
resulted in a cellulose:lignin ratio of 3 to 5 in 
the transgenic lines, as opposed to .9 in the 
control (table ). The relative abundance of 
the major hemicellulose component, xylan, 
was essentially unaffected in all transgenic 
lines, confirming our previous results (Hu et	
al., 999).
Conclusion
Lignin reductions in trees can be achieved by 
antisense 4CL, technology and over-expres-
sion of sense CAld5H results in S/G increases. 
These effects were independent but additive, 
with plants expressing both transgenes hav-
ing less lignin, a higher S/G ratio and more 
cellulose. These transgenics are potentially 
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valuable lignocellulosic substrates for woodpulp production. They may not be the ul-
timate lignocellulosics for bioethanol production, but they are benchmark transgenics 
and are rich sources of information for understanding cell-wall biosynthesis and thus for 
further metabolic engineering, allowing the generation of the ultimate raw materials for 
woodpulp production.
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The concept of plants as factories was launched approximately 5 years ago as a method 
for bio-manufacturing pharmaceuticals, vaccines and industrial enzymes. The advantages 
of the plant system include low-cost manufacturing with limited capital investment for 
growing the biomass, easy scale-up with planting of increased acreage and a system without 
the threat of animal pathogens whether viral, bacterial or prion.
Proof of Concept
The concept has been tested in a number of plant systems at several biotechnology com-
panies, including: ProdiGene (corn; Hood et	al., 003), SemBioSys (safflower; Moloney, 
00), Ventria (rice; Huang, 00), Medicago (alfalfa; Vezina et	al., 00), Biolex (Lemna; 
Gasdaska et	al., 003), Croptech (tobacco; Cramer et	al., 000), Large Scale Biology 
(tobacco; Grill et	al., 00) and Planet Biotechnology (tobacco; Larrick et	al., 00) as 
well as in university research laboratories. The proof of the concept is embodied in these 
research efforts. Plant systems can express proteins at high levels, assemble multimeric 
proteins such as antibodies, and correctly process them, e.g. cleave signal sequences and 
attach glycosylation sequences. Many types of proteins have been expressed in plant 
systems including those ranging in molecular weight from 5,000 daltons (Zhong et	al., 
999) to over 00,000 daltons (Lamphear et	al., 00). These various examples show the 
versatility of the system. The subject of this paper—bovine trypsin produced in transgenic 
maize—illustrates the concept of gene to market, i.e., steps in commercialization of a 
protein product.
Commercialization of a Protein Product from 
Transgenic Maize
Elizabeth E. Hood SuSan L. Woodard
Arkansas	State	University	 Texas	A	&	M	University
Jonesboro,	AR	 College	Station,	TX	
This	paper	illustrates	the	steps	in	commercialization	of	a	
	protein	product.
8 Agricultural Biotechnology: Beyond Food and Energy to Health and the Environment
trypsin is a pancreatic serine protease involved in food digestion. Commercially, it is 
produced from bovine refuse from slaughterhouses for applications in cell culture and 
protein processing. Many of the cell cultures are for production of pharmaceutical or 
vaccine proteins, requiring pharmaceutical-grade manufacturing conditions. With the 
existing problems arising from hoof and mouth and mad cow (bovine spongiform en-
cephalopathy) diseases, non-animal sources of trypsin are in high demand. Because bovine 
pancreatic trypsin is now available in maize lines, large-scale production for industrial 
and pharmaceutical applications can be achieved to meet this demand.
Molecular	Biology
In order to express a protein at commercial levels (i.e., as high as possible for the protein 
and plant host), several molecular and cellular parameters must be considered. The use 
of codons that are common to the host plant can enhance the translatability of the mes-
senger rNA. From experience, the leading amino acids appear to be the most critical in 
this regard, presumably because they initiate efficient translation. In the case of bovine 
trypsin, the native Bos	taurus gene was fused in frame with the maize-optimized barley 
alpha-amylase signal sequence (mo-BAASS; rogers, 985), providing twenty-five codon-
optimized amino acids for translation (Woodard et	al., 003), sufficient in this case to 
achieve good expression. Other parameters of interest for high expression of foreign genes 
for protein production include tissue specificity, subcellular localization, germplasm/breed-
ing and protein-specific considerations. For bovine trypsin, tissue specificity was achieved 
through use of the maize globulin- promoter, which is embryo-preferred. Although 
several subcellular locations were tested, the best location for high protein accumulation 
was the apoplast (cell wall) (Hood and Woodard, 00). By far, the greatest challenge 
with expression of bovine trypsin was regeneration of transgenic plants when the gene 
for the active enzyme was used. Therefore, the zymogen form of the protein, trypsinogen, 
was expressed from the holo-gene and transgenic plants, with high expression obtained 
(Woodard et	al., 003). Thus, optimal expression of trypsin in maize was achieved by 
expressing the zymogen form of the gene from the embryo-preferred globulin- promoter, 
and targeting the protein to the apoplast using the maize-optimized barley alpha-amylase 
signal sequence. Using these conditions, the highest first generation seed showed 3.3% 
of total soluble protein (tSP) by enzyme activity (trF, Figure ). 
Variation among transgenic events and among multiple plants from single events, i.e., 
clones, is commonly observed in maize-derived transgenic plants (Hood et	al., 003). 
Because of this, multiple individual lines from multiple events must be screened for the 
protein of interest, to choose the best lines to move forward. However, the maize varieties 
that perform best in tissue culture and transformation are not suitable for field growth. 
Therefore, lines selected for high first-generation expression are planted in field nurseries 
to be improved in agronomic characteristics through a breeding program. Breeding into 
elite inbred germplasm is conducted and resulting lines subsequently selected for high 
expression of the foreign gene of interest as well as for field performance. trypsinogen was 
recovered in bulk seed lots at 58 mg trypsin per kg of seed, or 0.00% of dry weight from 
fifth-generation elite inbred material (Woodard et	al., 003), or approximately double 
the first-generation high single seed.
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Figure. trypsin expression in various transgenic maize lines as a percent of total 
soluble protein (%tSP) from ground seed. trC—zymogen form of trypsin expressed 
from a constitutive promoter and targeted to the cell wall; trD—mature trypsin 
expressed from a constitutive promoter and targeted to the cell wall; trE—zymogen 
form of trypsin expressed from an endosperm-preferred promoter and targeted to 
the amyloplast; trF—zymogen form of trypsin expressed from an embryo-preferred 
promoter and targeted to the cell wall.
Biochemical	Characterization
For commercialization of a product from a new production platform, it is crucial to 
determine the biochemical qualities of the plant-derived protein, including its activity. 
Maize-derived trypsin was mostly active when extracted from ground transgenic seed, and 
exhibited several molecular-weight forms (Figure ). The largest disappeared upon treat-
ment with enterokinase, suggesting it was the trypsinogen form (Woodard et	al., 003). 
When each of the remaining high-molecular-weight forms was subjected to N-terminal 
micro-sequencing, the sequences were the same and matched exactly the sequence of 
the native bovine trypsin, confirming that the N-terminal signal sequence was correctly 
cleaved (Figure ). In addition, these forms were active (Woodard et	al., 003).
For	commercialization	of	a	product	from	a	new	production	
	platform,	it	is	crucial	to	determine	the	biochemical	qualities	of	
the	plant-derived	protein.
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Several methods of analysis were developed to determine the concentration of protein 
in transgenic maize seed. Enzyme-linked immunosorbent assays (ELISAs) provided 
disappointing results in that most transgenic lines exhibited very low concentrations of 
trypsin. However, Western blots suggested that the enzyme was present in substantially 
higher concentrations than the ELISAs had indicated (Figure ). Subsequently, enzyme 
assays were developed to assess the activity of the maize-derived enzyme, and the results 
agreed closely with the Western blots, suggesting that the trypsin was digesting protein 
components in the ELISA.
Physical parameters of maize-derived trypsin matched the native protein in all instances 
with the exception of the molecular weight of extracted protein (table ; Figure ). The 
differences in molecular weight were apparently due to O-linked glycosylation sequences 
on the maize-derived protein, and when removed by chemical means, the proteins had 
the same apparent molecular weight (Woodard et	al., 003). Specific activity, pH opti-
mum, Km and Vmax values were not significantly different between the two sources of 
enzyme (table ).
Figure . trypsin characterization. Western blot of maize-derived trypsin. Bt = Bos 
taurus; Zm=Zea	mays; tn=trypsin; tg=trypsinogen. Numbers to the left indicate mi-
gration of molecular-weight markers. Box to the right indicates N-terminal sequence 
of three active forms of maize-derived trypsin and values for trypsin concentration 
from several averaged samples using three assay methods.
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Product Development
A product is not just the protein of interest in a transgenic plant. It is the protein of interest 
utilized in a certain market application, each of which creates a different product. Thus, 
many products can be developed from one protein-expressing plant line. Development of 
crop-derived proteins into real-world industrial or pharmaceutical products comprises a 
number of activities including applications testing and market development, a freedom-
to-operate assessment, patent protection, a safety assessment, breeding into elite material 
for best field performance, small-scale production and formulation requirements. All 
aspects must be developed in a way that meets cost targets. 
Applications for trypsin include digestive aids, detergent additives, processing of 
commercial proteins, commercial cell culture, an active pharmaceutical product, eye-
care products and leather processing. The major question for maize-derived trypsin is 
whether it can substitute for the bovine product in these applications. In several trials, 
the maize-derived enzyme functioned equally as well as the bovine counterpart (S.L. 
Woodard, unpublished). 
Market development for maize-derived replacement products for existing markets 
mainly comprises focus on the advantages of a plant-derived protein. First and foremost, 
the plant-derived enzyme can be utilized in markets that are sensitive to the source of 
the product and the associated need to avoid animal pathogens. This is particularly true 
for cell culture, pharmaceutical use, and commercial reagent proteins that are utilized 
to process pharmaceutical proteins. A second advantage is low cost for markets not 
sensitive to these cleanliness issues. A third advantage is the ability to scale-up for large 
market applications for which microbial production systems are less appropriate because 
of capital requirements.
Freedom to operate (FtO) is a complex issue for plant-derived products—“can I 
practice my processes and produce my product without running afoul of others’ patents?” 
Table 1. biochemical characTerizaTion of bovine TrypSin from maize 
and naTive SourceS.
 Parameter Maize-derived trypsin Bovine trypsin
 Molecular weight (MALDI tOF) 3,97 daltons 3,30 daltons
 Specific activity 75 U/mg protein  U/mg protein
 Glycosylation O-linked none
 Km .7 mM 3. mM
 Vmax 0.9 0.30
 pH optimum 8. 8.7
Development	of	crop-derived	proteins	into	real-world	industrial	
or	pharmaceutical	products	comprises	a	number	of	activities.
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(Sweeney, 00). Determining FtO is a process that requires constant diligence and 
many licenses, particularly in competitive areas of research and technology development. 
Whenever new materials are brought into an entity or the entity’s materials are shared with 
others, FtO issues can be raised. And, obviously, not only materials are at stake. Often 
processes for creating products are patented; for example, transformation protocols and 
breeding strategies are equally subject to licensing requirements. Diligence in this area 
with company or university attorneys is critical to success.
Patent protection is essential to successful market entry, particularly if the technology 
or product can be manufactured by other firms, or the technology of interest makes a 
product possible when it previously was not available. Proteases in general are difficult 
to produce in xenogenic systems because of their detrimental effect on native protein 
content. In 000, ProdiGene was issued a broad-based patent (USP # ,087,558) describ-
ing the production of proteases in transgenic plants, claiming expression of any protease 
in any transgenic plant, where the protease is expressed in the zymogen form. This is a 
fundamental technology, because recovery of transgenic plants expressing high levels of 
active proteases is nearly impossible unless zymogens are expressed in seed.
Maize transgenic events are generated in material that has poor agronomic character-
istics. Thus, breeding into elite germplasm is essential for field performance that meets 
production requirements. This process takes from  to  years depending on the need 
to reach yield parity for profit margin and whether year-round nurseries are used for 
the acceleration of generations. If yield parity with commodity corn is required to meet 
production-cost requirements, then five to seven generations of crossing into elite inbred 
germplasm is required with two additional selfed generations before making a hybrid (D. 
Delaney, personal communication). The germplasm of choice depends upon the field 
production location, and if more than one zone will be required for crop production, 
more inbreds will be required for the breeding program. A minimum of two generations 
per year can be accomplished in midwestern US summer nurseries alternating with Puerto 
rican (or other Caribbean island) winter nurseries. However, with year-round nurseries 
in Hawaii, .5 to 3 generations per year can be accomplished. If the cost of the product 
and immediacy of the market opportunity warrant, the higher cost of year-round nurseries 
can often be justified, cutting significantly the time involved in development of genetic 
production material.
One of the major goals of the breeding program, in addition to lines with adequate field 
performance, is generating lines with commercial levels of expression of the gene of interest. 
Minimum concentrations of protein in corn meal for different types of products—purified 
pharmaceuticals, orally delivered vaccines, industrial enzymes or cellulases—are shown in 
table  (J. Howard, personal communication). For the trypZean™ product, the minimum 
concentration of trypsin in dry seed material should be 0.0–0.% to meet production-
Breeding	into	elite	germplasm	is	essential	for	field	performance	
that	meets	production	requirements.
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cost targets because in this lyophilized powder formulation it is considered a cell-culture 
reagent protein, thus falling between the purified pharmaceutical and industrial enzyme 
application requirements. As stated above, the concentration of trypsin in fifth-genera-
tion breeding material is approximately 0.00% of dry weight, somewhat lower than 
what will be required for a profitable product. However, because breeding and selection 
can generate material that expresses the recombinant protein at ten to a hundred times 
higher than the initial transformant (Hood et	al., 003), continued breeding and selection 
should yield lines with the required expression level.
During the breeding program, small-scale production can be accomplished from hybrid 
seed samples taken from the breeding material and subsequently grown in field plots. two 
goals can be achieved with this material: assessment of the improvement in agronomic 
character of interim hybrids and small-scale extraction/purification of the protein of 
interest for applications trials. These two assessments are critical to timely identification 
of potential problems in the product-development timeline.
The final formulation of the protein product is entirely a requirement of the applica-
tion. For maize-derived trypsin, the product trypZean™ is a lyophilized powder bottled 
for laboratory use as a cell-culture-dissociation reagent. For other uses, the formulation 
might be ) a stabilized liquid, ) ground, unextracted corn meal, or 3) ground, defatted 
corn-germ meal. In all cases, the cost of formulation must be compatible with the sale 
price of the product.
A product safety assessment includes understanding the hazard of the specific protein 
of interest alone or within the plant material. Once the inherent hazard of the protein has 
been quantified, one can determine the risk associated with various levels of exposure to 
it (risk is proportional to hazard multiplied by exposure) (Howard and Donnelly, 00). 
While this assessment will not satisfy all regulatory-compliance issues, it is a required 
component and will assist in establishing confinement measures for regulatory compliance. 
The field of product safety versus regulatory compliance is in flux and requires constant 
attention to remain apprised of status.
Production
Production of crop-derived proteins requires scale-up of activities similar to those described 
in product development. Additionally, it requires a plan for compliance with US Depart-
ment of Agriculture (USDA) and Food and Drug Administration (FDA) regulations, or 
Table 2. minimum concenTraTionS of foreign proTein in geneTically 
modified producTion maTerial for coST-effecTive producTion.
 Product Application requirement Minimum concentration
 For oral delivery of vaccines ~ mg required for dose 0.% DW
 For purified pharmaceuticals Less expression-sensitive 0.0% DW
 For industrial enzymes <$00/kg production cost >0.% DW
 For cellulase for ethanol 0 g/gallon ethanol >3% DW
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those of other agencies depending upon the product. The steps involved in production, 
growing, harvesting and associated activities, processing, and extraction/purification are 
outlined in table 3.
Corn containing bovine trypsin—or any transgene for protein production—should be 
grown in areas where crop development is efficient and cost-effective, i.e., the midwestern 
corn-belt. Otherwise much of the advantage of using a commodity crop for low-cost 
production is lost (Howard and Hood, 005). The total acreage required is a product 
of seed yield and recombinant protein concentration in the seed. For example, trypsin 
in the fifth generation was at a concentration of 0.00% of whole-seed dry weight. If 
the corn produced 50 bushels per acre, equal to 3,750 kg of grain per acre, the yield of 
trypsin per acre would be 5 g. If the desired production amount is 0 kg for market 
entry, approximately 5 acres would be required. Confinement to meet USDA regulations 
requires a buffer zone of  mile wide surrounding the field, plus other measures such as 
delayed planting compared to other corn-production fields in the area. Male sterility can 
also be utilized, but the trypsin material is not male sterile.
Table 3. producTion STepS and parameTerS To be conSidered during 
producTion of TrypSin from TranSgenic maize.
 Production step Considerations for trypsin in corn
 Growing Biological requirements for corn,
  seasonal and geographic limitations,
  recombinant protein yield,
  confinement regulations
 Harvesting/ transportation/Storage Mechanical issues, time,
  temperature sensitivity, cost,
  protein stability in tissue
 tissue processing Stability in tissue,
  potential for enrichment,
  small batches, whole seed,
  large batches, dry mill for germ,
  extract oil 
 Extraction/Purification Protein stability,
  biomass quantity versus yield,
  cGMP for pharma applications,
  formulations
Corn	containing	bovine	trypsin—or	any	transgene	for	protein	
production—should	be	grown	in	areas	where	crop	development	is	
efficient	and	cost-effective.
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Figure 3. relative contribution of maize kernel tissues to total seed weight. Numbers to 
the right compare the concentration of recombinant protein in each tissue based on a 
whole-seed expression level of 0.0% dry weight.
Corn seed is harvested mechanically when the moisture content is below approxi-
mately 0%. Shelling is accomplished best when moisture content is below 5%. Field 
drying is the most cost-effective method, but harvest should occur before a severe frost, 
and if necessary the ears can be mechanically dried after collection. Current regulations 
require dedicated equipment for non-food products from genetically modified crops. 
Once the grain is harvested, dried and shelled, it can be stored for months to years. Most 
foreign proteins in genetically modified seed are quite stable in dried grain (Hood et	al., 
997; Hood et	al., 003; Lamphear, 00), and trypsin is no exception (S.L. Woodard, 
unpublished).
One of the advantages of grain crops for bioproducts is the ability to partition proteins 
into specific tissue sinks (Figure 3). trypsin is expressed largely in the embryo of the kernel, 
with much less present in the endosperm. Because the embryo represents only 0% of the 
dry weight of the kernel, separating it from the endosperm effectively concentrates the 
protein ten-fold on a dry-weight basis. tissue separation can be accomplished with either 
dry-milling or wet-milling operations. The recombinant protein must be compatible with 
the temperatures used in either process, and the solutions used in the wet-milling process. 
In the future, oil will be extracted and sold as a co-product when the germ is isolated, 
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particularly if the transgenic product is deregulated. tissue processing is not usually cost 
effective at less than a million bushels. Therefore, at 7,500 bushels from 5 acres of corn, 
whole-seed grinding and subsequent extraction will be a more cost-effective production 
method than seed fractionation for trypsin.
Currently, trypsin is a purified, lyophilized product, trypZean™ (Sigma Chemical Co., 
St. Louis, MO). Thus, extraction and purification are necessary for its production and 
sale. Extraction buffers have been developed to maximize trypsin recovery and minimize 
extraction of native corn proteins. Subsequent purification protocols maximize recovery 
and stability balanced with purity. In many cases, 50% or less of the protein is recovered 
from the starting material, indicating that twice the acreage estimated above would be 
needed for production.
A	lack	of	public	acceptance	is	the	major	barrier	today	to	
	producing	biopharmaceutical	or	bioindustrial	products	in	plants.
Public Acceptance and Sale
A lack of public acceptance is the major barrier today to producing biopharmaceutical 
or bioindustrial products in plants. response to this public distrust has driven current 
regulations to be quite restrictive. The scientific community and the regulatory agencies are 
striving to gather substantive safety data to support regulations that are based on scientific 
principles and will protect the public as well as allow this new industry to develop. This 
topic has been discussed in detail in recent reviews on bioproduction and product safety 
(Howard and Donnelly, 00; Howard and Hood, 005). The critical asset for general 
public acceptance is whether the consumer sees benefits and whether these perceived 
benefits outweigh costs and risks. When products with obvious benefits are available to 
the consumer, public acceptance, science-based regulations and sales will fall into place.
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William	Goldner: I’ll take a few minutes to introduce you to the Specialty Crops regulatory 
Initiative—a USDA-sponsored program now getting underway. I believe it’s germane to 
the topics that we’ve been discussing. It’s a program that came to us based on the output 
of a biotechnology workshop held in November of 00 that I chaired with Ann Marie 
Thro, sponsored by the Agricultural research Service, Cooperative State research Edu-
cation and Extension Service and the Animal and Plant Health Inspection Service. The 
workshop was in response to the frustration that small business and public developers of 
specialty biotechnology crops have felt in terms of being unable to get their products—the 
crops they have developed—to market. And as we’ve seen today, including Beth Hood’s 
representation of what it takes to get a product to market, there are many hoops to go 
through as a crop developer. And university researchers, ArS researchers and small-busi-
ness developers of biotechnology crops generally are not prepared to address these issues. 
It takes a good deal of expertise, involving navigating a regulatory process that is always 
in some state of evolution with interaction with as many as three federal agencies, the 
FDA, EPA and APHIS itself. Only a few of the specialty crops have been deregulated 
and that’s really the issue that came up in the workshop—the need for an organization 
to assist public-sector and small-scale private-sector developers through the regulatory 
approval process. And there is precedence for this; the orphan-drug program in FDA 
assists pharmaceutical companies in bringing through the regulatory process drugs that 
serve only a small population of patients because of disease rarity. Also the USDA’s Ir- 
program addresses the needs for small-acreage pesticide use and assists companies to de-
velop datasets that meet the regulatory process to gain approval for use on minor crops.
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roger Beachy and Mike rodemeyer mentioned issues of management and stewardship 
that we as scientists are ill-equipped to deal with on a day-to-day basis. So, the concept is 
to develop the Specialty Crops regulatory Initiative to identify and prioritize need and 
public benefit, helping to facilitate the generation of required regulatory safety data for 
fruits and nuts, vegetables, ornamentals, nursery crops, even forest trees (anything but 
the four major row crops). This is analogous to what happens in the Ir- program for 
specialty pesticides. The idea is to facilitate the process and has nothing to do with the 
ultimate commercialization or marketing of biotechnology crops or the products from 
those crops.
The structure mimics that of the Ir  program in that three committees are proposed: 
a stakeholder/liaison group, a project-management group and ultimately a headquarters 
staff. A critical aspect is involvement of and partnership with several different communi-
ties: consumer groups, grower groups, distributors, university researchers and technology 
groups as well as government researchers and administration. The near-term challenges 
are clear. We must demonstrate an early ability to enable regulatory compliance for a 
new biotechnology-derived crop. Based on discussions so far, perhaps a non-food crop 
would be the most suitable target. In fact, a crop from outside the United States—one 
that would benefit a developing country—could be the target.
A long-term challenge is to make available a broader range of biotechnology crop options 
for public benefit, meeting economic and environmental needs. We’d welcome input from 
those involved in crop-development and also in the other aspects such as marketing and 
commodity groups. We can send you information on the initiative. There is a national 
planning committee and Beth Hood and I are members; Alan McHughen at the University 
of California, riverside, is the national chairman. Also on the committee are representa-
tives of the Agricultural research Service, APHIS, CSrEES, land-grant universities, the 
private sector and also of some commodity groups. A follow-up workshop will convene 
in November of 005 specifically to address the needs and requirements and suggestions 
of the stakeholders to help us craft and develop this important organization.
Alex	Day: I’m with the Kentucky Life Sciences Organization. I also founded a company 
called Sheltowee LLC. We do life-science business consulting and business development. 
I want to talk about what I see as a couple of obstacles that we face in bringing products 
to the market. The biggest obstacle is regulatory. Particularly for the pharmaceutical and 
health uses of some of these proteins, we haven’t been able to convince the regulators 
to show us the path. When I first became an entrepreneur I was told, “remember, the 
pioneer is known as the guy with all the arrows in his back.” We can’t even seem to find a 
pioneer who can get all the way through the process and take the arrows so that we know 
how to get the products through. So, we are dealing with a public-perception problem 
but also a problem with the regulatory agencies reacting to public perception. Another 
common problem is early-stage funding. I know that in our state it’s very difficult to 
bring in seed-stage funding. The definition of seed-stage funding has changed dramati-
cally over the past few years. There are very few venture-capital or other sources willing 
to make seed-stage investments.
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Another issue for early-stage products is meshing business with science. I’m more of a 
business person. I know enough of the science to be dangerous and to understand some 
of what’s discussed in forums like this. The science must be translated into terms that 
business people are going to understand, providing compelling reasons to put the money 
in to develop the products. That cross-talk—meshing business and science—is critical 
to taking products through the development process and bringing them to market. The 
Kentucky Life Science Organization—a non-profit trade organization—is trying to edu-
cate people all the way from the grass-roots level up to politicians as to why these things 
are important and what we can do to facilitate, to clear a path so that these products can 
be brought to market.
Roger	Conway: I want to discuss the need for a general field theory for commercialization. 
There has been a lot of frustration in the bioproducts and bioenergy areas. Some people 
have felt that we’ve done a lot of research, but haven’t accomplished as much as we’d like 
to. I’d argue that there might be under-investment and other links in a causal chain. 
You might want to think of it as a pipeline of different links that need to be looked at 
for commercialization. And, of course, research is important—the plant genomics, the 
conversion work is very important. We want to lower the cost of production, we want to 
increase yields—that’s an important component—but other things are important too: for 
example, having life-cycle analyses from cradle to grave to show environmentalists that 
these products are environmentally beneficial. This is something that is featured in our 
federal biobased-products-preferred procurement program that my office is responsible 
for. In addition, having AStM/ISO-compliant standards is important for demonstrating 
to potential buyers that your product really works, and in some cases in the bioproduct 
industry that hasn’t been done and needs to be done. We’ve dealt with the Defense Logistics 
Agency who are fastidious about the products they buy; when they put a lubricant in a 
army tank that’s going to Iraq they want to be sure it works. These are potentially huge 
markets, but the need for testing is extremely important. So that’s another link. 
Another link is in terms of regulatory initiatives. For example, the main reason that the 
ethanol industry has doubled recently is because of the reformulated gasoline program, 
which requires oxygenates. In California, MtBE has been replaced with ethanol—as a 
regulatory initiative—which has virtually doubled the use of ethanol. Other things can 
be done. For example, Lou Honary at the University of Northern Iowa has developed 
transformer fluids from soybean oil. There is a problem with fossil-fuel-based transformer 
fluids containing PCBs. Perhaps EPA could differentiate between bioproducts and fossil-
fuel products based on toxicity, biodegradability and flashpoint. We will continue dialog 
with EPA on these issues. 
Another link is product differentiation and commercialization, and the Federal Bio-
based Products Preferred Procurement Program that we are running is an opportunity 
for product scale-up because it offers a guaranteed market. It’s an opportunity for the 
private sector to see what’s happening in the public sector as we use these products and 
could greatly expand markets. 
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Another link is public-sector initiatives such as investment tax credits, which are highly 
effective, and the USDA CCC Bioenergy Program for example. The latter is responsible 
for creating the biodiesel industry as it is today. Before the Program, biodiesel consump-
tion was approximately  million gallons now it’s up to around 0 million gallons. The 
USDA can take pride in helping to advance that industry.
Financing issues are also important. Especially for rural areas, obtaining capital con-
tinues to be a problem. Having some sort of public-private cooperation may be useful. 
Having access to specialized insurance may help reduce the risk. Once again, tax-credit 
issues may help.
Finally, education and outreach: science-based outreach to the public sector is necessary, 
one that explains environmental issues and also explains the performance characteristics 
of these products.
So, in the past we may have under-invested in some of these links and I’d argue that 
we need to view this thing in a more holistic fashion. research is absolutely important, 
but there are other features that can help get these products to the market.
Allan	Bennett	(University	of	California,	Davis,	CA): For Beth. I was impressed with the 
seventy-five licenses for your product and I’m wondering if you have a sense of how many 
of them were actually required for FtO and the final product. Do you have any sense of 
the financial burden of those licenses on the trypZean™?
Elizabeth	Hood: A lot of the licenses were for our transformation system, promoters, 
leader sequences, trailer sequences and the selectable marker genes. Probably, some of 
them were package deals that we were able to bring with us from Pioneer—pass-through 
licenses, etc. I would say that the majority had an impact on the product. The financial 
burden? I couldn’t tell you because I think each set of them had a different percent roy-
alty based on sales in some cases and based on a flat fee in others. Therefore, the more 
products you develop the less the burden is on any one particular product. It’s important 
to have those licenses so that you can legally market the product. But you don’t pursue 
seventy-five licenses with the objective of only one product. You assume you’re going to 
have a pipeline of products.
Goldner: Do you anticipate any phenotypic effect from lowering the lignin content in 
the softwood or hardwood trees?
Hinchee: The process of product development is to put the trees in the field and then 
assess them for all the usual performance characteristics in terms of a breeding program 
and a clonal development program. Are they stress-tolerant? Are they disease-resistant? 
Do they perform like the non-transgenic trees with the exception of the reduced lignin 
trait? Our anticipation is that if we launch a softwood or a hardwood product with re-
duced lignin that it would be within a range that allows the pulping industry to benefit 
from that advantage, but doesn’t affect any of the other phenotypic characteristics and 
the health of the plantation can be maintained.
3
Ralph	Hardy	(NABC,	Ithaca,	NY): Will your reduced lignin trees now make it possible 
for new pulp and paper mills to be built in the United States? It’s my understanding that 
there hasn’t been a pulp and paper mill built in the United States for a long time because 
of the extensive costs of pollution control plus processing. Are you reducing lignin, capital 
and/or operating costs enough? And can you give us some range of what that might be? 
Is it a compelling number or a marginal number?
Hinchee: It’s analyzed on a mill basis and is premised on the fact that no more mills will 
be built in the United States. We are talking in terms of saving the US forestry and pulp 
and paper industries. They are looking for anything to improve efficiency because the 
profit margin is small and they are facing abundant supplies of wood from Siberia and 
other places where they are indiscriminately harvesting very old trees. to maintain the 
industry in the United States they must improve efficiency in a variety of ways. Genetic 
improvement is actually a no-cost opportunity to improve efficiency without major in-
vestment at the mill, apart from normal adjustments of boilers for lignin extraction for 
the variety feedstocks that come in already. It’s using genetics to enhance the survivability 
of an industry, in my opinion.
Allan	Eaglesham	(NABC,	Ithaca,	NY): Following on from Dr. Goldner’s question: is it 
possible to reduce lignin level to zero? And if not, is there potential to reduce it farther 
than what you’ve achieved already?
Chiang: The maximum is a 50% lignin reduction. We’ve produced 00 or 300 transgenic 
trees with low lignin and never got more than a 50% reduction. I believe that is related 
to total carbon-sink control regulating the three major cell-wall components: lignin, 
cellulose and hemicellulose. Low-lignin content has also been found in apple in nature. 
It was considered to be disease-related, but it’s not. It’s just a low lignin content, again 
about 50% lower than normal apple trees.
Jensen: Anybody have a question for our panelists?
Svetlana	Oard	 (Louisiana	State	University,	Baton	Rouge,	LA): What change would the 
panelists make in the regulations to expedite the gene-to-production process?
Conway:	As a USDA representative, it’s really not up to me to give an opinion about the 
regulations of our sister agencies and of other federal agencies, but I think it’s clear that 
there is potential for some regulatory evolution, using a science-based rational approach. 
That seems to be the consensus from everybody I’ve talked to here.
Day: Being the non-government guy, I’d be happy to provide all kinds of advice to FDA. 
We believe that the best opportunity for plant-based pharmaceuticals is probably going to 
be generic biologics. Provide us the guidelines for meeting bioequivalency. Those products 
are being produced in plants already and if we can just get the agency to actually stick a 
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stake in the ground and say, “This what you need to do,” then it would open the door 
for a lot of plant-based pharmaceuticals.
Goldner: I’m not specifically familiar with some of these regulations. I’d just say, generically, 
as an economist, that I’d prefer to see something that is economics-based on benefit/cost 
analysis. We have an OrACBA within the department in one of my sister offices—the 
Office of risk Assessment and Cost/Benefit Analysis—which reviews regulatory proce-
dures within the department and is led by an economist. So, I’m going to be provincial 
and declare that as my generic interest.
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The United States Department of Agriculture’s Animal and Plant Health Inspection Service 
(APHIS) has regulated genetically engineered (GE) organisms since 987 and, in 00, 
established Biotechnology regulatory Services (BrS) to place a renewed emphasis and 
priority on biotechnology. APHIS has authorized more than 0,000 permits and notifica-
tions for the introduction of GE organisms and deregulated over sixty products for use, 
establishing itself as an international leader in the safe regulation of GE products. 
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Cindy Smith
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APHIS	has	authorized	more	than	10,000	permits	and	
	notifications	for	the	introduction	of	GE	organisms	and	
	deregulated	over	sixty	products	for	use.	
As the science of biotechnology and the landscape in which it operates continue to 
evolve, APHIS’s role in regulating it becomes increasingly challenging. As a regulatory au-
thority of this rapidly growing technology, we must ensure that we protect US agriculture, 
allow for the safe development of GE organisms, and not unduly inhibit the advancement 
of the technology. One important challenge is to keep up with the science’s technological 
advances. An increasingly broad array of traits is being engineered into plants as scientists 
discover more genes from a wider assortment of organisms that might be useful to improve 
agriculture, protect the environment or benefit consumers. But perhaps one of the most 
challenging technological trends of the past few years, from a regulatory perspective, has 
been the use of agricultural crops to produce pharmaceutical compounds and other items 
not intended for food or feed. One regulatory challenge is to allow the cultivation of 
these and have effective systems in place that will prevent them from being mixed with 
other crops, some of which are to be used as food or feed. In addition, pharmaceutical 
technology has prompted interest from a new range of stakeholders. Since 987, BrS 
has issued 0 pharmaceutical and industrial permits in eleven crops; however, less than 
350 acres have been grown since 00. 
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Another important challenge is the changing social and political landscape. US citizens 
are becoming increasingly interested in biotechnology and want to play a larger role in 
government decision-making. In addition, citizens can be skeptical of the government 
and are willing to take action against government decisions. We have also seen an increase 
in the activity of public-interest groups who want to represent constituent views of the 
science and how government should regulate it. One outcome of this is that government 
agencies have become the target of lawsuits. In addition, biotechnology does not enjoy 
the same level of acceptance internationally as in the United States, posing an even greater 
challenge beyond our borders.
Biotechnology regulatory Services
Since its inception just 3 years ago, BrS has undergone significant reorganization and is 
better prepared to anticipate and respond to the challenges being brought forth by the 
evolving nature of biotechnology and the landscape. The newly reorganized BrS goes 
well beyond a staff of scientists to evaluate permit applications and petitions for deregula-
tion. It includes a Compliance and Inspection Branch, a Communications and Capacity 
Building Branch, a regulatory Analysis Branch, an Office of Science, and a forecasting 
function that help BrS address these challenges and keep pace with the advancing sci-
ence. In addition, we have developed five priority areas of emphasis that set program 
direction and provide the foundation for decision-making. These priority areas are the 
key to BrS’s ability to meet the challenges of regulating biotechnology in general, and 
specifically, plants engineered to produce pharmaceuticals.
The first priority is maintaining rigorous regulation that thoroughly and appropriately 
evaluates and ensures safety and is supported by strong compliance and enforcement. 
APHIS regulation relies on a science-based evaluation of risk, which will be even more 
important in the future. This approach allows us to focus our regulatory efforts on specific 
areas such as pharmaceutical plants and reduce burdens in areas of lower risk. In 003, we 
strengthened permit conditions for pharmaceuticals and industrials resulting in stringent 
confinement measures and a greater government role. For example, our confinement 
measures now include increased isolation distances and fallow zones, and restrict the use 
of the same land to produce pharmaceutical and industrial crops from the production 
of food or feed crops. APHIS also requires developers of pharmaceutical and industrial 
crops to have dedicated equipment and storage facilities for those crops. We currently 
inspect every pharmaceutical and industrial site at least seven times before, during, and 
after production. In addition, in 003, APHIS amended its regulations to require that 
industrials are tested under the permit system.
The	first	priority	is	maintaining	rigorous	regulation	that	
thoroughly	and	appropriately	evaluates	and	ensures	safety	and	is	
supported	by	strong	compliance	and	enforcement.	
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Environmental Impact Statement
to ensure that our regulations remain effective as the technology advances, APHIS is 
currently preparing an Environmental Impact Statement (EIS) that will be used in revis-
ing its regulations. The updated regulations will leverage the additional authorities of the 
Plant Protection Act of 000, significantly broadening APHIS’s authority and positioning 
the USDA to address a broader range of issues, including human health. In the Notice 
of Intent that was published in January 00, we stated that we are considering numer-
ous revisions. One change we are considering is the implementation of a multi-tiered, 
risk- and familiarity-based permitting system to replace the current permitting and no-
tification system. With respect to pharmaceuticals, another change we are considering is 
a new mechanism for maintaining regulatory oversight after a crop is commercialized. 
This mechanism would feature increased transparency and efficiency, and a greater role 
for the states. We are also considering the establishment of safety criteria that might allow 
for the deregulation of certain pharmaceutical crops. 
reducing the regulatory Burden
BrS is also committed to reducing the regulatory burden as appropriate to the risk. We 
appreciate that this is especially important for publicly funded researchers and small busi-
nesses. In pursuing this goal, we requested feedback on ways we could reduce regulatory 
burden in our January 00 Federal register notice that announced our intent to prepare 
an environmental impact statement on our proposed regulation changes. In addition, we 
have held workshops with the Pew Initiative on Food and Biotechnology and with USDA’s 
Agricultural research Service and Cooperative State research, Education, and Extension 
Service to identify possible regulatory barriers and potential solutions. The Ir- program 
for pesticide registration for use on minor crops has been proposed as a model that the 
government might follow to reduce the burden imposed on researchers and small busi-
nesses who are developing GE crops. It has also been suggested that alliances might be 
established between small businesses and university researchers such that the burden on 
generating required data might be shared, and thereby not be prohibitive to any individual 
researcher or small company who might seek to develop a GE crop. 
Fostering the technology
In addition to maintaining rigorous regulation, it is critical that we administer a compli-
ance program that is strong enough to ensure the safety of the science while also allowing 
for the advancement of the technology. This is especially true for higher risk crops, such 
as those used to produce pharmaceuticals. BrS’s Compliance and Inspection Branch is 
dedicated exclusively to ensuring that researchers maintain compliance through defined 
procedures that include violation-prevention efforts, risk-based criteria for quality inspec-
BRS	is	also	committed	to	reducing	the	regulatory	burden	as	
appropriate	to	the	risk.
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tion, standardized inspection and auditing processes, uniform enforcement, and thorough 
documentation of any compliance infractions. We also make investigation results available 
for public and stakeholder viewing. Compliance specialists and APHIS inspectors perform 
targeted inspections and audits of field tests and use established criteria to thoroughly 
evaluate all potential compliance infractions. 
The second priority is ensuring that our regulatory process and decision-making are 
transparent to stakeholders and the public. Being transparent about our processes, deci-
sions, and activities is critical for building public confidence in the regulatory system. 
We also understand that it is particularly important to be transparent in regard to phar-
maceuticals. We must meet the challenge of fulfilling this objective while also protecting 
developers’ confidential business information. Part of our transparency efforts include 
following the National Environmental Policy Act (NEPA), which establishes the crite-
ria on when to conduct an environmental assessment (EA). We make available on our 
Web-site all EAs conducted for pharmaceutical and industrial field tests, or in cases that 
we do not conduct an EA, we post APHIS’s categorical exclusion criteria and all NEPA 
decision documents. We also announce the EAs in the Federal register and allow for 
a comment period. Our Web-site also provides a listing of all pharmaceutical permits 
along with their current status, accompanying decision documents, total acreage, and 
any supplemental permit conditions. Though confidential business information (CBI) 
limits our ability to post all permit applications, we post as much information as we can. 
In one recent case, we posted permit applications where little or no CBI was claimed and 
in another recent case, we summarize the non-CBI information from permit applications 
in our EAs. In addition, even when specific location and size information of field tests 
is claimed as CBI, we provide the general location and size information. We have also 
completely redesigned our Web-site and have included a stakeholder registry that allows 
registered stakeholders to receive updates and other information relevant to selected topics 
of interest, such as regulation activities, communication and outreach, capacity building, 
and compliance issues.
In another effort to ensure transparency, in 00, we held multiple public meetings 
to discuss issues associated with the BrS proposal to revise regulations. BrS met with 
twenty-two stakeholder groups and heard a wide range of viewpoints on the proposed 
revisions and provided clarification on some of our agency’s objectives. In the near future, 
we will be holding similar stakeholder meetings on a monthly basis as we complete the 
process of developing a Programmatic EIS on our proposed regulatory changes.
Assuring Safety
The third priority is maintaining a science-based system that ensures that the best sci-
ence is used to support regulatory decision-making and to assure safety. While we work 
The	second	priority	is	ensuring	that	our	regulatory	process	and	
decision-making	are	transparent	to	stakeholders	and	the	public.
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to achieve this priority, we face the challenge of obtaining all of the available scientific 
information needed in order to make sound science-based decisions. to help achieve this 
goal, we have expanded our staff to include a diversified collection of scientific expertise 
in science fields, such as plant pathology, botany, entomology, ecology, animal science, 
virology, environmental science, biochemistry and molecular biology. to keep pace with 
this ever-evolving technology, BrS staff and scientists attend and host meetings and 
workshops, read literature, and interact with outside scientists, stakeholders, and the 
public. Additionally, in 00, BrS established the Office of Science, which works with 
the research community to identify biosafety research priorities and to communicate 
biosafety research results for the use of regulators globally. As part of its agenda, the Of-
fice of Science addresses scientific issues associated with pharmaceuticals and in August 
00, conducted a workshop on confinement that focused largely on pharmaceutical 
crops; more than 00 scientists and experts from six countries participated. The Office 
of Science also helps maintain science as the centerpiece of regulatory decision-making 
amidst the challenges of diverse political, economic, and personal viewpoints associated 
with the technology. We also encourage biotechnology research and are looking into the 
possibility of becoming a funding agency in the future, such that we might target areas 
of research that we identify as having a pressing need. 
The	third	priority	is	maintaining	a	science-based	system	that	
ensures	that	the	best	science	is	used	to	support	regulatory	decision-
making	and	to	assure	safety.
Communicating with Stakeholders
The fourth priority is maintaining communication, coordination, and collaboration 
with the full range of stakeholders. BrS works to meet the challenge of recognizing and 
reaching out to a broad range of stakeholders and interests. In regard to pharmaceuticals, 
it is particularly important to reach out to a broad diversity of stakeholders that includes 
not only the biotechnology industry and researchers, but also stakeholders such as in the 
food industry, commodity groups, public interest groups and the states. For example, 
we recently met with a food-industry group to discuss additional science-based measures 
that BrS should consider for two pharmaceutical field tests. 
In another example, we work closely with the states on issuing permits, particularly for 
pharmaceuticals. We provide information to support their decision-making, which may 
involve adding additional permit conditions to address the state’s concerns or, in some 
cases, providing support such that the state has a full understanding of the science.
The	fourth	priority	is	maintaining	communication,	coordination,	
and	collaboration	with	the	full	range	of	stakeholders.
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International Leadership
Finally, the fifth priority set forth by BrS is establishing international leadership to ensure 
that international biotechnology standards are science-based, international regulatory 
capacity-building is supported, and international implications of domestic policy and 
regulatory decisions are considered. BrS faces the challenge of providing international 
leadership to ensure the development of science- and risk-based regulatory systems while 
maintaining effective working relationships in which we recognize and respect the differ-
ences in their systems and they are in turn receptive to our approach and the benefits that 
it can offer. In addition, we must consider the international implications of any domestic 
policy decisions that we make and ensure that the policies that we put in place domesti-
cally can be applied equally internationally. These important international partnerships 
are now serving as a starting point for international discussions of the regulation and 
confinement of pharmaceutical crops.
Through our evolving regulatory structure, dedicated compliance function, focus 
on science and risk, increased transparency and communication with a broad range of 
stakeholders, we are focused on these priorities and managing the challenges posed by 
new trends such as pharmaceutical crops. As the science progresses, we will continue to 
evaluate the implications of new technologies, enhance our processes and procedures, 
and develop appropriate regulations to meet the challenges posed by this new science 
while continuing to safeguard American agriculture, the nation’s food supply and the 
environment.
The	fifth	priority	is	establishing	international	leadership.
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Agricultural biotechnology’s “waves” of grain are not amber, but red, white and green. 
“Green” applications were the first to arrive: the commercial food- and feed-production 
side of agricultural biotechnology. “red” refers to plant-made pharmaceutical applications, 
whereas “white” refers to industrial applications of biotechnology (including biofuels, 
bioremediation and chemical substitutes (e.g., enzymes that can replace chlorine bleach). 
Each sector has the potential to provide significant benefits to society, if the risks—includ-
ing adverse economic impacts—can be managed to the satisfaction of key stakeholders, 
from farm to fork.
This article sums up the regulatory and liability hurdles that stand in the way of 
launching new products in each of these categories, beginning with lessons learned from 
green products. A brief review of successes and failures and existing risk-management 
methods may help overcome legal barriers to entry. Also discussed are novel barriers to 
entry posed by risks that may not be compensable, including economic losses incurred 
by other growers. 
Liability Prevention and Biotechnology:  
A Brief History of Successful Industrial 
Stewardship
thomas P. redick
Global	Environmental	Ethics	Counsel
St.	Louis,	MO
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These liability risks and the market barriers they create are elusive and hard for American 
innovators to understand fully and manage effectively. Fortunately, industry-stewardship 
processes have evolved to anticipate and prevent novel liability risks, including the elusive 
economic-loss risks. Such stewardship standards also avoid regulatory recalls and help to 
support a sustained pipeline of productive innovation (Abramson and Carrato, 00). The 
largest of the biotech-seed companies have a wealth of experience in identity-preserved 
production. This allows them to draw upon historical data and experience as they strive 
to develop stewardship systems that meet modern standards and market expectations for 
genetic purity. 
the Product Pipeline and regulatory roadmap
The agricultural biotechnology industry can be visualized as a large oak tree, the trunk 
of which is made up of the top four crops: soy, corn, canola and cotton. Each of these 
four interwined trunks has its own history of successes and failures, and each has helped 
to established biotech crops as essential to modern agricultural production. The envi-
ronmental benefits of these genetically modified (GM) crops—from soil conservation to 
reduction in insecticide inputs—are now well documented.
Unfortunately, the tree lost entire limbs after the industry invested significant research 
funds (over $00 million in some cases) getting product lines ready for commercial 
launch. While some biotech crops have done remarkably well, there are many more in-
novative products of agricultural biotechnology that advanced to the verge of commercial 
launch, only to be shelved pending overseas regulatory approval or resolution of consumer 
concerns. These other crops lie scattered around the base of the oak like branches blown 
down by a storm. These product lines, like Bt potato, could have brought significant 
benefits to growers, consumers and the environment. to date, however, plans to revive 
the GM potato, tomato, wheat, beet, flax, barley, lettuce and other abandoned biotech 
crops are up in the air.
The challenge facing the agricultural biotechnology industry is to learn from past mis-
takes and to adjust to realities. While trees will grow in the paths of hurricanes, tropical 
species evolved roots and trunks that bend better than those of oaks. For agricultural 
biotechnology to succeed, innovators need to foresee the predictable market forces that 
may prevent product launch, and design business strategies that meet consumer demand 
without triggering the barriers erected by regulators or other consumers.
Green	Biotech:	Steadily	Growing	Despite	“ZAP”	Attacks	and	Traceability
Green-biotech products were first out of the door, paving the way for red and white prod-
ucts. The greenest of the green-biotech crops are the roundup ready™ and Bt families. 
The vast majority of soybean growers in the United States and Argentina have embraced 
roundup ready™ soybeans, in what is surely one of the fastest adoptions of new agricul-
tural technology in history. Herbicide-tolerant canola has become the dominant option in 
Canadian and US fields. Bt corn and cotton show similar track records of success, reducing 
pesticide use and demonstrating their food safety despite the skepticism of activists. 
These successful launches of multiple varieties of biotech corn, soy, cotton and canola 
are the fortunate ones, however. Many other equally useful and innovative crops have been 
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sidelined due to consumer and food-company queasiness over potential loss of market 
share. Any food company worth its salt will honor even a seemingly small percentage of 
concerned and vocal (i.e., “squeaky wheel”) customers, for perfectly valid business reasons. 
A business may not be able to justify losing a 5% share of a branded product’s market just 
to use a lower-cost input that benefits the environment (through reduced insecticide use 
or soil-conservation benefits). While this corporate marketing decision denies the majority 
of consumers the choice to support environmentally beneficial, lower-cost biotech crops, 
such is the stark reality of the modern mass-produced marketplace. 
This attention to detail led the biotech industry to build its own system for preventing 
the development of insect resistance, and to present it to the Environmental Protection 
Agency (EPA), which then imposed conditions on the growers of Bt crops to ensure 
compliance. For identity preservation, the same conscientious companies can adapt 
segregation practices, developed in seed production, to produce containment measures 
that are tailored to various types of agricultural biotechnology. These practices may be 
adjusted to ensure compliance with various levels of “tolerance” of adventitious presence 
of undesirable genotypes. 
The European Union has only recently lifted a 7-year moratorium on regulatory ap-
proval of GM crops, under threat of World trade Organization action by the United 
States, Canada and Argentina, who have lost billions in exports of grain (corn and soy) 
since 998 due to the European Union’s anti-biotech policy. This barrier to marketing of 
new biotech crops has been lifted only in part, for some varieties of biotech crops. 
to date, the first big success in biotech crops—roundup ready™ soybean—has proven 
its worth and gained access in major food and feed markets, but not environmental release. 
Major markets remain closed to many other biotech genetic events, and troubling moves 
toward traceability-based testing and associated recalls of unapproved biotech genetic 
events could make these barriers to entry pervasive and persistent. For example, the export 
barriers to entry forced soybean growers and processors (represented by the American 
Soybean Association, United Soybean Board and National Oilseeds Processors Associa-
tion, “ASA-USB-NOPA”) to develop a policy (the “eleven-point plan”) that dictates a 
closed-loop identity-preservation (CLIP) standard for varieties lacking regulatory approval 
in major export markets. As a result, upcoming Bt varieties of soybean (produced under 
license from Monsanto) can be marketed in the United States only if there is a system 
that meets CLIP’s eleven points.
As a result, Bt soybean will have to be submitted to major markets for approval (or be 
grown in a CLIP system) as long as “zero tolerance,” and testing to enforce it, are main-
tained in the European Union. The United States and its grain-exporting allies have yet 
to achieve a globally recognized tolerance for adventitious presence of GM products in 
a world where a zero adventitious presence (ZAP) regulatory import standard (enforced 
via genetic testing and mandatory disclosure laws) is increasingly prevalent. These poli-
cies are spreading to other nations that are key trading partners of the United States, 
with even more extreme standards emerging. For example, China has adopted “zero 
tolerance” for GM-food labels, which is even more strict than the European Union’s 
standard of 0.9%.
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Through a multilateral environmental agreement that became law on September , 
003, the Cartagena Protocol on Biosafety is promoting its “precautionary approach” to 
regulatory approval of biotech crops as a global standard. Paired with this delay-ridden 
approval process, the European Union has a ZAP standard for a variety that lacks approval. 
This is not unusual standing alone; the United States also has zero tolerance for unapproved 
varieties of biotech crops, but does not mandate disclosure or conduct extensive genetic 
testing (and rule-making is underway to allow some tolerance for adventitious presence 
where the variety in the pipeline is ultimately intended for food use). 
In contrast to the United States, the European Union has attempted to address toler-
ances in seed purity, only to find opposition to any number other than zero (i.e., less 
than the limit of testing). The European Union will use testing centers to track each GM 
event, forcing destruction of food based on traces of any unwanted DNA (e.g., this is 
currently occurring with one shipment to Ireland that contains Syngenta’s Bt0 corn, 
which carries a gene for antibiotic resistance that is unapproved for importation by Eu-
ropean Union nations. 
This testing process and “traceability” for GM events could become a global standard if 
the parties to the Biosafety Protocol impose, at its next meeting in Brazil (March 3–7, 
00), an international requirement that commodity shipments list all biotech genetic 
events that they “may contain” (using unique identifiers for each event). This law would 
spread traceability and labeling for GM content bound for food/feed (known as FFtL 
in industry email loops) to the parties to that protocol (0 and rising). If these nations 
are even more concerned about biotech crops than the European Union, they are free to 
impose even stricter standards than the European Union. 
The power of ZAP standards for unapproved biotech crops should not be underesti-
mated, since it empowers activists armed with genetic tests to force recalls of US shipments 
when they reach port. This is the least business-friendly arrangement imaginable, and it 
appears tailor-made for activists to rig to their tastes, testing only those corporate ship-
pers whose policies displease them. This testing for GM events is now occurring with 
shipments of corn seed and feed to the European Union and Japan. two seed shipments 
to Japan were found to contain Sygnenta’s unapproved variety Bt0. The shipment to 
Ireland may require disposal of over ,000 tonnes of corn-gluten feed.
In sum, the European Union is not alone in its quest to label GM food and trace bio-
tech crops globally, and the regulatory environment worldwide could be taking a distinct 
turn toward anti-biotech policies among US trading partners. The best example of this 
troubling trend may be China, which has its own thriving biotech research industry with 
hundreds of crops in the pipeline (and millions of GM poplar trees lining its rain-ravaged 
hillsides). China has bowed to the European Union and imposed a GM-food labeling 
standard. to complement this standard, China has legalized only commercial production 
of biotech cotton (non-food) despite pressing food-security needs (and despite reports 
of growers using pirated GM rice and corn in violation of its laws). These global trends 
are increasingly raising barriers to importation of GM crops, leaving some markets (like 
wheat and rice) without the benefits that come from biotech innovation.
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“Red”	Plant-Made	Pharmaceuticals
red biotechnology—plant-made pharmaceuticals (PMPs)—is necessary, according to 
pharmaceutical industry analysts, to meet increasing demands for protein-based large-
molecule drugs that can be produced only in living organisms. Shortages of certain new 
large-molecule drugs, which are generally produced in cell cultures, have led biotech 
companies to explore new production methods. Corn and rice are particularly suitable for 
production of proteins for pharmaceutical applications, given the relative ease of storing, 
transporting and refining the protein. 
The cost of maintaining compliance with “zero-tolerance contamination requirements” 
has led some observers to wonder whether “the economic payoffs from growing phar-
maceutical plants outweigh the costs associated with the risk of food contamination.” 
(Elbehri, 00). to weigh those costs in advance of creating a new PMP, the researcher 
needs to obtain data on identity-preservation costs, third-party oversight of the process, 
insurance coverage and other known expenses necessary to manage risk.
In general, the costs of insurance and third-party oversight for the production process 
will be hard to define. to the extent that these costs are part of a successful risk-manage-
ment strategy, however, estimates should be incorporated into long-range planning. The 
comparative costs for different regions (with varying risks) should be factored into analysis 
of the feasibility of marketing and probable return on investment. 
White	Biotechnology—Industrial	Biotech	Comes	of	Age
White biotechnology is defined as the industrial use of GM crops or microorganisms (e.g. 
bacteria, fungi) to create enzymes, proteins and other industrial compounds and materials. 
Industrial biotechnology is creating compounds that can replace of hazardous chemicals, 
providing “greening” companies with new options for reducing hazardous waste. In one 
remarkable instance of industry reaping corporate value and environmental benefit from 
biodiversity, Diversa of San Diego has taken a gene from a thermophilic bacterium that 
encodes an enzyme allowing paper-manufacturing companies to avoid using tons of toxic 
chlorine bleach (Hessler, 005).
When a plant is used as the source, rather than a microorganism, a “plant made indus-
trial product” (PMIP) results. If the PMIP crop per	se has significant export or consumer 
markets, the PMIP may encounter opposition at commercial launch. Concern has been 
expressed that PMIPS pose the same threat as PMPs, but do not have the same level of 
regulatory oversight. The PMIP has been cast as a neglected stepsister on issues like pol-
len drift, creating what appears to be a liability “bullseye.” This gap in understanding of 
pollen containment by regulators represents a threat to the food supply, since PMIPS that 
Corn	and	rice	are	particularly	suitable	for	production	of	proteins	
for	pharmaceutical	applications,	given	the	relative	ease	of	storing,	
transporting	and	refining	the	protein.	
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are not approved for use in food and could be declared an “adulterants” by the FDA, or 
trigger export losses upon detection by European-Union or other overseas officials. These 
liability risks were pointed out to USDA by the American Soybean Association and the 
regulatory gaps were closed.
Identity preservation of the crop used to produce a PMIP is necessary to deliver a pure 
product, and is equally essential to prevent the undesirable release of a PMIP in a manner 
that could lead to cataclysmic economic impacts. 
Nuisance	Claims	by	Neighboring	Growers	
Post-StarLink™ case law could allow neighboring growers to recover their economic losses 
from the source company, if they prove actual commingling of GM variety unapproved 
in the European Union [see,	In	re	StarLink	Corn	Products	Liability	Litigation,	Marvin	
Kramer	v.	Aventis	CropScience	USA	Holding	Inc.	(00),  F. Supp. d 88 (U.S. District 
Court, N.D. Illinois)].
StarLink™ was cited in a recent Canadian court decision denying a class action to organic 
growers who sought recovery of their economic losses from the marketing of GM canola 
varieties unapproved in the European Union [Hoffman	v.	Monsanto, 005 SKQB 5 
(005)]. This action was filed against Monsanto and Bayer Crop Sciences (BCS) seeking 
to enjoin the marketing of roundup ready® wheat, and also adjudicate liability for price 
impacts to canola based on “contamination” of organic and non-GM canola that could not 
be exported by Canadian farmers to the European Union. The canola sold by Monsanto 
and BCS was fully approved in Canada and posed no known health or environmental risks. 
The Hoffman court denied plaintiffs the class action they sought, but hinted at recogni-
tion of claims for violations of environmental statutes (if canola is deemed a “pollutant”) 
(http://0.83.9.88/judgments/005/QB005/ 005SKQB5.pdf ). 
The Hoffman court confirmed the basic idea that “pure economic loss” is not recoverable, 
holding that the facts did not present a situation allowing a claim for recovery of “pure 
economic loss” (with no “physical injury”), citing various policy reasons (005 SKQB 
5 at ¶ 80). The court also rejected the idea that defendants committed a “negligent 
undertaking” when they initiated identity preservation to preserve canola exports to 
Japan, then dropped that program when they received approval in Japan (even though 
the European market was still closed to any canola that was still commingled). While 
the plaintiffs still have a nuisance claim the court is willing to entertain, it remains to be 
seen how that action will play out (i.e., the plaintiffs may run into the same barrier that 
the US District Court in Eastern Missouri imposed in Monsanto	v.	Sample, if they cannot 
prove a “physical injury” from actual commingling of the GM canola with their export-
bound crops). With two causes of actions surviving, but no class certified, this decision 
(if not overturned on appeal) could lead to a flurry of individual filings if Saskatchewan’s 
certified organic farmers are willing to take Monsanto and BCS to court. 
Secrecy	of	Field	Trials
February 005 saw another landmark court decision relating to identity preservation of 
biotech crops. District Court Judge David A. Ezra rendered his final decision ordering 
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disclosure of PMP and PMIP field trials [Center	for	Food	Safety	v.	Veneman,	No.	03-CV-
621 (D. Haw, filed Nov. , 003)]. This Hawaii federal court ordered representatives of 
the USDA to hand over to Earthjustice attorneys the precise locations of open-air field 
tests of PMP crops. This was the first time the federal government was forced to disclose 
the location of field tests of GM crops. Earthjustice, representing citizen groups Center 
for Food Safety, Friends of the Earth, Pesticide Action Network North America, and 
KAHEA (The Hawaiian-Environmental Alliance) filed the lawsuit to compel USDA to 
review the environmental and public-health impacts of such activities. In August, 00, 
district court ordered the disclosure, rejecting the claims by the government and the 
Biotechnology Industry Organization (BIO) of potential “espionage,” “vandalism,” and 
“civil unrest.” The Court denied USDA and industry’s motion for a stay of disclosure, 
and the government handed the information to plaintiffs’ counsel.
The court has not yet ruled on the public-disclosure issue, however, and plaintiffs can-
not reveal the information to the general public. The disclosure should allow plaintiffs 
to pursue their original objective of seeking environmental reviews that will determine 
“how close these experiments are to conventional food crops” and ecologically sensitive 
areas [see Government Forced to Disclose Locations of test Sites of Biopharmaceutical 
Crops (USA). http://biotech. dnsalias.net/or/005/0/39.shtml].
Identity Preservation 0: the Legal tools
Where a company marketing a PMIP or PMP will encounter concern about liability 
risks, including adverse economic impacts from unwanted commingling, it can use iden-
tity-preservation measures to reassure domestic food businesses, exporters, and overseas 
importers. The use of the approved identity-preservation system will ensure that the PMIP 
is not commingled with food or grain exports. 
The	processes	for	identity	preservation	and	seed-purity	assurance	
are	rapidly	evolving	to	meet	the	demands	of	the	market.
Identity preservation of commodity grain crops to meet specialized customer needs 
has a long and successful history in seed production. The production of seeds generally 
operates on tolerances for unwanted input of various types, including genetic off-types. 
Historically, this posed no problem of commercial significance; corn out-crossed freely 
in commercial production. In today’s world, however, any corn that is bound for export 
must be “channelled” to particular elevators. One stray corn kernel that lacks regulatory 
approval in an overseas market can lead to destruction of an entire cargo, where the stan-
dard for commingling is “zero tolerance” and a trace of an unapproved variety is found (as 
occurred in 005 when the Syngenta Bt0 variety was detected in four separate shipments 
of US-origin corn). As a result, the processes for identity preservation and seed-purity 
assurance are rapidly evolving to meet the demands of the market.
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Industry	Standards
Innovation in agricultural biotechnology begins with the novel steps that lead to an 
invention meriting a patent; however, the path to market requires sound agricultural 
management. Industry standards for identity preservation provide a biotech-seed com-
pany (“the Company”) with a standard of care to follow that meets both quality-control 
and liability-prevention needs. to protect the Company’s investment in innovation, the 
developer of a new application using agricultural biotechnology, such as a PMP or PMIP, 
should adapt existing standards to create detailed methods for stewardship in the produc-
tion process. Stewardship methods for the agricultural management of biotech crops vary 
with the crop and the location of the production process. 
The simplest route to maintaining identity preservation is to anticipate the demands of 
customers and regulatory agencies, develop an industry standard and stick to it. Industry 
organizations, led by BIO, developed the Confinement Analysis and Critical Control 
Point (CACCP) concept for molecular farming applications including ProdiGene’s corn-
produced vaccine for piglets, and PMIPs (Phillips, 00).
A sound model for identity preservation of PMPs and PMIPs was generated by the 
Canadian Food Inspection Agency (CFIA, 00). After reviewing various methods for 
identity preservation, the CFIA recommended, in its January 00 report, eleven elements 
of confinement systems for “molecular farming crops” (i.e. PMPs and PMIPs). This paper 
is patterned after the CACCP system developed by BIO, and it mandates supervision 
by a third party, preferably regulators. One item that is missing, in comparison to the 
ASA/USB/NOPA “eleven point plan” is the express assumption of liability for system 
failure attributable to the biotech-seed company.
Identity preservation methods have been developed in consultation with growers 
and grain handlers. The ASA/USB/NOPA CLIP process has been used since 998 to 
protect US-export flows of soybeans to the European Union and other major markets, 
while allowing limited releases of new biotech soybeans. The ASA/USB/NOPA “eleven 
point plan” for the CLIP process requires the biotech-seed company to assume liability 
for system failure. This generally precludes the company from using contractual clauses 
that unfairly shift to growers all the risk of commingling. Properly and fairly operated, 
such systems for identity preservation will continue to provide grower and biotech-seed 
companies with protection from liability lawsuits. 
Similarly, the National Corn Growers has developed the “Know Before You Grow” 
process for identity preservation of corn-gluten feed that is bound for export. While 
exports of whole corn to the European Union have been foreclosed since 997 by the 
commingling of GM events that lacked regulatory approval, recent efforts to comply with 
the European Union’s new traceability directives (effective /8/0) have succeeded in 
keeping the $00 million per year in corn-gluten feed flowing to the European Union 
from the United States.
Identity-preservation methodology has been developed through trial and error, as 
major life-sciences companies developed their stewardship programs in consultation 
with growers associations. The ASA/USB/NOPA CLIP process has been applied for the 
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production of DuPont’s high oleic soybean, which is used in specialized biodegradable 
lubricant applications. This same eleven-point plan was previously presented in 998 to 
AgrEvo USA, the corporate predecessor of Aventis Crop Sciences, Inc., which adopted 
it for a Liberty Link® soybean stewardship program (which soybean was not, however, 
marketed in the United States, in contrast to the high oleic cultivar).
Under the CLIP system, the first level of concern involves the terms of the contract 
for sale of the biotech seed. The contract with the grower of the specialty PMP or PMIP 
crop should have conditions similar to those for certified seed production or federally 
permitted field trials, including regular inspections and scientifically defensible minimum 
isolation distances from neighboring crops. The contract should also guarantee the grower 
a premium adequate to cover the costs of preventing commingling with other crops (field 
isolation and inspection requirements can be costly for the grower). Only contracted 
growers should be allowed to grow the specialty crop. 
The second level concerns planning to coordinate the harvest process. Growers need 
training to ensure that combines and transport vehicles do not cause commingling and are 
cleaned out to industry standards. The Company needs to identify elevators where there 
is willingness to accept the identity-preserved production while keeping it completely 
separate from all other commodities. These elevators should be confined to particular 
regions, not widely scattered throughout the farm belt. Coordination of inspections 
between the elevator and the field inspectors will allow the midseason yield estimates 
to be matched to the actual delivery, to ensure that the entire crop is delivered and not 
diverted to other uses.
Thirdly, the CLIP system requires that the Company contract with a third party to 
certify the process. There are seed-certifying agencies that have conducted such audits 
for decades [e.g., the Association of Official Seed Certifying Agencies (http://www.aosca.
org) and newer specialized operations such as Novecta (http://www.novecta.com) and the 
United States Department of Agriculture’s Process Verified Program (http://processveri-
fied.usda.gov)].
Lastly, the CLIP system requires that the Company agrees to assume—and not attempt 
to disclaim or limit—the legal and financial liability that arises from negligence or other 
breaches. Under the ASA/USB/NOPA CLIP system, the focus is upon crops that may 
lead to lost trade with overseas soybean export markets. Commingling of an unapproved 
variety, in particular a PMIP or PMP variety that is not approved for any food or feed use 
at any tolerance, can lead to cataclysmic economic loss in major export crops. 
These systems have not worked perfectly, as the StarLink™ corn recall and ProdiGene 
commingling incidents illustrate. In the StarLink™ episode, Aventis Crop Sciences had 
been warned of the potentially “cataclysmic” economic impacts that existing US precedent 
pointed toward (Censky, 999). Despite this warning, Aventis sold StarLink™ corn with 
inadequate stewardship. Along the same lines, tiny ProdiGene’s sprouting corn volunteers 
contaminated a soybean field, despite a USDA inspector’s warning. This commingling 
incident ended at one elevator, but still required an interest-free loan from USDA to 
maintain a viable business.
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Detecting	Gaps	in	Regulation	and	Stewardship
The practice of identifying and managing risks adequately is not a perfect process, and 
troublesome gaps have emerged in regulation of particular aspects of biotechnology. One 
example in USDA regulation involves setback distances to preclude pollen drift from 
PMP plants. This glaring gap in regulatory oversight was apparent to anyone comparing 
the planting distances in the regulations, and it was quickly corrected through the timely 
intervention of the American Soybean Association. Had this gap not been corrected, the 
overview of a “bullseye” made a target for plaintiffs’ attorneys that exposed a failure to 
exercise “due care” in the segregation of crops.
This “biotech bullseye” episode provides a “near miss” in liability law, which helped to 
prevent serious commingling with PMPs. It also provides confirmation that the existing 
stewardship practices of the most responsible seed companies (Monsanto, DuPont, etc.) 
were more alert to the risks of out-crossing from PMP plants than were USDA regulators. 
The seed industry had already determined through testing that a -mile planting distance 
is required to maintain a very low tolerance for out-crossing in corn production. These 
seed companies foresaw the need for stewardship standards that track potential liability 
risks, including those that might elude a busy regulatory agency. 
This does not mean that USDA is incompetent in terms of managing risk, but merely 
highlights the need to supplement regulatory review with industry oversight. It is a basic 
principle of product-liability law that even the most proactive regulatory authority can 
only set a “one size fits all” minimum, based on limited knowledge of the product, while 
the alert company is expected to know its product and foresee its hazards with more 
precision. 
ISO 9000 and ISO 000 are process standards that can be used to identify customer 
needs and product hazards, and to implement processes to prevent both product-related 
(under ISO 9000) and environmental liability (under ISO 000). Biotech-seed compa-
nies may use these standards or a modified system that is not certified by an ISO registrar 
but still provides necessary oversight that regulation cannot impart.
The US Supreme Court recently affirmed the role of industry in post-market surveil-
lance for product risks. In Bates	v.	Dow (005), the Court put all pesticide manufacturers 
on notice of the power of tort law to keep them alert to new risks that emerge over time, 
which may elude the detection of regulators. This landmark decision expands the horizon 
of biotech-seed-company liability for certain EPA-registered crops, and creates a feedback 
loop, as described by Justice Stevens, requiring companies to adjust their practices to avoid 
the adverse event that triggered the state’s tort law. 
Companies that do not quickly react to feedback can find their markets disappearing 
due to consumer opposition. In the PMP setting, this occurred in the ProdiGene case; 
failure to remove volunteer PMP corn from a soybean field led to a $3 million loss of 
the elevator’s commingled contents. Subsequently, the biotech industry implemented 
additional safeguards and regulatory agencies reviewed inspection policies.
However, policy positions of major players in the chain of commerce shifted to a 
more anti-biotechnology position after StarLink™ (with help from the ProdiGene-PMP 
commingling event). The Grocery Manufacturers of America (GMA) began insisting on 
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abandoning any use of food crops for PMP production, whereas grower and grain associa-
tions merely insisted on the use of well tested closed-loop identity preservation. GMA’s 
position was not irrational or poorly considered; its board is made up of CEOs whose 
judgment is well informed. This position reflected a loss of trust from a critical group of 
customers—the primary buyers of “green” biotechnology products had lost faith in the 
ability of the makers of “white” and “red” products to maintain necessary segregation in 
production. Winning back trust, once lost, is much more difficult than the effort required 
not to breach that trust in the first instance. 
Will a Liability Backlash Follow the European Union’s 
Precautionary Approach?
two potential backlashes are created by the European Union’s ZAP approach to GM 
crops. First and foremost, there are hazards from food that are heightened by anti-bio-
tech regulations that deny consumers access to use of the best available technologies for 
controlling carcinogenic mycotoxins in their staple food supply. These toxins, which can 
be better controlled with use of Bt corn, are not a hazard of significance in the United 
States or the European Union (which have resources to detect it and avoid exposure). 
However, they pose a significant risk to the health of mothers and children in Africa, 
Central America and Mexico where less-varied diets lead to higher corn consumption in 
farming communities. 
The European Union has implemented both GM labeling and ZAP regulatory ap-
proval by invoking the “precautionary principle,” an approach to regulatory approval 
that would consider the presence of antibiotic-resistance genes in corn-gluten feed cause 
for concern and, paradoxically, would mandate the destruction of said feed. This would 
apply even if the destroyed feed would be healthier than the alternative due to lower 
mycotoxin levels. 
Although liability laws dictate the use of the best available technology to avoid feeding 
carcinogens to children and pregnant women, the regulatory environment instituted by 
the European Union to meet “collective preferences” operates to ban any trace of this best 
available technology—setting up a future where liability could apply even if the company 
in question were to assert as a defense in court, “The European Union made me do it.” 
The law in the European Union and the United States may provide a presumption of 
reasonable behavior based on regulatory requirements, but it can be overcome by a tort 
theory stating that there was a risk that required a warning or could be implemented at 
minimal cost (in the case of biotech crops, the cost of using them could be lower). 
There	are	hazards	from	food	that	are	heightened	by	anti-biotech	
regulations	that	deny	consumers	access	to	use	of	the	best	available	
technologies	for	controlling	carcinogenic	mycotoxins	in	their	staple	
food	supply..
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The anti-biotech activists who run the show in Germany have succeeded in creating 
their own innovative approach to liability, which helps to close the door to any grower who 
might attempt to use the “best available technology” for mycotoxin-insecticide reduction 
(the European Union has approved some varieties of Bt corn). German growers of biotech 
crops are discouraged by a GM liability law that forces them to avoid any commingling 
with other growers, who may have agreed to supply non-GM products. 
The concept of protecting the non-GM grower’s contractual promise of “zero” is also 
emerging in the negotiations of the Biosafety Protocol’s liability regime, which is now 
underway with hopes of producing a text by September , 007, for approval by the 
parties to the Biosafety Protocol. Activists have suggested innovations in liability law 
that would:
• reverse the burden of proof to the GM-crop grower or grain exporter,
• protect the economic loss of the non-GM grower (who may be harboring a reser-
voir of “biodiversity” in his choice of seed), and
• place the ultimate blame on the company that developed the biotech seed, since 
the GM event that “harmed” the non-GM grower can be traced.
The seed of anti-biotech liability law now sprouting in Germany could have a broad 
dispersal if the parties to the Biosafety Protocol do not come to their senses and reject 
such standards.
With member states free to impose their own liability regimes like this one, and balk 
at European Union-wide regulatory approval, the European Union’s misguided anti-
biotech-innovation policy could take decades—or an entire century—to reverse, even 
if it is shown without dispute to have caused well documented harm to human health 
and the environment. to ensure that the costs of the European Union’s precautionary 
approach and ZAP testing are counted, foundations that care about neglected popula-
tions of people (e.g., African refugees who are denied food aid based on traces of locally 
unapproved GM events) and neglected plants (e.g., wild and indigenous soybean, rice and 
other crops) need to stand up to the challenge of tracking the harm that can be caused 
by misguided regulation.
State Law Barriers and tools for Marketing Biotech Crops
While the US federal regulatory system is streamlined and efficiently operating to manage 
risks, there are emerging roles for states, counties and cities to react to authorities that 
seek to protect economic interests and social, cultural or indigenous concerns. These local 
While	the	US	federal	regulatory	system	is	streamlined	and	
efficiently	operating	to	manage	risks,	there	are	emerging	roles	for	
states,	counties	and	cities	to	react	to	authorities	that	seek	to	protect	
economic	interests	and	social,	cultural	or	indigenous	concerns.
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authorities may be reacting to international opposition that limits markets from particular 
states. In response to California’s rice industry, a bill was passed in 000, Assembly Bill 
, that licensed all rice for its economic impacts—specifically addressing the threat that 
biotech rice poses to export markets; Arkansas passed a similar law in March , 005, 
that gives the Arkansas State Plant Board the power to regulate “commercial impact” of 
rice commingling—without specifically mentioning biotech rice (HB 57, 3//05).
For example, Iowa has passed a law precluding any county from declaring itself GM 
free (a reaction, no doubt, to the three California counties that went “GM free” in 00). 
Iowa grower Bill Horan just reported that production of a PMP will finally be allowed 
to occur in Iowa, at a military base over a mile from other corn production. The Iowa 
experiment now underway will provide more data on the cost-effectiveness of growing 
pharmaceutical corn in the nation’s largest corn-producing state. 
The story of Ventria’s rice provides a narrative that touches upon the entire range of 
regulatory and liability issues facing new PMPs launched in the United States, and the 
key stakeholders in the commercial launch of a PMP. Ventria started out trying for state-
level regulatory approval in California. While the California rice Commission approved 
Ventria’s application, leaving it up to the state Department of Agriculture to decide, the 
announcement that a public hearing would be held resulted in Ventria’s choosing to 
relocate its operations to Missouri, giving up on California approval.
Missouri proved inhospitable to Ventria as well, as major food producers who use Mis-
souri and Arkansas rice expressed concern about commingling. Press reports indicated 
that a counterseasonal South American site may be next in line, or a small plot in North 
Carolina.
If	the	agricultural	biotechnology	industry	is	going	to	meet	
customer	expectations	for	segregation	of	the	green,	white	and	red,	
it	may	need	to	work	with	growers	to	create	districts	that	establish	
identity	preservation	as	a	matter	of	civic	law.
One little known legal aspect of the Ventria story is the unused Missouri “grower 
district” statute that was enacted in late 00 (effective January , 005) with Ventria in 
mind (but not used by Ventria) to line up growers in a dedicated region (a solution that 
might have reassured rice interests opposed to Ventria’s plans). A future PMP- or PMIP-
production system can avail itself of this tool, however. This concept of a grower district 
appears in a new Missouri statute that was passed in 00, around the time frame when 
Ventria moved its operations from California to Missouri in early 005. If the agricultural 
biotechnology industry is going to meet customer expectations for segregation of the 
green, white and red, it may need to work with growers to create districts that establish 
identity preservation as a matter of civic law.
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Other novel agricultural technologies have arrived on the scene with similar seg-
regation issues. Canola only recently became an edible food product by innovations 
adjusting rapeseed’s nutritional profile. The canola industry uses a variety of production 
methods to maintain the necessary segregation, including grower districts in Idaho and 
Washington. 
Another angle on PMP production that is under review is simply to go underground 
in the farm belt. This allows production to occur close to existing processing centers in 
the midwest (e.g. Sigma Aldrich in St. Louis, MO), while avoiding the controversy and 
exposure to eco-terrorism that can occur aboveground. Like any innovative step, however, 
this option will have to prove its economic worth before innovators will adopt it.
Conclusion
Despite past successes, and the knowledge gained from failures and near misses, the 
road to future commercial success in agricultural biotechnology remains as full of hid-
den economic hazards as the road to the Baghdad airport. The European Union and its 
like-minded trading partners will continue to hold their ZAP standards over the heads 
of grain exporters and will increasingly drive innovation in agricultural biotechnology 
into contained, closed-loop production systems. Like a game of three-dimensional chess, 
biotech crops will face three levels of regulatory oversight, starting with federal approvals, 
but with more requirements emerging at the state level (even in counties and/or cities), 
and overseas. For many biotech crops, international approvals that may be required 
prior to market launch in the United States (for soybean, rice, wheat and other primarily 
export-bound crops). As a result, US agricultural biotechnology operations will need to 
maintain perfect divisions between the green, white and red sectors—as neatly divided 
in the fields of America as the stripes in the Italian or Irish flags, which do not blur their 
colors together.
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With the introductions of genetically engineered organisms (GEOs) into the environ-
ment over the past 0 years, there has been a growing number of questions and concerns 
about consequences for natural and managed ecosystems. An emerging body of research 
evidence shows that GEOs are viable and capable of reproduction with wild relatives in 
natural ecosystems. There is also evidence that transgenes can move from one domesti-
cated variety to another. Also, given the fact that future GEOs may feature traits that have 
the potential to significantly modify the ecological niche that these organisms occupy, 
there has been interest in developing methods and approaches to confine certain GEOs 
and their transgenes to specifically designated areas. Of the various methods available to 
confine GEOs, those that are biological in nature are of particular interest. These include 
induced sterility and related methods—approaches that, in some cases, have been applied 
to non-engineered organisms such as shellfish and crop plants. 
Biological Confinement of GEOs:
Opportunities for Reducing Environmental Risks?
Kim Waddell
American	Vineyard	Foundation
Napa,	CA	
The	US	Department	of	Agriculture	requested	the	National	
Academies	to	review	and	evaluate	biological	methods	of	
confinement	for	GEOs.
In 000, the federal government completed an interagency review of its regulatory 
oversight of biotechnology products. This review revealed that ensuring confinement could 
become a regulatory requirement for approval of some GEOs. In 00, the US Depart-
ment of Agriculture requested the National Academies to review and evaluate biological 
methods of confinement for GEOs and report on their application in confining transgenic 
crop plants, shellfish, trees, grasses, fish, microbes, insects and other organisms. This paper 
summarizes that report (Biological	Confinement	of	Genetically	Engineered	Organisms) with 
the hope that biological confinement methods for current and future GEOs will be given 
adequate consideration as mechanisms to reduce environmental risk.
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The expert committee convened by the National Academies was asked to address a 
set of six questions: 
• What is the status of scientific understanding about various biological confine-
ment methods for genetically engineered organisms?
• What methods are available, and how feasible, effective, and costly are they?
• What do we know about when and why methods fail, and what can be done to 
mitigate such failures?
• When these methods are used in large-scale applications, what detection and 
culling procedures can be used if the biological confinement methods have failed? 
What is the cost-effectiveness of these procedures?
• What are the probable ecological consequences of large-scale use of biological 
confinement methods on wild populations, biological communities and land-
scapes?
• What new data and knowledge are required for addressing any of these important 
questions?
The report is organized into six chapters. The introductory chapter provides definitions 
and historical context for GEO confinement. The second chapter addresses the questions of 
when and why biological confinement (“bioconfinement”) should be considered. Chapters 
3,  and 5 are the heart of the report: bioconfinement methods for plants, animals, and 
microbes are analyzed and reviewed. The final chapter explores biological and operational 
opportunities and constraints for bioconfinement, examines the potential for confine-
ment failure and mitigation, and looks to the future in terms of unanswered research 
questions and needs that should be addressed in order for bioconfinement methods for 
GEOs to be successful.
Definition of Bioconfinement
There is a fundamental assumption in the report that the movement of GEOs or their 
genetic material might need to be restricted to designated areas, which in turn creates the 
need for confinement. Three types of confinement are defined—physical, physicochemical 
and biological—each involving barriers that prevent the survival, spread, or reproduction 
of the organism in the natural environment. Bioconfinement refers to the methods that 
utilize biological mechanisms to achieve confinement.
When and Why to Consider Bioconfinement?
The report repeatedly acknowledges that many, if not most, GEOs will not require biocon-
finement. Each should be determined on a case-by-case basis that takes into consideration 
the risk associated with the escape of the GEO or its transgenes. The most commonly 
known environmental risk is that of GE crop alleles being sexually transferred to wild 
Many,	if	not	most,	GEOs	will	not	require	bioconfinement.
93
relatives and conferring new traits that result in increased weediness. Other risks include 
effects of a GEO on non-target species (including humans). These range from potential 
food-safety concerns associated with crop plants engineered with genes expressing novel 
proteins not intended for the food chain to GE animals out-competing or driving related 
and locally rare taxa into extinction. 
The report notes that researchers and GEO developers need to consider the role of 
preventative action; in other words, are there options that might eliminate or mitigate the 
need for bioconfinement or that may also prevent failure of a given confinement effort? 
Such an assessment often presents a greater set of options in contrast to the often higher 
expense of remedial action. The question of “How much bioconfinement is enough?” 
must also be asked; an appropriate risk assessment, exploring the need for stringency 
and redundancy, will be influenced by the risks posed by the organism, its biology, the 
transgenes and other factors. 
The consequences of failure of bioconfinement are varied and are difficult to determine 
in advance. Potential consequences include negative ecological impacts at local to regional 
scales, and political impacts in instances where bioconfinement failure results in significant 
impacts for human or environmental health, followed by public outcry or concerns that 
the failure was due to negligence or inadequate regulatory oversight.
Plants
Many approaches are possible for the bioconfinement of plants, due in large part to the 
diversity of reproductive strategies they employ. Of the methods discussed in the report, 
a few are based on existing agronomic and horticultural practices. Other methods are 
newly developed and untested or are merely working hypotheses. An evaluation of the 
strengths and weaknesses is included in the discussion of each method. As a whole, the 
methods typically target sexual and/or vegetative reproduction. 
The report also evaluates these methods for their effectiveness at different special and 
temporal scales, given that they are the equivalent to natural mechanisms of reproductive 
isolation that act to maintain species barriers. In nearly every instance, bioconfinement 
of reduced numbers of GE plants planted in smaller regions for shorter periods of time 
is likely to be more successful than efforts with larger numbers planted over larger areas 
and when confinement needs to be maintained for longer periods of time.
These issues become more important as genetic engineering is applied to new types of 
plants, including long-lived species such as trees. Furthermore, new types of GE traits 
are being developed including traits that produce medicinal and chemical precursors for 
such products as vaccines and natural rubber. Our ability to combine multiple GE traits 
that make plants hardier and more prolific also presents potential environmental risks 
that might warrant bioconfinement.
Another	concern	involves	the	level	of	public	acceptance	of	sterile	
seeds	in	staple	food	crops.
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Overall, the outlook for confining plants is positive. When recommended methods 
work as planned, there is no reason to expect environmental problems. However, the 
report acknowledges that nearly all of the methods have limitations, mostly in the areas 
of availability and reliability. This is particularly true for long-lived, clonal plants. An-
other concern that might impact the use of bioconfinement involves the level of public 
acceptance of sterile seeds in staple food crops. This issue was raised some years ago with 
the public perception of “terminator” technology that a company considered using to 
protect their technology and investment.
Animals
For the discussion of bioconfinement of animals, the report limited its focus to insects 
and aquatic species, in large part because these two categories are active areas in current 
GE research and development efforts. Consequently, they are likely to be among the early 
GE products considered for commercialization. Finally, the potential for negative envi-
ronmental effects from confinement failure is much higher relative to terrestrial livestock 
species. Of the methods evaluated, the best understood systems are those applied to fish 
and shellfish species, due to the success of aquacultural programs employed around the 
world. These methods focus on disrupting sexual reproduction by a trio of approaches:
• sterilization through induction of triploidy;
• combination of triploidy with monosex lines; and
• interspecific hybrids alone or with triploidy.
In most instances, successful bioconfinement relies on the ecological characteristics of 
the GEO and the production site to reduce escape.
The best developed methods for animals involve the induction of sterility. However, 
no method is 00% effective, and the success of any method relies heavily on effective 
screening for failures prior to the release of the GE animals. Some early data involving 
GE salmon reveal that a high level of screening for triploidy appeared to be cost-effective. 
As for transgenic methods of confinement, the report acknowledges that they are at very 
early stages of research, so much needs to be understood before such approaches become 
commercially viable. One lesson from current aquaculture is that it is very difficult to 
monitor for failures after commercial release. Overall, animals pose some unique chal-
lenges for confinement, but given the level of experience gained from aquaculture, our 
understanding of bioconfinement methods may be more advanced for GE animals than 
for the other taxa discussed in the report.
Considerable	caution	is	warranted	since	relatively	little	is	known	
of	the	ecology	and	evolution	of	GE	microbes.
Microorganisms
The use of GE microbes offers significant potential benefits, given that viruses, bacteria, and 
fungi are pathogens of insects and of a variety of other pests. Microbes are also capable of 
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degrading certain pollutants. With genetic engineering, this capability could be extended 
to a broad list of toxins and pollutants in the environment. However, considerable caution 
is warranted since relatively little is known of the ecology and evolution of GE microbes. 
Furthermore, since reproduction is asexual in bacteria and often clonal in viruses, the 
methods developed for inducing sterility in plant and animals are not appropriate for 
many microbial species.
There are two major categories of bioconfinement methods. One focuses on “fitness 
reduction” for microbes. With “phenotypic handicapping,” the energy costs of expressing 
the GE trait causes a loss in competitive ability relative to naturally occurring microbes in 
the environment. The success of this confinement effort depends on the persistence of the 
GE-microbe population under such a handicap. However, a limitation with this method is 
the fact that microbes rapidly reproduce and can mutate, so subsequent generations may 
be more adapted to the environmental conditions and may be capable of coexistence. 
The second category, “suicide” genes, is oriented to confining the GE microbes in the 
wild. The mechanism involves the GEO carrying a suicide gene that is repressed while 
the microbe is “working”—for example metabolizing a pollutant in a lake—and is ac-
tivated when the microbe is no longer metabolizing the chemical in question, resulting 
in programmed death. 
One reality regarding GE microbes must be acknowleged. It is virtually impossible at 
this time to completely eliminate specific genotypes (GE genotypes for this discussion) 
in natural populations of microbes. This needs to be considered when deciding whether 
a GE microbe should be released into the environment.
Biological and Operational Considerations 
The bioconfinement methods characterized for plants, animals, and microbes share three 
features:
• all methods have strengths and weaknesses;
• all vary in efficacy depending on circumstances; and 
• no method will achieve 00% confinement. 
As noted earlier, in many cases GEOs will not require bioconfinement. For all three taxa 
the efficacy of bioconfinement will depend on the organism, the environment, and the 
temporal and spatial scales over which the organism is introduced. 
report recommendations
Given these shared features of bioconfinement methods, the report provides a number 
of recommendations (in italics):
•	 Evaluation	of	the	need	for	bioconfinement	should	be	considered	for	each	GEO	separately.
The report emphasizes making biosafety a primary goal from the start of developing any 
new GEO. This will be an efficient and effective way to prevent safety failures.
•	 The	need	for	bioconfinement	should	be	evaluated	in	the	early	stages	of	development	of	
a	GEO	or	its	products.
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Because methods can fail, and because it is unlikely that 00% confinement will be 
achieved by a single method, it is thought that redundancy in confinement methodology 
will decrease the probability of failing to attain the desired result. It is also understood that 
the spatial or temporal scale of a GEO field release can influence the potential for confine-
ment failure. The appropriate confinement option will depend on scale. Therefore,
•	 Bioconfinement	techniques	should	be	assessed	with	reference	to	the	temporal	and	spa-
tial	scales	of	field	release.	
The question of “How much bioconfinement is enough?” is challenging to answer with 
most GEOs, but with a systematic risk assessment and management approach, 
•	 An	adequate	level	of	bioconfinement	should	be	defined	early	in	the	development	of	a	
GEO,	after	considering	worst-case	scenarios	and	the	probability	of	their	occurrence.	
Following the decision to develop a new GEO, after a risk assessment, and the research 
to validate the assessment,
•	 An	integrated	confinement	system	(ICS)	approach	should	be	used	in	deployment	of	the	
GEO.
The ICS includes a number of features familiar to those who use best-management prac-
tices in the workplace. The recommended ICS approach includes 
• Commitment to confinement by senior decision-makers
• Establishment of a written plan for redundant confinement measures to be imple-
mented, including documentation, monitoring, and remediation 
• training of employees
• Dedication of permanent staff to maintain continuity
• Use of good management practices for applying confinement measures 
• Periodic audits by an independent entity to ensure that all elements are in place 
and working well
• Periodic internal review and adjustment to permit adaptive management of the 
system in light of lessons learned
• reporting to an appropriate regulatory body
Looking Ahead
Much of the report focuses on the front end of the process where determining whether, 
what kind and how much bioconfinement is needed. There is also the need to follow 
up once a bioconfinement strategy has been deployed with a GEO. Given the relative 
inexperience we have with GEOs and the deployment of confinement methods in the 
environment, the efficacy of the confinement system must be monitored. However, this 
is where our current knowledge is lacking and where our needs are perhaps greatest.
•	 Easily	identifiable	markers,	sampling	strategies,	and	other	methods	should	be	devel-
oped	to	facilitate	environmental	monitoring	of	GEOs.
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The fact is, the current lack of quality data and science is the single most significant fac-
tor limiting our ability to assess effective bioconfinement methods. Methods need to be 
tested in a variety of appropriate environments and in representative genotypes of the 
GEO under consideration. In order to implement effective bioconfinement of GEOs, 
the report recommends support for additional scientific research that 
•	 Characterizes	the	potential	ecological	risks	and	consequences	of	a	failure	of	bioconfine-
ment
•	 Develops	reliable,	safe,	and	environmentally	sound	bioconfinement	methods,	especially	
for	GEOs	used	in	pharmaceutical	production
•	 Designs	methods	for	accurate	assessment	of	the	efficacy	of	bioconfinement
•	 Integrates	the	economic,	legal,	ethical,	and	social	factors	that	might	influence	the	ap-
plication	and	regulation	of	specific	methods
•	 Models	the	dispersal	biology	of	organisms	targeted	for	genetic	engineering	and	release,	
where	sufficient	information	does	not	exist.
The objectives for this and any other research on bioconfinement are to minimize the 
risk or damage to human and environmental health. The success of these efforts will do 
much to bolster public confidence in the continued growth, development, and opportu-
nities presented by biotechnology.
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Thomas	Hoban:	It’s fun for me to come back here and talk to you again. I’ve been on a 
number of NABC programs over the years and have had some of the papers published. 
I am back this time as a disinterested observer because I’m really not involved in biotech 
much anymore. I’ve moved on to bigger and better things.  
So, let me reflect on some of the issues I see coming along. First of all, I’ll give you a 
few main points. The major issue is that this is about food, it isn’t about farms. Food is 
a very emotional and ethical subject for most people. People react with their guts, they 
don’t react with their minds. This is not about sound science, again this is about ethics, 
confidence and trust. The second main point is that American arrogance and aggression 
in this area—as in many other areas—has alienated most other countries. We’re now seen 
as using poor countries as pawns. We have no standing with the world when it comes to 
food because we are seen as barbarians when it comes to our own food lifestyles, certainly 
relative to Europe. So the European Union, with their cautious approach, is winning the 
hearts and minds of many other parts of the world right now because by contrast we look 
pretty callous. Again, this is all about confidence and trust. The data are in. I’ve seen some 
of it. People no longer trust the government in the United States. It’s clear that people 
especially fear large corporations. I’ve been teaching a lot with under-30-year-olds. Young 
people are convinced that the most serious threats to their lifestyles and to their future 
are large corporations. They are not afraid of NGOs and things. 
Another important consideration is that, regardless of what scientists and technologists 
say, organic food has become the gold standard against which everything else is judged. 
And much of their market appeal is that they can put right on the bag—even though 
FDA was supposed to write rules about this but didn’t—“non-GMO.” “Buy this product, 
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spend the extra dollar, because it doesn’t have GMOs in it.” That’s what we are seeing. I 
hope you all paid a lot of attention to Mark Nelson from the Grocery Manufacturers of 
America (GMA), because the big food companies have all bought organic lines. Kraft owns 
Boca. General Mills has Cascadia Farms. Kellogg’s has Morning Star Farms. On and on. 
They are going to play both sides of the aisle and they are ready to turn their businesses 
around and aim in that direction as they see the market develop. 
And as a sociologist, this is an interesting example of what we call cultural lag. And this 
is where the material culture, the science, the technology, is far outpacing our nonmate-
rial culture. I’d say we don’t have the knowledge, the attitudes, the regulatory or policy 
systems in place to deal with these technologies, and we’re only talking about plants. 
The big challenges are going to be in human genomics, human genetics, and NABC 
just sticks its head in the ground when it doesn’t even look at those issues. The fact that 
you’ve excluded animals from this discussion is really interesting because that’s the one 
that’s going to blow up in everybody’s face.
Let me get a little more specific. I’ve looked at a very good study from rutgers. I had a 
chance to review all the Council for Biotechnology Information tracking data, which I’m 
not going to talk about in detail, but there are some real clear trends in the United States. 
One of the most disturbing things is that the vast majority of people in the US still don’t 
have a clue that products in the supermarket contain genetically engineered ingredients. 
They are still saying, “Oh no, I don’t eat that.” It’s still a common fallacy. And as people 
find out, they are finding out because they are learning about the negative side. They’re 
not learning about it in any positive way. And, increasingly, the data that aren’t usually 
shared show that there is increasing concern over risk among US consumers. And that has 
increased over time. The food industry itself—in terms of the state of social acceptance—is 
about to pull the plug. You need to pay close attention to what GMA says about PMPs. 
And you aren’t even listening to the food retailers and the restaurant chains because all 
they’ve done is told the manufacturers, “Keep that junk out of our food.” You know the 
whole system is blocked at that end and there’s no sign that anything is going to come 
along that’s going to spring that open. A food retailer will still be very, very susceptible. 
And the bottom line, as I think we are finding, is there are no benefits for any of these 
stakeholders, including consumers. There is a perception of possible risk and so, in many 
ways, it’s very rational to reject the technology. With Europe, the interesting thing there 
is the data showed that things were actually looking a little better, then along came the 
WtO lawsuit to the front page of the paper, and the Europeans dug in deeper than in 
the past.
Where would I lay the blame for all this? I would lay it at the step of the Bush admin-
istration. The main indicator of that is they never bothered appointing a full-time FDA 
commissioner. It was just not important enough. We’ve got Les Crawford in there, nice 
man, strong industry advocate, strong lobbyist for industry, but they never bothered 
getting a confirmation on a full-time FDA commissioner. That just shows you where the 
priorities are. The WtO case was brought  weeks after the misplaced Iraq invasion that 
we are still trying to dig out from under. And the headlines in the European press were 
in terms of retaliation against the French for not backing us in Iraq. One thing I did 
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support: towards the end of the Clinton/Gore administration, FDA hearings were held 
on the future of food and regulations. The one thing that everybody agreed on, from 
Greenpeace to BIO to everybody in the middle, was that there ought to be mandatory 
premarket notification of FDA. Well, Les Crawford, in his great style, said, “You know, 
we don’t really need to do that because we can trust all the companies. They’re going to 
come in to us voluntarily.” And that shows you the mindset of the administration.
As I mentioned, there were supposed to be labels that would prevent misleading pro-
motion of products as being “non-GMO”: but, we never did it. The one that is going to 
come back and hit the hardest, though, is this continual push to try to convince people 
that meat and milk from cloned animals is substantially equivalent. The public knows 
that is not true. The scientists can’t even say it’s true. Everybody knows it took 300 mis-
takes to make Dolly and then she died early. Nobody wants to eat meat or milk from 
such animals. What I’ve seen is just pretty much characteristic of this administration: the 
wrong decisions at the wrong time at every possible opportunity. 
Finally, how about a few implications for the universities? I think there is still a lot 
that we can do. What this industry sorely needs is something that people may actually 
want, something that food consumers may actually demand. If you go back to some 
of the horticultural crops and produce, some of the flavor-saver constructs, and deliver 
something to the consumers that they actually like, you might even make supermarkets 
receptive. I think universities need to quit being so hung up on sound science. There are 
many, many other ways of knowing. And when it comes to food there are many, many 
other things that are much more important to people than sound science.
I’ve published a review of a film made my Deborah Garcia, The	Future	of	Food. It’s an 
unabashed attack. She’s likening herself to Michael Moore. It summarizes all the concerns 
that people have, and I think that’s one of the things that universities need to do more 
of. You need to start inviting and engaging the critics. You need to listen to someone else 
besides the biotech industry. And I know—coming from a land grant university—that 
the people with the money, it’s tempting to listen to them. But I really think that we 
need to do a much better job as universities of being honest brokers and asking the tough 
questions and coming up with answers that may or may not be politically correct.
Canice	Nolan	(European	Commission	to	the	United	States,	Washington,	DC): My mission 
is not to convert you to the European ideal. My objectives here in the United States are 
to listen, to inform and to promote the dialog. In the area of GM, dialog is something 
that has been missing for several years, mainly due to the fact that a WtO case is going 
on and our instruction in the past has always been, “When there is a court case going 
on, you speak through the lawyers, you don’t actually speak to the other parties.” This 
is important. Before coming here, I was responsible for six years for pesticide legislation 
in Europe. As a scientist, I learned very quickly that you don’t play political games. You 
don’t play with journalists because they are professionals and they will eat you alive. I’m 
a scientist and I prefer to stick to the science. I learned how valuable that was in the area 
of pesticides, because there are many people who don’t care what the risk assessment is, 
they just want it banned anyway. I heard reference to “zero zealots” this morning. I’ve also 
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heard these people referred to as the taliban: “tali ban this and ban that and ban the other,” 
and it doesn’t matter what’s out there. Now, with respect to GMOs, you have to see it 
in the larger context. We had food scares in Europe, mad cows, dioxins and so on in the 
90s, which threw the whole food supply system into doubt. At the end of the 90s there 
was a period of reflection that included GM. During that time we set up the European 
Food Safety Authority. We brought in a huge amount of new legislation on food safety. 
Also in the area of GM we brought in new rules, new scientific requirements, scientific 
assessments, rules on labeling, on traceability, and things had started moving again in 
the sense that requests were moving through the system. We had a new commission at 
the end of last year, and one of their first actions was to stop and say, “Well, GM: yes 
the commission is pushing it. We’ve analyzed case by case, we’ve seen where things are 
safe, we will go ahead and make positive proposals.” But the member states are still not 
on board. So, there was a period of reflection in February, 005, in the commission and 
it was agreed that the system we have in place is a good, correct system, so let’s continue 
with it as is. And we have continued pushing forward proposals. You might say everything 
is okay now, everything is moving; well, in fact, everything is not okay. Everything is not 
moving as we would like and there are a few reasons for this. One of them is that the real 
problem is not with the regulators, the problem is with consumers. And the politicians 
see that consumers don’t want this. The supermarkets see that the consumers don’t want 
this. And they’re not buying; they’re not sourcing. The food processors are not sourcing 
where there is a risk of GM and, until the consumers are convinced, I’m not sure that the 
markets will allow GM to go forward in Europe. It doesn’t matter what we as regulators 
say. It’s the market that will rule the game. And the politicians are just being responsive 
to the wishes, if you like, of the electorate. The GMO case is almost seen as big industry 
forcing unwanted food down people’s throats and the commission sees itself almost in a 
position of being a tool of industry in forcing this down people’s throats because the laws 
say that it is safe that you have to put it out there. I’d always thought that the American 
system was that the consumer is king and what the consumer wants the consumer should 
get and if the consumer doesn’t like this, well the consumer doesn’t have to have it. In 
the field of GM, I have the impression of the industry saying this is good, take it, buy 
it, eat it, it’ll do you good, and we have to get around that disconnect if we are going to 
make progress in this area.
Allan	Bennett	 (University	 of	California,	Davis,	CA): One of the themes that has gone 
through this meeting is the opportunity for a greater diversity of agbiotech products. Also 
a notion that was mentioned by roger Beachy has come up again: the opportunity for 
new players, including the public sector, as developers and providers of new GE crops. 
A few of us believe that the markets would react differently today if, in fact, there were 
additional players in this field and additional products representing broader diversity. 
Clearly, some high barriers are working against this objective of diversity of products 
and of players. The irrationalized regulatory environment and its smothering effect on 
development and deployment of new phyto-technologies has been addressed over and 
over at this meeting. The bad news that I want to present today is that you also need to 
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navigate a thicket of patents before you can even get to these regulatory hurdles. So, my 
role is to shine a little bit of light on the intellectual property environment that is also 
impacting what projects can advance and what institutions can effectively move along 
the path to product development.
Interestingly, these two areas—intellectual property and regulatory approvals—are not 
unrelated. The regulatory environment imposes high cost on the ultimate deployment of 
a product and, in industries where there are high regulatory hurdles, intellectual property 
becomes extremely important simply because no one is prepared, or willing, to invest the 
cost required for regulatory approval unless they have exclusivity to market the product. 
And so, in this sense, intellectual property is very important in fueling innovation and it 
is very important fueling innovation in this sector. Having said that, intellectual prop-
erty—if the landscape becomes too complex—can also inhibit innovation, and that’s the 
situation that we are dealing with here; it’s clearly important, but has developed into a 
complex landscape. So, what does this intellectual property landscape look like? We’ve 
studied it a little bit. It turns out there are sixteen to twenty thousand patents in the crop 
biotechnology sector, depending on what and how you count. That’s an interesting number 
given the very narrow base of products that we have in this arena. It’s clearly not for lack 
of innovation and innovative technologies that have been developed. These cover the 
so-called enabling technologies such as transformation methods, selectable markers and 
promoters. In an ideal world these enabling technologies would be very broadly available, 
licensed on a non-exclusive basis to enable a wide diversity of players but—unlike medical 
biotechnology, where in fact that did occur—it didn’t happen in agbiotech. Therefore, 
many of the enabling technologies are very narrowly owned and strategically deployed 
rather than supporting broad innovation. There is an initiative called BIOS, Biological 
Innovation for an Open Society, in Australia, which is attempting to invent new enabling 
technologies and make them broadly available free of charge. This group of sixteen to 
twenty-odd thousand patents also covers the trait technologies—genes that encode specific 
pharmaceutical proteins or traits such as disease resistance, which is the arena in which 
exclusive access is critically important. Elizabeth Hood indicated that somewhere in the 
neighborhood of seventy-five licenses were needed to encompass all of the technologies 
for the production of trypsin, very similar to the seventy-odd technologies required in 
the production of golden rice.
to address some of these issues, twenty-eight universities and not-for-profit research 
centers have joined forces to create the Public Intellectual Property resource for Agriculture 
(PIPrA). In this area, there is strength in numbers. Fully 5% of crop-biotech patents 
represent inventions that were made in the public sector, and this is about a 0-fold 
higher proportion than in any other technology sector. So PIPrA, as a collective orga-
nization, represents a very broad and significant portfolio of intellectual property. What 
is it doing? It’s deploying a unified database of all the public-sector intellectual property, 
helping organizations and individual researchers evaluate freedom to operate around 
specific technologies, developing transformation vectors that have maximum freedom 
to operate and it’s working towards a collective management—bundles of intellectual 
property for multiple institutions—to try to reduce these transaction costs. PIPrA has 
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a vision and this vision is related to something we heard yesterday: to be able to partner 
with an organization such as the Specialty Crops regulatory Initiative (SCrI), and jointly 
navigate both the intellectual property and the regulatory environments that will deliver 
the benefits of biotechnology to a broader base of crops and to consumers.
Bruce	Ferguson	(Edenspace,	Chantilly,	VA): My first question is for tom redick. Given this 
evolving standard of strict liability now that is being faced by seed producers and sellers 
and others in the agricultural chain, has any effect been observed yet on insurance rates 
or availability of insurance? Private insurance?
Tom	Redick: This is a rapidly evolving situation. Domestically we’ve had troublesome 
memoranda from our main brokers who appear to be having lunch with activists in their 
spare time, talking about how these risks are so great, and that we need to discontinue 
coverage on various aspects of production. And these insurers will actually pull all of my 
growers’ pearls, just in the name of biotech. They did the same thing with mold coverage. 
They said because of mold problems we’re not covering any losses from water damage. So 
the insurance industry is reacting. What we’ve done on the growers side is we’ve calmed 
them down, domestically. Internationally there’s a company called Swiss re. It’s a big 
re-insurer and they’re a big troublemaker. I think they’re having lunch with activists too 
and they sent an entire CD of material of what I would call inflammatory presentations 
to the biosafety meeting and handed it out and didn’t consult with industry in advance. 
So I do think there’s an insurance that’s available and, as I noted, physical injury has been 
recognized by the courts, from commingling, and that goes right into the basic standard 
insurance policy and gives coverage. That’s why, when the insurers tried to take it away, 
we really complained quite bitterly and said, “You already cover this and you’re not go-
ing to take it away.” But yeah, it’s something I’d love to see, frankly, more Europeans 
getting involved and just maintaining the level of insurance coverage that already exists 
so that they don’t pull it away. I think the activist goal is: eliminate all insurance and you 
eliminate the industry.
Ferguson: A quick follow up question for Cindy. Has there been any contingency planning 
or other activity looking at how the existing framework of government agriculture insur-
ance might be supplemented or extended to backstop farmers and others in this industry 
in the event that private insurance becomes much more expensive or unavailable?
Cindy	Smith: I want to make sure I captured your question. The question is: is the govern-
ment, from a regulatory perspective, looking at the question of liability insurance?
Audience	Member: My understanding is there is a pretty broad framework of crop-sup-
port insurance for instance for farmers, but I’m not certain, I haven’t looked at whether 
it applies to farmers who have economic harm from inadvertently having a little bit of 
DNA in crops sold to Europe. I see some headshake no, so I’m assuming that perhaps 
it doesn’t extend that broadly. I come from another industry where the government did 
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step in to provide liability backstop and I don’t think it’s a really directly comparable 
industry—the space launch industry—except to the extent that there were some hazards 
in commercial space launches that were very low risk yet could not be insured because 
they were so hard to calculate. The example often given was a commercial rocket landing 
on New York City; very low probability but hard to insure against. So, just as a reference, 
the government has stepped in—both in that and the nuclear power industry—to provide 
some creative frameworks for liability protection, for the participants in the industry. I 
just wondered if your office, or anybody else in the USDA, is looking at that whole area 
as another means of encouraging innovation in this sector?
Smith:	This is a little separate from my area, but relevant for other parts of USDA. Prob-
ably what I can offer most relevant to the question is what we’ve done. We’ve had some 
of this kind of dialog at USDA as compliance issues have arisen, particularly with the 
ProdiGene issue. At the time, we were questioning their ability to assume the loss that 
was going to be associated with their lack of compliance, and made a decision, which 
was later criticized, to have the department put up the initial money to ensure that the 
company could eventually directly assume the loss rather than have that loss spill over 
to farmers or others. So, the way we have addressed this to date has been to look at each 
individual situation and, with respect to what we’ve been regulating, and make every 
effort to hold the company directly accountable for lack of compliance. We’ve had some 
other situations too. Fortunately we’ve had a lot of success in getting companies to agree 
to address those issues. But clearly there’s a larger question here that is probably a whole 
other discussion that should be considered and include other parts of USDA and the 
insurance industry.
Henry	Miller	(Hoover	Institution,	Stanford,	CA): One concept that is dramatically under-
represented here is that the universe of recombinant DNA-modified organisms, whether 
you call them GMOs or GEOs or GEMs, is not a meaningful scientific category. It’s not 
amenable to generalizations about risk or safety and, if you doubt that, look at the lists 
of topics at the Keystone meetings and the Gordon conferences and they don’t focus on 
recombinant enzymology or recombinant bioenergetics. That has important implications 
because regulators like Cindy Smith saying that her agency has a scientific approach and 
it’s dedicated to science, doesn’t make it so. You labor within an irrational scope of what 
comes in overall to your system. And in science you don’t get to be scientific for just a 
little bit of the process. You have a process, as does EPA, where the degree of govern-
ment scrutiny is inversely proportional to the degree of risk. You are regulating a superior 
technology more stringently. And you are very congenial and you are very collegial but it 
doesn’t make your scheme any more rational and it doesn’t make the obstacles that you 
put in the path of research in industry and in academia any less.
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...in	a	vast	number	of	cases,	we	cannot	recognize...the	wild	parent-stocks	of	the	
plants	which	have	been	longest	cultivated	in	our	flower	and	kitchen-gardens....	
breeders	could	never	have	expected	or	even	have	wished	to	have	produced	the	
result	which	ensued.	—Charles Darwin (859)
With these words in his Origin	of	Species, Darwin made clear	the power of selection and 
plant breeding to alter the appearance and usefulness of crop plants. The selection of 
plants with improved agronomic traits, along with improved agricultural technology, have 
been key factors in maintaining agricultural productivity during exponential growth of 
the global population over the past two centuries (Evans, 998).
With the advent of genetic engineering, transfer of DNA between species became 
possible, thus vastly increasing the power of genetic modification. At the same time, ge-
netic engineering captured the public’s attention in a way that more conventional plant 
breeding techniques never did. Genetic modification has come to be feared in its own 
right, particularly in Europe and in several developing countries. The result is an oner-
ous patchwork of regulatory systems around the world. The regulatory requirements all 
too often mirror concerns voiced by groups opposed to the technology, and thus focus 
on the DNA of the transgene and its accompanying vector sequences, and any possible 
changes in the DNA around the transgene-insertion site, rather than on the trait itself. 
In consequence, the cost of regulation can run into the tens of millions of dollars per 
transgenic event. As such, the regulatory environment is actively preventing the market-
ing of dozens of transgenic crops, while contributing little, if anything, to public and 
environmental safety.
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Whether this DNA-centric regulation is warranted depends on the extent of DNA-
based changes that differ between the engineering process and traditional plant breeding. 
The prevailing wisdom has been that plant breeding primarily depended on pre-existing 
variation, and thus need not cause novel DNA changes. Furthermore, the nature and 
extent of the DNA-level variation within a crop have been poorly quantified until now, 
although there have been indications in the literature that the plant-breeding process 
itself is mutagenic, that plant genomes are fluid and dynamic, and that there is a large 
amount of DNA-level variation.
rasmussen and Phillips (997) provided one of the first insights that the plant-breed-
ing process is mutagenic when they concluded that barley breeders had achieved more 
progress from breeding and selection than could be explained by the amount of genetic 
variation originally present in the parents.
Are DNA Insertions Dangerous?
Traditional	breeding	 is	based	on	 sexual	reproduction	between	 like	organisms.	
The	 transferred	 genes	are	 similar	 to	 genes	 in	 the	 cell	 they	 join....	 In	 contrast,	
bioengineers	isolate	a	gene	from	one	type	of	organism	and	splice	it	haphazardly	
into	the	DNA	of	a	dissimilar	species,	disrupting	its	natural	sequence.	—Alliance 
for Biointegrity (http://www.bio-integrity.org/health-risks/ health-risks-ge-
foods.htm)
It has long been known that DNA content can change during tissue culture, in the 
neighborhood of 0% per culture cycle (e.g., De Paepe et	al., 98). More recently, ret-
rotransposon amplification has been implicated in tissue-culture-induced DNA changes 
(Jiang	et	al., 003).
Yet, DNA content changes in the absence of tissue culture. The literature contains many 
suggestions that plant genomes are highly variable. One early indication was the discovery 
that maize inbreds differ in the number of rDNA copies, ranging from a low of 5,000 in 
“W3” to 3,000 copies in “Illinois reverse High Protein” (Phillips, 978). total DNA 
content varies also within crop varieties. For example, soybean genotypes differ from each 
other by as much as % in DNA content (Graham et	al., 99). For red pepper, the dif-
ference goes up to 5%, (Mukherjee and Sharma, 990) and for maize, % (rayburn et	
al., 989)! It is clear from these results that plants can endure substantial changes to their 
DNA without ill effect. In the case of soybean, the % DNA is equivalent to almost 
0 million bp. Hence, an extra 3 bp of vector sequences in something like roundup 
ready© soybean cannot make any significant difference.
The	cost	of	regulation	can	run	into	the	tens	of	millions	of	dollars	
per	transgenic	event.	As	such,	the	regulatory	environment	is	
actively	preventing	the	marketing	of	dozens	of	transgenic	crops.

Furthermore, it must be emphasized that these changes in DNA content do not 
necessarily represent ancient events, but rather are the consequence of modern breeding 
attempts. The previously mentioned case of variation in soybean DNA amount is prob-
ably derived from adaptations to growing seasons at different latitudes (Graham et	al., 
99); a similar relationship is found between the length of the growing season and the 
DNA content of maize (Bullock and rayburn, 99). 
It is possible for DNA content to change within one generation. The most extreme 
example described is that of genotypes of flax that have heritable changes in plant size 
depending on the fertility of the soil (Durrant, 9). These changes are caused by loss 
(up to %) or gain (up to 0%) of DNA content in the weeks following seed germina-
tion (Evans	et	al., 9). Smaller changes, unaccompanied by dramatic differences in the 
phenotype, possibly occur all the time but go undetected. For example, DNA content in 
tall fescue differs between plants germinated at 0ºC rather than 30ºC (Ceccarelli et	al., 
997), and reflects gain or loss of ~30% in copy number of different retrotransposons.
The major component that accounts for variability in genome size is the presence of 
retrotransposon elements, which are a major constituent of plant genomes (Bennetzen, 
998). Again, the question remains whether retrotransposon movement took place in the 
ancient past or continues on to the present. Biologically, it would be difficult to explain 
why retrotransposition was once common, then came to a stop. In fact, the presence of 
retrotransposon sequences in expressed sequence tag (ESt) databases (Kuhl et	al., 00; 
Neumann, et	al., 003; Echenique et	al., 00) suggests that some retrotransposons are 
active to this day.
rapid genomic change is also evident upon polyploidization. DNA segments have 
been shown to appear and disappear within a generation following hybrid formation in 
Brassica (Song et	al., 995), wheat (Liu et	al., 998 a, b), tobacco (Skalická et	al., 005) 
and arabidopsis (Pontes et	al., 00; Madlung et	al., 005).
Collectively, these data strongly imply that plant genomes are quite able to endure 
insertions and excisions of DNA without ill effects. It cannot be concluded that “disrup-
tion of natural sequences” is dangerous.
What About Insertional Mutagenesis?
A	foreign	gene	could,	for	example,	be	inserted	in	the	middle	of	an	existing	gene	
that	instructs	a	plant	to	shut	off	production	of	a	toxin	in	its	fruit.	The	foreign	gene	
could	disrupt	the	functioning	of	this	existing	gene,	causing	the	plant	to	produce	
abnormal	levels	of	the	toxin	in	its	fruit.	This	phenomenon	is	known	as	“insertional	
mutagenesis”—unpredictable	changes	resulting	from	the	position	in	which	a	new	
gene	is	inserted.	—	Rachel’s	Environment	&	Health	News (http://www. rachel.
org/bulletin/bulletin.cfm?Issue_ID=93&bulletin_ID=8)
Collectively,	these	data	strongly	imply	that	plant	genomes	are	quite	
able	to	endure	insertions	and	excisions	of	DNA	without	ill	effects.
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In	most	cases	of	plant	modification,	DNA	insertion	takes	place	at	random,	un-
predictable	loci.	Such	random	insertion	may	lead	to	unintentional	changes	in	
gene	expression.	— OECD report of task Force for the Safety of Novel Foods 
and Feeds (000) [C(000)8/ADD]
Insertional mutagenesis differs from the previous topic in that the new DNA inserts itself 
into another gene or its regulatory sequences, rather than into the intergenic space. to 
evaluate the safety of insertional mutagenesis, it must be placed in context of transposable 
elements jumping in and out of genes, where they “can alter gene expression or serve as 
sites of chromosome breakage or rearrangement,” (Wessler, 00) just like transgenes, 
and usually without ill effects to the plants or those who consume them. 
It must be noted that all crop plants go through a period of field trials before being 
released commercially. These trials ensure that no unexpected or undesirable effects from 
the breeding process—conventional or engineered—are present in the final product.
Is Horizontal Gene transfer Unique to transgenics?
Unlike	traditional	crop	or	animal	breeding,	genetic	engineering	enables	scientists	
to	cross	genes	from	bacteria,	viruses,	and	even	humans	into	plants	and	animals.	
Never	before	have	scientists	been	able	to	break	the	species	barrier.	— The true 
Food Network (http://www.truefoodnow.org/ home_whatis.html)
Actually, plant breeders have been transferring genes between related species and related 
genera for decades. However, it is true that scientists had not crossed the species bar-
rier in terms of gene transfer between kingdoms until the advent of genetic engineering 
technology. Nevertheless, it must be acknowledged that DNA from unrelated species is 
transferred and incorporated into plant genomes. For example, plantain bananas contain 
the entire genome of the banana streak virus, rice contains DNA from the rice tungro 
bacilliform virus, and tomato has DNA from the tobacco vein clearing virus (Harper et	
al., 00). In fact, these authors concluded the following: “It appears that integration 
of viral sequences is widespread in the plant kingdom and has been occurring for a long 
period of time.” Genes from the bacterium, Agrobacterium	rhizogenes, have been found 
incorporated into the genome of some tobacco species (Aoki and Syono, 999; Ashby 
et	al., 997), while DNA from unrelated higher plants has been found to be transferred 
between their mitochondria, and, from there, to their nuclei (Bergthorsson	et	al., 003, 
00).
The true extent of horizontal gene transfer will become clear as more plant genomes 
are sequenced. In the interim, it is fair to say that, although not a common phenomenon, 
horizontal gene transfer does take place, at least on an evolutionary time scale, and does 
not appear to pose any hazards to recipient plants.
the Impact of New Genes in a Genome
Gene	expression	is	subject	to	a	regulatory	network	of	a	complexity	that	is	only	
just	being	realized.
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[Genetic	engineering]	assumes	that	genes	act	as	isolated	units	within	a	system.	
This	is	simply	not	true....Genes	inserted	at	random	into	the	genome	means	[sic]	
are	outside	of	these	regulatory	control—they	are	unregulated.	GE	goes	against	
the	current	understanding	of	the	complex	nature	of	the	genome.
…the	often	forcible	insertion	of	DNA	into	a	tightly	controlled	genetic	regulatory	
network	 is	 likely	 to	 produce	unintended	 effects.	— Greenpeace (http://www.
greenpeace.org/international/campaigns/genetic-engineering/failings-of-ge)
The new argument being made is that genes are controlled by a regulatory expression web 
in which no gene is independent. A new gene or a gene in the wrong place can upset this 
regulatory web. Yet, as discussed previously, genes and DNA sequences move into and 
between chromosomes. As additional examples, genes are known to have moved from 
the chloroplast to the nucleus (Cummings et	al., 003). In	situ fluorescent hybridization 
has shown how DNA elements move from one genome to another in a tetraploid wheat 
(Belyayev et	al., 000).
Furthermore, this “new” interpretation that gene expression is regulated by a fragile 
network of interdependent genes is based on the traditional concept that all members of 
the same species have the same genes in the same location. However, sequencing homolo-
gous DNA sequences from various maize inbreds is revealing a different reality: different 
individuals within the same species do not even have to have the same number of genes! 
Fu and Dooner (00) first discovered this phenomenon. Since then, the finding has 
been extended to other maize sequences (Brunner et	al., 005; Song and Messing, 003). 
In hindsight, this result is not altogether surprising, as it has been known for years that 
cytoplasmic male sterility in a variety of plants results from the creation of novel genes 
in the mitochondrion, along with novel fertility restorer genes in the nucleus (Schnable 
and Wise, 998). Nevertheless, the point is that to the extent to which these regulatory 
networks exist, they are sufficiently robust so as not to be affected significantly by the 
presence/absence or location of single genes or DNA sequences.
Antibiotic resistance Genes
Scientists	are	concerned	that	by	flooding	the	environment	with	antibiotic	toler-
ance	genes,	these	genes	will	be	taken	up	by	disease-causing	bacteria,	which	would	
then	become	uncontrollable	by	antibiotics.	— http://www.sare.org/sanet-mg/
archives/html-home/9-html/05.html
The	concern	that	resistance	can	be	passed	from	a	transgenic	plant	
to	a	pathogen	is	misguided.
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The concern that resistance can be passed from a transgenic plant to a pathogen is mis-
guided. As background, transgenic plants can have two antibiotic resistance (Ar) genes in 
them. One is used to distinguish transgenic from non-transgenic cells. These Ar genes are 
modified to be expressed by plant cells, but not by bacteria. Even if they were expressed 
by bacteria, it turns out that the specific Ar genes used during the genetic engineering 
process of crop plants are already ubiquitous. The gene for kanamycin resistance is an 
example. It has been calculated that the average human has ,000,000,000,000 kana-
mycin-resistant bacteria living in her/his gut, and eats an additional . million such 
bacteria each day (Flavell et	al., 99). The bottom line is that while it might be remotely 
possible to transfer an Ar gene from a plant to a pathogen, it is infinitely more probable 
that such a transfer would take place from the multitudes of Ar genes already present 
in the environment.
The second type of Ar gene used is associated with gene-gun-mediated transformation 
to keep the plasmid in the bacterium, usually by conferring resistance to ampicillin or 
tetracycline. In contrast to the plant markers, these are expressed in bacteria. However, 
they are also ubiquitous. For example, 90% of stool samples from Mexico contain am-
picillin-resistant E. coli (Calva et	al., 99). Fifty percent of the E. coli from the average 
person in France are ampicillin resistant. Using the estimate of 500 g/feces/person/day, 
and the presence of between  million and  billion E.	coli cells per g of feces, half of 
which are resistant to ampicillin, each French person liberates somewhere between 50 
million to .5 billion copies of the ampicillin-resistance gene each day (Berche, 998). 
Genes for tetracycline resistance are present in many soils. For example, a recent study 
from Denmark found tetracycline-resistance genes in 0% to 80% of sampled farm soils, 
and in all samples after enrichment with manure, using a detection limit of 0 to 03 
copies of the gene per g of soil (Agerso et	al., 00). Finally, % of wild rodent feces 
contain tetracycline-resistant bacteria (Hauschild et	al. 003). 
As of now, transfer of an Ar gene from a plant to a pathogen has not been documented 
under real-world conditions. Nevertheless, the point is that if it were to happen it would 
not matter, due to the number of resistance genes already in the environment. Thus, 
efforts to produce engineered plants without Ar genes unnecessarily complicates the 
engineering process, without gaining any safety benefits. 
regulatory Implications
The basis for a phenotypic-trait-based regulatory system, as opposed to a DNA-based 
system, has been laid out in a series of papers (Strauss, 003a, b; Bradford et	al., 005). 
The premise is that examining changes at the DNA level will most likely result in un-
necessary expense and not contribute towards environmental or health safety.
risk Categories
The first step in moving towards a trait-based regulatory system is recognizing that 
transgenes can be placed into low-, medium-, or high-risk categories based on their 
function.
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Low	Risk
The vast majority of transgenes would probably be in this category, and require little or 
even no oversight. Examples of transgenic crops in this category would include those:
• When the transgenic trait is functionally equivalent to one obtained by breeding
• When the transgenic trait is “domesticating,” that is, it lessens fitness in the wild
• No novel biochemical or enzymatic functions are imparted.
Medium	Risk
• Plant-made pharmaceuticals/plant-made industrial products (PMPs/PMIPs) of 
low animal/environmental toxicity
• resistance traits that require stewardship for their protection.
High	Risk
• PMPs/PMIPs with documented ability to cause harm in the environment or 
upon ingestion
• Plants used for bioremediation that accumulate heavy metals or other toxins
Avoid Event-Specific regulation
Once a trait produced by a transgene is deemed to be innocuous, additional transgenics 
produced with the same transgene should not have to go through the entire regulatory 
process, if at all, particularly if the same transgene is introduced into the same crop. Pu-
tatively, de	novo regulation of each transgenic event precludes unintended effects between 
the transgene and the recipient genetic background. Yet, the current regulatory climate is 
such that once a given transgenic event is approved, it in turn is backcrossed into hundreds 
if not thousands of different varieties, thus virtually ensuring the transgene will end up 
in various genetic backgrounds anyway. If anything, the widespread use of transgenes 
backcrossed into different genetic backgrounds is living proof that background effects, if 
they exist, are not important enough to regulate.
Adventitious Presence
It has long been recognized that zero tolerance is virtually impossible to achieve, be it in 
food products or in seed. Nevertheless, the continued and stringent regulation of trans-
genic products has given the public the distinct impression that these are dangerous, to 
Once	a	trait	produced	by	a	transgene	is	deemed	to	be	innocuous,	
additional	transgenics	produced	with	the	same	transgene	should	
not	have	to	go	through	the	entire	regulatory	process.
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the point that tolerances for the adventitious presence of transgenes and their products 
are far more strict than the tolerances for the presence of contaminants. For example, 
certified seed is allowed to have a low level of foreign matter and seeds from other varieties 
or even other crops, and some types of weeds. A case in point: certified canola seed may 
legally have two seeds from other crops per 50 g. It can also have fifty weed seeds per 50 
g, though none can be of a noxious weed, and only two can be of objectionable weeds. 
Also, there can be ninety diseased seeds per lb. Furthermore, one of every 500 canola 
plants in the seed field can be an off type or from another variety. It is unreasonable to 
expect transgenic seed to be present at lower levels than within these tolerances.
Likewise, the Food and Drug Administration/Office of regulatory Affairs (FDA/OrA) 
filth standards allow limited amounts of insect parts and rodent waste in food. As examples 
see CPG 70.0, Sec 578.00 and CPG 7.9, Sec 585.890 for cornmeal (permits 
less than one whole insect, or fewer than fifty insect fragments, or fewer than two rodent 
hairs, or less than one fragment of rodent excreta per 50 g) and for tomato paste (permits 
twenty-nine fly eggs, or fourteen fly eggs plus on maggot, or fewer than two maggots 
per 00 g), respectively. As another example, under the Codex	Alimenatarius (3...) 
international standards, white rice can have impurities of animal origin (including dead 
insects) of 0.% m/m maximum. There is something totally irrational about allowing 
0.% dead insects in white rice, but panicking if trace amounts of a transgenic protein 
were to appear in the same rice.
The	adventitious	presence	of	transgenes	and	their	products	
should	not	trigger	regulatory	action	as	long	as	they	are	not	
present	in	quantities	that	exceed	the	standards	currently	in	place	
for	certified	seed,	for	the	FDA/ORA	filth	standards,	or	for	the	
Codex Alimentarius.
The adventitious presence of transgenes and their products should not trigger regulatory 
action as long as they are not present in quantities that exceed the standards currently in 
place for certified seed, for the FDA/OrA filth standards, or for the Codex	Alimentarius.	
Another criterion that may be used is that the adventitious presence of transgenes and 
their products fits within FDA recommendations as to whether trace ingredients must 
be labeled. The following is from http://www.cfsan.fda.gov/~dms/flg-.html, on the 
need to label:
…depends	on	whether	the	trace	ingredient	is	present	in	a	significant	amount	
and	has	a	function	in	the	finished	food.	If	a	substance	is	an	incidental	additive	
and	has	no	function	or	technical	effect	in	the	finished	product,	then	it	need	not	
be	declared	on	the	label.
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Thus, if the adventitious presence would not trigger the FDA-labeling requirement, 
such adventitious presence should not be regulated. Under these criteria, low-level pres-
ence of transgenes and their products in foods should be exempted from regulations. In 
addition, there should be allowances for adventitious presence that are based on risks of 
specific classes of genes, and not on method (GE or not), with the classes discussed above. 
These should include the unlimited presence of specific selectable marker and reporter 
genes, and vector DNA sequences.
Additional Issues
Currently, genetically engineered Arabidopsis spp. are exempt from interstate movement 
restrictions under 7 CFr part 30, as are E.	coli	K-, Saccharomyces	cerevisiae and Bacil-
lus	subtilis. Note that these same organisms are currently regulatory exempt from NIH 
guidelines as per Appendix C, while Arabidopsis is exempt provided that it does not meet 
the criteria in Section III-E--b or other sections of the NIH Guidelines:
Examples	of	such	experiments	are	those	involving	recombinant	DNA-modified	
plants	that	are	not	noxious	weeds	or	that	cannot	interbreed	with	noxious	weeds	
in	the	immediate	geographic	area,	and	experiments	involving	whole	plants	and	
recombinant	DNA-modified	non-exotic	microorganisms	that	have	no	recognized	
potential	for	rapid	and	widespread	dissemination	or	for	serious	detrimental	impact	
on	managed	or	natural	ecosystems	(e.g., rhizobium	spp.	and	Agrobacterium	
spp.).
The key here is that NIH views Agrobacterium as low risk, whereas APHIS regulates 
interstate transport of all Agrobacterium strains, even when they have been disarmed and 
are no longer pathogenic. Accordingly, all interstate movement restrictions of transgenic 
organisms that are of low to moderate risk as defined above, or that could not establish 
in the environment without substantial human aid, need to be lifted. This would greatly 
facilitate research and breeding with GE materials, and regulatory effort could then be 
focused on the more important issue of environmental releases, not contained shipments. 
Exemptions from regulation should include:
• All disarmed Agrobacterium strains not containing t-DNA
• All low-risk transgenic plants as defined above (as seed, in soil, or in	vitro).
Summary
Plant genomes are variable and dynamic, constantly changing in response to breeding 
efforts and even to environmental conditions. They are buffered against the change that 
Ultimately,	it	is	the	trait	imparted	by	the	transgene	that	matters,	
and	as	such,	it	is	the	trait	that	should	be	the	focus	of	regulatory	
efforts,	should	these	be	warranted.
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small additions or deletions of DNA can cause. They are buffered against differences in 
genic content, which probably explains why polyploidy is prevalent in higher plants. 
Against this background, it is ludicrous to treat transgenes and their associated DNA 
changes as inherently dangerous. Ultimately, it is the trait imparted by the transgene that 
matters, and as such, it is the trait that should be the focus of regulatory efforts, should 
these be warranted. For most traits, their risk to health and the environment is low enough 
as to preclude the need for regulatory oversight.
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This paper consists of four sections. First, it describes the Center for Science in the Public 
Interest (CSPI) and its Biotechnology Project. Second, it discusses the current status of 
agricultural biotechnology in the United States, future trends for the technology and some 
of the controversy that surrounds it. Third, the paper discusses the current status and 
issues surrounding “biopharming,” a major topic at this conference. The paper concludes 
with a discussion of what is needed for broader acceptance of agricultural biotechnology, 
not just in the United States but also abroad.
the Center for Science in the Public Interest
CSPI is a nonprofit consumer-advocacy organization that has focused on improving the 
safety and nutritional quality of our food supply. It seeks to promote health through 
educating the public about nutrition and alcohol; it represents citizens’ interests before 
legislative, regulatory, and judicial bodies; and it works to ensure that advances in science 
are used for the public good. Its primary focus is on the United States, although it does 
have a satellite office in Canada. International activities involve food-safety and labeling 
issues, such as the Codex	Alimentarius and the trans-Atlantic Consumer Dialogue.
CSPI is primarily supported by the almost 900,000 member-subscribers to its Nutrition	
Action	Healthletter.	CSPI receives no funding from industry or the federal government; 
some funding comes from independent philanthropic foundations.
The	Biotechnology	Project
In 00, CSPI began an advocacy project on agricultural biotechnology, the goals of 
which include to accurately identify risks and benefits of biotechnology, to ensure that 
the US regulatory system is up to the task of preventing significant risk, and to keep the 
public informed about the facts surrounding agricultural biotechnology. 
Creating the Proper Environment for Acceptance 
of Agricultural Biotechnology
Gregory Jaffe
Center	for	Science	in	the	Public	Interest
Washington,	DC
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CSPI’s biotechnology positions are based upon current evidence about the risks and 
benefits of biotechnology, not upon an ideological viewpoint that agricultural biotechnol-
ogy is inherently good or bad. In 00, based on its review of currently available evidence, 
CSPI stated that “the genetically engineered foods that are currently on the market are 
safe” to eat and that environmental risks associated with those crops are manageable 
(CSPI, 00). Also, CSPI has stated on numerous occasions that currently engineered 
crops grown in the United States are yielding benefits to farmers and the environment 
by increasing yields and reducing the use of insecticides (CSPI, 00; Jacobson, 00a, 
00b; Jaffe, 00). CSPI publicly acknowledges these beneficial applications and wants 
to ensure that they will continue to be realized. CSPI has been disappointed that other 
crops that could provide similar environmental benefits, such as Monsanto’s NewLeaf ™ 
potato, have not been planted by farmers due to fear of a consumer backlash and a loss 
of market for the crop.
Of course, CSPI has also acknowledged that agricultural biotechnology has real risks 
that need to be assessed and addressed before products from genetically engineered (GE) 
crops are marketed. From the consumer’s point of view, the key question about biotech 
foods is “Are they safe?” (Jaffe, 00a). Thus, before a biotech food is marketed, there 
needs to be a determination that the engineered protein is not an allergen, that there is 
no toxic effect from the engineered crop, and that there is no other unintended effect 
from the genetic transformation (NrC, 000, 00; CSPI, 00). Environmental risks 
are also possible from engineered crops. There is the potential for harm to non-target 
species, or the spread of the introduced gene and its characteristics to wild relatives of the 
transformed crop, or the development of pesticide resistance in insects or weeds (NrC, 
000; CSPI, 00). Each possible environmental consequence needs to be thoroughly 
evaluated and adequately addressed before any biotech crop is released to the environ-
ment (Jaffe, 00a).
Current Status of Agricultural Biotechnology and 
Future Potential Applications
In many ways, the past 0 years have been extremely successful for the biotechnology 
industry. Several blockbuster products were marketed in the 990s, including soybeans, 
corn, cotton, and canola that are herbicide-tolerant and corn and cotton that produce 
their own insecticide that kills specific pests. Those GE crops have been widely adopted 
by farmers in the United States and, to a varying extent, in seventeen other countries 
around the globe. Over eight million farmers grew 00 million acres of GE crops in 00 
(ISAAA, 005). From 99 to 00, the global acreage of transgenic crops increased 7-
fold, from . million acres to approximately 00 million acres (ISAAA, 005). In the 
In	2001,	CSPI	stated	that	“the	genetically	engineered	foods	that	
are	currently	on	the	market	are	safe”	to	eat.
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United States, 3.5 million acres of GE corn (5% of all corn) and 3.5 million acres of 
GE soybeans (85% of all soybeans) were grown in 00 (USDA, 00).
Those herbicide-tolerant and insect-resistant crops—biotechnology’s “first genera-
tion”—have been found to be safe to humans and the environment in the United States. 
They have also provided benefits to farmers and the environment by increasing yields, 
reducing the use of insecticides or increasing farmer income. 
Although the biotechnology industry’s initial inventions have been quite successful, the 
introduction of new products with different traits has slowed considerably. In February, 
005, CSPI released a study, Withering	on	the	Vine:	Will	Agricultural	Biotech’s	Promises	
Bear	Fruit? (Jaffe, 005). That study analyzed publicly available data from federal regula-
tory agencies to determine whether the number of new commercial products has been 
increasing, decreasing or remained steady. 
The study found that sixty-two biotech crops completed the Food and Drug Admin-
istration’s (FDA) voluntary consultation process between 995 and 00 (Figure ). In 
the first 5 years (995 through 999), forty-seven of those crops (an average of 9. per 
year) completed the regulatory process, whereas only fifteen crops (an average of three 
per year) completed the process in the next five years (000 through 00). Thus, the 
number of products per year completing the regulatory process plunged by 8% between 
995–999 and 000–00. More than 75% of all biotech crops that have completed 
the FDA regulatory process did so between 995 and 999. 
Figure . Genetically engineered crops completing FDA’s 
voluntary consultation process (FDA, 005).
Similarly, publicly available data about the granting of petitions for non-regulated 
status by the Animal and Plant Health Inspections Service (APHIS) of the United Stated 
Department of Agriculture (USDA) show a decreasing trend starting in 000. From 99 
through 00 ( years), APHIS deregulated sixty-two biotech crops so that they could 
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be grown commercially without APHIS oversight. Forty-nine of those approvals occurred 
between 99 and 999 (an average of 8. per year) while only thirteen of those approvals 
occurred between 000 and 00 (an average of . per year) (Figure ). Thus, APHIS 
approved almost four times as many crops from 99 through 999 than from 000 
through 00. Clearly, the pipeline for new biotech crops has shrunk considerably, and 
few new products have become available for commercialization in recent years.
The CSPI study also found that the GE crops that completed the regulatory process 
starting in 000 tended to be variations of existing products with established and proven 
genes, rather than innovative applications of the technology. For example, of the fifteen 
consultations at FDA between 000 and 00, five involved Monsanto’s placing in 
corn, wheat, creeping bent grass, canola, and sugar beet the same gene for resistance to 
the herbicide glufosinate ammonium (roundup®) that was previously engineered into 
soybean and cotton and reviewed by FDA in 995. Three applications of the fifteen 
involved engineering corn, rice, and cotton with a different gene (for phosphinothricin 
acetyltransferase) conferring herbicide tolerance that several companies had previously 
engineered into other crops that completed the FDA consultation process in the 990s. 
The remaining seven GE products involved engineering corn and cotton with various 
cry genes from Bacillus	thuringiensis	that confer insect resistance.	Although some of those 
applications could be considered “new” because they used cry genes not previously ap-
proved to address different plant pests, the Bt technology had been reviewed by FDA in 
consultations that go as far back as 995. Therefore, in the past 5 years, the industry has 
not marketed a single new agronomic, nutritional, or other trait.
Figure . Genetically engineered crop petitions approved by USDA for 
non-regulated status (APHIS, 005a)
5
The CSPI study also looked at length of time to complete the regulatory reviews of 
engineered crops at FDA and APHIS, which it concluded has significantly increased 
between 000 and 00. For the sixty-two voluntary consultation reviews conducted by 
FDA, the submissions from 995 through 999 averaged . months for completion 
whereas the submissions from 000 to 00 averaged 3.9 months (Jaffe, 005). Similarly, 
at APHIS granting a petition for non-regulated status took an average completion time 
of 5.9 months from 99 to 999, but an average of 3. months from 000 to 00 
(Jaffe, 005). Thus, it took the federal government twice as long to review biotech crops 
from 000 to 00 than it did in the 990s, yet those products had no apparent novel 
considerations that might justify the longer reviews. 
While the pipeline has slowed, international controversy over current engineered crops 
has continued. Whereas most governments and many distinguished scientists have found 
that those crops are safe, some people continue to be concerned with their safety to hu-
mans and/or the environment. Similarly, many opponents of genetic engineering do not 
believe that the current crops have any benefits, not just to consumers, but to farmers or 
the environment. Also, people throughout the world have called for the labeling of those 
crops and products from them, and many governments have imposed such labeling and 
traceability requirements (USDA, 005).
The	controversy	over	genetic	engineering	will	only	increase	with	
the	next	generation	of	products.
The controversy over genetic engineering will only increase with the next generation 
of products. The biotechnology industry and university researchers in the United States 
and abroad have been inserting a wide range of engineered traits into many different 
organisms. While research on drought or salt tolerance may reduce the controversy 
over genetic engineering if they benefit small-scale farmers in developing countries, 
GE wheat and rice will likely increase the international controversy. Those applications 
are particularly controversial because those crops are grown primarily for human food 
needs, whereas the currently grown engineered corn and soybeans are primarily used for 
animal feed (Foreman, 005). Similarly, applications of genetic engineering to animals 
to make faster growing salmon or improved cattle will be extremely controversial as they 
raise both safety and ethical issues (NrC, 00a; Foreman, 005). Finally, engineering 
plants to make pharmaceuticals (“biopharming”) or industrial compounds is particularly 
worrisome when food crops are employed because no one wants to eat corn flakes with 
a pharmaceutical in them. 
It is clear that those future applications of biotechnology may result in more contro-
versy than the current crops. Already, the possibility that the next generation of products 
might come to market has sparked an increase in state legislation to hinder or prevent 
commercialization of those products. In the 003–00 legislative session, the Northern 
Plains states (Montana, North Dakota, and South Dakota) introduced legislation to 
curb the introduction of GE wheat, while Michigan, California and Alaska introduced 
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legislation to put limits on transgenic fish (Pew, 005). In addition, Hawaii and texas 
have introduced legislation limiting production of pharmaceuticals using food crops (Pew, 
005). Although the 005–00 legislative session has only just started, both Hawaii and 
Oregon have already introduced legislation on pharma crops. Thus, it is more important 
than ever to do whatever possible to ensure acceptance of those crops when they reach 
the marketplace.
Biopharming
Introduction
In the last couple of years, the biotechnology industry has engaged in genetically engineer-
ing plants to produce pharmaceuticals, industrial compounds, and other novel proteins 
(“biopharming” or “pharma crops”) (Jaffe, 00b). Products that manufacturers hope 
to market commercially include insulin from safflower, human serum albumin (used as 
blood volume replacement during shock, serious burns, and surgery) from corn, hepatitis 
B vaccine from tobacco, cholera and Norwalk virus vaccines in potatoes, and lactoferrin 
(a human protein that protects against infections) in rice.
For the 00 growing season, USDA, which regulates the planting of pharma crops, 
received twenty applications to grow them in ten states. (Jaffe, 00b). For the 005 
growing season, they received eighteen applications to grow them in seven states (APHIS, 
005a). Those applications involve the engineering of six different crops—corn, tobacco, 
safflower, barley, rice, and indian mustard—with corn, tobacco and rice constituting the 
majority of the applications (Figure 3).
Figure 3. Biopharming permit applications for 00 and 005, by crop (APHIS, 005b).
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Although those applications of the technology have the potential to provide consumer 
benefits, if misused they could harm consumers or the environment. In fact, many sci-
entists and other stakeholders believe that the risks from pharma crops are significantly 
greater than those from engineered crops grown for food purposes. The National research 
Council stated the following in its report entitled Environmental	Effects	of	Transgenic	Plants 
about the potential risks of biopharming (NrC, 00b):
Some	 of	 the	 coming	 applications	 of	 biotechnology	may	 involve	 the	 issuing	 of	
plants	to	produce	pharmaceutical	products,	biologics,	fuels,	and	other	substances	
not	intended	for	human	food	use.	The	introduction	of	such	transgenes	poses	the	
potential	for	environmentally	associated	risks	of	a	wholly different order	than	
those	associated	with	existing	 transgenic	crops.	 If	 such	a	 transgene	moves	 into	
food	crops,	either	through	pollen	transfer	or	physical	contamination,	there	could	
be	serious human safety risk.	If	such	a	transgene	moves	into	a	wild	relative,	
there	could	be	widespread	environmental	dissemination	of	the	pharmaceutical	
substance	or	other	nonfood	substances	that	could have impacts on wildlife as 
well as microbial populations.	(emphasis added)
While biopharming raises both environmental and food-safety issues, the controversy 
surrounding those crops has centered on the concern that they might inadvertently en-
ter the food supply, causing either recalls of food products or rejection by international 
trading partners. That concern has caused industry stakeholders who normally support 
agricultural biotechnology to become advocates either against biopharming or for more 
stringent regulations. The Food Products Association has stated that it “has grave concerns 
about the use of bioengineered food and feed plants to produce non-food products” and 
that (FPA, 003):
…given	a	voice	during	the	early	development	of	this	promising	technology,	[FPA]	
would	not	have	supported	the	use	of	food	crops	for	the	production	of	plant	made	
pharmaceuticals.
Similarly, the Grocery Manufacturers of America stated (GMA, 003b):
The	current	US	regulatory	 framework	does	not	 inspire	 confidence	among	our	
collective	members	that	these	drug	and	chemical	crops	will	remain	isolated	and	
confined	and	not	contaminate	the	food	supply.
In fact, it is as likely that an industry stakeholder will object to the planting of a pharma 
crop as one generally opposed to agricultural biotechnology. When the biopharming 
company Ventria Bioscience attempted to plant rice engineered to produce a pharmaceu-
tical, Anheuser-Busch objected and was able to use its market power to alter where and 
under what conditions that rice would be grown (Bennett, 005). Similarly, Agragen’s 
announced intention to grow flax engineered to produce albumin in North Dakota, re-
sulted in industry stakeholders such as AmeriFlax expressing opposition out of fear that, 
even without a contamination incident, their international markets for conventional 
flax will be jeopardized (Associated Press, 005). Thus, it is clear that biopharming using 
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food crops is radically changing the debate surrounding agricultural biotechnology so 
that stakeholders who either supported or would support certain applications of genetic 
engineering, don’t support biopharming in food crops.
Regulation	of	Biopharming	and	the	USDA
A rigorous and robust regulatory system for ensuring that biopharm crops are safe for 
humans and the environment would do the following:1
• Allow the planting of pharma crops only if the government issues a permit. The 
regulatory system should put in place mandatory permitting requirements that 
must be complied with before the growing of any pharma crop. The permitting 
process should be transparent and allow public participation before the issuance 
of the permit.
• Issue a permit only after a thorough environmental assessment of the potential 
risks from growing the pharma crop. Before a permit is issued, the government 
should conduct a thorough environmental assessment of the potential effects of 
growing the pharma crop, including the effects from flow of the introduced gene 
and the effects of the transgenic protein on species other than humans. 
• Issue permits that require strict biological and physical confinement measures. 
All permits should contain enforceable conditions requiring state-of-the-art 
confinement procedures. Those mandatory permit conditions should include 
isolation distances, geographic restrictions (such as not growing GE corn in 
parts of the country where commodity corn is grown), physical barriers (such as 
fences or greenhouses), the use of distinguishable varieties of the crop, biological 
confinement (such as male sterility), and so forth. The permit should also require 
extensive segregation and identity-preservation procedures that ensure that none 
of the harvested materials can commingle with crops destined for human or 
animal consumption. When using a food crop, the permit should have several 
redundant levels of confinement, even at the field-trial level.
• Require regular inspections of the pharmaceutical-producing crop by the regula-
tory agencies. As part of its regulation of pharma crops, both USDA and FDA 
should conduct regular, unannounced inspections of all facilities involved in the 
production of the pharmaceutical, from the laboratory to the farm to the manu-
facturing plant. Some of those inspections should occur after the crops have been 
harvested to prevent volunteer plants in future seasons. In addition, USDA and 
FDA should inspect neighboring fields and crops to confirm that containment 
has been achieved.
• Require that if a pharmaceutical is produced in a food crop, there should be a 
mandatory pre-market food-safety approval process by FDA’s Center for Food 
1The remainder of this article focuses on federal regulation of biopharming. It does not discuss state or local 
regulations, which could play a major role in overseeing the risks associated with pharma crops.
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Safety and Applied Nutrition. Although confinement measures need to be strictly 
adhered to, they will never result in 00% containment over the long term. Thus, 
before any pharmaceutical is grown commercially in a food crop, FDA should 
conduct a thorough food-safety analysis to ensure that human exposure to the 
transgenic crop in the food supply would not result in any health risks. If addi-
tional legal authority is needed to implement this requirement, FDA and USDA 
should seek it from Congress.
Such a regulatory system would be able to protect human health and the environment, 
provide consumers confidence that their concerns are being adequately addressed, and 
lead to general acceptance of biopharming applications that are found safe. Unfortu-
nately, the regulatory system for biopharming in the United States does not meet those 
minimum requirements.
The USDA regulates biopharming using its biotechnology regulations established under 
the authority of the Plant Pest Act (7 CFr 30). Under those regulations, a permit must 
be issued before any biopharm plant can be released into the environment. Applicants 
submit an application and USDA conducts some risk analysis of the proposed planting. 
USDA then issues a permit with specific confinement conditions and conducts inspec-
tions during the release to verify compliance.
Unfortunately, the USDA permitting system for biopharming is not as rigorous, trans-
parent, or protective as is needed to ensure safety for humans and the environment. First, 
it lacks transparency and the ability for the public to participate in many of the regulatory 
decisions. The non-confidential portion of the applications for biopharming permits are 
not made available to the public nor is any information about the general location or 
size of the release. Also, when the permit is issued, it is not made available to the public. 
In addition, the public is not informed about how many inspections are to be made at 
a particular site or the results of those inspections. Finally, there is no opportunity for 
public comment before the issuance of many biopharming permits. The public is given 
an opportunity to comment on a proposed permit only if an Environmental Impact 
Statement or Environmental Assessment is performed under the National Environmental 
Policy Act, which occurs in only a small minority of biopharming permits. In contrast, for 
every other engineered crop, before a petition for non-regulated status is granted (which 
is generally the last step before commercialization), the public is given the opportunity 
to comment on the regulatory decision.
The	USDA	permitting	system	for	biopharming	is	not	as	rigorous,	
transparent,	or	protective	as	is	needed	to	ensure	safety	for	humans	
and	the	environment.
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Due to the lack of transparency in USDA’s regulation of biopharming, it is difficult to 
assess whether or not their permitting system adequately protects the environment. The 
National research Council reviewed some of the environmental assessments for transgenic 
food crops and found that they were not thorough and did not address broad ecological 
issues (NrC, 00b). Some of the documents that have been released by USDA on their 
assessment of environmental issues surrounding biopharming have been extensive while 
others were extremely cursory. Thus, it is fair to state that USDA’s environmental assess-
ments for biopharming do not always thoroughly analyze gene flow, effects on non-target 
species, or any broad ecological effects of the transgenic plant. 
Based on the documents released to the public about the permit conditions imposed on 
biopharming (USDA guidance as well as proposed supplemental conditions), the USDA 
does not require strict biological and physical confinement measures using state-of-the-art 
technologies. USDA primarily employs geographic and temporal separations and has not 
required biological confinement measures (e.g. male sterility or chloroplast transformation) 
nor geographic restrictions (such as not growing pharma corn in corn-belt states). Only 
by using all available confinement measures in a redundant fashion can both human and 
environmental health be safeguarded from biopharm crops.
Finally, although USDA has the legal authority to address agricultural and environ-
mental issues surrounding biopharming, they have no Congressional mandate to address 
food-safety concerns. Under the Plant Protection Act, which USDA uses to promulgate 
its biotechnology regulations, there is no authority to safeguard the food supply. For this 
reason, USDA’s permitting process does not involve any food-safety assessment of a pharma 
crop before it is released into the environment. USDA’s assessment process does not de-
termine whether the gene product will be harmful to humans if it enters the food supply. 
At the same time, FDA does not conduct any food-safety assessments of pharma crops. 
Thus, there is an extremely large gap in the federal government’s regulation of biopharming 
where no agency assesses and addresses the food-safety risks of pharma crops.
The	Need	for	FDA	to	Regulate	Biopharming	and	Safeguard	the	Food	Supply	
The Federal Food Drug and Cosmetic Act regulates anything that is intended to be used as 
food or feed. However, a pharmaceutical corn plant or one producing avidin, for example, 
is not intended by the developer to be used as food or feed. Thus, those products are 
neither food additives, nor would they be subject to FDA’s voluntary notification process 
(or FDA’s proposed mandatory notification rule). FDA has limited authority over those 
products unless they show up in food. At that stage, FDA could consider foods containing 
the pharmaceutical compound (or industrial chemical) adulterated, and remove them 
from the market. The burden would be on FDA, however, to prove adulteration.
The current system is not the best way to ensure a safe food supply in view of the fact 
that contamination by pharma crops is inevitable. A possible solution to this problem 
would be for Congress to require a mandatory FDA approval process for all GE crops, both 
those intended for food use and pharma crops not intended for the food supply. Under 
that approval system, no GE food crop could be commercialized without a food-safety 
approval by FDA. For pharma crops to be commercialized, FDA would either need to 
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approve the crop as safe to eat or set a safe tolerance for the non-food substance. Then, 
if that GE crop entered the food supply, eating the engineered substance would be safe 
as long it was below the tolerance level; consumers would have no need to fear that they 
are eating unsafe food. In addition, the rigor of the food-safety assessment conducted by 
FDA should be proportionate to the physical and biological confinement of the crop. If 
the pharmaceutical crop is grown at a location far from other like plants, only a limited 
food-safety assessment might be required because the likelihood of contamination would 
be extremely small. If pharmaceutical corn is grown in Iowa, however, then a complete 
food-safety analysis might be warranted. 
Providing FDA with mandatory authority to review the safety of pharma crops before 
they are released into the environment is not a far-fetched idea. As far back as 00, a 
group of industry representatives at the Grain Quality Workshop concluded the follow-
ing (Maier, 00):
[We]	urge	the	FDA	that	when	future	commercialization	approvals	of	genetically	
modified	grains	and	oilseeds	for	non-food	and	feed	purposes	are	considered,	these	
approvals	also	meet	food	safety	requirements	because	inadvertent	traces	of	these	
genetically	modified	grains	and	oilseeds	will	be	detected	in	food	and	feed.
The Grocery Manufacturers of America (003a) also stated that pharma crops should 
not be grown:
…unless	FDA	has	concluded	that	any	release	of	the	nonfood	product	into	the	food	
supply	will	be	safe	and	that	it	will	have	no	adverse	effect	on	human	health.
Other countries have also included food-safety assessments for biopharming. In 
Canada, if a food or feed crop is used for biopharming (Canadian Food Inspection 
Agency, 000):
…the	developer	must	submit	exposure	and	hazard	data	for	human	and	livestock	
health	effects	assessment	[by	Health	Canada].	
Finally, in the 07th Congress, Senator richard Durbin from Illinois introduced the 
Genetically Engineered Foods Act (S. 5). That bill would require all GE food crops to 
have a mandatory premarket approval before commercialization, including pharma crops. 
Therefore, many stakeholders agree that there are significant risks to the food supply from 
pharma crops and that a regulatory agency, such as FDA, needs to play a mandatory role 
in ensuring that those crops do not cause harm to humans. 
Providing	FDA	with	mandatory	authority	to	review	the	safety	of	
pharma	crops	before	they	are	released	into	the	environment	is	not	
a	far-fetched	idea.
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the road Forward for Acceptance of Agricultural Biotechnology
With the current state of affairs and the many controversial new applications on the 
horizon, agricultural biotechnology is unlikely to obtain broader societal acceptance in 
the near future. This will be particularly true for applications of the technology such as 
biopharming.
to create the proper environment for greater acceptance of agricultural biotechnology 
products, there should be the following:
• a strong, but not stifling, regulatory system that manages the potential risks of 
products using scientific risk assessments and state of the art technology;
• a regulatory system that is transparent and participatory;
• independent risk-assessment research that informs the public and regulators about 
the potential risks of particular applications and how to manage those risks;
• applications of the technology that provide direct benefits to consumers, both in 
developed and developing countries;
• broader access to the technology through the free licensing of intellectual-prop-
erty rights to public-sector and developing-country researchers making products 
for the public good;
• involvement of the public early on in the development of products so that contro-
versial and/or risky applications can be avoided.
Agricultural biotechnology is one of the many tools available to move agriculture 
forward in the twenty-first century. It can provide beneficial products, including pharma-
ceuticals. to properly utilize biotechnology, however, the regulatory system must ensure 
that products are safe for humans and the environment. That system must be transparent 
and participatory if it is to engender trust among consumers. Only then will there be an 
environment in which consumers will embrace safe applications of biotechnology.
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An important issue that concerns us at BIO is that the biotechnology industry be good 
stewards. We expect that this will be important for a long time to come. Good stewardship 
relates to regulatory policy and—contrary to the philosophy that we need less regula-
tion—at BIO we understand the role that regulatory policy plays and we embrace it. It 
is the backbone for all that we do to ensure biotechnology’s success.
The Importance of Stewardship in Agricultural 
Biotechnology
Michael J. Phillips
Biotechnology	Industry	Organization
Washington,	DC
BIO is a trade association representing all facets of biotechnology. We have over ,00 
member companies—90% of which are small entrepreneurial entities—academic institu-
tions and state centers here in the United States. We have members in all fifty states and 
in thirty-four nations, and we are involved in r&D across all of the sectors, including 
food and agriculture, healthcare and industrial manufacturing. Our 005 annual meet-
ing in Philadelphia had close to 9,000 attendees, a record number indicating how this 
technology is growing in importance.
It can be hard to tell where food and agriculture ends and healthcare and industrial 
aspects begin, particularly in terms of plant-made pharmaceuticals (PMPs) and industrial 
products (PMIPs). It is appropriate, therefore, for BIO to examine all facets of biotech-
nology, particularly in terms of synergisms across these sectors.
005 marked the tenth anniversary of commercial planting of biotech crops. This, the 
most rapidly adopted technology in the history of agriculture, now plays an extremely 
important role for soybean, cotton, corn and canola, representing well over two thirds of 
all of the varieties that are being planted. 005 also marked the cumulative planting of 
one billion acres of biotech crops around the world, the achievement of which all of us 
who are part of this industry may be proud.
At	BIO	we	understand	the	role	that	regulatory	policy	plays	and	
we	embrace	it.
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ten years ago, we focused on agronomic traits. We have begun to move into quality 
traits and are now developing plants as factories for synthesis of pharmaceuticals and 
industrial products and materials—the third wave.
The United States has evolved an elaborate regulatory system that we refer to as the 
Coordinated regulatory Framework. There is a lot of history here, going back to the late 
980s. It is a science- and risk-based regulatory system and is transparent, and we are 
working with the regulatory agencies—USDA, EPA and FDA—to ensure that it will 
become more transparent in the future. The biotech industry has always embraced strong 
regulatory policy and oversight; we cannot overstate how important this is to us in terms 
of promoting consumer confidence.
Stewardship Areas
Within BIO, we have a robust training program and an active group is laying out prin-
ciples for development and confinement of PMPs and PMIPs. And late in 00, BIO 
released a containment analysis and critical control point (CACCP) plan for PMP and 
PMIP production. These areas constitute a strong stewardship program to help ensure 
that we are meeting all federal requirements.
Compliance training
A couple of years ago, the author met with the NABC board to discuss aspects of train-
ing deemed mutually important. We have now developed educational workshops dealing 
with compliance aspects affecting genetically engineered (GE) corn, cotton and soybeans. 
These workshops will be offered in conjunction with professional society meetings and 
conferences such as those organized by NABC. Not only do we want those in our industry 
to participate in these training courses, they will be offered also to universities and federal 
research agencies to help ensure that all abide by the federal requirements and understand 
the legal implications involved in conducting field trials with GE crops.
In	2004,	BIO	released	a	containment	analysis	and	critical	
control	point	(CACCP)	plan	for	PMP	and	PMIP	production.
Furthermore, we are planning to provide accreditation as part of the incentive to 
participate in these training programs. We are optimistic that we will be able to offer 
continuing education credits (CECs). We hope to begin offering classes and workshops 
in the fall of 005 in conjunction with professional society meetings and be fully opera-
tion throughout 00 and beyond. 
We	are	planning	to	provide	accreditation	as	part	of	the	incentive	
to	participate	in	these	training	programs.
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What will be involved? The courses will cover notification and permitting procedures, 
compliance and enforcement, transport and storage, trial-site management, harvest dis-
position and post-harvest management. An important aspect is auditing and verification, 
particularly by third parties, also requirements to be met with pesticidal products with 
regards to Environmental Use Permits. One-day workshops are envisioned; in some cases 
a half-day or two-thirds of a day may suffice.
CACCP
Within the PMP/PMIP arena, we have been working on drawing up principles for de-
velopment and confinement. A reference document that we published looks at two areas. 
One is the principle for controlled exposures to PMPs and PMIPs, and the other describes 
development practices for PMPs and PMIPs, which examines confinement systems that 
control exposure and cross-pollination, confirmation of confinement and the use of 
identity preservation systems. In 00, we finished the second phase of this project; the 
principles document was reduced down to a confinement analysis and critical control 
points (CACCP) approach to PMP and PMIP production. This terminology resonates 
with people in the food industry who understand the hazard analysis and critical control 
point (HACCP) system (which relates to risk analysis and food safety) which has many 
elements in common with risk assessment and management of PMPs and PMIPs.
The CACCP system entails seven principles: how the critical control points are deter-
mined, how limits are established, how the process is monitored (a very important aspect), 
how corrective actions are to be initiated, how verification procedures are establish, and 
record keeping and documentation. Whether in industry, at a university or within a 
federal research agency, all of these principles apply. 
Commitment of top management is essential. Prerequisites include GMPs and other 
good Q&A protocols, facility standards, supplier control, cleaning and sanitation, etc. Of 
primary importance are education and training, and as our compliance training programs 
evolve, we will include modules covering the CACCP system, for example. Participants in 
the training courses will return to their universities, companies or research agencies and 
develop institutional standard operating procedures to fit specific home-base needs.
For	biotechnology	to	continue	to	evolve,	commitment	to	good	
stewardship	on	the	part	of	the	industrial	sector	will	be	essential,	
together	with	embracement	of	federal	regulatory	policies.
Summary
Stewardship is an extremely important aspect of the development of biotechnology, one 
that BIO’s membership takes very seriously. Our goals include the highest standards of 
performance, to demonstrate transparency, openness and commitment to regulatory 
compliance. For biotechnology to continue to evolve, commitment to good stewardship 
Phillips
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on the part of the industrial sector will be essential, together with embracement of federal 
regulatory policies.
More information is available at http://www.bio.org or from the author at mphillips@
bio.org.
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